{"add": {"doc": {"field": [{"@name": "docid", "#text": "BR-TU.18584"}, {"@name": "filename", "#text": "25596_Shimojo_AndreaArrudaMartins_D.pdf"}, {"@name": "filetype", "#text": "PDF"}, {"@name": "text", "#text": "ANDR\u00c9A ARRUDA MARTINS SHIMOJO \n\n \n\n \n\n \n\n \n\n \n\nPLASMA RICO EM PLAQUETAS ASSOCIADO A \u00c1CIDO HIALUR\u00d4NICO \n\nE/ OU QUITOSANA PARA APLICA\u00c7\u00d5ES EM MEDICINA \n\nREGENERATIVA  \n\n \n\n \n\n \n\nPLATELET-RICH PLASMA ASSOCIATED TO HYALURONIC ACID AND/ \n\nOR CHITOSAN FOR APPLICATIONS IN REGENERATIVE MEDICINE \n\n  \n\n \n\n \n\n \n\n \n\nCampinas, 2015 \n\n  \n\n\n\nii \n\n \n\n  \n\n\n\niii \n\n \n\n \n\n\n\niv \n\n \n\n \n\n\n\nv \n\n \n\n \n\n\n\nvi \n\n \n\n  \n\n\n\nvii \n\n \n\nRESUMO \nEste trabalho teve como objetivo estudar o desempenho in vitro do plasma rico em plaquetas (PRP) com \n\nscaffolds de \u00e1cido hialur\u00f4nico (AH) ou quitosana (CHT) como um scaffold comp\u00f3sito para a prolifera\u00e7\u00e3o e \n\ndiferencia\u00e7\u00e3o osteog\u00eanica de c\u00e9lulas tronco mesenquimais derivadas de tecido adiposo humano (h-\n\nAdMSCs). O PRP \u00e9 um produto aut\u00f3logo obtido do sangue total (WB). O \u00e1cido hialur\u00f4nico \u00e9 um \n\nglicosaminoglicano e principal componente do fluido sinovial. A quitosana \u00e9 um polissacar\u00eddeo natural \n\nencontrado principalmente na carapa\u00e7a de crust\u00e1ceos. O PRP puro (P-PRP, rico em plaquetas e pobre \n\nem leuc\u00f3citos) foi obtido a partir da centrifuga\u00e7\u00e3o controlada do WB, e ativado com os agonistas soro \n\naut\u00f3logo e c\u00e1lcio. Os scaffolds foram estruturados em micropart\u00edculas ou esponjas, para atender os \n\nrequisitos de formula\u00e7\u00f5es injet\u00e1veis ou s\u00f3lidas, respectivamente. Nesse contexto, os seguintes scaffolds \n\nforam preparados e caracterizados: s\u00f3lidos porosos (esponjas) de quitosana n\u00e3o estabilizados (PCHTs) e \n\nestabilizados (SPCHTs); micropart\u00edculas de quitosana-tripolifosfato de s\u00f3dio (iCHT-TPPs); \n\nmicropart\u00edculas e esponjas de \u00e1cido hialur\u00f4nico autorreticulado (ACPs) e de \u00e1cido hialur\u00f4nico reticulado \n\ncom 1,4-butanodiol diglicidil \u00e9ter (HA-BDDE); e esponjas e micropart\u00edculas de ACP e CHT (PECs). \n\nPCHTs foram preparados por congelamento e liofiliza\u00e7\u00e3o de solu\u00e7\u00f5es de CHT, variando a concentra\u00e7\u00e3o \n\ne as condi\u00e7\u00f5es de congelamento. As estabiliza\u00e7\u00f5es foram realizadas pelo tratamento dos PCHTs com \n\nhidr\u00f3xido de s\u00f3dio, s\u00e9rie de etanol ou reticula\u00e7\u00e3o com tripolifosfato. Os iCHT-TPPs foram preparados por \n\nreticula\u00e7\u00e3o i\u00f4nica de quitosana com TPP em diferentes raz\u00f5es m\u00e1ssicas. ACPs foram obtidos por \n\nautoesterifica\u00e7\u00e3o organocatalisada. HA-BDDE foi preparado por eterifica\u00e7\u00e3o dos grupos hidrox\u00edlicos do \n\nHA com o ep\u00f3xido BDDE. PECs foram preparados por reticula\u00e7\u00e3o i\u00f4nica do ACP com a CHT. Para a \n\nprepara\u00e7\u00e3o de scaffolds comp\u00f3sitos, P-PRP ativado contendo h-AdMSCs foi imediatamente pipetado \n\nsobre a superf\u00edcie dos scaffolds. Os resultados mostraram que os scaffolds n\u00e3o apresentam \n\ncitotoxicidade. Micrografias obtidas por microscopia eletr\u00f4nica de varredura mostraram compatibilidade \n\nestrutural com as redes de fibrina formadas no interior dos poros ou na superf\u00edcie de scaffolds \n\ncomp\u00f3sitos. Os scaffolds comp\u00f3sitos estimularam o crescimento de h-AdMSCs e a diferencia\u00e7\u00e3o \n\nosteog\u00eanica. Os scaffolds comp\u00f3sitos tamb\u00e9m promoveram libera\u00e7\u00e3o gradual dos fatores de crescimento \n\nPDGF-AB e TGF-?1. Assim, conclu\u00edmos que os scaffolds comp\u00f3sitos estudados neste trabalho s\u00e3o \n\npromissores para engenharia de tecidos, particularmente para a cicatriza\u00e7\u00e3o e regenera\u00e7\u00e3o \u00f3ssea, no \n\n\u00e2mbito da medicina regenerativa.  \n\n \n\nPalavras-chave: Plasma rico em Plaquetas, Scaffolds, \u00c1cido hialur\u00f4nico, Quitosana, Medicina \n\nregenerativa. \n\n  \n\n\n\nviii \n\n \n\n  \n\n\n\nix \n\n \n\nABSTRACT \nThis work aimed to study the in vitro performance of platelet-rich plasma (PRP) with scaffolds of \n\nhyaluronic acid (HA) and/ or chitosan (CHT) as a composite scaffold for proliferation and osteogenic \n\ndifferentiation of human adipose-derived mesenchymal stem cells (h-AdMSCs). The PRP is an autologous \n\nproduct obtained from whole blood (WB). Hyaluronic acid is a glycosaminoglycan and the main \n\ncomponent of the synovial fluid. Chitosan is a natural polysaccharide found mainly in the carapace of \n\ncrustaceans. The pure PRP (P-PRP, rich in platelet and poor in leukocytes) was obtained from controlled \n\ncentrifugation of WB, and activated with the agonists autologous serum and calcium. The scaffolds were \n\nstructured in microparticles or sponges, to comply the requirements of injectable or solid formulations, \n\nrespectively. In this context, the following scaffolds were prepared and characterized: chitosan porous \n\nsolid (sponge) unstabilized (PCHTs) and stabilized (SPCHTs); chitosan-sodium tripolyphosphate \n\nmicroparticles (iCHT-TPPs); microparticles and sponges of auto-crosslinked hyaluronic acid (ACPs) and \n\nof hyaluronic acid crosslinked with 1,4-butanediol diglycidyl ether (HA-BDDE); and microparticles and \n\nsponges of ACP and CHT (PECs). PCHTs were prepared by freezing and lyophilization of CHT solutions, \n\nvarying the concentration and freezing conditions. Stabilization was performed by treating the PCHTs with \n\nsodium hydroxide, an ethanol series or by crosslinking with tripolyphosphate. The iCHT-TPPs were \n\nprepared by ionic crosslinking of chitosan with TPP at different mass ratios. ACPs was prepared by \n\norganocatalyzed auto-esterification. HA-BDDE was prepared by etherification of the hydroxyl groups of \n\nHA with the epoxide BDDE. PECs were prepared by ionic crosslinking of ACP with CHT. For the \n\npreparation of composite scaffolds, activated P-PRP containing h-AdMSCs was immediately pipetted onto \n\nthe surface of the scaffolds. The results showed that the scaffolds do not exhibit cytotoxicity. Micrographs \n\nobtained by scanning electron microscopy (SEM) showed structural compatibility with fibrin networks \n\nformed inside the pores or on the surface of scaffolds. The composite scaffolds stimulated the growth of h-\n\nAdMSCs and osteogenic differentiation. Composite scaffolds also promoted gradual release of growth \n\nfactors PDGF-AB and TGF-?1 and osteogenic differentiation. Thus, we conclude that the composite \n\nscaffolds studied in this work are promising for tissue engineering, particularly for healing and bone \n\nregeneration in regenerative medicine. \n\n \n\nKeywords: Platelet-rich plasma, hyaluronic acid, chitosan, scaffolds, regenerative medicine. \n  \n\n\n\nx \n\n \n\n \n\n  \n\n\n\nxi \n\n \n\nSUM\u00c1RIO \n \n\nRESUMO ........................................................................................................................ vii \n\nABSTRACT .....................................................................................................................ix \n\nAGRADECIMENTOS .................................................................................................... xxi \n\nLISTA DE FIGURAS ................................................................................................... xxiii \n\nLISTA DE TABELAS ................................................................................................... xxix \n\nCAP\u00cdTULO 1 \u2013 INTRODU\u00c7\u00c3O ....................................................................................... 1 \n\n1.1. Apresenta\u00e7\u00e3o .................................................................................................... 1 \n\n1.2. Relev\u00e2ncia do Trabalho .................................................................................... 2 \n\n1.3. Objetivo ............................................................................................................. 5 \n\nCAP\u00cdTULO 2 \u2013 REVIS\u00c3O BIBLIOGR\u00c1FICA ................................................................... 7 \n\n2.1. Engenharia de Tecidos e Medicina Regenerativa ............................................. 7 \n\n2.2. Plasma Rico em Plaquetas ............................................................................... 8 \n\n2.2.1. Defini\u00e7\u00f5es .................................................................................................... 8 \n\n2.2.2. PRP na regenera\u00e7\u00e3o de tecidos ................................................................ 10 \n\n2.3. Scaffolds ......................................................................................................... 12 \n\n2.3.1. Defini\u00e7\u00f5es .................................................................................................. 12 \n\n2.3.2. Scaffolds na regenera\u00e7\u00e3o de tecidos ......................................................... 13 \n\n2.3.3. Propriedades requeridas dos scaffolds ...................................................... 14 \n\n2.3.4. Materiais utilizados na fabrica\u00e7\u00e3o de scaffolds .......................................... 15 \n\n2.3.4.1. \u00c1cido hialur\u00f4nico (AH) .......................................................................... 16 \n\n2.3.4.2. Quitosana ............................................................................................. 20 \n\n2.3.4.3. Complexos Polieletrol\u00edticos de \u00c1cido Hialur\u00f4nico e Quitosana ............ 22 \n\n2.4. C\u00e9lulas Tronco Mesenquimais ........................................................................ 23 \n\n2.5. Scaffolds Comp\u00f3sitos ...................................................................................... 25 \n\n2.6. Refer\u00eancias ..................................................................................................... 27 \n\n\n\nxii \n\n \n\nCAP\u00cdTULO 3 \u2013 PERFORMANCE OF PRP ASSOCIATED WITH POROUS CHITOSAN \n\nAS A COMPOSITE SCAFFOLD FOR REGENERATIVE MEDICINE ............................ 41 \n\n3.1. Introduction ..................................................................................................... 42 \n\n3.2. Experimental ................................................................................................... 45 \n\n3.2.1. Materials .................................................................................................... 45 \n\n3.2.2. Methods ..................................................................................................... 45 \n\n3.2.2.1. Preparation of Porous Chitosan Scaffolds (PCHTs) ............................. 45 \n\n3.2.2.2. Characterization of Porous Chitosan Scaffolds (PCHTs) ..................... 46 \n\n3.2.2.3. PRP Preparations ................................................................................. 47 \n\n3.2.2.4. The Composite Scaffolds (?P-PRP/PCHTs)......................................... 48 \n\n3.2.2.5. Images of the h-AdMSCs-Seeded Composite Scaffolds ...................... 50 \n\n3.2.2.6. Induction of Osteogenic Differentiation ................................................. 50 \n\n3.2.2.7. Statistical Analysis ................................................................................ 50 \n\n3.3. Results and Discussion ................................................................................... 51 \n\n3.3.1. Experimental Design .................................................................................. 51 \n\n3.3.2. Effects of Freezing Conditions and Chitosan Concentration on PCHTs .... 51 \n\n3.3.2.1. Images of Porous Structure .................................................................. 51 \n\n3.3.2.2. Characterization of PCHTs ................................................................... 53 \n\n3.3.2.3. Cell Compatibility .................................................................................. 56 \n\n3.3.3. Characterization of the Composite Scaffolds ............................................. 57 \n\n3.3.3.1. Images of the Cell-Seeded ?P-PRP/PCHTs ......................................... 57 \n\n3.3.3.2. Growth Factor Release ........................................................................ 58 \n\n3.3.3.3. h-AdMSCs-Seeded Proliferation .......................................................... 60 \n\n3.3.3.4. Induction of Osteogenic Differentiation ................................................. 61 \n\n3.4. Conclusions ..................................................................................................... 61 \n\n3.5. References ...................................................................................................... 62 \n\nCAP\u00cdTULO 4 \u2013 STABILIZATION OF POROUS CHITOSAN IMPROVES THE \n\nPERFORMANCE OF ITS ASSOCIATION WITH PLATELET-RICH PLASMA AS A \n\nCOMPOSITE SCAFFOLD ............................................................................................. 69 \n\n4.1. Introduction ..................................................................................................... 70 \n\n\n\nxiii \n\n \n\n4.2. Materials and Methods .................................................................................... 72 \n\n4.2.1. Materials .................................................................................................... 73 \n\n4.2.2. Methods ..................................................................................................... 73 \n\n4.2.2.1. Preparation of porous chitosan (PCHT)................................................ 73 \n\n4.2.2.2. Stabilization of PCHT ........................................................................... 73 \n\n4.2.3. Characterization of SPCHTs ...................................................................... 74 \n\n4.2.3.1. Chemical modification .......................................................................... 74 \n\n4.2.3.2. Morphology and pore size .................................................................... 74 \n\n4.2.3.3. Swelling profile ..................................................................................... 74 \n\n4.2.3.4. Porosity ................................................................................................ 75 \n\n4.2.3.5. Mechanical resistance .......................................................................... 75 \n\n4.2.3.6. Degradation in phosphate buffered saline ............................................ 75 \n\n4.2.3.7. Cell compatibility .................................................................................. 76 \n\n4.2.4. Preparation of pure platelet-rich plasma (P-PRP) ...................................... 76 \n\n4.2.5. Preparation of activated P-PRP (aP-PRP) ................................................. 76 \n\n4.2.6. Preparation of composite scaffold (aP-PRP/SPCHTs) .............................. 76 \n\n4.2.7. h-AdMSCs isolation and pre-cultivation ..................................................... 77 \n\n4.2.8. h-AdMSCs-seeding in the composite scaffolds.......................................... 77 \n\n4.2.9. Characterization of the composite scaffold ................................................ 77 \n\n4.2.9.1. Release of GFs .................................................................................... 77 \n\n4.2.9.2. Images of the cell-seeded composite scaffolds .................................... 78 \n\n4.2.9.3. h-AdMSCs proliferation ........................................................................ 78 \n\n4.2.9.4. Induction of osteogenic differentiation .................................................. 79 \n\n4.2.9.5. Alkaline phosphatase activity (ALP) ..................................................... 79 \n\n4.2.10. Statistical analysis ................................................................................... 79 \n\n4.3. Results and discussion .................................................................................... 79 \n\n4.3.1. Modifications and surface chemistry .......................................................... 79 \n\n4.3.2. Physicochemical and mechanical properties of SPCHTs .......................... 80 \n\n4.3.3. Biological properties of SPCHTs ................................................................ 85 \n\n4.4. Conclusions ..................................................................................................... 88 \n\n\n\nxiv \n\n \n\n4.5. References ...................................................................................................... 89 \n\nCAP\u00cdTULO 5 \u2013 IN VITRO BIOLOGICAL PERFORMANCE OF INJECTABLE \n\nCHITOSAN-TRIPOLYPHOSPHATE SCAFFOLDS COMBINED WITH PLATELET-RICH \n\nPLASMA ........................................................................................................................ 95 \n\n5.1. Introduction ..................................................................................................... 96 \n\n5.2. Materials and Methods .................................................................................... 97 \n\n5.2.1. Materials .................................................................................................... 97 \n\n5.2.2. Preparation of injectable scaffolds of chitosan-sodium tripolyphosphate \n\n(iCHT-TPPs) ........................................................................................................ 98 \n\n5.2.3. Physicochemical Characterization ............................................................. 98 \n\n5.2.3.1. Chemical modification. ......................................................................... 98 \n\n5.2.3.2. Crosslink density Flory-Rehner calculations. ........................................ 98 \n\n5.2.3.3. Particle diameter measurements .......................................................... 99 \n\n5.2.3.4. Rheology measurements...................................................................... 99 \n\n5.2.3.5. Extrusion force. .................................................................................... 99 \n\n5.2.3.6. Swelling ratio (SR). ............................................................................... 99 \n\n5.2.3.7. Degradation in phosphate buffered saline. ......................................... 100 \n\n5.2.4. Biological characterization ....................................................................... 100 \n\n5.2.4.1. Cell compatibility. ............................................................................... 100 \n\n5.2.5. Preparation of pure platelet-rich plasma (P-PRP) .................................... 100 \n\n5.2.5.1. Activation of P-PRP (aP-PRP) ............................................................ 101 \n\n5.2.6. Preparation of composite scaffold (aP-PRP/iCHT-TPPs) ........................ 101 \n\n5.2.7. Characterization of aP-PRP/iCHT-TPPs .................................................. 101 \n\n5.2.7.1. Release of GFs .................................................................................. 101 \n\n5.2.8. h-AdMSCs isolation and pre-cultivation ................................................... 102 \n\n5.2.9. Culture of h-AdMSCs-seeding in the composite scaffolds ....................... 102 \n\n5.2.9.1. h-AdMSCs proliferation ...................................................................... 102 \n\n5.2.9.2. Images of the cell-seeded composite scaffolds .................................. 103 \n\n5.2.9.3. Induction of osteogenic differentiation ................................................ 103 \n\n5.2.9.4. Alkaline phosphatase activity (ALP) ................................................... 103 \n\n\n\nxv \n\n \n\n5.2.10. Statistical analysis ................................................................................. 104 \n\n5.3. Results and discussion .................................................................................. 104 \n\n5.3.1. Crosslinking in the injectable scaffolds of chitosan-sodium tripolyphosphate \n\n(iCHT-TPPs). ..................................................................................................... 104 \n\n5.3.2. Physicochemical and mechanical properties of iCHT-TPPs. ................... 105 \n\n5.3.3. Biological characterization ....................................................................... 108 \n\n5.4. Conclusions ................................................................................................... 112 \n\n5.5. References .................................................................................................... 113 \n\nCAP\u00cdTULO 6 \u2013 IMPROVEMENTS IN PLATELET-RICH PLASMA PERFORMANCE BY \n\nASSOCIATION WITH MICROPARTICLES OR SPONGES OF AUTO-CROSSLINKED \n\nHYALURONIC ACID ................................................................................................... 117 \n\n6.1. Introduction ................................................................................................... 118 \n\n6.2. Experimental ................................................................................................. 120 \n\n6.2.1. Materials .................................................................................................. 121 \n\n6.2.2. Methods ................................................................................................... 121 \n\n6.2.2.1. Preparation of HA-TBA ....................................................................... 121 \n\n6.2.2.2. Preparation of ACP ............................................................................ 121 \n\n6.2.2.3. Characterization of ACP ..................................................................... 122 \n\n6.2.2.4. Preparation of structured ACP ............................................................ 122 \n\n6.2.2.5 Characterization of structured ACP ..................................................... 122 \n\n6.2.2.6. Preparation of PRP ............................................................................ 125 \n\n6.2.2.7. Preparation of activated P-PRP (aP-PRP) ......................................... 125 \n\n6.2.2.8 Preparation of composite scaffolds ..................................................... 125 \n\n6.2.2.9. Characterization of composite scaffolds ............................................. 126 \n\n6.2.2.10. Statistical analysis ............................................................................ 128 \n\n6.3. Results .......................................................................................................... 128 \n\n6.3.1. Characterization of ACP .......................................................................... 128 \n\n6.3.2. Characterization of ACPs structured scaffolds......................................... 129 \n\n6.3.3. Characterization of the composite scaffolds ............................................ 132 \n\n6.4. Discussion ..................................................................................................... 136 \n\n\n\nxvi \n\n \n\n6.5. Conclusions ................................................................................................... 140 \n\n6.6. References .................................................................................................... 141 \n\nCAP\u00cdTULO 7 \u2013 STRUCTURATION OF HIGH MOLECULAR WEIGHT HYALURONIC \n\nACID IN MICROPARTICLES OR SPONGES IMPROVES ITS PERFORMANCE WHEN \n\nASSOCIATED TO PLATELET-RICH PLASMA ........................................................... 147 \n\n7.1. Introduction ................................................................................................... 148 \n\n7.2. Experimental Section .................................................................................... 150 \n\n7.2.1. Materials .................................................................................................. 150 \n\n7.2.2. Methods ................................................................................................... 151 \n\n7.2.2.1. Preparation and characterization of HA crosslinked with BDDE ......... 151 \n\n7.2.2.2. Preparation of structured HA-BDDE ................................................... 151 \n\n7.2.3. Characterization of the structures ............................................................ 151 \n\n7.2.3.1. mHA-BDDE ........................................................................................ 152 \n\n7.2.3.2. sHA-BDDE ......................................................................................... 153 \n\n7.2.4. PRP preparation and activation ............................................................... 154 \n\n7.2.5. Release of growth factors ........................................................................ 154 \n\n7.2.6. Association of mHA-BDDE or sHA-BDDE with P-PRP and h-AdMSCs-\n\nseeding .............................................................................................................. 155 \n\n7.2.7. h-AdMSCs cultivation .............................................................................. 155 \n\n7.2.8. Images of the cell-seeded composite scaffolds ....................................... 156 \n\n7.2.9. Induction of osteogenic differentiation ..................................................... 156 \n\n7.2.10. Alkaline phosphatase activity (ALP) ....................................................... 156 \n\n7.2.11. Statistical analysis ................................................................................. 157 \n\n7.3. Results and Discussion ................................................................................. 157 \n\n7.3.1. Experimental design ................................................................................ 157 \n\n7.3.2. Chemical modifications ............................................................................ 157 \n\n7.3.3. Physicochemical and mechanical properties of HA forms ....................... 158 \n\n7.3.3.1. mHA-BDDE ........................................................................................ 159 \n\n7.3.3.2. sHA-BDDE ......................................................................................... 161 \n\n\n\nxvii \n\n \n\n7.3.4. Effects of the association with P-PRP ...................................................... 162 \n\n7.3.4.1. SEM images ....................................................................................... 162 \n\n7.3.4.2. Release of growth factors ................................................................... 163 \n\n7.3.4.3. Proliferation of h-AdMSCs and ALP activity ....................................... 164 \n\n7.4. Conclusions ................................................................................................... 165 \n\n7.5. References .................................................................................................... 166 \n\nCAP\u00cdTULO 8 \u2013 STERILIZATION OF AUTO-CROSSLINKED HYALURONIC ACID \n\nSTRUCTURED IN MICROPARTICLES OR SPONGES ............................................. 171 \n\n8.1. Introduction ................................................................................................... 172 \n\n8.2. Materials and Methods .................................................................................. 173 \n\n8.2.1. Materials .................................................................................................. 173 \n\n8.2.2. Methods ................................................................................................... 173 \n\n8.2.2.1. Preparation of the HA-ACP scaffolds ................................................. 173 \n\n8.2.2.2. Sterilization Treatments ...................................................................... 174 \n\n8.2.2.3. HA-ACP sponges characterization ..................................................... 175 \n\n8.2.2.4. HA-ACP microparticles characterization ............................................ 175 \n\n8.2.2.5. Sterility Tests ...................................................................................... 175 \n\n8.3. Results and Discussion ................................................................................. 176 \n\n8.3.1. Effects of the treatments on physicochemical properties of the HA-ACP \n\nsponges ............................................................................................................. 176 \n\n8.3.2. Effects of the treatments on physicochemical properties of HA-ACP \n\nmicroparticles .................................................................................................... 178 \n\n8.3.3. Sterility evaluation .................................................................................... 179 \n\n8.4. Conclusion .................................................................................................... 181 \n\n8.5. References .................................................................................................... 181 \n\nCAP\u00cdTULO 9 \u2013 CONCLUS\u00d5ES .................................................................................. 183 \n\n9.1. Conclus\u00f5es ................................................................................................... 183 \n\n9.2. Trabalhos Futuros ......................................................................................... 184 \n\nANEXO 1 ..................................................................................................................... 187 \n\n \n\n\n\nxviii \n\n \n\n  \n\n\n\nxix \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nAo m?? marido Luther, q?? me apoiou em todos os momentos e \u00e0s minhas \n\nfilhas, Laura ? J\u00falia, q?? de uma forma especial ? carinhosa m? deram for\u00e7a ? coragem \n\npara concluir esta jornada. \n\n\n\nxx \n\n \n\n  \n\n\n\nxxi \n\n \n\nAGRADECIMENTOS \n \n\n\u00c0 Professora Dra. Maria Helena Andrade Santana pela oportunidade, orienta\u00e7\u00e3o, \n\ncarinho e confian\u00e7a durante a execu\u00e7\u00e3o deste trabalho. \n\nAo amigo Gilson Barbosa Maia Jr., t\u00e9cnico do Laborat\u00f3rio de Desenvolvimento \n\nde Processos Biotecnol\u00f3gicos (LDPB), pela paci\u00eancia, dedica\u00e7\u00e3o e amizade em todos \n\nos momentos. \n\nAo Professor Dr. Edvaldo Sabadini do Departamento de F\u00edsico-Qu\u00edmica do \n\nInstituto de Qu\u00edmica da Unicamp pela utiliza\u00e7\u00e3o do re\u00f4metro e ao seu aluno de \n\ndoutorado Thiago Heiji Ito pela colabora\u00e7\u00e3o e disponibilidade.  \n\nAo Professor Dr. William Dias Belangero e \u00e0 sua aluna Ana Am\u00e9lia Rodrigues do \n\nLaborat\u00f3rio de Biomateriais em Ortopedia da Faculdade de Ci\u00eancias M\u00e9dicas da \n\nUnicamp pela disponibiliza\u00e7\u00e3o de seu laborat\u00f3rio e pelas an\u00e1lises de citotoxicidade. \n\n\u00c0 Dra. \u00c2ngela Cristina Malheiros Luzo e \u00e0 funcion\u00e1ria Adriana da Silva Santos \n\nDuarte do Centro de Hematologia e Hemoterapia do Banco de Sangue de Cord\u00e3o \n\nUmbilical e Placent\u00e1rio da Unicamp pela disponibiliza\u00e7\u00e3o de seu laborat\u00f3rio e \n\nisolamento e caracteriza\u00e7\u00e3o das c\u00e9lulas mesenquimais. \n\nAo Dr. Jos\u00e9 F\u00e1bio Lana (Instituto de Osso e Cartilagem - IOC) por nos instigar a \n\nestudar esse assunto. \n\n\u00c0 Profa. Dra. Mariana Altenhofen da Silva, do Centro de Ci\u00eancias Agr\u00e1rias (CCA) \n\nda UFSCAR, pelo carinho em participar de todas as minhas bancas de qualifica\u00e7\u00e3o e \n\ndefesa do mestrado e doutorado. \n\nAos meus colegas do LDPB Amanda, Bruna, Fernanda, Yara, Patr\u00edcia, Rafaela, \n\nRhelvis. Em especial \u00e0 minha querida amiga Sofia Elisa Moraga Galdames que me \n\napoiou em todos os momentos bons e ruins deste trabalho. Obrigada amiga, voc\u00ea \n\ntornou isso bem mais leve e engra\u00e7ado. \n\n\u00c0s minhas amigas do Laborat\u00f3rio de Nano &amp; Biotecnologia para \n\nDesenvolvimentos Avan\u00e7ados (LaNBda), Caroline, Micaela, Aline e Lucimara. \n\nAos meus alunos de Inicia\u00e7\u00e3o Cient\u00edfica, Rafael Lichy, Isabela Cambraia de \n\nSouza Brissac e Lucas Martins Pina pela ajuda e principalmente para imensa paci\u00eancia. \n\n\n\nxxii \n\n \n\nAo meu marido Luther, pelo amor, incentivo, dedica\u00e7\u00e3o, paci\u00eancia, apoio e \n\ncompreens\u00e3o em todos os momentos. Sem voc\u00ea nada disso teria se realizado. \n\nAs minhas filhas Laura e J\u00falia, pelas f\u00e9rias perdidas, pelas incont\u00e1veis horas no \n\nlaborat\u00f3rio, pela compreens\u00e3o, amor e paci\u00eancia. \n\nEm especial \u00e0 minha querida amiga Aline Mara Barbosa Pires, aluna de p\u00f3s-\n\ndoutorado da Universidade Federal do Rio de Janeiro (UFRJ) que mesmo de muito \n\nlonge, me apoiou e incentivou em todos os momentos. Obrigada sempre. \n\nA toda minha fam\u00edlia, pelo apoio e incentivo. Em especial, quero agradecer \n\nminha tia Therezinha Zani pelo amor, apoio e pela torcida em todos os momentos mais \n\nimportantes da minha vida.  \n\nAo Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico (CNPq) pelo \n\nfinanciamento. \n\n  \n\n\n\nxxiii \n\n \n\nLISTA DE FIGURAS \n \n\nFigura 1. Disciplinas que contribuem atualmente na medicina regenerativa (Daar &amp; \n\nGreenwood, 2007). ........................................................................................................... 7 \n\nFigura 2. Tri\u00e2ngulo da prolifera\u00e7\u00e3o celular (Adaptado de Barnett &amp; Pomeroy, 2007; \n\nCrane &amp; Everts, 2008). ..................................................................................................... 8 \n\nFigura 3. Ilustra\u00e7\u00e3o esquem\u00e1tica da arquitetura da matriz e das c\u00e9lulas das quatro \n\ncategorias de concentrados de plaquetas classificados segundo Ehrenfest et al. (2009). \n\nP-PRP=plasma rico em plaquetas puro; L-PRP=plasma rico em plaquetas e leuc\u00f3citos; \n\nP-PRF=fibrina rica em plaquetas pura e L-PRF=fibrina rica em plaquetas e leuc\u00f3citos.\n\n ....................................................................................................................................... 10 \n\nFigura 4. Mecanismo de a\u00e7\u00e3o do PRP (Mishra et al., 2012). ........................................ 11 \n\nFigura 5. Estrutura molecular do \u00e1cido hialur\u00f4nico. ....................................................... 16 \n\nFigura 6. Grupos de modifica\u00e7\u00e3o qu\u00edmica da mol\u00e9cula de AH: (1) carbox\u00edlico, (2) \n\nhidrox\u00edlico, (3) acetamida, (4) Terminal Reduzido do Pol\u00edmero (Adaptado de Garg &amp; \n\nHales, 2004). .................................................................................................................. 17 \n\nFigura 7.  Prepara\u00e7\u00e3o de ACP por autoesterifica\u00e7\u00e3o organocatalisada usando o \n\nintermedi\u00e1rio ativado AH-CPMI (Schant\u00e9 et al., 2011). .................................................. 19 \n\nFigura 8. \u00c1cido hialur\u00f4nico reticulado com BDDE em meio alcalino (Malson &amp; Lindqvist, \n\n1986). ............................................................................................................................. 20 \n\nFigura 9. Estrutura molecular da quitosana. .................................................................. 21 \n\nFigure 10. SEM micrographs of PCHTs. Cross-sectional morphologies of (a) PCHTs 1% \n\n(?20\u00b0C); (b) PCHTs 2% (?20\u00b0C); (c) PCHTs 3% (?20\u00b0C); (d) PCHTs 3% (?80\u00b0C); and \n\n(e) PCHTs 3% (?196\u00b0C). Original magnification is \u00d7100 and the scale bar represents \n\n200 \u00b5m. .......................................................................................................................... 52 \n\nFigure 11. The weight loss of scaffolds with time in PBS at 37\u00b0C as a percentage of the \n\noriginal weight of the scaffold (? = 3). The data are plotted with the mean \u00b1 standard \n\n\n\nxxiv \n\n \n\nerror. (?) PCHTs 1% (?20\u00b0C); (?) PCHTs 2% (?20\u00b0C); (?) PCHTs 3% (?20\u00b0C); (?) \n\nPCHTs 3% (?80\u00b0C); and (?) PCHTs 3% (?196\u00b0C). ....................................................... 56 \n\nFigure 12. Proliferation of h-AdMSCs exposed to the PCHTs scaffolds after 24 hours of \n\ncultivation. Negative control (NTC) = DMEM with 10%FBS; positive control (PTC) \n\n=DMEM with phenol 0.5%. Mean \u00b1 standard deviation ? = 3. The population means are \n\nsignificantly different from positive control at *? &lt;0.05. ................................................. 57 \n\nFigure 13. Scanning electron microscopic images of ?P-PRP/PCHTs after 5 days of \n\ncultivation of h-AdMSCs. (a) ?-PRP; (b) ?P-PRP/PCHTs 1% (?20\u00b0C); (c) ?P-\n\nPRP/PCHTs 2% (?20\u00b0C); (d) ?P-PRP/PCHTs 3% (?20\u00b0C); (e) ?P-PRP/PCHTs 3% \n\n(?80\u00b0C); and (f) ?P-PRP/PCHTs 3% (?196\u00b0C). Original magnification is \u00d75,000 and the \n\nscale bar represents 3 \u00b5m. ............................................................................................. 58 \n\nFigure 14. Release profiles of growth factors from ?P-PRP in porous chitosan scaffolds \n\nas a function of [(a), (b)] chitosan concentrations and [(c), (d)] freezing conditions. (?) \n\nPCHTs 1% (?20\u00b0C); (?) PCHTs 2% (?20\u00b0C); (?) PCHTs 3% (?20\u00b0C); (?) PCHTs 3% \n\n(?80\u00b0C), (O) PCHTs 3% (?196\u00b0C), and (?) P-PRP activated with Ca+2/thrombin (used \n\nas control); TGF-?1 [(a), (c)]; and PDGF-AB [(b), (d)]. The concentration of platelets in \n\nP-PRP was 472,250 pq/mm3. Activated P-PRP alone was used as control. .................. 59 \n\nFigure 15. Proliferation kinetic profiles of h-AdMSCs seeded in ?P-PRP/PCHTs. (a) \n\nCHT concentration and (b) freezing conditions. (?) PCHTs 1% (?20\u00b0C); (?) PCHTs 2% \n\n(?20\u00b0C); (?) PCHTs 3% (?20\u00b0C); (?) PCHTs 3% (?80\u00b0C), (O) PCHTs 3% (?196\u00b0C), \n\nand (?) P-PRP activated with Ca+2/thrombin (control). The concentration of platelets in \n\nP-PRP was 374,000 pq/mm3. Activated P-PRP alone was used as control. .................. 60 \n\nFigure 16. ALP activities of cells cultured on ?P-PRP/PCHTs scaffolds prepared with \n\ndifferent CHT concentrations and freezing conditions (statistically significant differences \n\nfrom blank, ? = 3, *? &lt;0.05). Blank = the reagents used in the assay only. The \n\nconcentration of platelets in whole blood donors (average of 2 donors) was 163,500 \n\npq/mm3. After preparation of the PRP, the platelets were concentrated approximately \n\n1.74 times, with an average final concentration of 303,000 pq/mm3. ............................. 61 \n\nFigure 17. ATR-FTIR spectra of SPCHTs/TNaOH, SPCHTs/TEtOH, SPCHTs/CTPP and \n\nNTPCHTs. ...................................................................................................................... 80 \n\nFigure 18. Physicochemical and mechanical properties of the PCHTs. (a) Photographs \n\n\n\nxxv \n\n \n\nand SEM micrographs of the cross-section of the scaffolds. Original magnification is \n\n\u00d7100 and the scale bar represents 200 \u00b5m. (b) Young\u2019s moduli and pore size; (c) \n\nPorosity (*The means difference are significant at level at p<0.05); (d) Swelling profile in \n\nPBS pH 7.4 at 37\u00b0C; (e) Degradation profile in PBS pH 7.4 at 37\u00b0C expressed as weight \n\nloss. Values are the mean \u00b1 standard deviation. (?) SPCHTs/TNaOH; (?) \n\nSPCHTs/TEtOH; (?) SPCHTs/CTPP and (?) NTPCHTs. ............................................. 84 \n\nFigure 19. (a) SEM images of cells on aP-PRP/SPCHTs after 5 days of culture. Scale \n\nbars indicate 3 \u00b5m (magnification = 5,000x). (b) The compatibility of h-AdMSCs that \n\nwere exposed to SPCHTs. Negative control (NTC) = DMEM with 10% FBS; positive \n\ncontrol (PTC) = DMEM with phenol 0.5%. Mean \u00b1 standard deviation n = 3. The \n\npopulation means are significantly different from the positive control at *p<0.05. (c) \n\nProliferation profile of h-AdMSCs cultured in aP-PRP/SPCHTs as a function of time. aP-\n\nPRP and NTPCHTs were used as controls. Platelets were concentrated in aP-PRP at \n\napproximately 1.84 times the basal value. The average concentration was 393,000 \n\npq/mm3. (d) PDGF-AB release profile from aP-PRP/SPCHTs. Platelets were \n\nconcentrated in aP-PRP at approximately 2.09 times the basal value. The average \n\nconcentration was 472,250 pq/mm3. (e) TGF-?1 release profile from aP-PRP/PCHTs. \n\nPlatelets were concentrated in aP-PRP at approximately 2.09 times the basal value. The \n\naverage concentration was 472,250 pq/mm3. (f) ALP activity of cells cultured on \n\nSPCHTs (statistically significant differences from blank, n=3, *p<0.05). NTPCHTs is the \n\ncontrol group, blank = the reagents used in the assay only. Platelets were concentrated \n\nin aP-PRP at approximately 1.79 times the basal value. The average concentration was \n\n280,500 pq/mm3. (?) aP-PRP and (?) NTPCHT were both used as controls; (?) \n\nSPCHTs/TEtOH; (?) SPCHTs/TNaOH, and (?) SPCHTs/CTPP. .................................. 87 \n\nFigure 20. Interaction of chitosan with TPP by (a) ionic crosslinking or (b) deprotonation.\n\n ..................................................................................................................................... 104 \n\nFigure 21. FTIR spectrum of pure chitosan and iCHT-TPPs 2:1. ................................ 105 \n\nFigure 22. Degradation profile of iCHT-TPPs in PBS pH 7.4 at 37\u00b0C. (?) iCHT-TPPs \n\n2:1; (?) iCHT-TPPs 5:1 and (?) iCHT-TPPs 10:1. ....................................................... 107 \n\nFigure 23. Growth factor release profiles from aP-PRP combined with CHT-TPP \n\nscaffolds. (a) PDGF-AB and (b) TGF-?1. (?) PRP activated with Ca+2/serum used as \n\ncontrol; (?) aP-PRP/iCHT-TPPs 2:1; (?) aP-PRP/iCHT-TPPs 5:1 and (?) aP-PRP-iCHT-\n\n\n\nxxvi \n\n \n\nTPPs 10:1. The concentration of platelets in whole blood donors (average of 2 donors) \n\nwas 234,250 pq/mm3. After preparation of the P-PRP, the platelets were concentrated \n\napproximately 2.09 times, with an average final concentration of 472,250 pq/mm3. .... 109 \n\nFigure 24. Scanning electron microscopic images of aP-PRP and aP-PRP/iCHT-TPPs \n\nafter 5 days of cultivation of h-AdMSCs........................................................................ 110 \n\nFigure 25. (a) % of NTC as a measurement of the compatibility of h-AdMSCs that were \n\nexposed to the iCHT-TPPs. Negative control (NTC) = DMEM with 10% FBS; positive \n\ncontrol (PTC) = DMEM with phenol 0.5%. The population means are significantly \n\ndifferent from positive control at *p<0.05. (b) Proliferation profile of h-AdMSCs cultured \n\nin aP-PRP/iCHT-TPPs scaffolds as a function of time. Activated PRP was used as \n\ncontrol. (?) aP-PRP; (?) aP-PRP/iCHT-TPPs 2:1; (?) aP-PRP/iCHT-TPPs 5:1 and (?) \n\naP-PRP/iCHT-TPPs 10:1. The concentration of platelets in whole blood donors (average \n\nof 2 donors) was 215,375 pq/mm3. After preparation of the P-PRP, the platelets were \n\nconcentrated approximately 1.79 times, with an average final concentration of 383,500 \n\npq/mm3. Mean \u00b1 standard deviation n = 3. ................................................................... 111 \n\nFigure 26. ALP activities of h-AdMSCs cultured on composite scaffolds (*statistically \n\nsignificant differences from blank, n=3, p<0.05). Blank = the reagents used in the assay \n\nonly). The concentration of platelets in whole blood donors (average of 2 donors) was \n\n214,000 pq/mm3. After preparation of the P-PRP, the platelets were concentrated \n\napproximately 2.31 times, with an average final concentration of 473,500 pq/mm3. .... 112 \n\nFigure 27. Auto-crosslinking reaction using CMPI-activated HA intermediate (Schant\u00e9 et \n\nal., 2011). ..................................................................................................................... 122 \n\nFigure 28. ATR-FTIR spectra of ACP with 5% of carboxylic groups esterified. ........... 128 \n\nFigure 29. (a) Oscillation spectrum and (b) flow curve of (?) ACP Microparticles and (?) \n\nfluid HA (1% wt.). G\u2019 (closed symbol) and G\u201d (open symbol). ....................................... 129 \n\nFigure 30. Figure 4. SEM micrographs of cross-sectional of (a) ACP sponges and (b) \n\nHA sponge. ................................................................................................................... 131 \n\nFigure 31. (a) Viability of h-AdMSCs exposed to the structured ACP or HA (fluid and \n\nsponge). Negative control (NTC) = DMEM with 10% FBS; positive control (PTC) = \n\nDMEM with phenol 0.5%. Mean \u00b1 standard deviation n = 3. The population means are \n\n\n\nxxvii \n\n \n\nsignificantly different from the positive control at *p<0.05. (b) The weight remaining of \n\nthe structured ACP under the time course of degradation (at 37\u00b0C, in PBS). (?) ACP \n\nmicroparticles and (?) ACP sponges........................................................................... 132 \n\nFigure 32. Growth factor release profiles from P-PRP combined with HA and ACP \n\nstructured scaffolds. (a) PDGF-AB and (b) TGF-?1. (?) ACP microparticles; (?) fHA; (?) \n\nP-PRP alone; (?) ACP sponges and (?) sHA. The concentration of platelets in P-PRP \n\nwas 407,000 pq/mm3. ................................................................................................... 133 \n\nFigure 33. The proliferation profiles of h-AdMSCs cultured in structured HA and ACP \n\ncomposite scaffolds as a function of time. (a) Microparticles (concentration of platelets in \n\nP-PRP = 393,000 pq/mm3) and (b) sponges (concentration of platelets in P-PRP = \n\n472,250 pq/mm3). Activated P-PRP alone was used as control. .................................. 134 \n\nFigure 34. Scanning electron microscopy images of HA and ACP composite scaffolds \n\nafter 5 days of cultivation of h-AdMSCs. (a) ACP microparticles; (b) fluid HA; (c) ACP \n\nsponges and (d) HA sponge. Original magnification is \u00d75,000 and the scale bar \n\nrepresents 3 \u00b5m. .......................................................................................................... 135 \n\nFigure 35. Alkaline phosphatase (ALP) activity of h-AdMSCs-seeded cultured in the HA \n\nand ACP composite scaffolds on day 14. Blank = the reagents used in the assay only. \n\nStatistically significant differences from blank, n=3, *p<0.05. The concentration of \n\nplatelets in P-PRP was 473,500 pq/mm3. ..................................................................... 135 \n\nFigure 36. (a) The weight remaining of the HA-BDDE structures under the time course \n\nof degradation (At 37\u00b0C, in PBS). (?) sHA-BDDE and (?) mHA-BDDE. (b) Viability of h-\n\nAdMSC exposed to the HA-BDDE structures, sHA and fHA for 24 hours. Negative \n\ncontrol (NTC) = DMEM with 10% FBS; positive control (PTC) = DMEM with phenol \n\n0.5%. Mean \u00b1 standard deviation n = 3. The population means are significantly different \n\nfrom positive control at p<0.05. .................................................................................... 159 \n\nFigure 37. (a) Oscillation spectrum of mHA-BDDE and mHA-BDDE/aP-PRP. (?) aP-\n\nPRP; (?) mHA-BDDE; ( ) mHA-BDDE/aP-PRP 2:1; (?) mHA-BDDE/aP-PRP 1:1; (?) \n\nmHA-BDDE/aP-PRP 1:2. G\u2019 (closed symbol) and G\u201d (open symbol). (b) Shear viscosity \n\nspectra of (?) fluid HA (1% wt.) and (?) mHA-BDDE. .................................................. 160 \n\nFigure 38. Scanning electron micrographs. Cross-section morphologies of (a) HA-BDDE \n\nscaffold and (b) sHA. .................................................................................................... 162 \n\n\n\nxxviii \n\n \n\nFigure 39. Scanning electron microscopic images of aP-PRP/HA-BDDE scaffolds after \n\n5 days of cultivation of h-AdMSCs. Microparticles: (a) magnification of 2,500X and (b) \n\nmagnification of 10,000X. Sponges: (c) magnification of 1,000X and (d) magnification of \n\n10,000X. ....................................................................................................................... 163 \n\nFigure 40. Growth factor release profile from PRP combined with HA-BDDE scaffolds. \n\nPDGF-AB (a) and TGF-?1 (b). (?) PRP activated with serum/Ca+2 was used as control; \n\n(?) sHA-BDDE; (?) mHA-BDDE. The GFs were measurements from activated P-PRP \n\ncontaining average platelet concentration 495,000 pq/mm3. ........................................ 164 \n\nFigure 41. (a) Kinetic proliferation profiles of h-AdMSCs seeded in aP-PRP/HA-BDDE \n\nscaffolds structured in sponges and microparticles. aP-PRP was used as control. The \n\nconcentration of platelets in P-PRP was 273,000 pq/mm3. (b) ALP activities of cells \n\ncultured on aP-PRP/HA-BDDE scaffolds structured in sponges and microparticles \n\n(statistically significant differences from blank, n=3, *p<0.05). Blank = the colorimetric \n\nreagent used in the assay only. The concentration of platelets in whole blood donors \n\n(average of 2 donors) was 468,500 pq/mm3. ................................................................ 165 \n\nFigure 42. SEM cross-section images of HA-ACP sponges. (a) Unsterile; (b) UV (5 cm); \n\n(c) UV (60 cm); (d) Plasma and (e) Ethanol disinfection. Bar = 100 \u00b5m. ...................... 176 \n\nFigure 43. (a) FT-IR spectra and (b) DSC of HA-ACP sponges after the different \n\ntreatments. (1) Unsterile; (2) UV irradiation (5 cm); (3) UV irradiation (60 cm); (4) plasma \n\nradiation and (5) ethanol disinfection. ........................................................................... 177 \n\nFigure 44. Rheological characterization of HA-ACP microparticles after treatment in \n\nautoclave at 126\u00b0C, under a vapor pressure of 1.5 kgf/cm2 for: (?) 0 minute; (?) 1 \n\nminute; (?) 2.5 minutes; (?) 5 minutes; ( ) 10 minutes and ( ) 15 minutes. (a) \n\nOscillation spectrum and (b) flow curves. G\u2019 (closed symbol) and G\u201d (open symbol) \n\nmoduli. .......................................................................................................................... 178 \n\nFigure 45. Rheological characterization of HA-ACP microparticles after the treatments: \n\n(?) untreated; (?) UV1; (?) UV2; (?) plasma and ( ) ethanol disinfection. (a) Oscillation \n\nspectrum and (b) flow curves. G\u2019 (closed symbol) and G\u201d (open symbol) moduli. ........ 179 \n\n  \n\n\n\nxxix \n\n \n\nLISTA DE TABELAS \n \n\nTable 1. Physicochemical characterization of PCHTs. ................................................... 54 \n\nTable 2. Physicochemical and mechanical properties of iCHT-TPPs. ......................... 106 \n\nTable 3. Properties of fHA, sHA, and structured ACP (microparticles and sponges). .. 130 \n\nTable 4. Physicochemical and mechanical properties of HA in the forms: free (fHA), \n\nstructured in sponge (sHA), crosslinked with BDDE and structured in sponges (sHA-\n\nBDDE) or microparticles (mHA-BDDE)......................................................................... 158 \n\nTable 5. Results of heterotrophic plate count (bacteria) and fungal count (molds and \n\nyeasts) obtained after treatment of HA-ACP sponges. ................................................. 180 \n\nTable 6. Results of heterotrophic plate count (bacteria) and fungal count (molds and \n\nyeasts) obtained after sterilization of HA-ACP microparticles. ...................................... 180 \n \n\n \n\n  \n\n\n\nxxx \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\nxxxi \n\n \n\nLISTA DE ABREVIA\u00c7\u00d5ES DA REVIS\u00c3O \nBIBLIOGR\u00c1FICA \n \n\n \n\nACP.............................................................................................Auto-crosslinked polymer \n\nACPs...........................................................Scaffolds de \u00e1cido hialur\u00f4nico autorreticulado \n\naP-PRP.........................................................................Plasma rico em plaquetas ativado \n\nBDDE.......................................................................................1,4-butanodiol diglicidil \u00e9ter \n\nbFGF..............................................................Fator de crescimento de fibroblastos b\u00e1sico \n\nBMP-2....................................................................................Prote\u00edna morfog\u00eanica \u00f3ssea \n\nCHT.....................................................................................................................Quitosana \n\nCMPI................................................................................Iodeto de 2-cloro-1-metilpirid\u00ednio \n\nDMF.........................................................................................................Dimetilformamida \n\nDMSO.........................................................................................................Dimetilsulf\u00f3xido \n\nEGF......................................................................................Fator de crescimento epitelial \n\nFCs................................................................................................Fatores de crescimento \n\nFTC...........................................................................................................Fosfato tric\u00e1lcico \n\nGD...................................................................................................Grau de desacetila\u00e7\u00e3o \n\nGlcNAc................................................................................................N-acetilglucosamina \n\nGlcUA..................................................................................................\u00c1cido D-glucur\u00f4nico \n\nHA-BDDE.......Scaffolds de \u00e1cido hialur\u00f4nico reticulado com 1,4-butanodiol diglicidil \u00e9ter \n\nh-AdMSCs................C\u00e9lulas tronco mesenquimais derivadas de tecido adiposo humano \n\niCHT-TPPs...................................Scaffolds injet\u00e1veis de quitosana-tripolifosfato de s\u00f3dio \n\nIGF.................................................................Fator de crescimento semelhante \u00e0 insulina \n\nL-PRF......................................................................Fibrina rica em plaquetas e leuc\u00f3citos \n\nL-PRP..............................................................Plasma rico em plaquetas e em leuc\u00f3citos \n\nMM.......................................................................................................Massa molar m\u00e9dia \n\n\n\nxxxii \n\n \n\nMSCs....................................................................................C\u00e9lulas tronco mesenquimais \n\nPCHTs...............................................................................Scaffolds porosos de quitosana \n\nPDGF-AB.......................................................fator de crescimento derivado de plaquetas \n\nPECs.........................................................................................Complexos polieletrol\u00edticos \n\nPPP........................................................................................Plasma pobre em plaquetas \n\nP-PRF.................................................................................Fibrina rica em plaquetas pura \n\nP-PRP................................................................................Plasma rico em plaquetas puro \n\nPRP............................................................................................Plasma rico em plaquetas \n\nSer.................................................................................................................Soro aut\u00f3logo \n\nSPCHTs......................................................Scaffolds porosos de quitosana estabilizados \n\nTBA...........................................................................................................Tetrabutilam\u00f4nio \n\nTGF-?1.............................................................fator de crescimento transformador beta 1 \n\nTPP..................................................................................................Tripolifosfato de s\u00f3dio \n\nVEGF..................................................................Fator de crescimento endotelial vascular \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n1 \n\n \n\nCAP\u00cdTULO 1 \u2013 INTRODU\u00c7\u00c3O \n \n\n1.1. Apresenta\u00e7\u00e3o \n\n \n\nO presente trabalho foi redigido na forma de cap\u00edtulos, contendo uma introdu\u00e7\u00e3o \n\ngeral (Cap\u00edtulo 1), o objetivo e uma revis\u00e3o bibliogr\u00e1fica (Cap\u00edtulo 2) direcionada para \n\nos principais fundamentos considerados no desenvolvimento do trabalho.  \n\nO desempenho individual dos scaffolds estudados, assim como as metodologias, \n\nos resultados e as conclus\u00f5es espec\u00edficas est\u00e3o apresentados na forma de artigos \n\ncient\u00edficos submetidos a peri\u00f3dicos internacionais e na forma de uma patente cujo \n\nabstract tamb\u00e9m \u00e9 apresentado em anexo neste trabalho. \n\n \n\nCAP\u00cdTULO 3 \u2013 PERFORMANCE OF PRP ASSOCIATED WITH POROUS CHITOSAN \n\nAS A COMPOSITE SCAFFOLD FOR REGENERATIVE MEDICINE (artigo publicado \n\nem fevereiro de 2015 no peri\u00f3dico The Scientific World Journal). \n\n \n\nCAP\u00cdTULO 4 \u2013 STABILIZATION OF POROUS CHITOSAN IMPROVES THE \n\nPERFORMANCE OF ITS ASSOCIATION WITH PLATELET-RICH PLASMA AS A \n\nCOMPOSITE SCAFFOLD (artigo submetido ao peri\u00f3dico Materials Science and \n\nEngineering C: Materials for Biological Applications). \n\n \n\nCAP\u00cdTULO 5 \u2013 IN VITRO BIOLOGICAL PERFORMANCE OF INJECTABLE \n\nCHITOSAN-TRIPOLYPHOSPHATE SCAFFOLDS COMBINED WITH PLATELET-\n\nRICH PLASMA (artigo submetido ao peri\u00f3dico Tissue Engineering and Regenerative \n\nMedicine). \n\n \n\nCAP\u00cdTULO 6 \u2013 IMPROVEMENTS IN PLATELET-RICH PLASMA PERFORMANCE BY \n\nASSOCIATION WITH MICROPARTICLES OR SPONGES OF AUTO-CROSSLINKED \n\nHYALURONIC ACID (artigo submetido ao peri\u00f3dico Journal of Applied Polymer \n\nScience). \n\n \n\nCAP\u00cdTULO 7 \u2013 THE STRUCTURATION OF HIGH MOLECULAR WEIGHT \n\nHYALURONIC ACID IN MICROPARTICLES OR SPONGES IMPROVES ITS \n\n\n\n2 \n\n \n\nPERFORMANCE WHEN ASSOCIATED TO PLATELET-RICH PLASMA (artigo \n\nsubmetido ao peri\u00f3dico Trends in Biomaterials &amp; Artificial Organs). \n\n \n\nCAP\u00cdTULO 8 \u2013 STERILIZATION OF AUTO-CROSSLINKED HYALURONIC ACID \n\nSTRUCTURED IN MICROPARTICLES OR SPONGES (artigo submetido ao peri\u00f3dico \n\nBiotechnology Letters). \n\n \nANEXO 1 \u2013 COMPOSI\u00c7\u00c3O E FORMULA\u00c7\u00c3O DE SCAFFOLDS DE \u00c1CIDO \n\nHIALUR\u00d4NICO E QUITOSANA PARA ASSOCIA\u00c7\u00c3O COM PLASMA RICO EM \n\nPLAQUETAS E SEUS USOS EM TERAPIA REGENERATIVA somente abstract).  \n\n \n\nO \u00faltimo cap\u00edtulo (Cap\u00edtulo 9) apresenta as conclus\u00f5es gerais comparativas entre \n\nos desempenhos dos scaffolds e as sugest\u00f5es para trabalhos futuros.  \n\n \n\n1.2. Relev\u00e2ncia do Trabalho \n\n \n\nO aumento da expectativa de vida, o mau funcionamento e/ ou a perda de \n\ntecidos causados por les\u00f5es ou por doen\u00e7as, t\u00eam levado \u00e0 redu\u00e7\u00e3o da qualidade de \n\nvida de muitos pacientes e a um aumento do custo socioecon\u00f4mico. Mesmo com o \n\nprogresso da engenharia de tecidos e da medicina regenerativa, as terapias atuais \n\nainda apresentam in\u00fameras limita\u00e7\u00f5es.  \n\nAssim, o desenvolvimento de matrizes tridimensionais (scaffolds) combinadas \n\ncom diferentes tipos de c\u00e9lulas e mol\u00e9culas bioativas com atividades espec\u00edficas tem se \n\ntornado uma alternativa atrativa aos tratamentos atuais. \n\nA obten\u00e7\u00e3o de scaffolds biodegrad\u00e1veis onde c\u00e9lulas espec\u00edficas possam \n\ncrescer e se multiplicar em uma estrutura similar aos tecidos \u00e9 a base da engenharia de \n\ntecidos, que constitui um ramo da medicina regenerativa.  \n\nO principal objetivo de um scaffold \u00e9 mimetizar a matriz extracelular nativa do \n\ntecido desejado, permitindo ades\u00e3o, migra\u00e7\u00e3o, prolifera\u00e7\u00e3o, diferencia\u00e7\u00e3o e \n\nmanuten\u00e7\u00e3o do fen\u00f3tipo celular. Al\u00e9m disso, um scaffold deve ainda promover a \n\nvasculariza\u00e7\u00e3o e a migra\u00e7\u00e3o de nutrientes, e possuir taxa de degrada\u00e7\u00e3o e \n\npropriedades mec\u00e2nicas adequadas para suportar a forma\u00e7\u00e3o do novo tecido (Langer &amp; \n\nVacanti, 1993; Hutmacher, 2000; Lin et al., 2009). \n\nV\u00e1rias matrizes t\u00eam sido empregadas para a prolifera\u00e7\u00e3o e multiplica\u00e7\u00e3o de \n\ndiferentes c\u00e9lulas progenitoras, incluindo as c\u00e9lulas-tronco mesenquimais. Entretanto, a \n\n\n\n3 \n\n \n\nmaioria destas matrizes n\u00e3o fornece o ambiente biol\u00f3gico adequado para que as \n\nc\u00e9lulas possam proliferar e se multiplicar de forma semelhante aos sistemas in vivo. O \n\ndesenvolvimento de um scaffold para cultivo celular que seja mecanicamente est\u00e1vel, \n\nbiocompat\u00edvel e biodegrad\u00e1vel e que possa atender a especificidade das c\u00e9lulas que \n\ncomp\u00f5em os diferentes tecidos representa ainda um grande desafio para a engenharia \n\nde tecidos (George et al., 2008).  \n\nOs pol\u00edmeros naturais s\u00e3o os materiais mais atraentes para a prepara\u00e7\u00e3o de \n\nscaffolds, principalmente devido \u00e0s suas semelhan\u00e7as com a matriz extracelular, \n\nversatilidade qu\u00edmica, bom desempenho biol\u00f3gico, e intera\u00e7\u00f5es celulares espec\u00edficas \n\n(Costa-Pinto et al., 2011). \n\nO plasma rico em plaquetas (PRP) \u00e9 um concentrado de plaquetas aut\u00f3logas e \n\nde outros componentes do plasma capaz de liberar fatores de crescimento (FCs) e \n\ncitocinas utilizadas na regenera\u00e7\u00e3o de tecidos (Anitua et al., 2012; Foster et al., 2009). \n\nO PRP tem sido amplamente utilizado com sucesso na pr\u00e1tica cl\u00ednica da medicina \n\nregenerativa (Crane &amp; Everts, 2008; Cole et al., 2010). \n\nQuando ativado com soro aut\u00f3logo (ser) e CaCl2, o PRP produz a rede de fibrina \n\ncom estrutura semelhante a um gel que suporta a prolifera\u00e7\u00e3o e diferencia\u00e7\u00e3o celular, \n\nsendo assim um scaffold natural (Marx, 2004).  \n\nO PRP pode ser aplicado em feridas, na forma s\u00f3lida ou injet\u00e1vel, ou pode ser \n\nutilizado como um suplemento em cirurgias, para promover hemostasia e acelerar a \n\ncicatriza\u00e7\u00e3o atrav\u00e9s da libera\u00e7\u00e3o dos FCs e citocinas (Singh et al., 2014).  \n\nEmbora o PRP seja um scaffold natural eficaz, a libera\u00e7\u00e3o da maior parte dos \n\nFCs ocorre dentro da primeira hora ap\u00f3s a ativa\u00e7\u00e3o plaquet\u00e1ria. Al\u00e9m disso, a rede de \n\nfibrina n\u00e3o apresenta estabilidade mec\u00e2nica adequada para suportar a forma\u00e7\u00e3o do \n\nnovo tecido (McCarrel &amp; Fortier, 2009). \n\nAssim, nossa hip\u00f3tese \u00e9 que a associa\u00e7\u00e3o de PRP com \u00e1cido hialur\u00f4nico (AH) e/ \n\nou quitosana (CHT), produza scaffolds comp\u00f3sitos com melhores propriedades f\u00edsico-\n\nqu\u00edmicas, mec\u00e2nicas e biol\u00f3gicas, que possam promover a libera\u00e7\u00e3o gradual dos FCs e \n\nestimular a prolifera\u00e7\u00e3o e a diferencia\u00e7\u00e3o celular.  \n\nO AH \u00e9 um polissacar\u00eddeo natural linear composto de repetidas unidades \n\ndissacar\u00eddicas de \u00e1cido D-glicur\u00f4nico (GlcUA) e N-acetilglicosamina (GlcNAc) unidas \n\nalternadamente por liga\u00e7\u00f5es glicos\u00eddicas ?-1,3 e ?-1,4 (Ruhela et al., 2006, Meyer &amp; \n\nPalmer, 1934). \n\nAs fun\u00e7\u00f5es e aplica\u00e7\u00f5es do AH na engenharia de tecidos e medicina \n\nregenerativa est\u00e3o associadas basicamente \u00e0s suas propriedades biol\u00f3gicas \n\n\n\n4 \n\n \n\nfavor\u00e1veis, caracter\u00edsticas estruturais, e \u00e0s poss\u00edveis modifica\u00e7\u00f5es qu\u00edmicas do \n\npol\u00edmero, as quais determinam suas propriedades reol\u00f3gicas, de solubilidade, de \n\nhidrata\u00e7\u00e3o e de reconhecimento celular espec\u00edfico.  \n\nEntretanto, a r\u00e1pida degrada\u00e7\u00e3o in vivo e as propriedades mec\u00e2nicas \n\ninadequadas do AH exigem sua modifica\u00e7\u00e3o e/ ou estabiliza\u00e7\u00e3o para aplica\u00e7\u00f5es na \n\nmedicina em especial na medicina regenerativa. \n\nAssim, para a prepara\u00e7\u00e3o de um scaffold comp\u00f3sito de AH com prolongado \n\ntempo de resid\u00eancia in vivo e melhores propriedades mec\u00e2nicas em rela\u00e7\u00e3o ao AH \n\nnativo, foram utilizados o derivado autorreticulado ACP (auto-crosslinked polymers) \n\ncompletamente biocompat\u00edvel e o derivado reticulado com 1,4-butanodiol diglicidil \u00e9ter \n\n(HA-BDDE) que apresenta baixa citotoxicidade em rela\u00e7\u00e3o a outros agentes reticulante \n\ndispon\u00edveis no mercado. O ACP foi preparado atrav\u00e9s de rea\u00e7\u00e3o de autoesterifica\u00e7\u00e3o \n\norganocatalisada na qual \u00e9 formada uma liga\u00e7\u00e3o covalente entre os grupos hidrox\u00edlicos \n\ne carbox\u00edlicos de uma mesma cadeia e/ ou de cadeias diferentes de AH sem a adi\u00e7\u00e3o \n\nde agentes reticulantes t\u00f3xicos (Bellini et al., 2001). O HA-BDDE foi preparado por \n\nrea\u00e7\u00e3o de eterifica\u00e7\u00e3o dos grupos hidrox\u00edlicos do AH com o ep\u00f3xido BDDE em meio \n\nalcalino (Malson &amp; Lindqvist, 1986). \n\nA quitosana \u00e9 um polissacar\u00eddeo derivado da quitina (copol\u00edmeros ?-(1?4)-2-\n\namino 2-desoxi-D-glicose e ?-(1?4)-2-acetamida 2-desoxi-D-glicose) encontrada nas \n\ncarapa\u00e7as de crust\u00e1ceos marinhos e paredes celulares de alguns fungos (Muzzarelli, \n\n1973; Berger et al., 2004). \n\nPropriedades como biodegradabilidade, biocompatibilidade, adesividade, \n\ncapacidade de moldagem em diferentes formas e versatilidade de modifica\u00e7\u00e3o qu\u00edmica \n\nfazem com que a quitosana seja um biomaterial promissor para diversas aplica\u00e7\u00f5es na \n\nengenharia de tecidos e medicina regenerativa (Adekogbe &amp; Ghanem, 2005; Agnihotri \n\net al., 2004). \n\nA liofiliza\u00e7\u00e3o \u00e9 a t\u00e9cnica mais empregada para a prepara\u00e7\u00e3o de scaffolds de \n\nquitosana. Neste processo, as condi\u00e7\u00f5es de congelamento induzem a separa\u00e7\u00e3o de \n\nfase entre o sal de acetato de quitosana e a fase de cristal de gelo. A remo\u00e7\u00e3o de gelo \n\npor sublima\u00e7\u00e3o gera um material poroso, cujo tamanho e orienta\u00e7\u00e3o dos poros podem \n\nser controlados pela varia\u00e7\u00e3o da temperatura e da taxa de congelamento. Na maioria \n\ndos casos, estes scaffolds podem conter acetato de quitosana que pode levar ao \n\nintumescimento e dissolu\u00e7\u00e3o do scaffold em meio aquoso neutro. Neste caso tamb\u00e9m \u00e9 \n\nnecess\u00e1ria modifica\u00e7\u00e3o ou estabiliza\u00e7\u00e3o, realizadas normalmente por reidrata\u00e7\u00e3o ou \n\nreticula\u00e7\u00e3o (Shen et al., 2000) com hidr\u00f3xido de s\u00f3dio (Madihally &amp; Matthew, 1999; \n\n\n\n5 \n\n \n\nManjubala et al., 2006), tripolifosfato de s\u00f3dio (TPP) (Seol et al., 2004; Lee et al., 2000) \n\ne/ou s\u00e9rie de etanol (Nwe et al., 2009, Reis et al., 2008). \n\nEmbora existam in\u00fameros trabalhos na literatura utilizando scaffolds de AH e \n\nCHT, combinados ou n\u00e3o, para a regenera\u00e7\u00e3o de diferentes tecidos, estudos avaliando \n\na performance in vitro destes scaffolds combinados ao PRP ainda s\u00e3o escassos.  \n\nAl\u00e9m disso, os poucos trabalhos existentes na literatura enfatizam as aplica\u00e7\u00f5es \n\nin vitro ou in vivo desses scaffolds, ou simplesmente apresentam as suas aplica\u00e7\u00f5es \n\ncl\u00ednicas ou a cin\u00e9tica de libera\u00e7\u00e3o dos FCs do PRP, sem no entanto, estudar a rela\u00e7\u00e3o \n\nestrutura \u2013 fun\u00e7\u00e3o ou a combina\u00e7\u00e3o dos v\u00e9rtices do tri\u00e2ngulo de prolifera\u00e7\u00e3o celular: \n\nscaffolds, c\u00e9lulas e mol\u00e9culas bioativas (Crane &amp; Everts, 2008).  \n\nSendo assim, este trabalho se diferencia dos demais da literatura, pois al\u00e9m da \n\nextensa caracteriza\u00e7\u00e3o f\u00edsico-qu\u00edmica e mec\u00e2nica dos scaffolds, ele correlaciona essas \n\npropriedades com as capacidades: condutiva dos scaffolds, indutiva do PRP e g\u00eanica \n\ndas c\u00e9lulas tronco mesenquimais derivadas de tecido adiposo humano (h-AdMSCs) \n\nbaseado no tri\u00e2ngulo de prolifera\u00e7\u00e3o celular. \n\nDessa forma, neste trabalho foram preparados e caracterizados scaffolds de AH \n\ne/ou CHT estruturados em micropart\u00edculas ou esponjas, para atender os requisitos de \n\nformula\u00e7\u00f5es injet\u00e1veis ou s\u00f3lidas, respectivamente. Estes scaffolds foram combinados \n\ncom PRP ativado na forma de scaffolds comp\u00f3sitos e avaliados in vitro quanto a \n\ncin\u00e9tica de libera\u00e7\u00e3o de fatores de crescimento (fator de crescimento derivado de \n\nplaquetas (PDGF-AB) e fator de crescimento transformador ?1 (TGF-?1)), prolifera\u00e7\u00e3o \n\nde h-AdMSCs e diferencia\u00e7\u00e3o osteog\u00eanica atrav\u00e9s do marcador fosfatase alcalina \n\n(ALP). \n\n \n\n1.3. Objetivo \n\n \n\nO presente trabalho teve por objetivo estudar o desempenho in vitro do plasma \n\nrico em plaquetas ativado (aP-PRP) associado ao \u00e1cido hialur\u00f4nico e/ou quitosana \n\ncomo um scaffold comp\u00f3sito para a prolifera\u00e7\u00e3o e diferencia\u00e7\u00e3o osteog\u00eanica de c\u00e9lulas \n\ntronco mesenquimais derivadas de tecido adiposo humano (h-AdMSCs). \n\nPara atingir o objetivo mencionado, foram realizadas as seguintes etapas: \n\n? Prepara\u00e7\u00e3o e caracteriza\u00e7\u00e3o do PRP; \n\n? Prepara\u00e7\u00e3o e caracteriza\u00e7\u00e3o de scaffolds porosos s\u00f3lidos (esponjas) de \n\nquitosana n\u00e3o estabilizados (PCHTs), variando a concentra\u00e7\u00e3o de CHT e as \n\ncondi\u00e7\u00f5es de congelamento; \n\n\n\n6 \n\n \n\n? Prepara\u00e7\u00e3o e caracteriza\u00e7\u00e3o de scaffolds porosos s\u00f3lidos (esponjas) de \n\nquitosana estabilizados (SPCHTs); \n\n? Prepara\u00e7\u00e3o e caracteriza\u00e7\u00e3o de scaffolds injet\u00e1veis compostos de \n\nmicropart\u00edculas de quitosana reticulada com tripolifosfato de s\u00f3dio (iCHT-TPPs) \n\nem diferentes raz\u00f5es m\u00e1ssicas; \n\n? Prepara\u00e7\u00e3o e caracteriza\u00e7\u00e3o de scaffolds de \u00e1cido hialur\u00f4nico autorreticulado \n\n(ACPs) estruturados em micropart\u00edculas ou em esponjas. \n\n? Prepara\u00e7\u00e3o e caracteriza\u00e7\u00e3o de scaffolds de \u00e1cido hialur\u00f4nico reticulado com \n\n1,4-butanodiol diglicidil \u00e9ter (HA-BDDE) estruturados em micropart\u00edculas ou em \n\nesponjas. \n\n? Prepara\u00e7\u00e3o e caracteriza\u00e7\u00e3o de scaffolds de ACP e CHT (PECs) em diferentes \n\nraz\u00f5es m\u00e1ssicas, e estruturados em micropart\u00edculas ou em esponjas. \n\n? Avalia\u00e7\u00e3o de diferentes processos de esteriliza\u00e7\u00e3o na estabilidade de scaffolds \n\nde \u00e1cido hialur\u00f4nico autorreticulado (ACPs) estruturados em micropart\u00edculas e \n\nem esponjas. \n\n? Avalia\u00e7\u00e3o da citotoxicidade dos scaffolds; \n\n? Prepara\u00e7\u00e3o de scaffolds comp\u00f3sitos de aP-PRP e scaffolds de \u00e1cido hialur\u00f4nico \n\ne/ou quitosana; \n\n? Avalia\u00e7\u00e3o da cin\u00e9tica de libera\u00e7\u00e3o de fatores de crescimentos nos scaffolds \n\ncomp\u00f3sitos; \n\n? Avalia\u00e7\u00e3o in vitro da performance biol\u00f3gica dos scaffolds comp\u00f3sitos quanto a \n\nprolifera\u00e7\u00e3o e diferencia\u00e7\u00e3o osteog\u00eanica de h-AdMSCs. \n  \n\n\n\n7 \n\n \n\nCAP\u00cdTULO 2 \u2013 REVIS\u00c3O BIBLIOGR\u00c1FICA \n \n\n2.1. Engenharia de Tecidos e Medicina Regenerativa  \n\n \n\nO termo medicina regenerativa vem sendo utilizado muitas vezes como sin\u00f4nimo \n\nde engenharia de tecidos, embora a medicina regenerativa frequentemente implique na \n\nutiliza\u00e7\u00e3o de c\u00e9lulas tronco como fonte de c\u00e9lulas (Berthiaume et al., 2011). \n\nSegundo Greenwood et al. (2006), \u201cmedicina regenerativa \u00e9 um campo \n\ninterdisciplinar (Figura 1) de pesquisa e aplica\u00e7\u00f5es cl\u00ednicas, focado no reparo, \n\nsubstitui\u00e7\u00e3o ou regenera\u00e7\u00e3o de c\u00e9lulas, tecidos ou \u00f3rg\u00e3os visando restaurar fun\u00e7\u00f5es \n\nprejudicadas por defeitos cong\u00eanitos, doen\u00e7as, traumas e envelhecimento e que utiliza \n\na combina\u00e7\u00e3o de v\u00e1rias abordagens tecnol\u00f3gicas que incluem a utiliza\u00e7\u00e3o de mol\u00e9culas \n\nsol\u00faveis, terapia g\u00eanica, terapia com c\u00e9lulas-tronco e progenitoras, engenharia de \n\ntecidos e reprograma\u00e7\u00e3o de c\u00e9lulas e de tecidos\u201d.  \n\n \n\n \n\nFigura 1. Disciplinas que contribuem atualmente na medicina regenerativa (Daar &amp; \n\nGreenwood, 2007). \n\nPor outro lado, \u201cengenharia de tecidos \u00e9 definida como um campo interdisciplinar \n\nMedicina \nRegenerativa\n\nEngenharia \nde Tecidos\n\nCi\u00eancia de \nMateriais\n\nBiologia\n\nTransplante \nde c\u00e9lulas, \ntecidos e \norg\u00e3os\n\nGen\u00e9tica e \nBiologia \n\nMolecular\n\nBiologia de \nC\u00e9lulas\n\n\n\n8 \n\n \n\nque aplica os princ\u00edpios da engenharia e de ci\u00eancias da vida para o desenvolvimento de \n\nsubstitutos biol\u00f3gicos que restauram, mant\u00e9m ou melhoram a fun\u00e7\u00e3o do tecido ou de \n\num conjunto de \u00f3rg\u00e3os\u201d (Langer &amp; Vacanti, 1993). Seu objetivo \u00e9 superar as limita\u00e7\u00f5es \n\ndos tratamentos convencionais com base em transplantes de \u00f3rg\u00e3os.  \n\nA medicina regenerativa e a engenharia de tecidos t\u00eam se tornado campos de \n\npesquisa promissores e importantes, uma vez que podem oferecer alternativas vi\u00e1veis \n\ne menos invasivas para o reparo e regenera\u00e7\u00e3o de \u00f3rg\u00e3os e tecidos (Vindigni et al., \n\n2009).  \n\nA engenharia de tecidos \u00e9 um campo relativamente novo dentro da medicina \n\nregenerativa, que utiliza como base o tri\u00e2ngulo de prolifera\u00e7\u00e3o celular proposto por \n\nCrane &amp; Everts (2008) (Figura 2), o qual \u00e9 composto pelas capacidades indutiva dos \n\nfatores de crescimento, condutiva dos scaffolds e g\u00eanica das c\u00e9lulas tronco ou \n\nprogenitoras.  \n\n \n\n \n\nFigura 2. Tri\u00e2ngulo da prolifera\u00e7\u00e3o celular (Adaptado de Barnett &amp; Pomeroy, 2007; \n\nCrane &amp; Everts, 2008). \n\n \n\n2.2. Plasma Rico em Plaquetas \n\n \n\n2.2.1. Defini\u00e7\u00f5es \n\nPlasma rico em plaquetas (PRP) \u00e9 um produto aut\u00f3logo, preparado a partir do \n\nMol\u00e9culas \nBioativas \n\nC\u00e9lulas Scaffolds\n\nTri\u00e2ngulo\n\nde \n\nProlifera\u00e7\u00e3o \n\nCelular\n\nCapacidade \n\nIndutiva\n\nCapacidade \n\nCondutiva\n\nCapacidade \n\nG\u00eanica\n\n\n\n9 \n\n \n\nsangue total, composto por um concentrado de plaquetas, leuc\u00f3citos e prote\u00ednas, \n\ndisperso em uma pequena fra\u00e7\u00e3o de plasma (Marx et al., 1998; Marx, 2004). \n\nPlaquetas s\u00e3o fragmentos citoplasm\u00e1ticos anucleados presentes no sangue e \n\nproduzidos na medula \u00f3ssea a partir dos megacari\u00f3citos. S\u00e3o os menores \n\ncomponentes do sangue, e apresentam formato irregular e di\u00e2metro de 2-3 \u00b5m. As \n\nplaquetas cont\u00eam um grande n\u00famero de prote\u00ednas, citocinas e outros fatores bioativos, \n\ntais como fatores de crescimento, que iniciam e regulam aspectos b\u00e1sicos da \n\ncicatriza\u00e7\u00e3o de tecidos.  \n\nLeuc\u00f3citos s\u00e3o as c\u00e9lulas brancas do sangue, compostos de linf\u00f3citos, \n\ngranul\u00f3citos e agranul\u00f3citos.  \n\nPlasma \u00e9 a por\u00e7\u00e3o fluida do sangue que cont\u00e9m fatores de coagula\u00e7\u00e3o e outras \n\nprote\u00ednas e \u00edons.  \n\nA contagem normal de plaquetas no sangue \u00e9 de 150.000 a 400.000 \n\nplaquetas/?L (Foster et al., 2009, Engebretsen et al., 2010).  \n\nO plasma rico em plaquetas (PRP) cont\u00e9m uma concentra\u00e7\u00e3o de plaquetas de \n\npelo menos 1.000.000 plaquetas/ ?L em 5 mL de plasma e est\u00e1 associado com a \n\ncicatriza\u00e7\u00e3o. O PRP cont\u00e9m de 1,5 a 7 vezes a concentra\u00e7\u00e3o de FCs do sangue total e \n\n\u00e9 normalmente obtido por centrifuga\u00e7\u00e3o diferencial (Foster et al., 2009). \n\nA libera\u00e7\u00e3o de fatores de crescimento ocorre ap\u00f3s o processo de degranula\u00e7\u00e3o \n\ndas plaquetas. As plaquetas s\u00e3o o primeiro tipo celular recrutado para o local da les\u00e3o e \n\ns\u00e3o respons\u00e1veis pela ativa\u00e7\u00e3o da resposta inflamat\u00f3ria inicial do processo de \n\ncicatriza\u00e7\u00e3o (Cole et al., 2010). \n\nFatores de crescimento (FCs) s\u00e3o mediadores biol\u00f3gicos naturais que exercem \n\nv\u00e1rios efeitos sobre os processos de reparo e de regenera\u00e7\u00e3o. S\u00e3o polipept\u00eddios \n\ncapazes de regular diversos eventos celulares que incluem s\u00edntese de DNA, \n\nquimiotaxia, diferencia\u00e7\u00e3o e s\u00edntese de matriz extracelular. \n\nNo PRP estes fatores de crescimento incluem 3 is\u00f4meros do fator de \n\ncrescimento derivado de plaquetas (PDGF-??, PDGF-?? e PDGF-??), 2 is\u00f4meros do \n\nfator de crescimento transformador ? (TGF-?1 e TGF-?2), o fator de crescimento \n\nendotelial vascular (VEGF), o fator de crescimento semelhante \u00e0 insulina (IGF), o fator \n\nde crescimento de fibroblastos b\u00e1sico (bFGF) e o fator de crescimento epitelial (EGF) \n\n(Cole et al., 2010; Engebretsen et al., 2010).  \n\nV\u00e1rias t\u00e9cnicas para a prepara\u00e7\u00e3o do PRP t\u00eam sido utilizadas gerando diferentes \n\nprodutos com diferentes propriedades biol\u00f3gicas e aplica\u00e7\u00f5es.  \n\nA classifica\u00e7\u00e3o mais atual (Figura 3) \u00e9 a estabelecida por Ehrenfest et al. (2009) \n\n\n\n10 \n\n \n\nde acordo com o conte\u00fado de leuc\u00f3citos e de fibrina: plasma rico em plaquetas puro (P-\n\nPRP): plasma rico em plaquetas e leuc\u00f3citos (L-PRP), fibrina rica em plaquetas pura (P-\n\nPRF) e fibrina rica em plaquetas e leuc\u00f3citos (L-PRF). \n\n \n\n \n\nFigura 3. Ilustra\u00e7\u00e3o esquem\u00e1tica da arquitetura da matriz e das c\u00e9lulas das quatro \n\ncategorias de concentrados de plaquetas classificados segundo Ehrenfest et al. (2009). \n\nP-PRP=plasma rico em plaquetas puro; L-PRP=plasma rico em plaquetas e leuc\u00f3citos; \n\nP-PRF=fibrina rica em plaquetas pura e L-PRF=fibrina rica em plaquetas e leuc\u00f3citos. \n\n \n\n2.2.2. PRP na regenera\u00e7\u00e3o de tecidos  \n\nO plasma rico em plaquetas \u00e9 uma terapia simples, eficiente e minimamente \n\ninvasiva para a obten\u00e7\u00e3o de FCs aut\u00f3logos. Sendo uma prepara\u00e7\u00e3o aut\u00f3loga, o PRP \n\ntem a vantagem de evitar a transmiss\u00e3o de doen\u00e7as e o aparecimento de rea\u00e7\u00f5es \n\nimunog\u00eanicas. \n\nMariani et al. (2014) demonstraram que o PRP pode ser utilizado na inibi\u00e7\u00e3o do \n\ncrescimento bacteriano contra diferentes pat\u00f3genos, fornecendo prote\u00e7\u00e3o adicional \n\ncontra poss\u00edveis contamina\u00e7\u00f5es bacterianas durante interven\u00e7\u00f5es cir\u00fargicas. \n\nNa regenera\u00e7\u00e3o de tecidos, o PRP atua como um selante do tecido e como um \n\ncarreador de fatores de crescimento, onde as plaquetas iniciam a regenera\u00e7\u00e3o do \n\ntecido atrav\u00e9s da libera\u00e7\u00e3o local dos FCs via degranula\u00e7\u00e3o de seus ?-gr\u00e2nulos.  \n\nAs plaquetas no PRP s\u00e3o transportadas atrav\u00e9s de um co\u00e1gulo, que cont\u00e9m \n\nmol\u00e9culas de ades\u00e3o celular incluindo fibronectina, fibrina e vitronectina. Na \n\ncicatriza\u00e7\u00e3o de feridas, este co\u00e1gulo age como uma matriz condutora ou scaffold \n\nnatural sobre o qual as c\u00e9lulas aderem e iniciam o processo de cicatriza\u00e7\u00e3o. \n\n\n\n11 \n\n \n\nAs plaquetas atuam no processo de hemostasia, cicatriza\u00e7\u00e3o de feridas e re-\n\nepiteliza\u00e7\u00e3o. Elas liberam diversos FCs que estimulam a angiog\u00eanese, promovendo \n\ncrescimento vascular e prolifera\u00e7\u00e3o de fibroblastos, que por sua vez proporcionam um \n\naumento na s\u00edntese de col\u00e1geno (Marx, 2004). Al\u00e9m disso, os FCs promovem a \n\nprolifera\u00e7\u00e3o celular e influenciam a diferencia\u00e7\u00e3o atuando diretamente na repara\u00e7\u00e3o e \n\nregenera\u00e7\u00e3o de tecidos (Nguyen et al., 2011) \n\nNos est\u00e1gios iniciais do processo de cicatriza\u00e7\u00e3o (Figura 4), as plaquetas s\u00e3o \n\nativadas na cascata de coagula\u00e7\u00e3o via col\u00e1geno end\u00f3geno, e os fatores de crescimento \n\ne as citocinas s\u00e3o liberados por estas plaquetas ativadas para auxiliar na cicatriza\u00e7\u00e3o. \n\nA sequ\u00eancia de eventos que conduz \u00e0 forma\u00e7\u00e3o do novo tecido (quimiotaxia, migra\u00e7\u00e3o, \n\nprolifera\u00e7\u00e3o e diferencia\u00e7\u00e3o celular) \u00e9 regulada pelos fatores de crescimento, muitos \n\ndos quais est\u00e3o presentes no PRP (Tsay et al., 2005). \n\n \n\n \n\nFigura 4. Mecanismo de a\u00e7\u00e3o do PRP (Mishra et al., 2012). \n\nO processo de cicatriza\u00e7\u00e3o, na qual os fatores de crescimento participam, \n\nRestaura\u00e7\u00e3o e regenera\u00e7\u00e3o \n\ndo tecido\n\nAplica\u00e7\u00e3o do PRP \nin vivo\n\nAtiva\u00e7\u00e3o do PRP \nvia col\u00e1geno \n\nend\u00f3geno\n\nLibera\u00e7\u00e3o de \nfatores de \n\ncrescimento e \ncitocinas\n\nRecrutamento de \nc\u00e9lulas \n\nreparativas\n\nEstimula\u00e7\u00e3o de \nc\u00e9lulas-tronco \n\nlocais e genes de \nmatrix extracelular\n\nInibi\u00e7\u00e3o da \ninflama\u00e7\u00e3o, \napoptose e \n\nmetaloproteinase\n\n\n\n12 \n\n \n\nenvolve tr\u00eas fases interpostas: (1) a fase inflamat\u00f3ria, (2) a fase de prolifera\u00e7\u00e3o e (3) a \n\nfase de matura\u00e7\u00e3o e/ ou de remodela\u00e7\u00e3o.  \n\nA fase inicial ocorre imediatamente ap\u00f3s a les\u00e3o e envolve hemostasia e \n\nrecrutamento de mediadores inflamat\u00f3rios com dura\u00e7\u00e3o de aproximadamente 1 \n\nsemana. A les\u00e3o tecidual ativa a ciclooxigenase-2 e leva \u00e0 vasodilata\u00e7\u00e3o. Os FCs \n\natraem os macr\u00f3fagos e fibroblastos. A fase de prolifera\u00e7\u00e3o permanece durante as 2 \n\nsemanas seguintes com forma\u00e7\u00e3o de matriz extracelular, granula\u00e7\u00e3o, contra\u00e7\u00e3o e \n\nreepiteliza\u00e7\u00e3o. A fase de remodelagem continua at\u00e9 que a produ\u00e7\u00e3o de col\u00e1geno e do \n\ntecido de cicatriza\u00e7\u00e3o seja finalizada. Esta fase pode durar at\u00e9 1 ano e nela o col\u00e1geno \n\ntipo I substitui os proteoglicanos e a fibronectina para formar uma matriz mais forte com \n\nmaior resist\u00eancia \u00e0 tra\u00e7\u00e3o (Nguyen et al., 2011). \n\nEmbora os mecanismos envolvidos na utiliza\u00e7\u00e3o do PRP ainda n\u00e3o estejam \n\ncompletamente elucidados, sua f\u00e1cil aplica\u00e7\u00e3o na pr\u00e1tica cl\u00ednica e seu poss\u00edvel \n\nresultado ben\u00e9fico tornam o PRP uma promissora ferramenta para a \u00e1rea m\u00e9dica \n\n(Alsousou et al., 2009). \n\nO plasma rico em plaquetas foi utilizado pela primeira vez por Ferrari et al. \n\n(1987) em cirurgia card\u00edaca com cora\u00e7\u00e3o aberto como um componente de transfus\u00e3o \n\naut\u00f3logo. Inicialmente, o PRP foi utilizado principalmente em cirurgias orais para \n\npromover a cicatriza\u00e7\u00e3o do tecido e integra\u00e7\u00e3o do implante, e controlar hemorragias \n\n(Anitua, 1999; Marx et al., 1998). Subsequentemente, tamb\u00e9m foi empregado em outras \n\ncirurgias incluindo cirurgias nos ombros (Everts et al., 2008), quadris (Everts et al., \n\n2007), procedimentos nas articula\u00e7\u00f5es dos joelhos (S\u00e1nchez et al., 2008; Ishida et al., \n\n2007), reconstru\u00e7\u00e3o de ligamentos (Radice et al., 2010) e cicatriza\u00e7\u00e3o \u00f3ssea \n\n(Kawasumi et al., 2008).  \n\nMais recentemente, o PRP com suas variantes tem sido empregado na forma \n\ninjet\u00e1vel visando a cicatriza\u00e7\u00e3o de diversos tecidos incluindo pele (Judith et al., 2010; \n\nJudith et al., 2012), m\u00fasculos (van Ark et al., 2013), tend\u00f5es (de Vos et al., 2010; Kaux \n\n&amp; Crielaard, 2013), cartilagem (Kon et al., 2010; Kon et al., 2011) e osso (Jia et al., \n\n2011; Jiang et al., 2012).  \n\n \n\n2.3. Scaffolds \n\n \n\n2.3.1. Defini\u00e7\u00f5es \n\nScaffolds s\u00e3o matrizes tridimensionais tempor\u00e1rias que funcionam como a matriz \n\nextracelular, organizando as c\u00e9lulas tridimensionalmente e estimulando o crescimento e \n\n\n\n13 \n\n \n\na forma\u00e7\u00e3o do tecido desejado (Hutmacher, 2000).  \n\nOs scaffolds s\u00e3o divididos em flu\u00eddos (injet\u00e1veis) e s\u00f3lidos (convencionais), e \n\npodem ser fabricados em diversos formatos, os quais dependem da aplica\u00e7\u00e3o desejada \n\ne do processo de fabrica\u00e7\u00e3o utilizado: esponjas (Amaral et al., 2006; Manferdini et al., \n\n2010), hidrog\u00e9is (Bhattacharyya et al., 2008, Kim et al., 2010), fibras (Yamane et al., \n\n2005, Iwasaki et al., 2011), membranas (Mathews et al., 2011; Mucha et al., 2012) \n\nmicro e nano part\u00edculas (Cruz et al., 2008; Cust\u00f3dio et al., 2014), tubos (Venkatesan et \n\nal., 2012) e esferas (Shu &amp; Zhu, 2002).  \n\nV\u00e1rios processos t\u00eam sido desenvolvidos para fabricar diferentes tipos de \n\nscaffolds entre eles destacam-se: evapora\u00e7\u00e3o de solvente/ lixivia\u00e7\u00e3o de part\u00edculas \n\n(solvent casting/ particulate leaching) (Mikos et al., 1994); espuma de g\u00e1s (gas foaming) \n\n(Nam et al., 2000), liofiliza\u00e7\u00e3o (freeze-drying) (Madihally and Mathew, 1999); \n\neletrofia\u00e7\u00e3o (electrospinning) (Huang et al., 2003), prototipagem r\u00e1pida (rapid \n\nprototyping) (Peltola et al., 2008) e separa\u00e7\u00e3o de fases termicamente induzida \n\n(thermally induced phase separation) (Pavia et al., 2008). \n\nA t\u00e9cnica de processamento escolhida deve obedecer, em termos gerais, aos \n\nseguintes crit\u00e9rios (Boccaccini et al., 2002):  \n\n? O processo ou produ\u00e7\u00e3o n\u00e3o deve afetar as propriedades dos materiais, isto \u00e9, a \n\nsua biocompatibilidade ou propriedades f\u00edsico-qu\u00edmicas;  \n\n? A t\u00e9cnica deve permitir um controle da porosidade, tamanho de poros, sua \n\ndistribui\u00e7\u00e3o e interconectividade;  \n\n? Grupos diferentes de matrizes devem exibir varia\u00e7\u00f5es m\u00ednimas nas suas \n\npropriedades, quando processadas nas mesmas condi\u00e7\u00f5es.  \n\nAs principais caracter\u00edsticas que diferenciam as v\u00e1rias t\u00e9cnicas s\u00e3o a aplica\u00e7\u00e3o \n\ndesejada e/ ou o uso de solventes; calor ou press\u00e3o; ou a utiliza\u00e7\u00e3o de aditivos \n\nrespons\u00e1veis pela gera\u00e7\u00e3o dos poros (Agrawal &amp; Ray, 2001). \n\n \n\n2.3.2. Scaffolds na regenera\u00e7\u00e3o de tecidos \n\nNa engenharia de tecidos e medicina regenerativa, os scaffolds representam a \n\ncapacidade condutiva e podem ser utilizados para transportar as c\u00e9lulas antes da sua \n\nimplanta\u00e7\u00e3o in vivo, ou servirem apenas como um material bioativo atraindo as c\u00e9lulas \n\ndo tecido onde \u00e9 implantado.  \n\nAl\u00e9m de permitir a ades\u00e3o e a migra\u00e7\u00e3o celular dentro do suporte e promover a \n\nprolifera\u00e7\u00e3o e a diferencia\u00e7\u00e3o celular, o scaffold deve fornecer um ambiente no qual as \n\nc\u00e9lulas possam manter seu fen\u00f3tipo e sintetizar as prote\u00ednas e/ou outras mol\u00e9culas \n\n\n\n14 \n\n \n\nnecess\u00e1rias (Monteiro, 2008).  \n\n \n\n2.3.3. Propriedades requeridas dos scaffolds \n\nScaffolds utilizados em engenharia de tecidos e medicina regenerativa devem \n\napresentar propriedades biol\u00f3gicas e f\u00edsicas compat\u00edveis com as condi\u00e7\u00f5es fisiol\u00f3gicas \n\nin vitro e in vivo. Como mencionado anteriormente, a principal fun\u00e7\u00e3o dos scaffolds \u00e9 \n\nproporcionar um suporte tempor\u00e1rio adequado que permita os processos celulares \n\nnecess\u00e1rios para a regenera\u00e7\u00e3o do tecido. Para isso, v\u00e1rios requisitos, dependentes do \n\ntipo de c\u00e9lula utilizada e do tecido a ser regenerado, devem ser considerados no \n\ndesenvolvimento de scaffolds (Sachlos &amp; Czernuszka, 2003). Os scaffolds devem: \n\n? Possuir estrutura tridimensional; \n\n? Possuir poros interconectados e de tamanho apropriado para favorecer a \n\nintegridade e a vasculariza\u00e7\u00e3o do tecido; \n\n? Possuir porosidade que proporcione elevada \u00e1rea superficial para intera\u00e7\u00e3o \n\nc\u00e9lula-scaffold; \n\n? Ser biodegrad\u00e1vel e biocompat\u00edvel; \n\n? N\u00e3o apresentar nenhum componente ou subproduto de sua degrada\u00e7\u00e3o que \n\nprovoque rea\u00e7\u00f5es inflamat\u00f3rias ou t\u00f3xicas; \n\n? Apresentar superf\u00edcie qu\u00edmica que favore\u00e7a a ades\u00e3o, prolifera\u00e7\u00e3o e \n\ndiferencia\u00e7\u00e3o das c\u00e9lulas; \n\n? Apresentar propriedades mec\u00e2nicas adequadas para implanta\u00e7\u00e3o e \n\nmanipula\u00e7\u00e3o; \n\n? Ter bioatividade satisfat\u00f3ria para explorar o processo de repara\u00e7\u00e3o natural do \n\ntecido; \n\n? Ser facilmente fabricado em uma variedade de formas e tamanhos. \n\nAl\u00e9m dos requisitos necess\u00e1rios para a prepara\u00e7\u00e3o dos scaffolds s\u00f3lidos, os \n\nscaffolds fluidos devem apresentar as seguintes propriedades (Hou et al., 2004): \n\n? Injetabilidade; \n\n? Solidifica\u00e7\u00e3o sob condi\u00e7\u00f5es brandas; \n\n? Coesividade; \n\n? For\u00e7a mec\u00e2nica e resist\u00eancia a for\u00e7as in situ; \n\n? Possibilidade de incorpora\u00e7\u00e3o de mol\u00e9culas bioativas. \n\nDo ponto de vista cl\u00ednico, a utiliza\u00e7\u00e3o de scaffolds fluidos \u00e9 muito interessante, \n\npois minimiza o desconforto do paciente, o risco de infec\u00e7\u00e3o, a forma\u00e7\u00e3o de cicatrizes e \n\no custo do tratamento j\u00e1 que n\u00e3o requer interven\u00e7\u00e3o cir\u00fargica para sua implanta\u00e7\u00e3o \n\n\n\n15 \n\n \n\n(Hou et al., 2004).  \n\nO material fluido pode preencher de forma homog\u00eanea o defeito ou ponto de \n\nreparo, pode incorporar v\u00e1rios agentes terap\u00eauticos, e, finalmente, n\u00e3o exige \n\nprocedimento cir\u00fargico invasivo para sua implanta\u00e7\u00e3o (Gutowska et al., 2001). \n\nAl\u00e9m disso, a alta hidrata\u00e7\u00e3o destes materiais mimetiza a matriz extracelular \n\nsendo, portanto, ideais para a prolifera\u00e7\u00e3o e diferencia\u00e7\u00e3o celular. \n\n \n\n2.3.4. Materiais utilizados na fabrica\u00e7\u00e3o de scaffolds \n\nA sele\u00e7\u00e3o dos materiais para a produ\u00e7\u00e3o dos scaffolds \u00e9 uma das etapas mais \n\nimportantes e v\u00e1rios materiais t\u00eam sido propostos para sua fabrica\u00e7\u00e3o, entre eles est\u00e3o \n\nos metais, os pol\u00edmeros de origem natural ou de origem sint\u00e9tica, os materiais \n\ncer\u00e2micos e os comp\u00f3sitos.  \n\nEmbora os materiais met\u00e1licos e cer\u00e2micos tenham contribu\u00eddo para muitos \n\navan\u00e7os na \u00e1rea m\u00e9dica, principalmente na substitui\u00e7\u00e3o de tecidos ortop\u00e9dicos, eles \n\napresentam duas importantes desvantagens para a aplica\u00e7\u00e3o em engenharia de \n\ntecidos: n\u00e3o s\u00e3o biodegrad\u00e1veis e a processabilidade destes materiais \u00e9 bastante \n\nlimitada (Liu &amp; Ma, 2004).  \n\nOs pol\u00edmeros biodegrad\u00e1veis s\u00e3o considerados os materiais ideais para a \n\nprodu\u00e7\u00e3o destas matrizes e podem ser divididos em naturais e sint\u00e9ticos.  \n\nOs pol\u00edmeros biodegrad\u00e1veis naturais podem ser obtidos de fontes animais ou \n\nvegetais. S\u00e3o id\u00eanticos ou semelhantes \u00e0s subst\u00e2ncias j\u00e1 encontradas no corpo e, \n\nportanto, a probabilidade de toxicidade ou de estimular uma rea\u00e7\u00e3o inflamat\u00f3ria cr\u00f4nica \n\n\u00e9 reduzida. Estes materiais tamb\u00e9m t\u00eam, geralmente, atividade biol\u00f3gica inerente, \n\nproporcionando assim sinaliza\u00e7\u00e3o para c\u00e9lulas sem a necessidade de adi\u00e7\u00e3o de fatores \n\nex\u00f3genos. Eles tamb\u00e9m s\u00e3o suscept\u00edveis a enzimas presentes no organismo e, \n\nportanto, s\u00e3o inerentemente biodegrad\u00e1veis, sendo poss\u00edvel controlar suas taxas de \n\ndegrada\u00e7\u00e3o atrav\u00e9s de modifica\u00e7\u00f5es qu\u00edmicas.  \n\nNo entanto, s\u00e3o frequentemente imunog\u00eanicos e sua manipula\u00e7\u00e3o e/ ou \n\nprocessamento s\u00e3o muito mais dif\u00edceis que a de pol\u00edmeros sint\u00e9ticos devido a sua \n\ncomplexidade.  \n\nAl\u00e9m disso, o processo de extra\u00e7\u00e3o desses materiais a partir de um tecido \n\nmuitas vezes altera sua estrutura natural. Outra desvantagem \u00e9 a variabilidade natural \n\ndos materiais derivados de fontes animais (Mann, 2003).  \n\nAssim, a escolha do material para a produ\u00e7\u00e3o dos scaffolds deve levar em \n\nconsidera\u00e7\u00e3o as vantagens e desvantagens desses materiais bem como a aplica\u00e7\u00e3o \n\n\n\n16 \n\n \n\npretendida. \n\nA seguir s\u00e3o apresentadas as principais carater\u00edsticas dos biomateriais, \u00e1cido \n\nhialur\u00f4nico e quitosana, utilizados neste trabalho para preparar os scaffolds comp\u00f3sitos \n\nestudados. \n\n \n\n2.3.4.1. \u00c1cido hialur\u00f4nico (AH) \n\nO AH \u00e9 um biopol\u00edmero viscoel\u00e1stico linear, composto de repetidas unidades \n\ndissacar\u00eddicas de \u00e1cido D-glicur\u00f4nico (GlcUA) e N-acetilglicosamina (GlcNAc) unidas \n\nalternadamente por liga\u00e7\u00f5es glicos\u00eddicas ?-1,3 e ?-1,4 (Figura 5), encontrado \n\nnaturalmente nos tecidos conjuntivos de mam\u00edferos (Kuo et al., 2000) e produzido por \n\nbact\u00e9rias do g\u00eanero Streptococcus (Pires et al., 2010). \n\nDevido a suas propriedades f\u00edsicas, o AH tem fun\u00e7\u00f5es no preenchimento de \n\nespa\u00e7os, na lubrifica\u00e7\u00e3o, na absor\u00e7\u00e3o de choque e na exclus\u00e3o de prote\u00ednas. Al\u00e9m \n\ndisso, suas propriedades bioqu\u00edmicas incluem a modula\u00e7\u00e3o da resposta inflamat\u00f3ria \n\ndas c\u00e9lulas, a intera\u00e7\u00e3o com os proteoglicanos da matriz extracelular e a captura de \n\nradicais livres (Monheit &amp; Coleman, 2006). Estudos tamb\u00e9m mostraram que o AH ligado \n\na prote\u00ednas e a receptores espec\u00edficos desempenha importante papel na embriog\u00eanese, \n\nna transdu\u00e7\u00e3o de sinais, na motilidade celular e est\u00e1 ainda associado ao c\u00e2ncer e a \n\nmet\u00e1stase (Kogan et al., 2007). \n\n \n\n \n\nn = n\u00famero de repeti\u00e7\u00f5es de unidades dissacar\u00eddicas \n\nFigura 5. Estrutura molecular do \u00e1cido hialur\u00f4nico.  \n \n\nSendo assim, o \u00e1cido hialur\u00f4nico tem sido amplamente aplicado nas \u00e1reas \n\nm\u00e9dicas e cosm\u00e9ticas, principalmente em cirurgias oft\u00e1lmicas (Balazs, 1983); em \n\nterapias para o controle da artrite (Balazs &amp; Denlinger, 1993), implante de pr\u00f3teses; \n\ncicatriza\u00e7\u00e3o de feridas; preven\u00e7\u00e3o de ades\u00e3o de tecidos (Garg &amp; Hales, 2004) e \n\npreenchimento d\u00e9rmico (Holmstr\u00f6m &amp; Ricici, 1967). Al\u00e9m disso, devido a suas \n\n\n\n17 \n\n \n\npropriedades f\u00edsico-qu\u00edmicas e fun\u00e7\u00f5es biol\u00f3gicas, o \u00e1cido hialur\u00f4nico e seus derivados \n\nmodificados tamb\u00e9m t\u00eam sido amplamente utilizados na administra\u00e7\u00e3o de f\u00e1rmacos \n\n(Kim et al., 2005; Hahn et al., 2006) e na engenharia de tecidos (Ohri et al., 2004; West \n\net al., 1985). \n\nAs fun\u00e7\u00f5es e aplica\u00e7\u00f5es do \u00e1cido hialur\u00f4nico (AH) est\u00e3o associadas \n\nbasicamente \u00e0s suas caracter\u00edsticas estruturais e \u00e0s poss\u00edveis modifica\u00e7\u00f5es qu\u00edmicas \n\ndo pol\u00edmero, as quais determinam suas propriedades reol\u00f3gicas, de solubilidade, de \n\nhidrata\u00e7\u00e3o e de reconhecimento celular espec\u00edfico. \n\nO AH \u00e9 n\u00e3o-imunog\u00eanico, biocompat\u00edvel e biodegrad\u00e1vel, e por isso, possui \n\ndiversas aplica\u00e7\u00f5es como biomateriais. Entretanto, sua aplica\u00e7\u00e3o na prepara\u00e7\u00e3o de \n\nscaffolds requer pr\u00e9via modifica\u00e7\u00e3o do pol\u00edmero visando melhorar suas propriedades \n\nmec\u00e2nicas e qu\u00edmicas, e principalmente aumentar seu tempo de resid\u00eancia nos tecidos \n\n(biodisponibilidade). Como o AH natural apresenta um tempo de resid\u00eancia de 1 a 2 \n\ndias e a maioria das aplica\u00e7\u00f5es m\u00e9dicas desse biopol\u00edmero requer um tempo de \n\nresid\u00eancia maior, modifica\u00e7\u00f5es qu\u00edmicas do AH tem se tornado essenciais na \n\nprepara\u00e7\u00e3o de produtos para aplica\u00e7\u00f5es m\u00e9dicas e cosm\u00e9ticas (Romagnoli &amp; \n\nBelmontesi, 2008, Monheit &amp; Coleman, 2006). \n\nA mol\u00e9cula de AH apresenta quatro grupos funcionais que podem ser \n\nmodificados quimicamente: carbox\u00edlico, hidrox\u00edlico, acetamida e o terminal reduzido do \n\npol\u00edmero (Figura 6). Al\u00e9m disso, as liga\u00e7\u00f5es glicos\u00eddicas tamb\u00e9m podem ser \n\nhidrolisadas para formar cadeias menores ou oligossacar\u00eddeos. \n\n \n\n \nFigura 6. Grupos de modifica\u00e7\u00e3o qu\u00edmica da mol\u00e9cula de AH: (1) carbox\u00edlico, (2) \n\nhidrox\u00edlico, (3) acetamida, (4) Terminal Reduzido do Pol\u00edmero (Adaptado de Garg &amp; \n\nHales, 2004). \n\nAl\u00e9m das modifica\u00e7\u00f5es do AH atrav\u00e9s da adi\u00e7\u00e3o de mol\u00e9culas em sua cadeia \n\n(conjuga\u00e7\u00e3o), o AH pode tamb\u00e9m ser modificado atrav\u00e9s de reticula\u00e7\u00e3o.  \n\n\n\n18 \n\n \n\nA reticula\u00e7\u00e3o do AH fornece mol\u00e9culas maiores e mais est\u00e1veis, com \n\nbiocompatibilidade similar \u00e0 do AH n\u00e3o modificado. O pol\u00edmero pode ser reticulado \n\natrav\u00e9s de liga\u00e7\u00f5es covalentes irrevers\u00edveis (reticula\u00e7\u00e3o qu\u00edmica), ou atrav\u00e9s da \n\nforma\u00e7\u00e3o de v\u00e1rias liga\u00e7\u00f5es i\u00f4nicas revers\u00edveis (reticula\u00e7\u00e3o f\u00edsica). \n\nA reticula\u00e7\u00e3o pode ser realizada atrav\u00e9s da exposi\u00e7\u00e3o direta do AH ao agente \n\nreticulante, ou atrav\u00e9s da rea\u00e7\u00e3o de um derivado de AH altamente reativo \n\nprimariamente sintetizado com o agente reticulante em uma rea\u00e7\u00e3o secund\u00e1ria.  \n\nA maioria dos m\u00e9todos reportados na literatura para reticular o AH emprega \n\nreagentes polifuncionais tais como bis-epoxidos, carbodiimidas, dihidrazidas e divinil \n\nsulfona (Band, 1998). Entretanto, os agentes reticulantes mais comuns normalmente \n\napresentam elevada citotoxicidade, a qual limita sua aplica\u00e7\u00e3o nas \u00e1reas m\u00e9dica e \n\ncosm\u00e9tica.  \n\nA seguir ser\u00e3o discutidas brevemente as rea\u00e7\u00f5es de modifica\u00e7\u00f5es qu\u00edmicas do \n\nAH utilizadas neste trabalho. \n\n \n\n? Modifica\u00e7\u00e3o do grupo carbox\u00edlico por amida\u00e7\u00e3o com iodeto de 2-cloro-1-\n\nmetilpirid\u00ednio (CMPI). Magnani et al. (2000) descreveram a rea\u00e7\u00e3o de amida\u00e7\u00e3o usando \n\nCMPI como o agente de ativa\u00e7\u00e3o dos grupos carbox\u00edlicos do AH. Esta rea\u00e7\u00e3o \u00e9 \n\nnormalmente realizada em dimetilformamida (DMF) ou dimetilsulf\u00f3xido (DMSO), um \n\nsolvente org\u00e2nico anidro, para minimizar a hidr\u00f3lise do CMPI. Inicialmente, o \n\nhialuronato de s\u00f3dio \u00e9 convertido no sal de tetrabutilam\u00f4nio (TBA) para permitir a sua \n\nsolubiliza\u00e7\u00e3o no solvente org\u00e2nico. Para formar as liga\u00e7\u00f5es cruzadas entre as cadeias \n\nde AH, CMPI reage com o grupo carbox\u00edlico do HA, forma um intermedi\u00e1rio pirid\u00edneo e \n\nlibera o \u00edon cloreto, o qual \u00e9 neutralizado pelo tetrabutilam\u00f4nio. Trietilamina neutraliza o \n\n\u00edon iodeto liberado (Figura 7). Quando nenhuma amina \u00e9 adicionada ao meio reacional, \n\na esterifica\u00e7\u00e3o ocorre entre o intermedi\u00e1rio AH-CMPI ativado e os grupos hidrox\u00edlicos \n\nde uma mesma cadeia ou de cadeias diferentes de AH, formando uma liga\u00e7\u00e3o \u00e9ster \n\nentre as cadeias de AH. Neste caso, temos uma rea\u00e7\u00e3o de autoesterifica\u00e7\u00e3o na qual \u00e9 \n\nformado o derivado autorreticulado de \u00e1cido hialur\u00f4nico (ACP = auto-crosslinked \n\npolymers) (Della Valle, 1994; Della Valle &amp; Romeo, 1989). Os grupos carbox\u00edlicos do \n\nAH ativados por CMPI tamb\u00e9m podem reagir com um grupo carbox\u00edlico n\u00e3o ativado, \n\npor\u00e9m o anidrido resultante \u00e9 inst\u00e1vel e subsequentemente reage com um grupo \n\nhidrox\u00edlico formando a mesma liga\u00e7\u00e3o \u00e9ster. A desvantagem desse m\u00e9todo \u00e9 a \n\nnecessidade de uma etapa adicional para a prepara\u00e7\u00e3o do TBA-AH e de ter que ser \n\nrealizado em um solvente org\u00e2nico que requer um processo de purifica\u00e7\u00e3o longo. \n\n\n\n19 \n\n \n\n \n\nFigura 7.  Prepara\u00e7\u00e3o de ACP por autoesterifica\u00e7\u00e3o organocatalisada usando o \n\nintermedi\u00e1rio ativado AH-CPMI (Schant\u00e9 et al., 2011).  \n\n \n\nNa rea\u00e7\u00e3o de autoesterifica\u00e7\u00e3o organocatalisada \u00e9 formada uma liga\u00e7\u00e3o \n\ncovalente entre os grupos hidrox\u00edlicos e carbox\u00edlicos de uma mesma cadeia e/ ou de \n\ncadeias diferentes de AH, formando assim lactonas ou liga\u00e7\u00f5es \u00e9steres \n\nintermoleculares. Nos derivados ACP, os grupos carbox\u00edlicos do AH est\u00e3o \n\ncompletamente ou parcialmente esterificados. No caso de \u00e9steres parcialmente \n\nesterificados, os grupos carbox\u00edlicos remanescentes podem ainda ser totalmente ou \n\nparcialmente esterificados com \u00e1lcoois mono- ou polivalentes, formando assim grupos \n\n\u00e9steres externos; podem permanecer livres e/ou serem salinizados com bases \n\nmet\u00e1licas ou org\u00e2nicas (Bellini et al., 2001). \n\nA reticula\u00e7\u00e3o por autoesterifica\u00e7\u00e3o da mol\u00e9cula de AH \u00e9 uma excelente \n\nalternativa para prepara\u00e7\u00e3o de derivados reticulados completamente biocompat\u00edveis e \n\nque apresentam prolongado tempo de resid\u00eancia in vivo e/ ou melhores propriedades \n\nmec\u00e2nicas em rela\u00e7\u00e3o ao AH nativo.  \n\nEmbora sejam utilizados compostos org\u00e2nicos como os solventes e os \n\ncatalisadores da rea\u00e7\u00e3o, as etapas de lavagem do produto final mant\u00eam sua \n\nbiocompatibilidade (Bellini et al., 2001, Collins &amp; Birkinshaw, 2007). \n\nA principal vantagem da forma\u00e7\u00e3o das liga\u00e7\u00f5es \u00e9steres sem a adi\u00e7\u00e3o de agentes \n\nreticulantes t\u00f3xicos em rela\u00e7\u00e3o a outros m\u00e9todos de reticula\u00e7\u00e3o \u00e9 aus\u00eancia de \n\nmol\u00e9culas estranhas inseridas nas cadeias de AH. Sendo assim, durante o processo de \n\ndegrada\u00e7\u00e3o do ACP in vivo, somente AH nativo \u00e9 gerado.  \n\nAl\u00e9m disso, o ACP pode ser preparado com v\u00e1rios graus de reticula\u00e7\u00e3o, os quais \n\npermitem adequar suas propriedades para in\u00fameras aplica\u00e7\u00f5es. \n\n \n\n? Modifica\u00e7\u00e3o do grupo hidrox\u00edlico por forma\u00e7\u00e3o de liga\u00e7\u00f5es \u00e9ter utilizando \n\nep\u00f3xidos. Malson &amp; Lindqvist (1986) patentearam a reticula\u00e7\u00e3o de AH utilizando 1,4-\n\nbutanodiol-diglicid\u00edl \u00e9ter (BDDE) em uma solu\u00e7\u00e3o 0.25 M NaOH. A rea\u00e7\u00e3o consiste da \n\nabertura do anel ep\u00f3xido para formar liga\u00e7\u00f5es \u00e9ter com os grupos hidrox\u00edlicos do AH \n\n\n\n20 \n\n \n\n(Figura 8). Quando AH \u00e9 submetido a valores de pH (pH> 13) acima do pKa dos grupos \n\nhidrox\u00edlicos do AH (pKa~10), estes s\u00e3o desprotonados e se tornam mais do \n\nnucleof\u00edlicos que os grupos carbox\u00edlicos desprotonados. Os ep\u00f3xidos, portanto, reagem \n\npreferencialmente com os grupos hidrox\u00edlicos para formar liga\u00e7\u00f5es \u00e9ter.  \n\nNo entanto, quando o pH \u00e9 menor do que o valor de pKa do grupo hidrox\u00edlico, \n\numa quantidade menor de grupos hidrox\u00edlicos \u00e9 desprotonada e os grupos carbox\u00edlicos \n\nani\u00f4nicos tornam-se predominantes, promovendo assim a forma\u00e7\u00e3o da liga\u00e7\u00e3o \u00e9ster. \n\nIsto tem sido demonstrado por De Belder &amp; Malson (1986), que realizaram a reticula\u00e7\u00e3o \n\nde AH com BDDE em condi\u00e7\u00f5es \u00e1cidas (pH 2-4,5).  \n\nAtualmente, BDDE \u00e9 usado na prepara\u00e7\u00e3o da maioria dos hidrog\u00e9is de AH \n\nreticulados dispon\u00edveis no mercado. Al\u00e9m da s\u00edntese f\u00e1cil, a degrada\u00e7\u00e3o dos produtos \n\nde AH-BDDE n\u00e3o demonstram citotoxicidade e os compostos ep\u00f3xidos s\u00e3o hidrolisados \n\nem di\u00f3is simples (Nishi et al., 1995). \n\n \n\n \n\nFigura 8. \u00c1cido hialur\u00f4nico reticulado com BDDE em meio alcalino (Malson &amp; Lindqvist, \n\n1986).  \n\n2.3.4.2. Quitosana  \n\nQuitosana (CHT) \u00e9 um polissacar\u00eddeo derivado da quitina (copol\u00edmeros ?-(1?4)-\n\n2-amino 2-desoxi-D-glicose e ?-(1?4)-2-acetamida 2-desoxi-D-glicose), encontrada em \n\nabund\u00e2ncia na natureza, principalmente na carapa\u00e7a de crust\u00e1ceos. A quitosana pode \n\nser obtida a partir da quitina por meio de desacetila\u00e7\u00e3o alcalina, podendo tamb\u00e9m estar \n\nnaturalmente presente em alguns fungos pertencentes aos g\u00eaneros Mucor e \n\nZygomicetes (Silva et al., 2006). \n\nA Figura 9 representa a estrutura qu\u00edmica parcial da quitosana. \n\n\n\n21 \n\n \n\n \n\nFigura 9. Estrutura molecular da quitosana. \n\nOs principais par\u00e2metros que influenciam as caracter\u00edsticas da quitosana s\u00e3o a \n\nsua massa molar (MM) e seu grau de desacetila\u00e7\u00e3o (GD), o qual representa o conte\u00fado \n\nde unidades desacetiladas. Em geral, o produto N-desacetilado da quitina s\u00f3 passa a \n\nser considerado quitosana quando o GD se torna igual ou superior a 60%, percentagem \n\na partir da qual o biopol\u00edmero se torna sol\u00favel em solu\u00e7\u00f5es \u00e1cidas dilu\u00eddas. O grau de \n\ndesacetila\u00e7\u00e3o \u00e9 um par\u00e2metro muito importante, pois \u00e9 capaz de influenciar as \n\ncaracter\u00edsticas qu\u00edmicas, f\u00edsicas e biol\u00f3gicas do biopol\u00edmero.  \n\nDo ponto de vista qu\u00edmico, o GD da quitosana exerce influ\u00eancia sobre algumas \n\nde suas propriedades, tais como hidrofilicidade, capacidade de reticula\u00e7\u00e3o na presen\u00e7a \n\nde determinados agentes reticulantes, solubilidade e viscosidade (Gonsalves et al., \n\n2011).  \n\nNa sua forma cristalina, a quitosana \u00e9 normalmente insol\u00favel em solu\u00e7\u00e3o aquosa \n\nacima de pH 7, no entanto, em \u00e1cidos dilu\u00eddos (pH<6.0), os grupos amino livres \n\nprotonados da glicosamina facilitam a solubilidade da mol\u00e9cula (Madihally &amp; Matthew, \n\n1999). \n\nNos \u00faltimos anos, pesquisadores das \u00e1reas m\u00e9dica e farmac\u00eautica t\u00eam \n\ndemonstrado grande interesse na utiliza\u00e7\u00e3o de quitosana devido principalmente a suas \n\npropriedades intr\u00ednsecas. A quitosana \u00e9 um pol\u00edmero biocompat\u00edvel, devido \u00e0 sua \n\nmetaboliza\u00e7\u00e3o por certas enzimas humanas como a lisozima, sendo considerado, \n\nportanto, biodegrad\u00e1vel (Nordtveit et al., 1996; Muzzarelli, 1997). Al\u00e9m disso, devido \u00e0 \n\nsua carga positiva em pH fisiol\u00f3gico, a quitosana \u00e9 tamb\u00e9m bioadesiva (He et al., 1998; \n\nCalvo et al., 1997; Bertram &amp; Bodmeier, 2006), o que aumenta sua reten\u00e7\u00e3o no local da \n\naplica\u00e7\u00e3o. A quitosana tamb\u00e9m promove a cicatriza\u00e7\u00e3o de feridas (Antonov et al., 2008; \n\nDai et al., 2011) e tem efeito antimicrobiano (Muzzarelli et al., 1990; Liu et al., 2001; Li \n\net al., 2013). Finalmente, a quitina \u00e9 muito abundante, e a produ\u00e7\u00e3o da quitosana \u00e9 de \n\nbaixo custo e ecologicamente interessante (Berger et al., 2004).  \n\nAl\u00e9m destas propriedades, estudos recentes mostraram que a quitosana e seus \n\nderivados s\u00e3o candidatos promissores a scaffolds principalmente devido \u00e0 facilidade de \n\n\n\n22 \n\n \n\nmodifica\u00e7\u00e3o qu\u00edmica, possibilidade de ser moldada em v\u00e1rias formas (membranas, g\u00e9is, \n\nesferas, esponjas, micro- e nanopart\u00edculas) e \u00e0 sua elevada afinidade \u00e0s \n\nmacromol\u00e9culas in vivo. \n\nA versatilidade qu\u00edmica da quitosana resulta principalmente da presen\u00e7a dos \n\ngrupos amino em sua estrutura. Apesar da maioria das modifica\u00e7\u00f5es qu\u00edmicas da \n\nquitosana ocorrer em seus grupos amino C-2, as hidroxilas em C-3 e C-6 das unidades \n\nestruturais do biopol\u00edmero tamb\u00e9m s\u00e3o suscept\u00edveis a rea\u00e7\u00f5es.  \n\nA natureza qu\u00edmica da quitosana fornece possibilidades para as modifica\u00e7\u00f5es \n\ncovalentes e i\u00f4nicas, as quais tamb\u00e9m permitem a modula\u00e7\u00e3o das propriedades \n\nmec\u00e2nicas e biol\u00f3gicas dos biomateriais produzidos, ampliando seu espectro de \n\naplica\u00e7\u00e3o na engenharia de tecidos e medicina regenerativa. (Gonsalves et al., 2011). \n\n \n\n2.3.4.3. Complexos Polieletrol\u00edticos de \u00c1cido Hialur\u00f4nico e Quitosana  \n\nComplexos polieletrol\u00edticos (PECs) s\u00e3o complexos polim\u00e9ricos formados pela \n\nrea\u00e7\u00e3o entre pol\u00edmeros de cargas opostas. A forma\u00e7\u00e3o e as propriedades dos PECs \n\ndependem da raz\u00e3o das cargas ani\u00f4nicas e cati\u00f4nicas dos pol\u00edmeros, do grau de \n\nneutraliza\u00e7\u00e3o, da for\u00e7a i\u00f4nica e da val\u00eancia dos \u00edons na solu\u00e7\u00e3o eletrol\u00edtica. Os PECs \n\npreparados a partir pol\u00edmeros naturais, tais como \u00e1cido hialur\u00f4nico e quitosana, t\u00eam a \n\nvantagem de serem n\u00e3o t\u00f3xicos e bioabsorv\u00edveis (Kim et al., 2004a; Kim et al., 2004b). \n\nComo dito anteriormente, o \u00e1cido hialur\u00f4nico tem sido amplamente utilizado \n\ncomo scaffolds na cicatriza\u00e7\u00e3o de feridas e na regenera\u00e7\u00e3o de tecidos, entretanto, a \n\nelevada densidade de cargas negativas do AH pode reduzir a ades\u00e3o celular e interferir \n\nnos processos biol\u00f3gicos envolvidos na regenera\u00e7\u00e3o tecidual limitando sua aplica\u00e7\u00e3o \n\n(Ren et al., 2005; Correia et al., 2011). Uma boa alternativa para contornar esta \n\nlimita\u00e7\u00e3o \u00e9 combinar o AH com polic\u00e1tions tais como a quitosana.  \n\nTestes in vitro mostraram que os PECs formados de CHT e AH podem ser \n\nutilizados como um material de suporte para o transplante de condr\u00f3citos aut\u00f3logos e/ \n\nou como scaffolds para a engenharia de tecidos, principalmente de tecidos da \n\ncartilagem (Sechriest et al., 1999). \n\nCorreia et al. (2011) prepararam scaffolds de CHT com diferentes concentra\u00e7\u00f5es \n\nde AH (1, 5, 10%) por liofiliza\u00e7\u00e3o. Os scaffolds de CHT-AH n\u00e3o apresentaram \n\ncitotoxicidade e promoveram ades\u00e3o celular. Al\u00e9m disso, a incorpora\u00e7\u00e3o de AH at\u00e9 uma \n\n\n\n23 \n\n \n\nconcentra\u00e7\u00e3o de 5% melhorou as propriedades f\u00edsico-qu\u00edmicas e biol\u00f3gicas dos \n\nscaffolds de CHT, favorecendo a ades\u00e3o de condr\u00f3citos, prolifera\u00e7\u00e3o celular e a \n\nprodu\u00e7\u00e3o de cartilagem, quando comparados aos scaffolds de CHT e a outras raz\u00f5es \n\nCHT-AH. \n\nScaffolds porosos de AH e CHT foram preparados por Coimbra et al. (2011) \n\nvisando regenera\u00e7\u00e3o de polpa dent\u00e1ria. Estudos in vitro mostraram que as c\u00e9lulas \n\ntronco mesenquimais (MSCs) aderiram e proliferaram sobre a superf\u00edcie do scaffold, o \n\nque demonstrou a biocompatibilidade e n\u00e3o citotoxicidade do biomaterial.  \n\nMajima et al. (2007) prepararam fibras de CHT com 0,1 % de \u00e1cido hialur\u00f4nico \n\nque foram utilizadas como scaffolds para a engenharia de tecidos de ligamentos e \n\ntend\u00f5es. Ensaios in vivo mostraram baixa toxicidade e baixa indu\u00e7\u00e3o da inflama\u00e7\u00e3o. \n\nAl\u00e9m disso, ensaios in vivo mostraram que as propriedades mec\u00e2nicas do ligamento ou \n\ndo tend\u00e3o engenheirado podem conferir maior estabiliza\u00e7\u00e3o das articula\u00e7\u00f5es.  \n\nLee et al. (2003) prepararam esponjas de AH-CHT em v\u00e1rios pHs por liofiliza\u00e7\u00e3o \n\ne avaliaram seu efeito de cicatriza\u00e7\u00e3o de feridas na pele de ratos Wistar com ou sem o \n\nagente antimicrobiano sulfadiazina de prata. Os resultados mostraram a prolifera\u00e7\u00e3o de \n\nfibroblastos na ferida e uma redu\u00e7\u00e3o significativa de agentes infecciosos.  \n\n \n\n2.4. C\u00e9lulas Tronco Mesenquimais  \n\n \n\nC\u00e9lulas tronco mesenquimais s\u00e3o c\u00e9lulas indiferenciadas tradicionalmente \n\nencontradas na medula \u00f3ssea. No entanto, as MSCs podem tamb\u00e9m ser isoladas a \n\npartir de outros tecidos, incluindo o tecido adiposo (h-AdMSCs).  \n\nAtualmente, as h-AdMSCs s\u00e3o as c\u00e9lulas mais utilizadas na medicina \n\nregenerativa devido principalmente \u00e0 facilidade de obten\u00e7\u00e3o de grandes quantidades de \n\nc\u00e9lulas. \n\nAs h-AdMSCs podem ser facilmente obtidas atrav\u00e9s de lipoaspira\u00e7\u00e3o, que \u00e9 um \n\nm\u00e9todo mais barato e menos invasivo que o procedimento de pun\u00e7\u00e3o realizado para a \n\nobten\u00e7\u00e3o das MSCs derivadas da medula \u00f3ssea.  \n\nAl\u00e9m disso, a frequ\u00eancia de h-AdMSCs no tecido adiposo (5000 c\u00e9lulas/g de \n\ngordura) \u00e9 muito maior em rela\u00e7\u00e3o \u00e0s MSCs da medula \u00f3ssea (100-1000 c\u00e9lulas/g) \n\n(Chavez-Munoz et al., 2013; Lin et al., 2008). \n\nMorfologicamente, as h-AdMSCs s\u00e3o fibroblastoides, com formato fusiforme. \n\n\n\n24 \n\n \n\nQuando submetidas a diferentes est\u00edmulos, as h-AdMSCs apresentam potencial \n\npara se diferenciarem, in vitro ou in vivo, em c\u00e9lulas de tecidos mesod\u00e9rmicos, como os \n\nadip\u00f3citos, as cartilagens, os ossos e o m\u00fasculo esquel\u00e9tico; e n\u00e3o mesod\u00e9rmicos, \n\ncomo os hepat\u00f3citos, as c\u00e9lulas pancre\u00e1ticas end\u00f3crinas, os neur\u00f4nios, os hepat\u00f3citos \n\ne as c\u00e9lulas endoteliais vasculares, possibilitando assim um vasto campo de aplica\u00e7\u00f5es \n\nna medicina regenerativa (Yarak &amp; Okamoto, 2010) \n\nAs h-AdMSCs tamb\u00e9m compartilham algumas caracter\u00edsticas importantes das \n\nMSCs adultas, incluindo plasticidade, alto potencial proliferativo, capacidade de secretar \n\nmol\u00e9culas protetoras bioativas e capacidade para modular a resposta imune (Bailey et \n\nal., 2010).  \n\nApesar das h-AdMSCs e PRP apresentarem propriedades ben\u00e9ficas para os \n\nprocessos celulares utilizados na regenera\u00e7\u00e3o de tecidos, estudos utilizando a \n\ncombina\u00e7\u00e3o de h-AdMSCs e PRP ainda s\u00e3o escassos.  \n\nA seguir s\u00e3o citados os principais trabalhos da literatura utilizando a combina\u00e7\u00e3o \n\nde PRP e h-AdMSCs, sem a presen\u00e7a de scaffolds. \n\nBaseados na avalia\u00e7\u00e3o cl\u00ednica por ultrassonografia, Guercio et al. (2014) \n\nverificaram que a combina\u00e7\u00e3o de PRP e AdMSCs \u00e9 uma terapia promissora para o \n\ntratamento de les\u00f5es em tend\u00f5es de cavalos de competi\u00e7\u00e3o.  \n\nPak et al. (2013) mostraram que terapias com h-AdMSCs/ PRP podem ser \n\nconsideradas seguras quando utilizadas na forma de inje\u00e7\u00f5es percut\u00e2neas locais para o \n\ntratamento de diferentes condi\u00e7\u00f5es ortop\u00e9dicas.  \n\nEm estudos realizados por van Pham et al. (2013), PRP promoveu a prolifera\u00e7\u00e3o \n\nde h-AdMSCs e a diferencia\u00e7\u00e3o condrog\u00eanica. Al\u00e9m disso, estes autores observaram \n\nque PRP combinado com h-AdMSCs melhorou a cicatriza\u00e7\u00e3o da cartilagem das \n\narticula\u00e7\u00f5es em modelos murinos quando comparados com PRP sem a presen\u00e7a de \n\nc\u00e9lulas. \n\nO efeito da libera\u00e7\u00e3o de FC do PRP e de BMP-2 (prote\u00edna morfog\u00eanica \u00f3ssea) \n\nencapsulada em microesferas na prolifera\u00e7\u00e3o e diferencia\u00e7\u00e3o osteog\u00eanica de h-\n\nAdMSCs foi verificado por Chen et al. (2012). Para isso, estes autores prepararam 5 \n\ncomp\u00f3sitos: h-AdMSCs/ plasma pobre em plaquetas (PPP); h-AdMSCs/ PRP; BMP-2/ \n\nPPP; h-AdMSCs/BMP/PRP e h-AdMSCs/ BMP-2/ PPP. Os resultados mostraram que a \n\nlibera\u00e7\u00e3o controlada de BMP-2 em combina\u00e7\u00e3o com o PRP \u00e9 melhor do que uma \u00fanica \n\nadministra\u00e7\u00e3o de PRP ou de BMP-2 na diferencia\u00e7\u00e3o osteog\u00eanica de h-AdMSCs. \n\nKakudo et al. (2008) verificaram que concentra\u00e7\u00f5es menores que 20% de PRP \n\nativado promovem significantemente a prolifera\u00e7\u00e3o de h-AdMSCs. \n\n\n\n25 \n\n \n\n2.5. Scaffolds Comp\u00f3sitos \n\n \n\nEmbora o PRP seja uma fonte de FCs plaquet\u00e1rios, a libera\u00e7\u00e3o da maior parte \n\ndesses fatores de crescimento ocorre dentro da primeira hora ap\u00f3s a ativa\u00e7\u00e3o \n\nplaquet\u00e1ria, apesar da libera\u00e7\u00e3o continuar durante todo o per\u00edodo de viabilidade das \n\nplaquetas (7 dias) (McCarrel &amp; Fortier, 2009) \n\nHokugo et al. (2005) mostraram que nenhuma regenera\u00e7\u00e3o \u00f3ssea foi observada \n\ncom o tratamento usando PRP livre, devido a sua r\u00e1pida excre\u00e7\u00e3o do s\u00edtio de aplica\u00e7\u00e3o. \n\nAl\u00e9m disso, segundo Rossi et al. (2013), a efic\u00e1cia dos FCs no processo de \n\nregenera\u00e7\u00e3o depende tamb\u00e9m da forma como esses FCs s\u00e3o disponibilizados no \n\ntecido lesionado.  \n\nAssim, a libera\u00e7\u00e3o gradual dos FCs tem sido considerada ben\u00e9fica nas terapias \n\nutilizando PRP.  \n\nEm adi\u00e7\u00e3o, na prepara\u00e7\u00e3o do PRP, ocorre a forma\u00e7\u00e3o de uma rede de fibrina, \n\nscaffold natural, decorrente da ativa\u00e7\u00e3o das plaquetas e decomposi\u00e7\u00e3o do fibrinog\u00eanio. \n\nNo entanto, a rede de fibrina formada \u00e9 fr\u00e1gil e possui viscoelasticidade e viscosidade \n\nlimitadas pelo endurecimento das fibras sob altos n\u00edveis de cisalhamento, al\u00e9m de \n\nsofrer degrada\u00e7\u00e3o r\u00e1pida no meio biol\u00f3gico. \n\nPara proteger os FCs contra prote\u00f3lise, prolongando assim sua atividade in vivo \n\ne melhorar a estabilidade da rede de fibrina do PRP, Tabata (2003) sugeriu combinar as \n\nfun\u00e7\u00f5es dos scaffolds com a tecnologia de libera\u00e7\u00e3o controlada. \n\nEntretanto, trabalhos utilizando PRP associado a scaffolds visando potencializar \n\na utiliza\u00e7\u00e3o dos FCs do PRP ainda s\u00e3o escassos.  \n\nO desenvolvimento de scaffolds adequados para a utiliza\u00e7\u00e3o eficaz do PRP \u00e9 \n\nainda um grande desafio para a engenharia de tecidos.  \n\nEmbora v\u00e1rios trabalhos tenham descrito as propriedades f\u00edsico-qu\u00edmicas, \n\nmec\u00e2nicas e biol\u00f3gicas, e/ou as aplica\u00e7\u00f5es cl\u00ednicas de diferentes scaffolds de quitosana \n\ne \u00e1cido hialur\u00f4nico, ainda existem poucos trabalhos usando a combina\u00e7\u00e3o desses \n\nscaffolds com PRP, ou seja, utilizando scaffolds comp\u00f3sitos.  \n\nAl\u00e9m disso, somente o trabalho descrito por Rossi et al. (2013) utilizou os tr\u00eas \n\nv\u00e9rtices da prolifera\u00e7\u00e3o celular, usando scaffolds de quitosana, PRP e fibroblastos \n\ncomo fonte de c\u00e9lulas.  \n\nOs principais trabalhos da literatura que descrevem a utiliza\u00e7\u00e3o de scaffolds \n\ncomp\u00f3sitos de AH e CHT, que foram utilizados como base para este trabalho s\u00e3o \n\ndescritos a seguir.  \n\n\n\n26 \n\n \n\nOuyang et al. (2013) patentearam diferentes scaffolds comp\u00f3sitos de quitosana \n\nsol\u00favel combinada com PRP para a repara\u00e7\u00e3o de tecidos, usando trombina e/ ou CaCl2 \n\ncomo agonistas.  \n\nEsponjas de glutamato de quitosana e de hialuronato de s\u00f3dio combinadas com \n\nlisado de plaquetas e preparadas por liofiliza\u00e7\u00e3o utilizando glicina como crioprotetor, \n\nforam usadas por Rossi et al. (2013) como matrizes para a incorpora\u00e7\u00e3o de FCs \n\nderivados do PRP. Os resultados de crescimento celular para fibroblastos obtidos para \n\nas esponjas de CHT e de AH foram similares aos valores encontrados para o lisado de \n\nplaquetas fresco.  \n\nKutlu et al. (2012) prepararam comp\u00f3sitos de quitosana/ PRP por 2 m\u00e9todos \n\ndiferentes: PRP foi adicionado ao gel de quitosana antes da liofiliza\u00e7\u00e3o e PRP foi \n\nembebido no scaffold liofilizado. Estes autores demonstraram que scaffolds de \n\nquitosana, especialmente na forma de g\u00e9is, podem ser apropriados carreadores para o \n\nPRP fornecendo libera\u00e7\u00e3o controlada dos fatores de crescimento.  \n\nUma terapia de etapa \u00fanica para o tratamento de defeitos osteocondrais de \n\ncoelhos utilizando fragmentos aut\u00f3logos de cartilagem e scaffolds compostos de \u00e1cido \n\nhialur\u00f4nico (AH), cola de fibrina humana e PRP foi proposta por Marmotti et al. (2012). \n\nEsses autores observaram que os fragmentos de cartilagem aut\u00f3logos em AH/ cola de \n\nfibrina/ PRP fornecem uma fonte eficiente de c\u00e9lulas e permitem uma melhor repara\u00e7\u00e3o \n\ndo defeito. A cola de fibrina, no entanto, dificultou o processo de cicatriza\u00e7\u00e3o nos \n\ncoelhos.  \n\nFathi (2012) demonstrou que a utiliza\u00e7\u00e3o de PRP sozinho ou em combina\u00e7\u00e3o \n\ncom AH acelerou a cicatriza\u00e7\u00e3o de feridas em coelhos adultos comparado ao AH livre \n\nusado como controle. \n\nA efic\u00e1cia do uso de PRP e da viscossuplementa\u00e7\u00e3o com inje\u00e7\u00f5es intra-\n\narticulares de AH para o tratamento de les\u00f5es degenerativas da cartilagem do joelho e \n\nosteoartrite foram comparadas por Kon et al. (2011). Inje\u00e7\u00f5es aut\u00f3logas de PRP \n\nmostraram maior efic\u00e1cia e maior dura\u00e7\u00e3o que as inje\u00e7\u00f5es de AH na redu\u00e7\u00e3o da dor e \n\ndos sintomas; e recupera\u00e7\u00e3o da fun\u00e7\u00e3o articular. Melhores resultados foram \n\nconseguidos em pacientes mais jovens e em degenera\u00e7\u00f5es da cartilagem menos \n\nintensas, enquanto que um pior resultado foi obtido em articula\u00e7\u00f5es mais degeneradas \n\ne em pacientes mais idosos, em quem os resultados foram semelhantes aos da \n\nviscossuplementa\u00e7\u00e3o. \n\nHe et al. (2010) estudaram a ativa\u00e7\u00e3o e a ades\u00e3o plaquet\u00e1ria em scaffolds de \n\nquitosana e quitosana-heparina combinados com PRP. Eles observaram, in vitro, que \n\n\n\n27 \n\n \n\nos scaffolds de quitosana-heparina quando combinados com PRP apresentam \n\nsupress\u00e3o da ades\u00e3o e ativa\u00e7\u00e3o das plaquetas em rela\u00e7\u00e3o com os scaffolds de \n\nquitosana/PRP. \n\nO efeito de PRP, de esponjas de quitosana e da combina\u00e7\u00e3o deles, na \n\nregenera\u00e7\u00e3o \u00f3ssea de defeitos cranianos de coelhos foi investigado por Oktay et al. \n\n(2010). Para isso, eles criaram e enxertaram 4 defeitos cranianos, com um di\u00e2metro de \n\n4,5 mm com os 3 grupos. Os coelhos foram mortos entre a quarta e oitava semana, e \n\nos defeitos foram analisados histologicamente. Maior forma\u00e7\u00e3o \u00f3ssea foi observada no \n\ngrupo contendo PRP com preenchimento completo do defeito com osso trabecular. Os \n\ndefeitos que foram preenchidos somente com esponjas de quitosana mostraram uma \n\nquantidade limitada de osso, e a presen\u00e7a de tecido fibroso.  \n\nUma nova abordagem terap\u00eautica para estimular a regenera\u00e7\u00e3o de feridas \n\ncomplexas em membros inferiores, com base em um tratamento composto de PRP e \n\ncurativo de AH foi avaliada por Cervelli et al. (2011). Ap\u00f3s um \u00fanico tratamento, os \n\nautores observaram que o tempo m\u00e9dio de re-epiteliza\u00e7\u00e3o foi de 8,1 semanas em \n\n73,3% dos pacientes tratados com o PRP-AH versus 30% dos pacientes tratados \n\napenas com AH. \n\nUm comp\u00f3sito injet\u00e1vel de fosfato tric\u00e1lcico/ quitosana (FTC/CHT) e PRP para a \n\nreconstru\u00e7\u00e3o de defeitos de t\u00edbias de cabras foi preparado por Bi et al. (2010). Esses \n\nautores mostraram que a adi\u00e7\u00e3o de PRP aumentou a biocompatibilidade e a \n\nosteocondutividade do FTC/CHT sem comprometer sua for\u00e7a mec\u00e2nica e injetabilidade. \n\nChang et al. (2009) mostraram que comp\u00f3sitos preparados pela associa\u00e7\u00e3o de \n\nPRP ativado e microesferas de CaSO4/ quitosana, preparadas utilizando campo \n\neletrost\u00e1tico de alta tens\u00e3o, melhoraram a regenera\u00e7\u00e3o \u00f3ssea em torno dos alv\u00e9olos \n\norais de porcos.  \n\nA possibilidade de utilizar quitosana como substituto da trombina durante a \n\nprepara\u00e7\u00e3o PRP foi avaliada por Shen et al. (2006). Os resultados obtidos por estes \n\nautores mostraram aumento na ades\u00e3o e da agrega\u00e7\u00e3o de plaquetas, al\u00e9m de maiores \n\nconcentra\u00e7\u00f5es de fatores de crescimento do PRP ap\u00f3s utiliza\u00e7\u00e3o da quitosana, \n\nsugerindo que quitosana e/ ou seus derivados podem substituir a trombina em \n\nprepara\u00e7\u00f5es do PRP. \n\n \n\n2.6. Refer\u00eancias \n\n \n\nADEKOGBE, I.; GHANEM, A. Fabrication and characterization of DTBP-crosslinked \n\n\n\n28 \n\n \n\nchitosan scaffolds for skin tissue engineering. Biomaterials, vol.26, p.7241\u20137250, 2005. \n\nAGNIHOTRI, S.A.; MALLIKARJUNA, N.N.; AMINABHAVI, T.M. Recent advances on \nchitosan-based micro- and nanoparticles in drug delivery. Journal Controlled Release, \nvol.100, n.1, p.5-28, 2004. \n\nAGRAWAL, C.M.; RAY, R.B. Biodegradable polymeric scaffolds for musculoskeletal \ntissue engineering. Journal of Biomedical Materials Research \u2013 Part A, vol.55, \np.141\u2013150, 2001. \n\nALSOUSOU, J.; THOMPSON, M.; HULLEY, P.; NOBLE, A.; WILLETT, K. The biology of \nplatelet-rich plasma and its application in trauma and orthopaedic surgery. Journal of \nBone and Joint Surgery \u2013 Part B, vol.91, p.987-96, 2009. \n\nAMARAL, I.F.; SAMPAIO, P.; BARBOSA, M.A. Three-dimensional culture of human \nosteoblastic cells in chitosan sponges: The effect of the degree of acetylation. Journal \nof Biomedical Materials Research \u2013 Part A, vol.76, p.335\u2013346, 2006. \n\nANITUA, E. Plasma rich in growth factors: preliminary results of use in the preparation of \nfuture sites for implants. International Journal of Oral &amp; Maxillofacial Implants, vol.4, \np.529-535, 1999. \n\nANITUA, E.; ALKHRAISAT, M.H.; ORIVE, G. Perspectives and challenges \ninregenerative medicine using plasma rich in growth factors. Journal of Controlled \nRelease, vol.157, p.29-38, 2012. \n\nANTONOV, S.F.; KRYZHANOVSKAYA, E.V.; FILIPPOV, Y.I.; SHINKAREV, S.M.; \nFROLOVA, M.A. Study of Wound-Healing Properties of Chitosan. Russian Agricultural \nSciences, vol.34, n.6, p.426\u2013427, 2008. \n\nBAILEY, A.; KAPUR, S.; KATZ, A.J. Characterization of adipose-derive stem cells: an \nupdate. Current Stem Cell Research &amp; Therapy, vol.5, p.95\u2013102, 2010. \n\nBALAZS, E.A. Sodium hyaluronate and viscosurgery. In: MILLER, D.; STEGMANN, R. \n(Ed.). Healon (sodium hyaluronate). A guide to its use in Ophthalmic Surgery. New \nYork: Wiley, 1983, p. 5-28.  \n\nBALAZS, E.A.; DENLINGER, J.L. Viscosupplementation: a new concept in the treatment \nof osteoarthritis. Journal of Rheumatology, vol.39, p.3-9, 1993. \n\nBAND, P.A. Hyaluronan derivatives: chemistry and clinical applications. In: \nLAURENT T.C. (Eds.). The chemistry biology and medical applications of hyaluronan \nand its derivatives. London: Portland Press, p. 33-42, 1998. \n\nBARNETT, M.D.; POMEROY, G.C. Use of Platelet-Rich Plasma and Bone Marrow Y \nDerived Mesenchymal Stem Cells. Techniques in Foot and Ankle Surgery, vol.6, n.2, \np.89\u201394, 2007. \n\n\n\n29 \n\n \n\nBELLINI, D.; PAPARELLA, A.; O\u2019REGAN, M.; CALLEGARO, L. Autocross-linked \nhyaluronic acid and related pharmaceutical compositions for the treatment of \narthrophaties. United States Patent: U.S. 6,251,876 B1, 2001. \n\nBERGER, J.; REIST, M.; MAYER, J.; FELT, O.; PEPPAS, N.; GURNY, R. Structure and \ninteractions in covalently and ionically crosslinked chitosan hydrogels for biomedical \napplications. European Journal of Pharmaceutics and Biopharmaceutics, vol.57, \np.19\u201334, 2004. \n\nBERTHIAUME, F.; MAGUIRE, T.J.; YARMUSH, M.L. Tissue Engineering and \nRegenerative Medicine: History, Progress, and Challenges. Annual Review of \nChemical and Biomolecular Engineering, vol.2, p.403\u201330, 2011. \n\nBERTRAM, U.; BODMEIER, R. In situ gelling, bioadhesive nasal inserts for extended \ndrug delivery: In vitro characterization of a new nasal dosage form. European Journal \nof Pharmaceutical Sciences, vol.27, n.1, p.62-71, 2006. \n\nBHATTACHARYYA, S.; GUILLOT, S.; DABBOUE, H.; TRANCHANT, J.F.; SALVETAT, \nJ.P. Carbon nanotubes as structural nanofibers for hyaluronic acid hydrogel scaffolds. \nBiomacromolecules, vol.9, n.2, p.505-509, 2008.  \n\nBI, L.; CHENG, W.; FAN, H.; PEI, G. Reconstruction of goat tibial defects using an \ninjectable tricalcium phosphate/chitosan in combination with autologous platelet-rich \nplasma. Biomaterials, vol.31, p.3201\u20133211, 2010. \n\nBOCCACCINI, AR.; ROETHER, J.A.; HENCH, L.L.; MAQUET, V.; JEROME, R. \nComposites approach to tissue engineering. Ceramic Engineering and Science, \nvol.23, n.4, p.805-816, 2002. \n\nCALVO, P.; VILA-JATO, J.L.; ALONSO, M.J. Evaluation of cationic polymer-coated \nnanocapsules as ocular drug carriers. International Journal of Pharmaceutics, \nvol.153, p.41\u201350, 1997. \n\nCERVELLI, V.; LUCARINI, L.; SPALLONE, D.; PALLA, L.; COLICCHIA, G.M.; \nGENTILE, P.; ANGELIS, B. Use of Platelet-Rich Plasma and Hyaluronic Acid in the \nLoss of Substance with Bone Exposure. Advances in Skin &amp; Wound Care, vol.24, n.4, \np.176-181, 2011. \n\nCHANG, S.J.; KUO, S.M.; LAN, C-W.; MANOUSAKAS, I.; TSAI, P.H. Evaluation of \nchitosan/CaSO4/ platelet-rich plasma microsphere composites as alveolus osteogenesis \nmaterial. Biomedical Engineering: Applications, Basis and Communications, \nvol.21, n.2, p.115\u2013122, 2009. \n\nCHAVEZ-MUNOZ, C.; NGUYEN, K.T.; XU, W.; HONG, S.J.; MUSTOE, T.A.; GALIANO, \nR.D. Transdifferentiation of adipose-derived stem cells into keratinocyte-like cells: \nengineering a stratified epidermis. PLOS One, vol.8, n.12, p.1-13, 2013. \n\nCHEN, L.; LU, X.; LI, S.; SUN, Q.; LI, W.; SONG, D. Sustained Delivery of BMP-2 and \n\n\n\n30 \n\n \n\nPlatelet rich Plasma-released Growth Factors Contributes to Osteogenesis of Human \nAdipose-derived Stem Cells. Orthopedics, vol.35, n.9, p.e1402\u2013e1409, 2012. \n\nCOIMBRA, P.; ALVES, P.; VALENTE, T.A.M.; SANTOS, R.; CORREIA, I.J.; FERREIRA, \nP. Sodium hyaluronate/chitosan polyelectrolyte complex scaffolds for dental pulp \nregeneration: Synthesis and characterization. International Journal of Biological \nMacromolecules, vol.49, p.573\u2013 579, 2011. \n\nCOLE, B.J.; SEROYER, S.T.; FILARDO, G.; BAJAJ, S.; FORTIER, L.A. Platelet-Rich \nPlasma: Where Are We Now and Where Are We Going? Sports Health, vol.2, n.3, \np.203-210, 2010. \n\nCOLLINS, M.N.; BIRKINSHAW, C. Investigation of the Swelling Behavior of Crosslinked \nHyaluronic Acid Films and Hydrogels Produced Using Homogeneous Reactions. \nJournal of Applied Polymer Science, vol.109, p.923-931, 2008. \n\nCORREIA, C.R.; TEIXEIRA, L.S.M.; MORONI, L.; REIS, R.L.; VAN BLITTERSWIJK, \nC.A.; KARPERIEN, M.; MANO, J.F. Chitosan Scaffolds Containing Hyaluronic Acid for \nCartilage Tissue Engineering. Tissue Engineering \u2013 Part C, vol.17, n.7, p. 717-730, \n2011. \n\nCOSTA-PINTO, A.R.; REIS, R.L.; NEVES, N.M. Scaffolds Based Bone Tissue \nEngineering: The Role of Chitosan. Tissue Engineering \u2013 Part B, vol.17, p.331\u2013347, \n2011. \n\nCRANE, D.; EVERTS, P.A.M. Platelet Rich Plasma (PRP) Matrix Grafts, PPM \nCommunications, vol.8, p.1-10, 2008. \n\nCRUZ, D.M.G.; IVIRICO, J.L.E.; GOMES, M.M.; RIBELLES, J.L.G.; S\u00c1NCHEZ, M.S.; \nReis, R.L.; MANO, J.F. Chitosan microparticles as injectable scaffolds for tissue \nengineering. Journal of Tissue Engineering and Regenerative Medicine, vol.2, \np.378\u2013380, 2008. \n\nCUST\u00d3DIO, C.A.; SANTO, V.R.; OLIVEIRA, M.B.; GOMES, M.E.; REIS, R.L.; MANO, \nJ.F. Functionalized Microparticles Producing Scaffolds in Combination with Cells. \nAdvanced Functional Materials, vol.24, p.1391\u20131400, 2014. \n\nDAAR, A.S.; GREENWOOD, H.L. A proposed definition of regenerative medicine. \nJournal of Tissue Engineering and Regenerative Medicine, vol.1, p.179\u2013184, 2007. \n\nDAI, T.; TANAKA, M.; HUANG, Y.Y.; HAMBLIN, M.R. Chitosan preparations for wounds \nand burns: antimicrobial and wound-healing effects. Expert Review of Anti-infective \nTherapy, vol.9, p.857\u2013879, 2011. \n\nDE BELDER, A.; MALSON, T. Gel for preventing adhesion between body tissues and \nprocess for its production. Patent: WO 1986/000/912 A1, 1986. \n\nDE VOS, R.J.; WEIR, A.; VAN SCHIE, H.T.M.; BIERMA-ZEINSTRA, S.M.A.; VERHAAR, \n\n\n\n31 \n\n \n\nJ.A.N.; WEINANS, H.; TOL, J.L. Platelet-Rich Plasma Injection for Chronic Achilles \nTendinopathy. Journal of the American Medical Association, vol.303, n.2, p.144-149, \n2010. \n\nDELLA VALLE, F. Crosslinked carboxy polysaccharides. Patent: EP 341,745, 1994 \n\nDELLA VALLE, F.; ROMEO, A. Cross-linked carboxy polysaccharides. Patent: WO/ \n1989/10941, 1989. \n\nEHRENFEST, D.M.D.; RASMUSSON, L.; ALBREKTSSON, T. Classification of platelet \nconcentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich \nfibrin (L-PRF). Trends Biotechnology, vol.27, p.158-167, 2009. \n\nENGEBRETSEN, L.; STEFFEN, K.; ALSOUSOU, J.; ANITUA, E.; BACHL, N.; \nDEVILEE, R.; EVERTS, P.; HAMILTON, B.; HUARD, J.; JENOURE, P.; KELBERINE, \nF.; KON, E.; MAFFULLI, N.; MATHESON, G.; MEI- DAN, O.; MENETREY, J.; \nPHILIPPON, M.; RANDELLI, P.; SCHAMASCH, P.; SCHWELLNUS, M.; VERNEC, A.; \nGEOFFREY, V. IOC consensus paper on the use of platelet-rich plasma in sports \nmedicine. British Journal of Sports Medicine, vol.44, p.1072\u20131081, 2010. \n\nEVERTS P.A.; JAKIMOWICZ, J.J.; VAN BEEK, M.; SCH\u00d6NBERGER, J.P.A.M.; \nDEVILEE, R.J.J.; OVERDEVEST E.P.; KNAPE, J.T.A.; VAN ZUNDERT, A. Reviewing \nthe Structural Features of Autologous Platelet-Leukocyte Gel and Suggestions for Use \nin Surgery. European Surgical Research, vol.39, p.199\u2013207, 2007. \n\nEVERTS, P.A.; DEVILEE, R.J.J.; MAHONEY, C.B.; VAN, E.R.P.A.; OOSTERBOS, \nC.J.M.; STELLENBOOM, M.; KNAPE, J.T.A.; VAN ZUNDERT, A. Exogenous \napplication of platelet-leukocyte gel during open subacromial decompression contributes \nto improved patient outcome. European Surgical Research, vol.40, p.203-210, 2008. \n\nFATHI, W.K. The Effect of Hyaluronic Acid and Platelet - Rich Plasma on Soft Tissue \nWound Healing: An Experimental Study on Rabbits. Al\u2013Rafidain Dental Journal, \nvol.12, n.1, p.115-125, 2012. \n\nFERRARI, M.; ZIA, S.; VALBONESI, M.; HENRIQUET, F.; VENERE, G.; SPAGNOLO, \nS.; GRASSO, M.A.; PANZANI, I. A new technique for hemodilution, preparation of \nautologous platelet-rich plasma and intraoperative blood salvage in cardiac surgery. \nInternational journal of artificial organs, vol.10, n.1, p.47-50, 1987. \n\nFOSTER, T.E.; PUSKAS, B.L.; MANDELBAUM, B.R.; GERHARDT, M.B.; RODEO, S.A. \nPlatelet-Rich Plasma From Basic Science to Clinical Applications. American Journal of \nSports Medicine, vol.37, n.11, p.2258-2272, 2009. \n\nGARG, H.G.; HALES, C.A. Chemistry and Biology of Hyaluronan, Boston, USA, \nElsevier, 2004. \n\nGEORGE, J.; ONODERA, J.; MIYATA, T. Biodegradable honeycomb collagen scaffold \nfor dermal tissue engineering. Journal of Biomedical Materials Research \u2013 Part A, \n\n\n\n32 \n\n \n\nvol.87, p.1103-1111, 2008. \n\nGONSALVES, A.A.; ARA\u00daJO, C.R.M.; SOARES, N.A.; GOULART, M.O.F.; DE ABREU, \nF.C. Diferentes estrat\u00e9gias para a reticula\u00e7\u00e3o de quitosana. Qu\u00edmica Nova, vol.XY, \nn.00, p.1-9, 2011.  \n\nGREENWOOD, H.L.; SINGER, P.A.; DOWNEY, G.P.; MARTIN, D.K.; \nTHORSTEINSD\u00d3TTIR, H.; DAAR, A.S. Regenerative Medicine and the Developing \nWorld. PLoS Medicine, vol.3, n.9, p.1496-1500, 2006. \n\nGUERCIO, A.; DI MARCO, P.; CASELLA, S.; RUSSOTTO, L.; PUGLISI, F.; MAJOLINO, \nC.; GIUDICE, E.; DI BELLA, S.; PURPARI, G.; CANNELLA, V.; PICCIONE, G.; \nMesenchymal stem cells derived from subcutaneous fat and platelet-rich plasma used in \nathletic horses with lameness of the superficial digital flexor tendon. Journal of Equine \nVeterinary Science, vol.35, n.1, p. 19-26, 2014. \n\nGUTOWSKA, A.; JEONG, B.; JASIONOWSKI, M. Injectable Gels for Tissue \nEngineering. Anatomical Record, vol.263, p.342-349, 2001.  \n\nHAHN, S.K,; OH, E.J.; MIYAMOTO, H.; SHIMOBOUJI, T. Sustained release formulation \nof erythropoietin using hyaluronic acid hydrogels crosslinked by Michael addition. \nInternational Journal of Pharmaceutics, vol.322, p.44-51, 2006. \n\nHE, P.; DAVIS, S.S.; ILLUM, L. In vitro evaluation of the mucoadhesive properties of \nchitosan microspheres. International Journal of Pharmaceutics, vol.166, p.75\u201388, \n1998. \n\nHOKUGO, F.; OZEKI, M.; KAWAKAMI, O.; SUGIMOTO, K.; MUSHIMOTO, K.; MORITA, \nS.; TABATA, Y. Augmented Bone Regeneration Activity of Platelet-Rich Plasma by \nBiodegradable Gelatin Hydrogel. Tissue Engineering, vol.11, n.7/8, p.1224\u20131233, \n2005.  \n\nHOLMSTR\u00d6M, B.; RICICI, J. Production of Hyaluronic Acid by a Streptococcal Strain in \nBatch Culture. Journal of Applied Microbiology, vol.15, p.1409-1413, 1967. \n\nHOU, Q.; DE BANK, P.A.; SHAKESHEFF, K.M. Injectable scaffolds for tissue \nregeneration. Journal of Materials Chemistry, vol.14, p.1915-1923, 2004. \n\nHUANG, Z-M.; ZHANG, Y-Z.; KOTAKI, M.; RAMAKRISHN, S. A review on polymer \nnanofibers by electrospinning and their applications in nanocomposites. Composites \nScience and Technology, vol.63, n.15, p.2223\u20132253, 2003. \n\nHUTMACHER, D.W. Scaffolds in tissue engineering bone and cartilage. Biomaterials, \nvol.21, p.2529-2543, 2000. \n\nISHIDA, K.; KURODA, R.; MIWA, M.; TABATA, Y.; HOKUGO, A.; KAWAMOTO, T.; \nSASAKI, K.; DOITA, M.; KUROSAKA, M. The Regenerative Effects of Platelet-Rich \nPlasma on Meniscal Cells In Vitro and Its In Vivo Application with Biodegradable Gelatin \n\n\n\n33 \n\n \n\nHydrogel. Tissue Engineering, vol.13, n.5, p.1103-1115, 2007. \n\nIWASAKI, N.; KASAHARA, Y.; YAMANE, S.; IGARASHI, T.; MINAMI, A.; NISIMURA, S-\nI. Chitosan-Based Hyaluronic Acid Hybrid Polymer Fibers as a Scaffold Biomaterial for \nCartilage Tissue Engineering. Polymers, vol.3, p.100-113, 2011. \n\nJIA, X.; PETERS, P.G.; SCHON, L. The use of platelet-rich plasma in the management \nof foot and ankle conditions. Operative Techniques in Sports Medicine, vol.19, p.177-\n184, 2011. \n\nJIANG, Z-Q.; LIU, H-Y.; ZHANG, L-P.; WU, Z-Q.; SHANG, D-Z. Repair of calvarial \ndefects in rabbits with platelet-rich plasma as the scaffold for carrying bone marrow \nstromal cells. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and \nEndodontology, vol.113, p.327-333, 2012. \n\nJUDITH, R.; NITHYA, M.; ROSE, C.; MANDAL, A.B. Biopolymer gel matrix as acellular \nscaffold for enhanced dermal tissue regeneration. Biologicals, vol.40, p.231-239, 2012. \n\nJUDITH, R.; NITHYA, M.; ROSE, C.; MANDAL, AB. Application of a PDGF-containing \nnovel gel for cutaneous wound healing. Life Sciences, vol.87, p.1\u20138, 2010. \n\nKAKUDO, N.; MINAKATA, T.; MITSUI, T.; KUSHIDA, S.; NOTODIHARDJO, F.Z.; \nKUSUMOTO, K. Proliferation-promoting effect of platelet-rich plasma on human \nadipose-derived stem cells and human dermal fibroblasts. Plastic and Reconstructive \nSurgery, vol.122, p.1352\u20131360, 2008. \n\nKAUX, J-F.; CRIELAARD, J-M. Platelet-rich plasma application in the management of \nchronic tendinopathies. Acta Orthopaedica Belgica, vol.79, p.10-15, 2013. \n\nKAWASUMI, M.; KITOH, H.; SIWICKA, K.A.; ISHIGURO, N. The effect of the platelet \nconcentration in platelet-rich plasma gel on the regeneration of bone. Journal of bone \nand joint surgery, vol.90B, p.966-972, 2008. \n\nKIM, J.; KIM, I.S.; CHO, T.H.; KIM, H.C.; YOON, S.J.; CHOI, J.; PARK, Y.; SUN, K.; \nHWANG, S.J.; In vivo evaluation of MMP sensitive high-molecular weight HA-based \nhydrogels for bone tissue engineering. Journal of Biomedical Materials Research \u2013 \nPart A, vol.95, p.673\u2013681, 2010. \n\nKIM, S.J.; HAHN, S.K.; KIM, M.J.; KIM, D.H.; LEE, Y.P. Development of a novel \nsustained release formulation of recombinant human growth hormone using sodium \nhyaluronate microparticles. Journal of Controlled Release, vol.104, p.323\u2013335, 2005. \n\nKIM, S.J.; LEE, K.J.; KIM, S.I. Swelling Behavior of Polyelectrolyte Complex Hydrogels \nComposed of Chitosan and Hyaluronic Acid. Journal of Applied Polymer Science, \nvol.93, p.1097-1101, 2004a. \n\nKIM, S.J.; SHIN, S.R.; LEE, K.B.; PARK, Y.D.; KIM, S.I. Synthesis and Characteristics of \nPolyelectrolyte Complexes Composed of Chitosan and Hyaluronic Acid. Journal of \n\n\n\n34 \n\n \n\nApplied Polymer Science, vol.91, p.2908-2913, 2004b. \n\nKOGAN, G.; \u0160OLT\u00c9S, L.; STERN, R. Hyaluronic Acid: a natural biopolymer with a \nbroad range of biomedical and industrial applications. Biotechnology Letters, vol.29, \np.17-25, 2007. \n\nKON, E.; BUDA, R.; FILARDO, G.; DI MARTINO, A.; TIMONCINI, A.; CENACCHI, A.; \nFORNASARI, PA.; GIANNINI, S.; MARCACCI, M. Platelet-rich plasma: intra-articular \nknee injections produced favorable results on degenerative cartilage lesions. Knee \nSurgery, Sports Traumatology, Arthroscopy, vol.18, p.472\u2013479, 2010. \n\nKON, E.; MANDELBAUM, B.; BUDA, R.; FILARDO, G.; DELCOGLIANO, M.; \nTIMONCINI, A.; FORNASARI, P.M.; GIANNINI, S.; MARCACCI, M. Platelet-Rich \nPlasma Intra-Articular Injection Versus Hyaluronic Acid Viscosupplementation as \nTreatments for Cartilage Pathology: From Early Degeneration to Osteoarthritis. \nArthroscopy: The Journal of Arthroscopic and Related Surgery, vol.27, n.11, \np.1490-1501, 2011. \n\nKUO, J.W.; SWANN, D.A.; PRESTWICH, G.D. Water-insoluble derivatives of hyaluronic \nacid and their methods of preparation and use. United States Patent: U.S. 6,013,679, \n2000. \n\nKUTLU, B.; AYDIN, R.S.T.; AKMAN, A.C.; G\u00dcM\u00dc?DERELIO?LU, M.; NOHUTCU, R.M. \nPlatelet-rich plasma-loaded chitosan scaffolds: Preparation and growth factor release \nkinetics. Journal of Biomedical Materials Research \u2013 Part B, vol.101, p.28\u201335, 2012. \n\nLANGER, P.; VACANTI, J.P. Tissue Engineering. Science, vol.260, n.5110, p.920-926, \n1993. \n\nLEE, S.B.; LEE, Y.M.; SONG, K.W.; PARK, M.H. Preparation and Properties of \nPolyelectrolyte Complex Sponges Composed of Hyaluronic Acid and Chitosan and Their \nBiological Behaviors. Journal of Applied Polymer Science, vol.90, p.925\u2013932, 2003. \n\nLEE, Y.M.; PARK, Y.J.; LEE, S.J.; KU, Y.; HAN, S.B.; CHOI, S.M.; KLOKKEVOLD, P.R.; \nCHUNG, C.P. Tissue engineered bone formation using chitosan/tricalcium phosphate \nsponges. Journal of Periodontology, vol.71, p.410-417, 2000. \n\nLI, X.; MIN, M.; DU, N.; GU, Y.; HODE, T.; NAYLOR, M.; CHEN, D.; NORDQUIST, R.E.; \nCHEN, W.R. Chitin, chitosan, and glycated chitosan regulate immune responses: the \nnovel adjuvants for cancer vaccine. Clinical and Developmental Immunology, \nvol.387023, p.1-8, 2013. \n\nLIN, G.; GARCIA, M.; NING, H.; BANIE, L.; GUO, Y-L.; LUE, T.F.; LIN, C-S. Defining \nStem and Progenitor Cells within Adipose Tissue. Stem cells and development, vol.17, \np.1053\u20131064, 2008. \n\nLIN, Y-C.; TAN, F-J.; MARRA, K.G.; JAN, S-S.; LIU, D-C. Synthesis and \ncharacterization of collagen/ hyaluronan/ chitosan composite sponges for potential \n\n\n\n35 \n\n \n\nbiomedical applications. Acta Biomaterialia, vol.5, p.2591-2600, 2009. \n\nLIU, X.; MA, P.X. Polymeric Scaffolds for Bone Tissue Engineering. Annals of \nBiomedical Engineering, vol.32, n.3, p.477\u2013486, 2004. \n\nLIU, X.F.; GUAN, Y.L.; YANG, D.Z.; LI, Z.; YAO, K.D. Antibacterial action of chitosan \nand carboxymethylated chitosan. Journal of Applied Polymer Science, vol.79, \np.1324\u20131335, 2001. \n\nMADIHALLY, S.V.; MATTHEW, H.W.T. Porous chitosan scaffolds for tissue \nengineering. Biomaterials, vol.20, p.1133\u20131142, 1999.  \n\nMAGNANI, A.; RAPPUOLI, R.; LAMPONI, S.; BARBUCCI, R. Novel Polysaccharide \nHydrogels: Characterization and Properties. Polymers for Advanced Technologies, \nvol.11, p.488-495, 2000. \n\nMAJIMA, T.; IRIE, T.; SAWAGUCHI, N.; FUNAKOSHI, T.; IWASAKI, N.; HARADA, K.; \nMINAMI, A.; NISHIMURA, S.-I. Chitosan-based hyaluronan hybrid polymer fiber scaffold \nfor ligament and tendon tissue engineering. Proceedings of the Institution of \nMechanical Engineers \u2013 Part H: J. Engineering in Medicine, vol. 221, p.537-546, \n2007. \n\nMALSON, T.; LINDQVIST, B. Gels of crosslinked hyaluronic acid for use as a vitreous \nhumor substitute. Patent WO 1986/000/079, 1986. \n\nMANFERDINI, C.; GUARINO, V.; ZINI, N.; RAUCCI, M.G.; FERRARI, A.; GRASSI, F.; \nGABUSI, E.; SQUARZONI, S.; FACCHINI, A.; AMBROSIO, L.; LISIGNOLI, G. \nMineralization behavior with mesenchymal stromal cells in a biomimetic hyaluronic acid-\nbased scaffold. Biomaterials, vol.31, p.3986\u20133996, 2010. \n\nMANJUBALA, I.; SCHELER, S.; B?SSERT, J.; JANDT, K.D. Mineralisation of chitosan \nscaffolds with nano-apatite formation by double diffusion technique. Acta Biomaterialia, \nvol.2, p.75-84, 2006. \n\nMANN, B.K. Biologic gels in tissue engineering. Clinics in Plastic Surgery, vol.30, \np.601\u2013 609, 2003. \n\nMARIANI, E.; FILARDO, G.; CANELLA, V.; BERLINGERI, A.; BIELLI, A.; CATTINI, L.; \nLANDINI, M.P.; KON, E.; MARCACCI, M.; FACCHINI, A. Platelet-rich plasma affects \nbacterial growth in vitro. Cytotherapy, vol.16, p.1294-1304, 2014. \n\nMARMOTTI, A.; BRUZZONE, M.; BONASIA, D.E.; CASTOLDI, F.; ROSSI, R.; PIRAS, \nL.; MAIELLO, A.; REALMUTO, C.; PERETI, G.M. One-step osteochondral repair with \ncartilage fragments in a composite scaffold. Knee Surgery, Sports Traumatology, \nArthroscopy, vol.20, n.12, p.2590-2601, 2012. \n\nMARX, R.E. Platelet-rich plasma: Evidence to support its use. Journal of Oral and \nMaxillofacial Surgery, vol.62, p.489\u2013496, 2004. \n\n\n\n36 \n\n \n\nMARX, R.E.; CARLSON, E.R.; EICHSTAEDT, R.M.; SCHIMMELE, S.R.; STRAUSS, \nJ.E.; GEORGEFF, K.R. Platelet-rich plasma Growth factor enhancement for bone grafts. \nOral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, vol.85, p.638-646, \n1998. \n\nMATHEWS, S.; BHONDE, R.; GUPTA, P.K.; TOTEY, S. A novel tripolymer coating \ndemonstrating the synergistic effect of chitosan, collagen type 1 and hyaluronic acid on \nosteogenic differentiation of human bone marrow derived mesenchymal stem cells. \nBiochemical and Biophysical Research Communications, vol.414, p.270\u2013276, 2011. \n\nMCCARREL, T.; FORTIER, L. Temporal Growth Factor Release from Platelet-Rich \nPlasma, Trehalose Lyophilized Platelets, and Bone Marrow Aspirate and Their Effect on \nTendon and Ligament Gene Expression. Journal of Orthopaedic Research, vol.27, \np.1033\u20131042, 2009. \n\nMEYER, K.; PALMER, J. The polysaccharide of vitreous humor. Journal of Biological \nChemistry, vol.107, p.629-634, 1934. \n\nMIKOS, A.G.; THORSEN, A.J.; CZERWONKA, L.A.; BAO, Y.; LANGER, R.; WINSLOW, \nD.N.; VACANTI, J.P. Preparation and characterization of (L-Lactic Acid) foams. \nPolymer, vol.35, p.1068-1077, 1994. \n\nMISHRA, A.; HARMON, K.; WOODALL, J.; VIEIRA, A. Sports Medicine Applications of \nPlatelet Rich Plasma. Current Pharmaceutical Biotechnology, vol.13, p.1185-1195, \n2012. \n\nMONHEIT, G.D.; COLEMAN, K.M. Hyaluronic Acid Fillers. Dermatology and Therapy, \nvol.19, p.141-150, 2006. \n\nMONTEIRO, N.S. Caracteriza\u00e7\u00e3o de matrizes de Quitosana para a regenera\u00e7\u00e3o de \ntecidos produzidas pela t\u00e9cnica de TIPS. Disserta\u00e7\u00e3o de Mestrado em Engenharia \nBiom\u00e9dica, Faculdade de Ci\u00eancias e Tecnologia da Universidade Nova de Lisboa, \n2008. \n\nMUCHA, M.; MICHALAK, I.; BALCERZAK, J.; TYLMAN, M. Chitosan scaffolds, films \nand microgranules for medical application - preparation and drug release studies, \nPolimery, vol.57, n.10, p.714-721, 2012. \n\nMUZZARELLI, R. Chitosan in: MUZZARELLI R. (Ed.). Natural Chelating Polymers. \nOxford: Pergamon Press, 1973, p.144\u2013176. \n\nMUZZARELLI, R.; TARSI, R.; FILIPPINI, O.; GIOVANETTI, E.; BIAGINI, G.; VARALDO, \nP.E. Antimicrobial properties of N-carboxybutyl chitosan. Antimicrobial Agents and \nChemotherapy, vol.34, p.2019-2023, 1990. \n\nMUZZARELLI, R.A.A. Human enzymatic activities related to the therapeutic \nadministration of chitin derivatives. Cellular and Molecular Life Sciences, vol.53, \np.131\u2013140, 1997. \n\n\n\n37 \n\n \n\nNAM, Y.S.; YOON, J.J.; PARK, T.G. A novel fabrication method for macroporous \nscaffolds using gas foaming salt as porogen additive. Journal of Biomedical Materials \nResearch \u2013 Part B, vol.53, p.1\u20137, 2000. \n\nNGUYEN, R.T.; BORG-STEIN, J.; MCINNIS, K. Applications of Platelet-Rich Plasma in \nMusculoskeletal and Sports Medicine: An Evidence-Based Approach. American \nJournal of Physical Medicine &amp; Rehabilitation, vol.3, p.226-250, 2011. \n\nNISHI, C.; NAKAJIMA, N.; IKADA, Y. In vitro evaluation of cytotoxicity of diepoxy \ncompounds used for biomaterial modification. Journal of Biomedical Materials \nResearch, vol.29, n.7, p.829\u2013834, 1995. \n\nNORDTVEIT, R.J.; V\u00c2RUM, K.M.; SMIDSRD, O. Degradation of partially N-acetylated \nchitosans with hen egg white and human lysozyme. Carbohydrate Polymers, vol.29, \np.163-167, 1996. \n\nNWE, N.; FURUIKE, T.; TAMURA, H. The Mechanical and Biological Properties of \nChitosan Scaffolds for Tissue Regeneration Templates Are Significantly Enhanced by \nChitosan from Gongronella butleri. Materials, vol.2, p.374-398, 2009. \n\nOHRI, R.; HAHN, S.K.; STAYTON, P.S.; HOFFMAN, A.S.; GIACHELLI, M. Hyaluronic \nacid grafting mitigates calcification of glutaraldhyde-fixed bovine pericardium. Journal of \nBiomedical Materials Research \u2013 Part A, vol.70, p.159\u2013165, 2004. \n\nOKTAY, E.O.; DEMIRALP, B.; DEMIRALP, B.; SENEL, S.; AKMAN, A.; ERATALAY, K.; \nAKINCIBAY, H. Effects of platelet-rich plasma and chitosan combination on bone \nregeneration in experimental rabbit cranial defects. Journal of Oral Implantology, \nvol.36, p.175\u2013184, 2010. \n\nOUYANG, W.; BUSCHMANN, M.; CHEVRIER, A. Soluble physiological chitosan \nformulations combined with platelet-rich plasma (PRP) for tissue repair. United States \nPatent Application Publication: U.S. 0,004,474 A1, 2013.  \n\nPAK, J.; CHANG, J-J.; LEE, J.H.; LEE, S.H. Safety reporting implantation of autologous \nadipose tissue-derived stem cells with platelet-rich plasma into human articular joints. \nBMC Musculoskeletal Disorders, vol.14, n.337, p.1-8, 2013. \n\nPAVIA, F.C.; CARRUBBA, V.L.; PICCAROLO, S.; BRUCATO, V. Characterization of \nChitosan Based Hybrid Nanofiber Scaffolds for Tissue Engineering. Journal of \nBiomedical Materials Research \u2013 Part A, vol.86, n.2, p.459\u2013466, 2008. \n\nPELTOLA, S.M.; MELCHELS, F.P.; GRIJPMA, D.W.; KELLOM\u00c4KI, M. A review of rapid \nprototyping techniques for tissue engineering purposes. Annals of Medicine, vol.40, \nn.4, p.268-280, 2008. \n\nPIRES, A.M.B.; MACEDO, A.C.; EGUCHI, S.Y.; SANTANA, M.H.A. Microbial production \nof hyaluronic acid from agricultural resource derivatives. Bioresource Technology, \nvol.101, p.6506-6509, 2010. \n\n\n\n38 \n\n \n\nRADICE, F.; Y\u00c1NEZ, R.; GUTI\u00c9RREZ, V.; ROSALES, J.; PINEDO, M.; CODA, S. \nComparison of Magnetic Resonance Imaging Findings in Anterior Cruciate Ligament \nGrafts With and Without Autologous Platelet-Derived Growth Factors. Arthroscopy: \nThe Journal of Arthroscopic and Related Surgery, vol.26, n.1, p.50-57, 2010. \n\nREIS, R.L.; NEVES, N.M.; MANO, J.F.; GOMES, M.E.; MARQUES, A.P.; AZEVEDO \nH.S. (Eds.). Natural-based polymers for biomedical applications. Cambridge: \nWoodhead Publishing, 2008. \n\nREN, D.; YI, H.; WANG, W.; MA, X. The enzymatic degradation and swelling properties \nof chitosan matrices with different degrees of N-acetylation. Carbohydrate Research, \nvol.340, p.2403-2410, 2005. \n\nROMAGNOLI, M.; BELMONTESI, M. Hyaluronic acid-based fillers: theory and pratice. \nClinics in Dermatology, vol.26, p.123-159, 2008. \n\nROSSI, S.; FACCENDINI, A.; BONFERONI, M.C.; FERRARI, F.; SANDRI, G.; DEL \nFANTE, C.; PEROTTI, C.; CARAMELLA, C.M.; Sponge-like dressings based on \nbiopolymers for the delivery of platelet lysate to skin chronic wounds. International \nJournal of Pharmaceutics, vol.440, p.207-215, 2013. \n\nRUHELA, D.; RIVIERE, K.; SZOKA JR, F.C. Efficient synthesis of an aldehyde \nfunctionalized hyaluronic acid and its application in the preparation of hyaluronan-lipid \nconjugates. Bioconjugate Chemistry, p.17, p.1360-1363, 2006. \n\nSACHLOS, E.; CZERNUSZKA, J.T. Making tissue engineering scaffolds work. Review \non the application of solid freeform fabrication technology to the production of tissue \nengineering scaffolds. European Cells &amp; Materials, vol.5, p.29-40, 2003. \n\nS\u00c1NCHEZ, M.; ANITUA, E.; AZOFRA, J.; AGUIRRE, J.J.; ANDIA, I. Intra-articular \ninjection of an autologous preparation rich in growth factors for the treatment of knee \nOA: a retrospective cohort study. Clinical and experimental rheumatology, vol.26, \np.910-913, 2008. \n\nSCHANT\u00c9, C.E.; ZUBER, G.; HERLIN, C.; VANDAMME, T.F. Chemical modifications of \nhyaluronic acid for the synthesis of derivatives for a broad range of biomedical \napplications. Carbohydrate Polymers, vol.85, p.469\u2013489, 2011. \n\nSECHRIEST, V.F.; MIAO, Y.J.; NIYIBIZI, C.; WESTERHAUSEN-LARSON, A.; \nMATTHEW, H.W.; EVANS, C.H.; FU, F.H.; SUH, J.K. GAG-augmented polysaccharide \nhydrogel: A novel biocompatible and biodegradable material to support chondrogenesis. \nJournal of Biomedical Materials Research \u2013 Part A, vol.49, p.534\u2013541, 1999. \n\nSEOL, Y.J.; LEE, J.Y.; PARK, Y.J.; LEE, Y.M.; YOUNG, K.; RHYU, I.C.; LEE, S.J.; HAN, \nS.B.; CHUNG, C.P.; Chitosan sponges as tissue engineering scaffolds for bone \nformation. Biotechnology Letters, vol.26, p.1037-1041, 2004. \n\nSHEN, E.C.; CHOU, T.C.; GAU, C.H.; TU, H.P.; CHEN, Y.T.; FU, E. Releasing growth \n\n\n\n39 \n\n \n\nfactors from activated human platelets after chitosan stimulation: a possible bio-material \nfor platelet-rich plasma preparation. Clinical Oral Implants Research, vol.17, p.572\u2013\n578, 2006. \n\nSHEN, F.; CUI, Y.L.; YANG, L.F.; YAO, K.D.; DONG, X.H.; JIA, W.Y.; SHI, H.D. A study \non the fabrication of porous chitosan/gelatin network scaffold for tissue engineering. \nPolymer International, vol.49, p.1596-1599, 2000. \n\nSHU, X.Z.; ZHU, K.J. Controlled drug release properties of ionically cross-linked \nchitosan beads: the influence of anion structure. International Journal of \nPharmaceutics, vol.233, p.217\u2013225, 2002. \n\nSILVA, H.S.R.C.; DOS SANTOS, K.S.C.R.; FERREIRA, E.I. Quitosana: derivados \nhidrossol\u00faveis, aplica\u00e7\u00f5es farmac\u00eauticas e avan\u00e7os. Qu\u00edmica Nova, vol.29, n.4, p.776-\n785, 2006. \n\nSINGH, A.; ALI, S.; MAHDI, A.A.; SRIVASTAVA, R.N. Role of Platelets Rich Plasma in \nManagement of Osteoporotic Fractures. Annual Research &amp; Review in Biology, vol.4, \nn.8, p.1187-1210, 2014. \n\nTABATA, Y. Tissue regeneration based on growth factor release. Tissue engineering, \nvol.9, n.1, p.S5-15, 2003. \n\nTSAY, R.C.; VO, J.; BURKE, A.; EISIG, S.B.; LU, H.H.; LANDESBERG, R. Differential \nGrowth Factor Retention by Platelet-Rich Plasma Composites. Journal of Oral and \nMaxillofacial Surgery, vol.63, p.521-528, 2005. \n\nVAN ARK, M.; VAN DEN AKKER-SCHEEK, I.; MEIJER, L.T.B; ZWERVER, J. An \nexercise-based physical therapy program for patients with patellar tendinopathy after \nplatelet-rich plasma injection. Physical Therapy in Sport, vol.14, p.124-130, 2013. \n\nVAN PHAM, P.; BUI, K.H.; NGO, D.Q.; VU, N.B.; TRUONG, N.H.; PHAN, N.L-C.; LE, \nD.M.; DUONG, T.D.; NGUYEN, T.D.; LE, V.T.; PHAN, N.K. Activated platelet-rich \nplasma improves adipose-derived stem cell transplantation efficiency in injured articular \ncartilage. Stem Cell Research &amp; Therapy, vol.4, n.4, p.91-102, 2013. \n\nVENKATESAN, J.; RYUA, B.; SUDHAC, P.N.; KIMA, S-K. Preparation and \ncharacterization of chitosan\u2013carbon nanotube scaffolds for bone tissue engineering. \nInternational Journal of Biological Macromolecules, vol.50, p.393\u2013 402, 2012. \n\nVINDIGNI, V.; CORTIVO, R.; IACOBELLIS, L.; ABATANGELO, G.; ZAVAN, B.; \nHyaluronan Benzyl Ester as a Scaffold for Tissue Engineering. International Journal of \nMolecular Sciences, vol.10, p.2972-2985, 2009. \n\nWEST, D.C.; HAMPSON, IN.; ARNOLD, F.; KUMAR, S. Angiogenesis induced by \ndegradation products of hyaluronic acid. Science, vol.228, p.1324\u20131326,1985. \n\nYAMANE, S.; IWASAKI, N.; MAJIMA, T.; FUNAKOSHI, T.; MASUKO, T.; HARADA, K.; \n\n\n\n40 \n\n \n\nMINAMI, A.; MONDE, K,; NISHIMURA, S-I. Feasibility of chitosan-based hyaluronic acid \nhybrid biomaterial for a novel scaffold in cartilage tissue engineering. Biomaterials, \nvol.26, p.611\u2013619, 2005. \n\nYARAK, S.; OKAMOTO, O.K. C\u00e9lulas-tronco derivadas de tecido adiposo humano: \ndesafios atuais e perspectivas cl\u00ednicas. Anais Brasileiros De Dermatologia, vol.85, n. \n5, p.647-56, 2010. \n\n  \n\n\n\n41 \n\n \n\nCAP\u00cdTULO 3 \u2013 PERFORMANCE OF PRP \nASSOCIATED WITH POROUS CHITOSAN AS A \n\nCOMPOSITE SCAFFOLD FOR REGENERATIVE \n\nMEDICINE \n\nArtigo publicado em fevereiro de 2015 no peri\u00f3dico The Scientific World Journal. \n\n \n\nAndr\u00e9a Arruda Martins Shimojo, Amanda Gomes Marcelino Perez, Sofia Elisa Moraga \n\nGaldames, Isabela Cambraia de Souza Brissac and Maria Helena Andrade Santana* \n\n \n\nDepartment of Engineering of Materials and of Bioprocesses, School of Chemical \n\nEngineering, UNICAMP, P.O. Box 6066, 13083-970 Campinas, SP, Brazil \n\n \n\n*Correspondence should be addressed to Maria Helena Andrade Santana; \n\nmariahelena.santana@gmail.com \n\n \n\nAbstract. This study aimed to evaluate the in vitro performance of activated platelet-rich \n\nplasma associated with porous sponges of chitosan as a composite scaffold for \n\nproliferation and osteogenic differentiation of human adipose tissue-derived \n\nmesenchymal stem cells. The sponges were prepared by controlled freezing (?20, ?80, \n\nor ?196\u00b0C) and lyophilization of chitosan solutions (1, 2, or 3% w/v). The platelet-rich \n\nplasma was obtained from controlled centrifugation of whole blood and activated with \n\ncalcium and autologous serum. The composite scaffolds were prepared by embedding \n\nthe sponges with the activated platelet-rich plasma. The results showed the \n\nperformance of the scaffolds was superior to that of activated platelet-rich plasma alone, \n\nin terms of delaying the release of growth factors and increased proliferation of the stem \n\ncells. The best preparation conditions of chitosan composite scaffolds that coordinated \n\nthe physicochemical and mechanical properties and cell proliferation were 3% (w/v) \n\nchitosan and a ?20\u00b0C freezing temperature, while ?196\u00b0C favored osteogenic \n\nmailto:mariahelena.santana@gmail.com\n\n\n42 \n\n \n\ndifferentiation. Although the composite scaffolds are promising for regenerative \n\nmedicine, the structures require stabilization to prevent the collapse observed after five \n\ndays. \n\n \n\n3.1. Introduction \n\n \n\nIn tissue engineering, a scaffold is a three-dimensional matrix for the stimulation \n\nof cell proliferation and the formation of new tissue. To achieve this goal, scaffolds must \n\nmeet some specific requirements such as mimicking the native extracellular matrix \n\n(ECM) of the target tissue; allowing cell attachment, migration, proliferation, and \n\ndifferentiation and maintenance of the target phenotype; promoting vascularization and \n\nnutrient delivery; and having a biodegradation rate and mechanical properties that are \n\nadequate to support the formation of the new tissue (Langer &amp; Vacanti, 1993). \n\nAccording to Crane &amp; Everts (2008), tissue regeneration is based on a \n\nproliferation triangle composed of the three fundamental elements: cells, growth factors \n\n(GFs) and scaffolds, which are in a close relationship through their capabilities. Thus, \n\nscaffolds provide the conductive matrix for supporting the genic capability of progenitor \n\ncells mediated by the inductive capability of GFs (Chen et al., 2002). Optimal conditions \n\nfor tissue regeneration must come from the interaction of the properties of those \n\nelements. \n\nThe cell responses to the surface chemistry of scaffolds depend on their \n\nhydrophobicity, protein adsorption, surface charge, and roughness, softness, and \n\nstiffness. Additionally, the porous architecture characterized by the pore size, porosity, \n\nconnectivity, and tortuosity plays important roles, as described and discussed by Chang \n\n&amp; Wang (2011). Therefore, bringing together all these properties in solid scaffolds is an \n\nenormous technological challenge.  \n\nThe fibrin matrix is the natural scaffold formed from the coagulation cascade in \n\nthe healing process. Under injury, thrombin cleaves the soluble plasma protein \n\nfibrinogen into peptide fragments, yielding insoluble fibrin peptides that aggregate and \n\nform fibrils. A fibrin network is then formed, which entraps platelets and other blood \n\ncomponents (Bensa\u00efd et al., 2003; Weisel &amp; Nagaswami, 1992). Calcium acts as a \n\n\n\n43 \n\n \n\ncofactor of thrombin, modulates the elongation of fibers during polymerization by \n\npromoting lateral branching, and functions in clot stability (Falvo et al., 2010; Ryan et al., \n\n1999). Calcium and thrombin also activate platelets, allowing the release of GFs and \n\ncytokines. Therefore, the fibrin matrix provides an optimized medium for cell proliferation \n\nand healing.  \n\nBased on these features, platelet-rich plasma (PRP) has been widely used in \n\nregenerative medicine. PRP is an autologous product prepared from whole blood by \n\nseparating the red blood cells and concentrating the platelets and other components of \n\nplasma. However, although viscoelastic, the fibrin matrix alone lacks stability to be \n\nefficient when regenerative medicine is the goal.  \n\nTo mimic the natural healing process and improve the stability of the fibrin matrix, \n\nwe propose in this work the use of the fibrin network from activated PRP with porous \n\nchitosan as a composite scaffold for tissue regeneration.  \n\nOur hypothesis is that the chemical nature of the chitosan surface supports the \n\nfibrin network by electrostatic attachment, thus prolonging its stability, without changing \n\nthe paracrine affinity of mesenchymal cells to fibrin fibers. As a consequence, the \n\ncomposite scaffold must improve cell proliferation and tissue differentiation compared to \n\nPRP alone.  \n\nRelated works showed the effects of chitosan on blood coagulation through the \n\nstrong adhesion of platelets to the surface of chitosan particles, as well as chitosan \n\n(0.1\u20131mg/mL) incorporated with PRP to enhance the release of PDGF-AB and TGF-?1 \n\nfrom platelets (Kojima et al., 2004; Okamoto et al., 2003). Shen et al. (2006) \n\ndemonstrated that chitosan could be an appropriate substitute for thrombin, as an \n\nagonist in PRP preparation. Chang et al. (2009) showed that growth factors could \n\nsustain release until 12 h at approximately 1 ng/mL from chitosan/CaSO4/PRP \n\nmicrospheres after activation with thrombin. Kutlu et al. (2012) showed that scaffolds \n\nprepared by the freeze-drying of PRP added to chitosan gel (2% w/v) were more \n\neffective than chitosan sponges soaked with PRP on controlled GF release. Oktay et al. \n\n(2010) applied PRP-embedded chitosan sponges to defects and showed a histological \n\ntendency toward increased bone formation. Mathews et al. (2011) demonstrated that \n\nchitosan enhanced mineralization by upregulating the genes associated with \n\n\n\n44 \n\n \n\nmineralization and calcium-binding proteins.  \n\nChitosan is a polysaccharide derived from chitin (copolymers ?-(1?4)-2-amino-2-\n\ndeoxy-D-glucose and ?-(1?4)-2-acetamido 2-deoxy-D-glucose) found in the shells of \n\nmarine crustaceans and insects and the cell walls of some fungi (Muzzarelli, 1973; \n\nBerger et al., 2004).  \n\nIn the last ten years, considerable attention has been given to chitosan-based \n\nmaterials in the field of tissue engineering (Nwe et al., 2009; Martins et al., 2014). The \n\nbeneficial properties of chitosan have been proven, such as biodegradability (Nordtveit \n\net al., 1996; Koga, 1998), biocompatibility (Molinaro et al., 2002; R\u00fccker et al., 2006), \n\nantibacterial activity (Muzzarelli et al., 1990; Li et al., 2013), cell adhesion (He et al., \n\n1998; Bertram &amp; Bodmeier, 2006), and wound healing properties (Antonov et al., 2008; \n\nDai et al., 2011). Moreover, the chemical nature of chitosan gives many possibilities for \n\nionic and covalent modifications that allow for the modulation of the mechanical and \n\nbiological properties of biomaterials (Agnihotri et al., 2004; Adekogbe &amp; Ghanem, 2005).  \n\nRegarding the technological aspects, chitosan can be easily processed in diverse \n\nforms in the absence of toxic solvents, such as films (Mucha et al., 2012), sponges \n\n(Madihally &amp; Matthew, 1999; Amaral et al., 2006), fibers (Majima et al., 2007), beads \n\n(Shu &amp; Zhu, 2002), hydrogels (Tan et al., 2009), and microparticles/nanoparticles \n\n(Lavertu et al., 2006). Furthermore, chitosan supports sterilization (Rao &amp; Sharma, \n\n1995), is abundant in nature, and requires only low-cost processing in nonaggressive \n\necological conditions before being used as a raw material (Berger et al., 2004).  \n\nFreeze-drying is the most common and simplest method to produce porous \n\nchitosan scaffolds. The freezing process provides the nucleation of ice crystals from \n\nsolution and further growth along the lines of thermal gradients. Exclusion of the \n\nchitosan acetate salt from the ice crystal phase and subsequent ice removal by \n\nlyophilization generate a porous material (Cardea et al., 2010; Costa-Pinto et al., 2011).  \n\nMadihally &amp; Matthew (1999) reported that the pore size of chitosan scaffolds \n\nproduced by lyophilization can be controlled within the range of 1\u2013250 ?m. A more \n\nuniform and interconnected pore structure can be obtained when lower freezing \n\ntemperatures are used. Furthermore, the pore orientation is related to the geometry of \n\nthe moldings used and can also be controlled by changing thermal gradients during \n\n\n\n45 \n\n \n\nfreezing (Shen et al., 2000).  \n\nThe microstructure, crystallinity, and mechanical strength of the porous chitosan \n\nmatrix also can be controlled by the chitosan concentration, molecular weight, and \n\ndeacetylation degree (Madihally &amp; Matthew, 1999; Nettles et al., 2002).  \n\nIn this work, the effects of PRP association were studied regarding to the porous \n\nstructure of solid sponges, which were produced by varying chitosan concentration and \n\nfreezing conditions. The biological performance of association was evaluated in terms of \n\ngrowth factor release kinetics, proliferation, and osteogenic differentiation of seeded \n\nhuman adipose tissue-derived mesenchymal stem cells (h-AdMSCs). \n\n \n\n3.2. Experimental \n\n \n\n3.2.1. Materials \n\nChitosan (average molecular weight [Mw] = 4 \u00d7 105 Da, degree of deacetylation = \n\n83\u00b1 4%) was purchased from Polymar (Fortaleza, CE, Brazil) and purified according to \n\nthe protocol described by Nasti et al. (2009). Other chemicals were of reagent grade and \n\nwere used without any further purification. All biological experiments were performed \n\nwith human adipose tissue-derived stem mesenchymal cells (h-AdMSCs) and approved \n\nby the Ethics Committee of the Medical Sciences School of the University of Campinas \n\n(UNICAMP; CAAE: 0972.0.146.000-11). The donors were healthy individuals aged \n\nbetween 30 and 40 years old who were previously assessed through clinical \n\nexaminations. \n\n \n\n3.2.2. Methods \n\n3.2.2.1. Preparation of Porous Chitosan Scaffolds (PCHTs) \n\nPCHTs were prepared by freezing at a controlled temperature of a chitosan \n\nsolution previously poured in 24-well culture plates (TPP, polystyrene, diameter = 15.4 \n\nmm) to give them a cylindrical shape, followed by lyophilizing in lyophilizer L101 \n\n(Liobras, S\u00e3o Carlos, SP, Brazil) at a temperature of approximately ?30\u00b0C for 48 hours.  \n\n \n\n\n\n46 \n\n \n\nEffects of Chitosan Concentration. Chitosan solutions with concentrations of 1, 2, \n\nor 3% (w/v) were prepared by dissolution in 0.2 mol.L?1 acetic acid for 24 hours at room \n\ntemperature. The solutions were frozen at ?20\u00b0C for 24 hours and lyophilized. \n\n \n\nEffects of Freezing Conditions. Chitosan solution (3% w/v) was prepared as \n\npreviously described. The solution was frozen at ?20\u00b0C in a freezer for 24 hours; ?80\u00b0C \n\nin an ultrafreezer for 24 hours; or ?196\u00b0C by immersion in liquid N2; and lyophilized. \n\n \n\n3.2.2.2. Characterization of Porous Chitosan Scaffolds (PCHTs) \n\nMorphology and Pore Size. The morphology of PCHTs was evaluated by \n\nscanning electron microscopy (SEM) using an LEO 440i Electron Microscopy/Oxford \n\n(Cambridge, England) operated at 5 kV accelerating voltage. The scaffolds were gold-\n\ncoated using a sputter coater POLARON SC7620, VG Microtech (Uckfield, England) for \n\n180 s at a current of 3 mA. Pore size (? = 20) was measured using software Image J \n\n1.47t. \n\n \n\nMechanical Properties. Mechanical compression tests of PCHTs (? = 3) were \n\nperformed using a Universal Testing Machine, MTS model 810-Flex Test 40 (MTS \n\nSystems Corporation, Eden Prairie, MN, USA) up to 60% strain, according to Correia et \n\nal. (2011). The testing machine was equipped with a 1.5 kN load cell, and the loading \n\nrate was 5 mm/min. Young\u2019s modulus was calculated in the initial linear section of the \n\nstress-strain curve, when the strain was lower than 10%.  \n\n \n\nDegradation in PBS. The degradation profile of the PCHTs in PBS at 37\u00b0C was \n\nperformed by the gravimetric method described by Tang &amp; Spector (2007) through \n\nmeasurements of loss weight. \n\n \n\nWater Sorption. The water sorption was determined by swelling of PCHTs \n\n(previously weighted) in PBS (LB Laborclin, Pinhais, PR, Brazil) at pH 7.4 for 24 hours \n\nat 37\u00b0C. The swollen PCHTs were weighed after the removal of excess water by \n\nkeeping the surfaces on a filter paper. The swelling ratio (SR) was also calculated using \n\n\n\n47 \n\n \n\nEquation (1): \n\n \n\n?? =\n??\n\n??\n                                                                                                                        Equation (1) \n\n \n\nwhere ?? and ?? are the weights of the scaffolds in the swelled state and the dry state, \n\nrespectively.  \n\n \n\nPorosity. The porosity (?) of the PCHTs was determined according to the protocol \n\nused by Wang et al. (2003) and calculated by Equation (2): \n\n \n\n? (%) =  \n???(\n\n??\n\n?\n)\n\n??\n ? 100                                                                                              Equation (2) \n\n \n\nwhere ?? is the total volume of PCHTs (cm3), ? is the density of nonporous CHT (1.342 \n\ng/cm3), and ?? is the weight of sponge (g). Values are expressed as the mean \u00b1 \n\nstandard deviation (? = 3). \n\n \n\nCell Compatibility. The compatibility was carried out by exposing PCHTs to h-\n\nAdMSCs followed by cultivation at 37\u00b0C for 24 hours and evaluation by MTT assay (3-\n\n[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyltetrazolium bromide) (MTT, Molecular Probes) \n\naccording to a modified Mosmann method (1983). The MTT assay is a colorimetric test \n\nbased on the reduction of yellow tetrazolium salt into a purple formazan product in \n\npresence of cells (G\u00fcm\u00fcdereliolu &amp; Aday, 2011). \n\n \n\n3.2.2.3. PRP Preparations \n\nPRP Concentration. P-PRP (plasma rich in platelets and poor in leukocytes) was \n\nprepared according to Perez et al. (2013). Briefly, whole blood (WB) was collected into \n\n3.5 mL vacuum tubes (Vacuette, Campinas, SP, Brazil) containing sodium citrate 3.2% \n\n(w/v) as an anticoagulant. WB was initially centrifuged in a Rotina 380R centrifuge \n\n(Hettich Zentrifugen, Tuttlingen, Germany) at 100 \u00d7g for 10 minutes at 25\u00b0C. After the \n\nformation of three layers (a bottom layer composed mainly of red blood cells (RBCs); an \n\nupper layer composed of plasma, platelets, and some WB cells; and an intermediate \n\n\n\n48 \n\n \n\nlayer, or buffy coat, composed mostly of WB cells), only the upper layer was collected to \n\nobtain PPRP. The concentration of platelets, WB cells, and RBCs in WB and P-PRP \n\nwere determined using the ABX Micros ES 60 hematology analyzer (HORIBA ABX \n\nDiagnostics, Montpellier, France). \n\n \n\nP-PRP Activation. Activated P-PRP (?P-PRP) was obtained by adding \n\nautologous serum (Ser) and 10% (w/v) CaCl2 solution as agonists using the following \n\nproportions: agonist/P-PRP = 20% (v/v), Ser/CaCl2 volumetric ratio = 9. Autologous \n\nserum was prepared by collecting 5 mL of WB in tubes without anticoagulant. After 30 \n\nminutes to form clots, WB was centrifuged at 2000 \u00d7g for 10 minutes (Perez et al., \n\n2014). \n\n \n\n3.2.2.4. The Composite Scaffolds (?P-PRP/PCHTs) \n\nPreparation. ?P-PRP/PCHTs was prepared for embedding by dripping ?P-PRP, \n\nimmediately after activation, into PCHTs. The preparation was carried out in 48-well \n\nmicroplates using a ratio of 200 \u00b5L of ?P-PRP to 10\u201320 mg of PCHTs. \n\n \n\nRelease of GFs. The release of platelet-derived growth factor AB (PDGF-AB) and \n\ntransforming growth factor ?1 (TGF-?1) was performed after 1 hour of gelation of ?P-\n\nPRP associated with PCHTs in the presence of the culture medium (Dulbecco\u2019s \n\nModified Eagle\u2019s Medium (DMEM-LG) (Gibco, Grand Island, NY, USA) with low glucose \n\nconcentration). The culture medium (1.5 mL) was added to ?P-PRP/PCHTs in 48-well \n\nmicroplates, which were maintained in an incubator with 5% CO2 throughout the assays. \n\nThe total volume of culture medium was withdrawn at 3, 6, 12, 24, and 72 hours, and the \n\nsame volume of fresh medium was replaced without removing the hydrogels from the \n\nwells. The samples were stored at ?80\u00b0C for further characterization. The \n\nconcentrations of the released GFs PDGF-AB and TGF-?1 were measured using \n\nenzyme-linked immunosorbent assay (ELISA) kits (R&amp;D Systems, Minneapolis, MN, \n\nUSA) according to the manufacturer\u2019s instructions and specifications. \n\n \n\nh-AdMSCs Proliferation. The cultivation of h-AdMSCs was carried out in 24-well \n\n\n\n49 \n\n \n\ntissue culture plates by adding 1 mL DMEM to the seeded composite scaffolds (? = 4). \n\nThe composite scaffolds seeded were maintained at 37\u00b0C for 10 days. Cell proliferation \n\nwas quantified using the thiazolyl blue tetrazolium bromide (MTT) assay. At 3, 5, 7, and \n\n10 cultivation days, the composite scaffolds were removed and transferred to 24-well \n\nplates. MTT (1 mL of 1 mg/mL) was then added, and the cultivation proceeded at 37\u00b0C \n\nfor 4 hours. The MTT solution was then discarded, and 1 mL of DMSO was added to \n\ndissolve the purple formazan crystals. The samples were shaken at 120 rpm for 30 min \n\nto ensure homogeneous dissolution of the formazan dye, and then 200 \u00b5L of each \n\nsample was transferred to a 96-well plate. Optical density was measured at 595 nm \n\nusing a microplate reader (Filter Max F5, Molecular Devices). The isolation and pre-\n\ncultivation of h-AdMSCs as well as the cell seeding were performed as described below. \n\n \n\nh-AdMSCs Isolation and Pre-cultivation. Human subcutaneous adipose tissue \n\nthat was initially acquired from liposuction surgery was washed with sterile PBS, \n\nseparated into fractions of 10 g, digested with 20 mg of collagenase type 1A and \n\nmaintained in 20 mL of DMEM-LG containing 10% BSA (bovine serum albumin) and 10 \n\n\u00b5L of gentamicin for 30 min in a 37\u00b0C bath. After complete digestion, the reaction was \n\nquenched with 10 mL fetal bovine serum (FBS) and immediately centrifuged for 15 min \n\nat 1500 rpm. The supernatant was discarded, and the pellet was suspended in 10 mL \n\nDMEM-LG with 10% FBS. After pre-cultivation for 24 h, the culture medium was \n\nchanged every 3 days; after the fourth passage, the cells were characterized by \n\nimmunophenotyping (data not shown) using flow cytometry and according to their \n\nadipogenic, osteogenic, and chondrogenic differentiation and then used in the \n\nsubsequent experiments. \n\n \n\nh-AdMSCs-Seeding. The pre-cultured h-AdMSCs were trypsinized and \n\nresuspended in P-PRP to a final cell concentration of 1 \u00d7 104 cells/mL. P-PRP \n\ncontaining h-AdMSCs was activated and immediately embedded to the PCHTs in a 24-\n\nwell tissue culture plate, using 200 \u00b5L of h-AdMSCs + ?P-PRP per 10\u201320 mg of PCHTs. \n\nThe composite scaffolds with h-AdMSCs were kept at room temperature for 45 minutes \n\nfor consolidation of the fibrin network. Pure PRP was used as control. \n\n\n\n50 \n\n \n\n \n\n3.2.2.5. Images of the h-AdMSCs-Seeded Composite Scaffolds \n\nThe images of the cell-seeded composite scaffolds were obtained by scanning \n\nelectron microscopy after 5 days of h-AdMSCs proliferation. The cell-seeded composite \n\nscaffolds were fixed in a solution of 4% paraformaldehyde and 2.5% glutaraldehyde in \n\nphosphate buffer, pH 7.4, for 2 hours. The samples were than dehydrated in ethanol for \n\n15 min intervals in aqueous 50%, 70%, 95%, and 100% ethanol solutions (2x) and dried \n\nat the critical point dryer BAL-TEC CPD 030 (Schalksm\u00fchle, Germany). After gold \n\ncoating (Sputter Coater POLARON, SC7620, VG Microtech), the cell-seeded composite \n\nscaffolds were visualized with a SEM (Leo440i, LEO) with an accelerating voltage of 20 \n\nkV. \n\n \n\n3.2.2.6. Induction of Osteogenic Differentiation \n\nh-AdMSCs seeded in the composite scaffolds were induced to differentiate into \n\nthe osteogenic lineage by providing the osteogenic medium containing DMEM-LG \n\nsupplemented with 10% FBS, 1% ?-glycerol-phosphate (Sigma-Aldrich, St. Louis, MO, \n\nUSA), 1% L-ascorbic acid (Sigma-Aldrich, St. Louis, MO, USA), 1% dexamethasone \n\n(Sigma-Aldrich, St. Louis, MO, USA), and 1% penicillin/streptomycin solution (Gibco, \n\nGrand Island, NY, USA). The medium was changed every 7 days. \n\n \n\nEvaluation of Differentiation. Differentiation was evaluated by measuring the \n\nalkaline phosphatase activity (ALP) on day 14. The supernatant (200 \u00b5L) was collected \n\nand mixed with the same volume of p-nitrophenyl phosphate (SIGMAFAST p-nitrophenyl \n\nphosphate tablets, Sigma, Saint Louis, MO, USA) as substrate and incubated at room \n\ntemperature for 30 minutes. Absorbance was read immediately at 405 nm. \n\n \n\n3.2.2.7. Statistical Analysis \n\nEach experiment was carried out in triplicate unless otherwise specified. All \n\nresults are presented as the mean \u00b1 standard deviation (SD).The experimental data \n\nfrom all the studies were analyzed using Analysis of Variance (ANOVA). Statistical \n\nsignificance was set to ? value ? 0.05. \n\n\n\n51 \n\n \n\n \n\n3.3. Results and Discussion \n\n \n\n3.3.1. Experimental Design \n\nIn this study, we prepared novel composite scaffolds by association of PRP with \n\nthe 3D-porous structure of chitosan. First, different 3D-porous structures of chitosan \n\n(PCHTs) were prepared by freeze-drying by varying the CHT concentration and freezing \n\nconditions (temperature and freezing rate). Second, the microstructure and mechanical \n\nproperties of the PCHTs were characterized and evaluated for cell compatibility. The \n\nsurface chemistry, hydrophilicity, and positive charge of \u2013NH2 groups in acidic medium \n\nwere maintained unaltered.  \n\nThe composite scaffolds (?P-PRP/PCHTs) were obtained by embedding the \n\nPCHTs with immediately activated P-PRP in a 24-well microplate. The release of the \n\nGFs (PDGF-AB and TGF-?1) from the composite scaffolds was evaluated in DMEM \n\nculture medium. Afterwards, pre-cultured h-AdMSCs were added to PRP before \n\nactivation in order to obtain cell-seeded composite scaffolds. In vitro examination of h-\n\nAdMSCs proliferation kinetics was performed over 10 days by using the cell-seeded \n\ncomposite scaffolds in DMEM. Additionally, osteogenic differentiation was evaluated by \n\nALP activity measurements after 14 days. Thus, we verified the correlation between the \n\nstructure and function of PCHTs by controlling the concentration and freezing conditions \n\nof chitosan solution. \n\n \n\n3.3.2. Effects of Freezing Conditions and Chitosan Concentration on \n\nPCHTs \n\n3.3.2.1. Images of Porous Structure \n\nFigures 10(a) \u2013 10(c) show images of the porous structure from controlled \n\nfreezing at ?20\u00b0C by varying the concentration of the chitosan solution (1, 2, or 3%) and \n\nsubsequent lyophilization. The images show highly porous structures with rounded \n\npores that interconnected, regardless of CHT concentration. Differences in chitosan \n\nmolecular weight, deacetylation degree, and purity make difficult comparisons even for \n\n\n\n52 \n\n \n\nsimilar treatment. Madihally &amp; Matthew (1999) showed a higher pore interconnectivity \n\ndegree and more open pores for 1% (w/w) chitosan concentration for a similar \n\ndeacetylation degree, but other properties were not characterized. \n\n  \n\n(a) (b) \n\n   \n\n(c) (d) (e) \n\nFigure 10. SEM micrographs of PCHTs. Cross-sectional morphologies of (a) PCHTs 1% \n\n(?20\u00b0C); (b) PCHTs 2% (?20\u00b0C); (c) PCHTs 3% (?20\u00b0C); (d) PCHTs 3% (?80\u00b0C); and \n\n(e) PCHTs 3% (?196\u00b0C). Original magnification is \u00d7100 and the scale bar represents \n\n200 \u00b5m. \n\n \n\nFreezing conditions produced a more prominent effect on the morphology of the \n\npores [Figures 10(d) \u2013 10(e)] attributed the variations in the freezing rate used to \n\nachieve the temperatures evaluated. In contrast with rounded pores at ?20\u00b0C (3% CHT) \n\n[Figure 10(c)], we observed pores with leaf structure at ?80\u00b0C [Figure 10(d)], while \n\nsmaller and elongated open pores were produced at ?196\u00b0C [Figure 10(e)]. In all cases, \n\nthe pores were uniformly distributed and radially oriented and had a high degree of \n\ninterconnectivity. \n\nThe pore structures allow uniform cell spatial distribution throughout the scaffold, \n\nfacilitating homogeneous tissue formation. Moreover, the differences in pore \n\nmorphologies obtained are suitable to several cell linage and type of tissue to be \n\n\n\n53 \n\n \n\nregenerated. \n\n \n\n3.3.2.2. Characterization of PCHTs \n\nPhysicochemical and Mechanical Properties. Table 1 shows physicochemical \n\ncharacterization of the PCHTs. At ?20\u00b0C, the mean diameter of rounded pores could be \n\ncontrolled around the 300\u2013400 \u00b5m, regardless of the CHT concentration, although there \n\nis a large distribution. \n\nHowever, the elongated pores from Figures 10(d) \u2013 10(e) were markedly \n\ndecreased with freezing conditions from 2615 \u00b5m (?80\u00b0C) to 280 \u00b5m (?196\u00b0C) because \n\ncrystal growth and hence pore size are functions of both heat and mass transfer rates, \n\ndetermined by the temperature and freezing rate. At ?80\u00b0C, the observed differences in \n\npore shape and size suggest parallel ice crystal growth, which in turn was caused by the \n\nstrongly one-dimensional nature of the thermal gradients established during freezing, as \n\ndiscussed by Madihally &amp; Matthew (1999). \n\nThe diverse nature of tissue architectures requires scaffolds with optimal pore \n\nsizes, such as 5 \u00b5m for neovascularization (Brauker et al., 1995), 5\u201315 \u00b5m for fibroblast \n\ningrowth (Klawitter &amp; Hulbert, 1971), 20 \u00b5m for the ingrowth of hepatocytes (Yang et al., \n\n2001), 200\u2013900 \u00b5m for osteoconduction (Salgado et al., 2004), and 20\u2013125 \u00b5m for \n\nregeneration of adult mammalian skin (Yannas et al., 1989). \n\nAccording to these data, the rounded pores obtained at ?20\u00b0C or elongated at \n\n?196\u00b0C are adequate for bone tissue, although other properties could also influence the \n\nchoice. Moreover, because human adipose tissue-derived mesenchymal stem cells (h-\n\nAdMSCs) exhibit a spindle-like shape and are 80\u2013100 \u00b5m in diameter and ?200 \u00b5m in \n\nlength (Chavez-Munoz et al., 2013), the range of pore sizes in our PCHTs allows cells to \n\nmigrate freely into the scaffolds, favoring the formation of a new tissue. \n\n \n\n \n\n \n\n \n\n \n\n\n\n54 \n\n \n\nTable 1. Physicochemical characterization of PCHTs. \nCHT \n\nconcentration \n(%) \n\nFreezing \ntemperature \n\n(\u00b0C) \n\nSwelling ratio \n(n=3) \n\nPore size  \n(\u00b5m)  \n\n(n=20) \n\nPorosity  \n(%)  \n\n(n=3) \n\nYoung\u2019s Moduli \n(MPa)  \n(n=3) \n\n1 -20 6.5 \u00b1 0.4 425 \u00b1 102 97.1 \u00b1 0.3 0.037 \u00b1 0.002 \n2 -20 5.5 \u00b1 0.9 418 \u00b1 113 94.7 \u00b1 0.8 0.5 \u00b1 0.1 \n3 -20 4.7 \u00b1 0.9 336 \u00b1 138 93.1 \u00b1 0.5 1.1 \u00b1 0.1 \n3 -80 5.1 \u00b1 0.9 2615 \u00b1 600* 91.7 \u00b1 0.3 0.28 \u00b1 0.01 \n3 -196 6.4 \u00b1 0.6 280 \u00b1 62* 92.5 \u00b1 0.1 1.01 \u00b1 0.05 \n\n*mean longitudinal size.  \n\n \n\nThe porosity is also an important aspect of cell migration and proliferation, \n\nguiding and promoting the formation of new tissue. Porosity is defined as the percentage \n\nof void space in a solid and is a morphological property independent of material (L\u00e9on y \n\nL\u00e9on, 1998). A porosity higher than 90% and pore interconnectivity are basic \n\nrequirements for scaffolds in tissue engineering because they affect the diffusion of \n\nphysiological nutrients and gases to and the removal of metabolic waste and byproducts \n\nfrom cells that have penetrated the scaffold (Leong et al., 2003; Liu &amp; Ma, 2004). \n\nMoreover, the porosity often compromises the mechanical and structural stability of the \n\nscaffolds and must be evaluated in accordance with the application and degradation rate \n\nof materials utilized (Loh &amp; Choong, 2013).  \n\nThe porosity values of PCHTs scaffolds ranged from 91.0 to 97.0% (Table 1), \n\nwhich are adequate for TE, independent of CHT concentration or freezing conditions. \n\nHowever, the porosity decreased with increasing chitosan concentration. The highest \n\nporosity was provided from 1% chitosan solution, but there was not a direct relationship \n\nwith freezing conditions. The PCHTs prepared at ?80\u00b0C showed a significantly lower \n\nporosity even with higher pore size, probably due to their leaf structure. \n\nTo guide tissue regeneration, scaffolds should also have sufficient mechanical \n\nstrength during in vitro culturing to maintain the spaces required for cell in-growth and \n\nmatrix elaboration (Leong et al., 2003). Moreover, their mechanical properties should be \n\nsimilar to the properties of tissues generated to provide an adequate structural support \n\nin the stage of healing (Cheung et al., 2007). \n\nScaffolds for the regeneration of hard tissue must exhibit a mechanical modulus \n\nin the range of 10\u20131,500 MPa, while scaffolds for soft tissues must exhibit a mechanical \n\nmodulus in the range of 0.4\u2013350 MPa (Hollister, 2005). \n\n\n\n55 \n\n \n\nIn this work, we observed a drastic decrease in Young\u2019s modulus (Table 1) with a \n\ndecrease in CHT concentration. Better mechanical properties were found for a CHT \n\nconcentration of 3%.  \n\nThe PCHTs 3% (w/v) prepared at ?80\u00b0C showed lower mechanical strength than \n\nthose prepared at ?20\u00b0C and ?196\u00b0C with the same CHT concentration, which could be \n\nattributed to its leaf structure and pore size. There was no significant difference (? &lt;\n\n0.05) in mechanical properties for PCHTs 3% (w/v) frozen at ?20\u00b0C or ?196\u00b0C. Thus, \n\nthe range of Young\u2019s moduli found for PCHTs suggests their application for soft tissue \n\nengineering. For hard tissues, these scaffolds must be crosslinked and/or reinforced by \n\nthe addition of fillers. \n\nThe water absorption capacity (swelling ratio) of the scaffolds affects cell growth \n\nindirectly (Enrione et al., 2010). The hydration of the scaffolds is a necessary step for \n\ncell incorporation and proliferation. \n\nPCHTs scaffolds showed a high swelling capacity in PBS (pH 7.4) regardless of \n\nchitosan concentration and freezing conditions, allowing for rapid hydration when culture \n\nmedium was added. \n\n \n\nDegradation in PBS. Scaffold degradation is also an important parameter for the \n\nformation of new tissue. The scaffold degradation rate must be tuned appropriately with \n\nthe growth rate of the new tissue in such a way that by the time the injury site is \n\ncompletely regenerated, the scaffold is completely degraded (Salgado et al., 2004). \n\nDegradation can occur through mechanisms that involve physical or chemical processes \n\nand/or biological processes that are mediated by biological agents, such as enzymes \n\n(Langer &amp; Vacanti, 1993).  \n\nHere, we evaluated in vitro the profile degradation of PCHTs in PBS (pH 7.4) at \n\n37\u00b0C; we supposed that degradation occurred by solubilization due to the presence of \n\nresidual acetate molecules. \n\nFigure 11 shows the degradation profile of PCHTs. \n\n\n\n56 \n\n \n\n0 3 6 9 12 15\n\n0\n\n10\n\n20\n\n30\n\n40\n\n50\n\n \n\n \n\nW\ne\n\nig\nh\n\nt \nlo\n\ns\ns\n\n (\n%\n\n)\n\nTime (days)\n \n\nFigure 11. The weight loss of scaffolds with time in PBS at 37\u00b0C as a percentage of the \n\noriginal weight of the scaffold (? = 3). The data are plotted with the mean \u00b1 standard \n\nerror. (?) PCHTs 1% (?20\u00b0C); (?) PCHTs 2% (?20\u00b0C); (?) PCHTs 3% (?20\u00b0C); (?) \n\nPCHTs 3% (?80\u00b0C); and (?) PCHTs 3% (?196\u00b0C). \n\nWe observed the highest weight loss, approximately 45%, for PCHT 1% (?20\u00b0C) \n\nafter 7 days, while for PCHTs 2% (?20\u00b0C), 3% (?20\u00b0C), and 3% (?196\u00b0C) weight loss \n\nwas approximately 35% after 3 days. The PCHTs 3% (?80\u00b0C) showed the lowest weight \n\nloss (~20%), probably due to their leaf structure retaining lower concentration of acetate \n\nmolecules. \n\nOur results suggest that the PCHTs need further stabilization, to ensure the \n\nbalance between tissue regeneration and degradation rate of the scaffold. \n\n \n\n3.3.2.3. Cell Compatibility \n\nFigure 12 shows the cell compatibility of h-AdMSCs cultured in the presence of \n\nPCHTs, as assayed by MTT. The results revealed no potential cytotoxicity in 24 hours \n\nfor the scaffolds according to the standard values (PTC). \n\nHowever, we observed lower proliferation of h-AdMSCs on PCHTs prepared with \n\nchitosan concentration of 3% (w/v) compared to the negative control. \n\nNevertheless, the PCHTs are potentially useful for in vivo applications regardless \n\nof CHT concentration and freezing conditions. \n\n\n\n57 \n\n \n\nP\nC\nH\nTs\n\n 1\n%\n\n (-\n20\n\n\u00b0C\n)\n\nP\nC\nH\nTs\n\n 2\n%\n\n (-\n20\n\n\u00b0C\n)\n\nP\nC\nH\nTs\n\n 3\n%\n\n (-\n20\n\n\u00b0C\n)\n\nP\nC\nH\nTs\n\n 3\n%\n\n (-\n80\n\n\u00b0C\n)\n\nP\nC\nH\nTs\n\n 3\n%\n\n (-\n19\n\n6\u00b0\nC\n)\n\nN\nTC\n\nP\nTC\n\n0.0\n\n5.0x10\n3\n\n1.0x10\n4\n\n1.5x10\n4\n\n2.0x10\n4\n\n2.5x10\n4\n\n3.0x10\n4\n\n*\n\n**\n\n*\n\n \n\n \n\nC\ne\n\nll\n n\n\nu\nm\n\nb\ne\n\nr/\n w\n\ne\nll\n\n*\n\n \nFigure 12. Proliferation of h-AdMSCs exposed to the PCHTs scaffolds after 24 hours of \n\ncultivation. Negative control (NTC) = DMEM with 10%FBS; positive control (PTC) \n\n=DMEM with phenol 0.5%. Mean \u00b1 standard deviation ? = 3. The population means are \n\nsignificantly different from positive control at *? &lt;0.05. \n\n \n\n3.3.3. Characterization of the Composite Scaffolds \n\n3.3.3.1. Images of the Cell-Seeded ?P-PRP/PCHTs \n\nSEM characterization (Figure 13) of the ?P-PRP/PCHTs on the 5th day of culture \n\nshowed fibrin networks covering the pores and surface of PCHTs, as a consequence of \n\nthe interaction of fibrin fibers and CHT. This interaction supported cell proliferation by \n\nimproving the mechanical strength of the fibrin network, in addition to providing \n\nadditional surface area to cell adhesion, proliferation and differentiation. \n\n   \n\n(a) (b) (c) \n\n\n\n58 \n\n \n\n   \n\n(d) (e) (f) \n\nFigure 13. Scanning electron microscopic images of ?P-PRP/PCHTs after 5 days of \n\ncultivation of h-AdMSCs. (a) ?-PRP; (b) ?P-PRP/PCHTs 1% (?20\u00b0C); (c) ?P-\n\nPRP/PCHTs 2% (?20\u00b0C); (d) ?P-PRP/PCHTs 3% (?20\u00b0C); (e) ?P-PRP/PCHTs 3% \n\n(?80\u00b0C); and (f) ?P-PRP/PCHTs 3% (?196\u00b0C). Original magnification is \u00d75,000 and the \n\nscale bar represents 3 \u00b5m. \n\n. \n\n \n\n3.3.3.2. Growth Factor Release \n\nFigure 14 shows PDGF-AB and TGF-?1 release kinetics from ?P-PCHTs \n\ndetermined by ELISA. \n\n0 10 20 30 40 50 60 70 80\n\n0\n\n5000\n\n10000\n\n15000\n\n20000\n\n25000\n\n \n\n \n\nC\nu\n\nm\nu\n\nla\nti\n\nv\ne\n\n T\nG\n\nF\n-?\n?\n (\n\np\ng\n\n/ \nm\n\nL\n P\n\nR\nP\n\n)\n\nTime (hours)  \n\n0 10 20 30 40 50 60 70 80\n\n0\n\n2000\n\n4000\n\n6000\n\n8000\n\n10000\n\n12000\n\n \n\n \n\nC\nu\n\nm\nu\n\nla\nti\n\nv\ne\n\n P\nD\n\nG\nF\n\n-A\nB\n\n (\np\n\ng\n/ \nm\n\nL\n P\n\nR\nP\n\n)\n\nTime (hours)\n \n\n(a) (b) \n\n\n\n59 \n\n \n\n0 10 20 30 40 50 60 70 80\n\n0\n\n5000\n\n10000\n\n15000\n\n20000\n\n25000\n\n \n\n \n\nC\nu\n\nm\nu\n\nla\nti\n\nv\ne\n\n T\nG\n\nF\n-?\n\n1\n (\n\np\ng\n\n/ \nm\n\nL\n P\n\nR\nP\n\n)\n\nTime (hours)  \n\n0 10 20 30 40 50 60 70 80\n\n0\n\n3000\n\n6000\n\n9000\n\n12000\n\n15000\n\n \n\n \n\nC\nu\n\nm\nu\n\nla\nti\n\nv\ne\n\n P\nD\n\nG\nF\n\n-A\nB\n\n (\np\n\ng\n/ \nm\n\nL\n P\n\nR\nP\n\n)\n\nTime (hours)  \n\n \n\n(c) (d) \n\nFigure 14. Release profiles of growth factors from ?P-PRP in porous chitosan scaffolds \n\nas a function of [(a), (b)] chitosan concentrations and [(c), (d)] freezing conditions. (?) \n\nPCHTs 1% (?20\u00b0C); (?) PCHTs 2% (?20\u00b0C); (?) PCHTs 3% (?20\u00b0C); (?) PCHTs 3% \n\n(?80\u00b0C), (O) PCHTs 3% (?196\u00b0C), and (?) P-PRP activated with Ca+2/thrombin (used \n\nas control); TGF-?1 [(a), (c)]; and PDGF-AB [(b), (d)]. The concentration of platelets in \n\nP-PRP was 472,250 pq/mm3. Activated P-PRP alone was used as control. \n\n \nThe curves show diffusion profiles, indicating no collapse of the porous structure \n\nof chitosan scaffolds during the course of the assays, regardless of the CHT \n\nconcentration and freezing conditions.  \n\nPDGF-AB released from PCHTs ended within 24 hours of incubation, whereas \n\nTGF-?1 tended to continue after 72 hours. \n\nA controlled release of TGF-?1 and PDGF-AB was achieved for all CHT \n\nconcentrations, related to the scaffolds of activated P-PRP only. The slowest release \n\nwas observed for a chitosan concentration of 3%. \n\nIn contrast, for the PCHTs 3% freezing at ?80\u00b0C and ?196\u00b0C, we observed a \n\ncontrolled release of TGF-?1, but a strong burst release of PDGF-AB. \n\nThus, PCHTs prepared with 3% CHT at ?20\u00b0C provided a controlled release of \n\nPDGF-AB and TGF-?1 and can be an efficient vehicle for release of GFs from PRP. \n\n \n\n\n\n60 \n\n \n\n3.3.3.3. h-AdMSCs-Seeded Proliferation  \n\nFigure 15 shows the proliferation profile of h-AdMSCs cultured in ?P-\n\nPRP/PCHTs. \n\n2 3 4 5 6 7 8 9 10 11\n\n0\n\n1x10\n5\n\n2x10\n5\n\n3x10\n5\n\n4x10\n5\n\n5x10\n5\n\n6x10\n5\n\n \n\n \n\nC\ne\n\nll\n n\n\nu\nm\n\nb\ne\n\nr/\n w\n\ne\nll\n\nTime (days)  \n\n2 4 6 8 10\n\n0.0\n\n5.0x10\n4\n\n1.0x10\n5\n\n1.5x10\n5\n\n2.0x10\n5\n\n2.5x10\n5\n\n \n\n \n\nC\ne\n\nll\n n\n\nu\nm\n\nb\ne\n\nr/\n w\n\ne\nll\n\nTime (days)\n \n\n \n\n(a) (b) \nFigure 15. Proliferation kinetic profiles of h-AdMSCs seeded in ?P-PRP/PCHTs. (a) \n\nCHT concentration and (b) freezing conditions. (?) PCHTs 1% (?20\u00b0C); (?) PCHTs 2% \n\n(?20\u00b0C); (?) PCHTs 3% (?20\u00b0C); (?) PCHTs 3% (?80\u00b0C), (O) PCHTs 3% (?196\u00b0C), and \n\n(?) P-PRP activated with Ca+2/thrombin (control). The concentration of platelets in P-\n\nPRP was 374,000 pq/mm3. Activated P-PRP alone was used as control. \n\n \n\nThe cell number per well determined after 3 days exceeded the number of \n\nseeded cells (1.4 \u00d7 104 cells/well) in all the ?P-PRP/PCHTs, meaning that the cells kept \n\nin the matrices retained their viability, regardless of the CHT concentration and freezing \n\nconditions.  \n\nThe cell number per well of ?P-PRP/PCHTs prepared with 1, 2, and 3% (w/v) of \n\nchitosan [Figure 15(a)] showed significant differences (? &lt;0.05) compared to control \n\n(?P-PRP). Therefore, PCHTs must have stabilized fibrin networks as we initially \n\nhypothesized.  \n\nHowever, regarding freezing condition, no significant variations for ?P-\n\nPRP/PCHTs prepared at ?80\u00b0C or ?196\u00b0C and ?P-PRP were observed [Figure 15(b)]. In \n\nall cases, cell viability decreased after 7 days, probably due to collapse of the structure. \n\nWe also observed that the exponential phase of the cultures [Figure 15(a)] \n\n\n\n61 \n\n \n\nstarted after the maximum release of GFs (Figure 14), and the decline phase matched \n\nthe largest weight loss of the PCHTs (Figure 11). \n\n \n\n3.3.3.4. Induction of Osteogenic Differentiation \n\nOsteogenic differentiation of h-AdMSCs was investigated 14 days after cell \n\nseeding. ALP, an early marker of osteogenic differentiation, was determined, and the \n\nresults are shown in Figure 16. The expression of ALP activity showed no significant \n\ndifference (? &lt;0.05) with CHT concentration. However, higher osteogenic differentiation \n\nwas obtained with ?P-PRP/PCHTs 3% (?196\u00b0C). \n\nBl\nan\n\nk\n\naP\n-P\n\nRP\n/P\n\nCH\nTs\n\n 1%\n (-\n\n20\n\u00b0C\n\n)\n\naP\n-P\n\nRP\n/P\n\nCH\nTs\n\n 2%\n (-\n\n20\n\u00b0C\n\n)\n\naP\n-P\n\nRP\n/P\n\nCH\nTs\n\n 3%\n (-\n\n20\n\u00b0C\n\n)\n\naP\n-P\n\nRP\n/P\n\nCH\nTs\n\n 3%\n (-\n\n80\n\u00b0C\n\n)\n\naP\n-P\n\nRP\n/P\n\nCH\nTs\n\n 3%\n (-\n\n19\n6\u00b0\n\nC)\n\n0.0\n\n0.2\n\n0.4\n\n0.6\n\n0.8\n\n1.0\n\n1.2\n\n1.4\n\n1.6\n\n*\n\n*\n\n**\n\n \n\n \n\nA\nL\n\nP\n a\n\nc\nti\n\nv\nit\n\ny\n i\nn\n\n 4\n0\n\n5\n n\n\nm\n (\n\nU\n. \nA\n\n.)\n\n*\n\n \nFigure 16. ALP activities of cells cultured on ?P-PRP/PCHTs scaffolds prepared with \n\ndifferent CHT concentrations and freezing conditions (statistically significant differences \n\nfrom blank, ? = 3, *? &lt;0.05). Blank = the reagents used in the assay only. The \n\nconcentration of platelets in whole blood donors (average of 2 donors) was 163,500 \n\npq/mm3. After preparation of the PRP, the platelets were concentrated approximately \n\n1.74 times, with an average final concentration of 303,000 pq/mm3. \n\n \n\n3.4. Conclusions \n\n \n\nComposite scaffolds were prepared with porous chitosan and ?-PRP. The \n\nperformance of the composite scaffolds was superior to ?P-PRP alone, indicating that \n\nthe porous chitosan stabilized the fibrin network, supporting our initial hypothesis. \n\n\n\n62 \n\n \n\nChitosan concentration and freezing conditions influenced the physicochemical and \n\nbiological properties of the scaffolds. On the average, physicochemical, mechanical, and \n\nh-AdMSCs proliferation improved by the use of 3% (w/v) chitosan and ?20\u00b0C freezing \n\ntemperature, while ?196\u00b0C favored osteogenic differentiation. Additional stabilization of \n\nthe porous structure is needed for applications in regenerative medicine. \n\n \n\nConflict of Interests. The authors declare that there is no conflict of interests regarding \n\nthe publication of this paper.  \n\n \n\nAcknowledgments. The authors acknowledge the financial support from the National \n\nCouncil of Technological and Scientific Development (CNPq, Brazil). They also thank \n\nDr. William Dias Belangero and Dr. Ana Am\u00e9lia Rodrigues of the Faculty of Medical \n\nSciences (University of Campinas) for assistance and Dr. \u00c2ngela Cristina Malheiros \n\nLuzo of the Haematology and Hemotherapy Center (University of Campinas) for the \n\ndonation of h-AdMSCs. \n\n \n\n3.5. References \n \n\nADEKOGBE, I.; GHANEM, A. Fabrication and characterization of DTBP-crosslinked \nchitosan scaffolds for skin tissue engineering. Biomaterials, vol.26, p.7241\u20137250, \n2005. \n\nAGNIHOTRI, S.A.; MALLIKARJUNA, N.N.; AMINABHAVI, T.M. Recent advances on \nchitosan-based micro- and nanoparticles in drug delivery. Journal of Controlled \nRelease, vol.100, n.1, p.5-28, 2004. \n\nAMARAL, F.; SAMPAIO, P.; BARBOSA, M.A. Three-dimensional culture of human \nosteoblastic cells in chitosan sponges: The effect of the degree of acetylation. Journal \nof Biomedical Materials Research, vol.76A, p.335\u2013346, 2006.  \n\nANTONOV, S.F.; KRYZHANOVSKAYA, E.V.; FILIPPOV, Y.I.; SHINKAREV, S.M.; \nFROLOVA, M.A. Study of Wound-Healing Properties of Chitosan. Russian \nAgricultural Sciences, vol.34, n.6, p.426-427, 2008. \n\nBENSA\u00cfD, W.; TRIFFITT, J.T.; BLANCHAT, C.; OUDINA, K.; SEDEL, L.; PETITE, H.A \nbiodegradable fibrin scaffold for mesenchymal stem cell transplantation. Biomaterials, \nvol.24, n.14, p.2497\u2013502, 2003. \n\n\n\n63 \n\n \n\nBERGER, J.; REIST, M.; MAYER, J.; FELT, O.; PEPPAS, N.; GURNY, R. Structure \nand interactions in covalently and ionically crosslinked chitosan hydrogels for \nbiomedical applications. European journal of pharmaceutics and \nbiopharmaceutics, vol.57, p.19\u201334, 2004. \n\nBERTRAM, U.; BODMEIER, R. In situ gelling, bioadhesive nasal inserts for extended \ndrug delivery: In vitro characterization of a new nasal dosage form. European Journal \nof Pharmaceutical Sciences, vol.27, n.1, p.62-71, 2006. \n\nBRAUKER, H.; CARR-BRENDEL, V.E.; MARTINSON, L.A.; CRUDELE, J.; \nJOHNSTON, W.D.; JOHNSON, R.C. Neovascularization of synthetic membranes \ndirected by membrane micro architecture. Journal of Biomedical Materials \nResearch, vol.29, p.1517\u20131524, 1995. \n\nCARDEA, S.; PISANTI, P.; REVERCHON, E. Generation of chitosan nanoporous \nstructures for tissue engineering applications using a supercritical fluid assisted \nprocess. Journal of Supercritical Fluids, vol.54, p.290\u2013295, 2010. \n\nCHANG, H-I.; WANG, Y. Cell Responses to Surface and Architecture of Tissue \nEngineering Scaffolds. In: EBERLI D., (Ed.). Regenerative Medicine and Tissue \nEngineering \u2013 Cells and Biomaterials, Cratia: InTech, chapter 27, p. 569-588, 2011. \n\nCHANG, S.J.; KUO, S.M.; LAN, C-W.; MANOUSAKAS, I.; TSAI, P.H. Evaluation of \nchitosan/CaSO4/ platelet-rich plasma microsphere composites as alveolus \nosteogenesis material. Biomedical Engineering: Applications, Basis and \nCommunications, vol.21, n.2, p.115\u2013122, 2009. \n\nCHAVEZ-MUNOZ, C; NGUYEN, K.T.; XU, W.; HONG, S.J.; MUSTOE, T.A.; \nGALIANO, R.D. Transdifferentiation of adipose-derived stem cells into keratinocyte-\nlike cells: engineering a stratified epidermis. Public Library of Science One, vol.8, \nn.12, p.1-13, 2013. \n\nCHEN, G.; USHIDA, T.; TATEISHI, T. Scaffold Design for Tissue Engineering. \nMacromolecular Bioscience, vol.2, pp.67-77, 2002. \n\nCHEUNG, H-Y.; LAU, Q-T.; LU, T-P.; HUI, D. A critical review on polymer-based bio-\nengineered materials for scaffold development. Composites: Part B, vol.38, p.291-\n300, 2007. \n\nCORREIA, C.R.; TEIXEIRA, L.S.M.; MORONI, L.; REIS, R.L.; VAN BLITTERSWIJK, \nC.A.; KARPERIEN, M.; MANO, J.F. Chitosan Scaffolds Containing Hyaluronic Acid for \nCartilage Tissue Engineering, Tissue Engineering: Part C, vol.17(7), p.717-730, \n2011. \n\nCOSTA-PINTO, R.; REIS, R.L.; NEVES, N.M. Scaffolds Based Bone Tissue \nEngineering: The Role of Chitosan. Tissue Eng. Part B, vol.17, p.331\u2013347, 2011. \n\nCRANE, D.; EVERTS, P.A.M. Platelet Rich Plasma (PRP) Matrix Grafts, PPM \n\n\n\n64 \n\n \n\nCommunications, vol.8, p.1-10, 2008. \n\nDAI, T.; TANAKA, M.; HUANG, Y.Y.; HAMBLIN, M.R. Chitosan preparations for \nwounds and burns: antimicrobial and wound-healing effects. Expert Review of Anti-\ninfective Therapy, vol.9, p.857\u2013879, 2011. \n\nENRIONE, J.; OSORIO, F.; LOPEZ, P.; WEINSTEIN-OPPENHEIMER, C.; FUENTES, \nM.A.; CERIANI, R.; BROWN, D.I.; ALBORNOZ, F.; S\u00c1NCHEZ, E.; VILLALOBOS, P.; \nSOMOZA, R.A.; YOUNG, M.E.; ACEVEDO, C.A. Characterization of a \ngelatin/chitosan/hyaluronan scaffold-polymer. Electronic Journal of Biotechnology, \nvol.13, n.5, p.1-11, 2010. \n\nFALVO, M.R.; GORKUN, O.V.; LORD, S.T. The molecular origins of the mechanical \nproperties of fibrin. Biophysical Chemistry, vol.152, p.15\u201320, 2010. \n\nG\u00dcM\u00dc?DERELIO?LU, M.; ADAY, S. Heparin-functionalized chitosan scaffolds for \nbone tissue engineering. Carbohydrate Research, vol.346, p.606\u2013613, 2011. \n\nHE, P.; DAVIS, S.S.; ILLUM, L. In vitro evaluation of the mucoadhesive properties of \nchitosan microspheres. International Journal of Pharmaceutics, vol.166, p.75\u201388, \n1998. \n\nHOLLISTER, S. J. Porous scaffold design for tissue engineering. Nature Materials, \nvol.4, p.518-590, 2005. \n\nKLAWITTER, J.; HULBERT, S.F. Application of porous ceramics for the attachment of \nload-bearing internal orthopedic applications. Journal of Biomedical Materials \nResearch A Symposium, vol.2, p.161\u2013168, 1971.  \n\nKOGA, D. Chitin enzymology\u2014chitinase, In: Chen, R.; Chen, H.C. (Eds.). Advances \nin Chitin Science, vol.3, p.16\u201323, 1998. \n\nKOJIMA, K.; OKAMOTO, Y.; MIYATAKE, K.; FUJISE, H.; SHIGEMASA, Y.; MINAMI, \nS. Effects of chitin and chitosan on collagen synthesis in wound Healing. Journal of \nVeterinary Medical Science, vol.66, p.1595\u20131598, 2004. \n\nKUTLU, B.; AYDIN, R.S.T.; AKMAN, A.C.; G\u00dcM\u00dc?DERELIO?LU, M.; NOHUTCU, \nR.M. Platelet-rich plasma-loaded chitosan scaffolds: Preparation and growth factor \nrelease kinetics. Journal of Biomedical Materials Research, vol.101B, p.28\u201335, \n2012. \n\nLANGER, R.; VACANTI, J.P. Tissue engineering. Science, vol.260, n.5110, pp. 920\u2013\n926, 1993.  \n\nLAVERTU, M.; METHOT, S.; TRAN-KHANH, N.; BUSCHMANN, M.D. High efficiency \ngene transfer using chitosan/DNA nanoparticles with specific combinations of \nmolecular weight and degree of deacetylation. Biomaterials, vol.27, p.4815-4824, \n2006. \n\n\n\n65 \n\n \n\nLE\u00d3N Y LE\u00d3N, C.A. New perspectives in mercury porosimetry. Advances in Colloid \nand Interface Science, vol.76-77, p.341-372, 1998. \n\nLEONG, F.; CHEAH, C.M.; CHUA, C.K. Solid freeform fabrication of three-dimensional \nscaffolds for engineering replacement tissues and organs. Biomaterials, vol.24, \np.2363\u20132378, 2003. \n\nLI, X.; MIN, M.; DU, N.; GU, Y.; HODE, T.; NAYLOR, M.; CHEN, D.; NORDQUIST, \nR.E.; CHEN, W.R. Chitin, Chitosan, and Glycated Chitosan Regulate Immune \nResponses: The Novel Adjuvants for Cancer Vaccine, Hindawi Publishing \nCorporation Clinical and Developmental Immunology, p.1-8, 2013. \n\nLIU, X.; MA, P.X. Polymeric Scaffolds for Bone Tissue Engineering. Annals of \nBiomedical Engineering, vol.32, n.3, p.477\u2013486, 2004. \n\nLOH, Q.L.; CHOONG, C.; Three-Dimensional Scaffolds for Tissue Engineering \nApplications: Role of Porosity and Pore Size. Tissue Engineering: Part B, vol.19, n.6, \np.485-503, 2013. \n\nMADIHALLY, S.V.; MATTHEW, H.W.T. Porous chitosan scaffolds for tissue \nengineering. Biomaterials, vol.20, p.1133-1142, 1999. \n\nMAJIMA, T.; IRIE, T.; SAWAGUCHI, N.; FUNAKOSHI, T.; IWASAKI, N.; HARADA, K.; \nMINAMI, A.; NISHIMURA, S.-I. Chitosan-based hyaluronan hybrid polymer fiber \nscaffold for ligament and tendon tissue engineering. Proceedings of the Institution \nof Mechanical Engineers \u2013 Part H: J. Engineering in Medicine, vol. 221, p.537-\n546, 2007. \n\nMARTINS, M.; ENG, G.; CARIDADE, S.G.; MANO, J.F.; REIS, R.L.; VUNJAK-\nNOVAKOVIC, G. Electrically Conductive Chitosan/Carbon Scaffolds for Cardiac \nTissue Engineering. Biomacromolecules, vol.15, p.635?643, 2014. \n\nMATHEWS, S.; BHONDE, R.; GUPTA, P.K.; TOTEY, S. A novel tripolymer coating \ndemonstrating the synergistic effect of chitosan, collagen type 1 and hyaluronic acid \non osteogenic differentiation of human bone marrow derived mesenchymal stem cells. \nBiochemical and Biophysical Research Communications, vol.414, p.270\u2013276, \n2011. \n\nMOLINARO, G.; LEROUX, J.C.; DAMAS, J.; ADAM, A. Biocompatibility of \nthermosensitive chitosan-based hydrogels: an in vivo experimental approach to \ninjectable biomaterials. Biomaterials, vol.23, p.2717-2722, 2002. \n\nMOSSMAM, T.J. A rapid colorimetric assay of cellular growth and survival: application \nto proliferation and cytotoxicity assays. Journal of Immunological Methods, vol.65, \np.55-63, 1983. \n\nMUCHA, M.; MICHALAK, I.; BALCERZAK, J.; TYLMAN, M. Chitosan scaffolds, films \nand microgranules for medical application \u2014 preparation and drug release studies. \n\n\n\n66 \n\n \n\nPolimery, vol.57, n.10, p.714-721, 2012. \n\nMUZZARELLI, R. Chitosan. In: MUZZARELLI R. (Eds.). Natural Chelating Polymers. \nOxford: Pergamon Press, 1973, p. 144\u2013176. \n\nMUZZARELLI, R.; TARSI, R.; FILIPPINI, O.; GIOVANETTI, E.; BIAGINI, G.; \nVARALDO, P.E. Antimicrobial Properties of N-Carboxybutyl Chitosan. Antimicrobial \nagents and chemotherapy, vol.34, n.10, p.2019-2023, 1990. \n\nNASTI, A.; ZAKI, M.N.; DE LEONARDIS, P.; UNGPHAIBOON, S.; SANSONGSAK, P.; \nRIMOLI, M.G.; TIRELLI, N. Chitosan/TPP and Chitosan/TPP-hyaluronic Acid \nNanoparticles: Systematic Optimisation of the Preparative Process and Preliminary \nBiological Evaluation. Pharmaceutical Research, vol.26, n.8, p.1918-1930, 2009. \n\nNETTLES, D.L.; ELDER, S.H.; GILBERT, J.A. Potential Use of Chitosan as a Cell \nScaffold Material for Cartilage Tissue Engineering. Tissue Engineering, vol.8, n.6, \np.1009-1016, 2002. \n\nNORDTVEIT, R.J.; V\u00c2RUM, K.M.; SMIDSRD, O. Degradation of partially N-acetylated \nchitosans with hen egg white and human lysozyme. Carbohydrate Polymers, vol.29, \np.163-167, 1996. \n\nNWE, N.; FURUIKE, T.; TAMURA, H. The Mechanical and Biological Properties of \nChitosan Scaffolds for Tissue Regeneration Templates Are Significantly Enhanced by \nChitosan from Gongronella butleri. Materials, vol.2, p.374-398, 2009. \n\nOKAMOTO, Y.; YANO, R.; MIYATAKE, K.; TOMOHIRO, I.; SHIGEMASA, Y.; MINAMI, \nS. Effects of chitin and chitosan on blood coagulation. Carbohydrate Polymers, \nvol.53, p.337\u2013342, 2003. \n\nOKTAY, E.O.; DEMIRALP, B.; DEMIRALP, B.; SENEL, S.; CEVDET A.; ERATALAY, \nK.; AKINCIBAY, H. Effects of platelet-rich plasma and chitosan combination on bone \nregeneration in experimental rabbit cranial defects. Journal of Oral Implantology, \nvol.36, p.175\u2013184, 2010. \n\nPEREZ, A.G.M.; LICHY, R.; LANA, J.F.S.D.; RODRIGUES, A.A.; LUZO, A.C.M.; \nBELANGERO, W.D.; SANTANA, M.H.A. Prediction and Modulation of Platelet \nRecovery by Discontinuous Centrifugation of Whole Blood for the Preparation of Pure \nPlatelet-Rich Plasma. BioResearch Open Access, vol.2, p. 307-314, 2013. \n\nPEREZ, A.G.M.; RODRIGUES, A.A.; LUZO, A.C.M.; LANA, J.F.S.D.; BELANGERO, \nW.D.; SANTANA M. H. A. Fibrin network architectures in pure platelet-rich plasma as \ncharacterized by fiber radius and correlated with clotting time. Journal of Materials \nScience: Materials in Medicine, vol.25(8), p.1967-1977, 2014. \n\nRAO, S.B.; SHARMA, C.P. Sterilization of chitosan: implications. Journal of \nBiomaterials Applications, vol.10, n.2, p.136-43, 1995. \n\n\n\n67 \n\n \n\nRUCKER, M.; LASCHKE, M. W.; JUNKER, D.; CARVALHO, C.; SCHRAMM, A.; \nMULHAUPT, R.; GELLRICH, N.C; MENGER, M.D. Angiogenic and inflammatory \nresponse to biodegradable scaffolds in dorsal skinfold chambers of mice. \nBiomaterials, vol.27, p.5027-5038, 2006. \n\nRYAN, E.; MOCKROS, L.F.; WEISEL, J.W.; LORAND, L. Scientific Commons: \nStructural origins of fibrin clot rheology. Biophysical Journal, vol.77, p.2813-2826, \n1999. \n\nSALGADO, J.; COUTINHO, O.P.; REIS, R.L. Bone Tissue Engineering: State of the \nArt and Future Trends. Macromolecular Bioscience, vol.4, p.743-765, (2004). \n\nSHEN, E.C.; CHOU, T.C.; GAU, C.H.; TU, H.P.; CHEN, Y.T.; FU, E. Releasing growth \nfactors from activated human platelets after chitosan stimulation: a possible bio-\nmaterial for platelet-rich plasma preparation. Clinical Oral Implants Research, vol.17, \np.572\u2013578, 2006. \n\nSHEN, F.; CUI, Y.L.; YANG, L.F.; YAO, K.D.; DONG, X.H.; JIA, W.Y.; SHI, H.D. A \nstudy on the fabrication of porous chitosan/gelatin network scaffold for tissue \nengineering. Polymer International, vol.49, p.1596-1599, 2000. \n\nSHU, X.Z.; ZHU, K.J. Controlled drug release properties of ionically cross-linked \nchitosan beads: the influence of anion structure. International Journal of \nPharmaceutics, vol.233, p.217\u201325, 2002. \n\nTAN, H.P.; CHU, C.R.; PAYNE, K.A.; MARRA, K.G. Injectable in situ forming \nbiodegradable chitosan-hyaluronic acid based hydrogels for cartilage tissue \nengineering. Biomaterials, vol.30, p.2499\u20132506, 2009. \n\nTANG, S.; SPECTOR, M. Incorporation of hyaluronic acid into collagen scaffolds for \nthe control of chondrocyte-mediated contraction and chondrogenesis. Biomedical \nMaterials, vol.2, p.S135\u2013S141, 2007. \n\nWANG, Y.; LIN, M.; WANG, D.; HSIEH, H. Fabrication of a novel porous PGA\u2013\nchitosan hybrid matrix for tissue engineering. Biomaterials, vol.24, p.1047\u201357, 2003. \n\nWEISEL, J.W.; NAGASWAMI, C. Computer modeling of fibrin polymerization kinetics \ncorrelated with electron microscope and turbidity observations: clot structure and \nassembly are kinetically controlled. Biophysical Journal, vol.63, n.1, p.111\u2013128, \n1992. \n\nYANG, S.; LEONG, K.F.; DU, Z.; CHUA, C.K. The design of scaffolds for use in tissue \nengineering\u2014part I: traditional factors. Tissue Engineering, vol.7, n.6, p.679\u2013689, \n2001. \n\nYANNAS, V.; LEE, E.; ORGILL, D.P.; SKRABUT, E.M.; MURPHY, G.F. Synthesis and \ncharacterization of a model extracellular matrix that induces partial regeneration of \nadult mammalian skin. Proceedings of the National Academy of Sciences of the \n\n\n\n68 \n\n \n\nUnited States of America, vol.86, p.933-937, 1989. \n\n  \n\n\n\n69 \n\n \n\nCAP\u00cdTULO 4 \u2013 STABILIZATION OF POROUS \nCHITOSAN IMPROVES THE PERFORMANCE OF \n\nITS ASSOCIATION WITH PLATELET-RICH \n\nPLASMA AS A COMPOSITE SCAFFOLD \n\nArtigo submetido ao peri\u00f3dico Materials Science and Engineering C: Materials for Biological Applications. \n\n \n\nA. A. M. Shimojo1, A. G. M. Perez1, S. E. M. Galdames1, I. C. S. Brissac1, M. H. A. \n\nSantana1 \n\n \n\n1Department of Engineering of Materials and of Bioprocesses, School of Chemical \n\nEngineering, UNICAMP, P.O. Box 6066, 13083-970 Campinas, SP, Brazil. \n\n \n\n*Correspondence to: Andr\u00e9a Arruda Martins Shimojo, phone: +55-19-35213969, FAX: \n\n+55-19-35213890, e-mail: lshimojo51@gmail.com \n\n \n\nAbstract. This study offers innovative perspectives for optimizing of scaffolds based on \n\ncorrelation structure-function aimed the regenerative medicine. Thus, we evaluated in \n\nvitro the performance of stabilized porous chitosan (SPCHTs) associated with activated \n\nplatelet-rich plasma (aP-PRP) as a composite scaffold for the proliferation and \n\nosteogenic differentiation of human adipose-derived mesenchymal stem cells (h-\n\nAdMSCs). The porous structure of chitosan (PCHT) was prepared similarly to solid \n\nsponges by controlled freezing (-20\u00b0C) and lyophilization of a 3% (w/v) chitosan solution. \n\nStabilization was performed by treating the PCHT with sodium hydroxide (TNaOH), an \n\nethanol series (TEtOH) or by crosslinking with tripolyphosphate (CTPP). The aP-PRP \n\nwas obtained from the controlled centrifugation of whole blood and activated with \n\nautologous serum and calcium. Imaging of the structures showed fibrin networks inside \n\nand on the surface of SPCHTs as a consequence of electrostatic interactions. SPCHTs \n\nwere non-cytotoxic, and the porosity, pore size and Young\u2019s modulus were \n\nmailto:lshimojo51@gmail.com\n\n\n70 \n\n \n\napproximately 96%, 145 \u00b5m and 1.5 MPa for TNaOH and TEtOH and 94%, 110 \u00b5m and \n\n1.8 MPa for CTPP, respectively. Stabilization maintained the integrity of the SPCHTs for \n\nat least 10 days of cultivation. SPCHTs showed controlled release of the growth factors \n\nTGF-?1 and PDGF-AB. Although generating different patterns, all of the stabilization \n\ntreatments improved the proliferation of seeded h-AdMSCs on the composite scaffold \n\ncompared to aP-PRP alone, and differentiation of the composite scaffold treated with \n\nTEtOH was significantly higher than for non-stabilized PCHT. We conclude that the \n\nstabilized of porous chitosan scaffolds improved the in vitro performance of PRP and \n\nhave potential in regenerative medicine.  \n\n \n\nKeywords: Regenerative medicine; scaffolds; chitosan; platelet-rich plasma; growth \n\nfactors. \n\n \n\n4.1. Introduction \n \n\nPlatelet-rich plasma (PRP) is an autologous product from whole blood (WB) \n\ncomprised primarily of a high concentration of platelets dispersed in plasma (P-PRP) but \n\nthat can also include concentrated leukocytes (L-PRP) (Ehrenfest et al., 2009). \n\nCurrently, PRP therapy has been used in various medical specialties and has been \n\nresponsible for several successful outcomes. Various clinical uses including sports \n\nmedicine, orthopedics and the recovery of musculoskeletal injuries have been reported \n\nrecently (Lana et al., 2014). \n\nActivated PRP (aPRP) releases growth factors (GFs) and various cytokines from \n\nplatelets and leukocytes as well as stimulating the decomposition of fibrinogen in fibrin \n\nfibers, which arrange themselves in a network structure that supports cell proliferation \n\nand differentiation (Marx, 2004). Therefore, tissue repair occurs from a cascade of \n\nmultiple reactions mediated by GFs (Jacobson et al., 2008), in which cytokines play an \n\nimportant role (Kanaji et al., 2011). \n\nPreparation of PRP first involves the separation of red blood cells and the \n\nconcentration of platelets and other components of WB. Usually, separation is \n\nperformed by centrifugation, and activation is promoted by thrombin and calcium. \n\n\n\n71 \n\n \n\nAdequate centrifugation conditions and multiple spins must be used to obtain a high \n\nyield of platelets and preserve integrity (Perez et al., 2013). The architecture of the fibrin \n\nnetwork is determined by the activation conditions (Perez et al., 2014) and plays an \n\nimportant role in GF release and cell proliferation.  \n\nCrane &amp; Everts (2008) described tissue regeneration based on the triangle of \n\nproliferation, which represents cooperation between genic, conductive and inductive \n\ncapabilities, using the cells, scaffold and GFs as basic elements. PRP is beneficial to \n\ntissue regeneration because it acts as an inducer and conductive matrix (scaffold) for \n\ncell proliferation. Furthermore, aPRP influences the paracrine activity of mesenchymal \n\ncells (MSCs), which is an important mechanism determining their efficacy in \n\nregenerative therapies (Liu et al., 2002; Hom et al., 2007). \n\nIn regenerative PRP therapies, we would consider first generation therapies to be \n\nPRP alone, followed by the second generation of PRP associated with bone marrow \n\ncells, and finally a third generation using PRP and h-AdMSCs. However, the \n\nperformance of the fibrin network as a scaffold in regeneration requires further attention. \n\nStructural stability is an important issue because MSCs needs the maintenance of a 3-\n\ndimensional fibrin architecture for proliferation, migration and differentiation.  \n\nSome of the available literature suggests that the association of PRP with \n\nchitosan is beneficial to osteogenic regeneration (Ouyang et al., 2013; Rossi et al., \n\n2013; Kutlu et al., 2013; Bi et al., 2010; Oktay et al., 2010; Chang et al., 2009; Shen et \n\nal., 2006; Kojima et al., 2004; Okamoto et al., 2003). \n\nIn our previous studies, we observed the association of aP-PRP with PCHTs \n\ncontrolled the release of GFs and also improved the in vitro proliferation and \n\ndifferentiation of h-AdMSCs compared to aP-PRP only. However, the PCHTs collapsed \n\nafter five days of cell cultivation and required stabilization.  \n\nPorous chitosan scaffolds are produced primarily by a freezing process, which \n\nprovides the nucleation of ice crystals from solution and further growth along the lines of \n\nthermal gradients. Exclusion of the chitosan acetate salt from the ice crystal phase and \n\nsubsequent ice removal by lyophilization generates a porous material. After freeze-\n\ndrying, the acetate molecules are in solid form in the scaffold cavities as ions bound to \n\nthe cationic amine groups in the chitosan. When the acetate is not removed or \n\n\n\n72 \n\n \n\nneutralized, the scaffold will swell rapidly and ultimately dissolve upon rehydration in a \n\nneutral aqueous medium, requiring stabilization of the scaffold.  \n\nStabilization using multiple methods has been studied, including rehydration and/ \n\nor crosslinking (Shen et al., 2000), immersion in sodium hydroxide (Madihally &amp; Mathew, \n\n1999; Manjubala et al., 2006), tripolyphosphate (Seol et al., 2004; Lee et al., 2000) and/ \n\nor an ethanol series (Nwe et al., 2009; Reis et al., 2008). Neutralization with NaOH \n\nremoves acid remnants and regenerates the NH2 groups on the chitosan, yielding a \n\nhydrophilic surface. The stabilization occurs by inhibition of the repulsion between \n\nchitosan chains and the formation of hydrogen bonds, hydrophobic interactions and \n\nchitosan crystallites (Noriega &amp; Subramanian, 2011). An adequate NaOH concentration \n\nmust be applied to maintain the shape and volume of the chitosan scaffold during the \n\ncell culture period (Nwe et al., 2009). \n\nStabilization with an ethanol series occurs because CHT decreases in solubility \n\nas the polarity of mixed solvents decreases, and affects not only the solubility of CHT \n\nbut also the elasticity of the hydrogel (Sano et al., 1999). \n\nCationic chitosan can be crosslinked by multivalent counterions such as \n\ntripolyphosphate to form an intermolecular and/or intramolecular network structure. The \n\nreactions occurs through the ionic interaction between the NH3+ protonated groups of \n\nchitosan and the negatively charged counterions of TPP, including the OH- and P3O105- \n\nions coexisting in the TPP solution (Bhumkar &amp; Pokharkar, 2006). \n\nIn this work, we extended previous findings by studying the effects of PCHT \n\nstabilization on the performance of the composite scaffold aP-PRP/SPCHT. Stabilization \n\nwas performed by treating PCHT with sodium hydroxide (TNaOH), an ethanol series \n\n(TEtOH) or by crosslinking with tripolyphosphate (CTPP). The in vitro performance of \n\nthe composite scaffolds was evaluated based on physicochemical and biological \n\nproperties, and these results are important to optimize composite scaffolds for use in \n\nimplants or for wound healing.  \n\n \n\n4.2. Materials and Methods \n \n\n\n\n73 \n\n \n\n4.2.1. Materials \n\nChitosan (average molecular weight [Mw] = 4 x 105 Da, degree of deacetylation = \n\n83 \u00b1 4%) was purchased from Polymar\u00ae (Fortaleza, CE, Brazil) and purified according \n\nto a protocol described by Nasti et al. (2009). Other chemicals were reagent grade and \n\nwere used without any further purification. PRP was prepared from whole blood (WB) of \n\ndonors, who were healthy individuals aged between 30 and 40 years old and previously \n\nassessed through their clinical examinations. The human adipose tissue-derived \n\nmesenchymal stem cells, h-AdMSCs, were provided by Umbilical Cord Blood Bank of \n\nHaematology and Hemotherapy Center of University of Campinas. All biological \n\nexperiments were approved by the Ethics Committee of the Medical Sciences School of \n\nthe University of Campinas (UNICAMP; CAAE: 0972.0.146.000-11). \n\n \n\n4.2.2. Methods \n\n4.2.2.1. Preparation of porous chitosan (PCHT) \n\nPCHT was prepared from a chitosan solution 3% (w/v) prepared by dissolving \n\nchitosan in 0.2 mol.L-1 acetic acid. To obtain a cylindrical shape, the solution was added \n\nto the wells of a 24 well culture plate (TPP\u00ae, polystyrene, diameter=15.4 mm). The \n\nsponge-like porous structure was generated by freezing at -20\u00b0C for 24 hours and \n\nlyophilizing in a lyophilizer Liobras L101 (Liobras, S\u00e3o Carlos, SP, Brazil) at a \n\ntemperature of approximately -30\u00b0C for 48 hours.  \n\n \n\n4.2.2.2. Stabilization of PCHT  \n\nPCHT was stabilized by treatment with dilute NaOH (TNaOH), an ethanol series \n\n(TEtOH) or by crosslinking with tripolyphosphate (CTPP) (Madihally &amp; Matthew, 1999). \n\nAll of these treatments began with the slow immersion of PCTS in specific aqueous \n\nsolutions, some of which were followed by washing. For TNaOH, 0.05 mol.L-1 NaOH \n\nsolution was used, and the PCHT was equilibrated for ~10 min and then washed twice \n\nwith water and twice with phosphate buffered saline (pH 7.4). TEtOH treatment was \n\nperformed by immersing the PCHT in absolute ethanol for ~1 h, then immersing \n\nsequentially in 70% and 50% (v/v)  ethanol for ~30 min each. For CTPP treatment, the \n\n\n\n74 \n\n \n\nPCHT was immersed in 5% (w/v) TPP solution, equilibrated for ~2 h and then washed \n\ntwice with water and twice with phosphate buffered saline (pH 7.4). The final mass ratio \n\nin the stabilized scaffold of CHT/TPP was 2:1. The stabilized PCHT (SPCHTs) were \n\nfrozen at -20\u00b0C and lyophilized at a temperature of approximately -30\u00b0C for 48 hours \n\nagain.  \n\n \n\n4.2.3. Characterization of SPCHTs \n\n4.2.3.1. Chemical modification \n\nInfrared spectrometry (FT-IR) was used to identify the chemical modifications in \n\nthe SPCHT scaffolds. Infrared spectra of PCHTs were obtained using an Infrared \n\nSpectrometer Fourier Transform (FT-IR) Thermo Scientific Nicolet Model 6700 (Thermo \n\nFisher Scientific, Waltham, MA, USA) in the spectral range of 4000\u2013675 cm-1. \n\nMeasurements were made in ATR mode with the SMART OMNI-SAMPLER accessory \n\nin the spectral range between 4000-675 cm-1 at a resolution of 4 cm-1 and 64 scans. \n\nATR-IR(chitosan): 3500\u20133000 (? OH and NH2), 2875 (?CH), 1645 (amide I), 1550 (amide II) \n\n1380, 1067, 1020 cm?1 (Nasti et al., 2009). \n\n \n\n4.2.3.2. Morphology and pore size \n\nThe morphology of the SPCHTs was evaluated by scanning electron microscopy \n\n(SEM) using a LEO 440i Electron Microscopy/Oxford (Cambridge, England) operated at \n\n5 kV accelerating voltage The scaffolds were gold-coated using a sputter coater \n\nPOLARON SC7620, VG Microtech (Uckfield, England) for 180 s at a current of 3 mA. \n\nPore size (n=20) was measured using an Image J 1.47t.  \n\n \n\n4.2.3.3. Swelling profile \n\nThe swelling profile in function of time of the SPCHTs was determined by swelling \n\nfreeze-dried scaffolds of known weight in phosphate buffered saline (PBS) (LB \n\nLaborclin, Pinhais, PR, Brazil) at pH 7.4 and 37\u00b0C. The swelling ratio (SR) was \n\ncalculated using Equation (1): \n\n \n\n\n\n75 \n\n \n\n?? =\n??\n\n??\n                                                                                                                        Equation (1) \n\n \n\nin which ?s and ?d are the weights of the scaffolds at the swelling state and the dry \n\nstate, respectively. \n\n4.2.3.4. Porosity \n\nPorosity (?) of the SPCHTs was measured according to the protocol used by \n\nWang et al. (2003), and calculated using Equation (2):  \n\n \n\n? (%) =  \nVm?(\n\nWm\n\n?\n)\n\nVm\n? 100                                                                                     Equation (2) \n\n \n\nin which ?m is the total volume of CHT scaffolds (cm3), ? is the density of the non-porous \n\nchitosan scaffold (1.342 g/cm3) and ?m is the weight of scaffold (g). Values are \n\nexpressed as the mean \u00b1 standard deviation (n=3). \n\n \n\n4.2.3.5. Mechanical resistance \n\nMechanical compression tests of the SPCHTs (n=3) were performed using a \n\nUniversal Testing Machine, MTS model 810-Flex Test 40 (MTS Systems Corporation, \n\nEden Prairie, MN, USA) at up to 60% of strain, according to Correia et al. (2011). The \n\ntesting machine was equipped with a 1.5 kN load cell, and the loading rate was 5 \n\nmm/min. The Young\u2019s modulus was calculated in the initial linear section of the stress\u2013\n\nstrain curve, when the strain was lower than 10%.  \n\n \n\n4.2.3.6. Degradation in phosphate buffered saline \n\nDegradation of SPCHTs was examined by the weight loss of previously weighed \n\nSPCHTs (?o), which was monitored as a function of incubation time in PBS at 37\u00b0C. At \n\nspecified time intervals, PCHTs were removed from the PBS and weighed (?t). The \n\nweight loss ratio is defined in Equation (3) (Tan et al., 2009). \n\n \n\nweight loss (%) =\n(w0?wt)\n\nw0\n? 100                                                                        Equation (3) \n\n \n\n\n\n76 \n\n \n\n4.2.3.7. Cell compatibility \n\nThe compatibility of the SPCHTs was performed by exposing h-AdMSCs to \n\nSPCHTs followed by cultivation at 37\u00b0C for 24 hours and evaluation by MTT (3-[4,5-\n\ndimethyl-thiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay (MTT, Molecular Probes), \n\naccording to a modified Mosmann method (1983). The MTT assay is a colorimetric test \n\nbased on the reduction of yellow tetrazolium salt into a purple formazan product in the \n\npresence of cells (G\u00fcm\u00fc?derelio?lu &amp; Aday, 2011). \n\n \n\n4.2.4. Preparation of pure platelet-rich plasma (P-PRP) \n\nP-PRP, which is rich in platelets and poor in leukocytes, was prepared according \n\nto Perez et al. 2013. Briefly, whole blood (WB) was collected in 3.5 mL vacuum tubes \n\n(Vacuette\u00ae, Campinas, SP, Brazil) containing sodium citrate 3.2% (w/v) as an \n\nanticoagulant. WB was initially centrifuged in a Rotina 380R centrifuge (Hettich\u00ae \n\nZentrifugen, Tuttlingen, Germany) at 100xg for 10 minutes at 25\u00baC. After the formation \n\nof three layers: a bottom layer of red blood cells (RBCs); an upper layer of plasma, \n\nplatelets and some WBCs; and an intermediate layer, or buffy coat, composed mostly of \n\nWBCs; only the upper layer was collected as P-PRP. The concentration of platelets, \n\nWBCs and RBCs in WB and P-PRP was determined using the ABX Micros ES 60 \n\nhematology analyzer (HORIBA ABX Diagnostics, Montpellier, France). \n\n \n\n4.2.5. Preparation of activated P-PRP (aP-PRP) \n\naP-PRP was prepared by activation of P-PRP using autologous serum (Ser) and \n\n10% (w/v) CaCl2 solution as agonists in the following proportions: agonist/P-PRP=20% \n\n(v/v); Ser/CaCl2 volumetric ratio=9. Autologous serum was prepared by collecting 5 mL \n\nof WB in tubes without anticoagulant. After 30 minutes of clot formation, WB was \n\ncentrifuged at 2000xg for 10 minutes (Perez et al., 2014).  \n\n \n\n4.2.6. Preparation of composite scaffold (aP-PRP/SPCHTs) \n\naP-PRP/SPCHTs were prepared by dripping aP-PRP, immediately after \n\nactivation, onto SPCHTs. The preparation was carried out in 48-well microplates using \n\n\n\n77 \n\n \n\n200 \u00b5L of aP-PRP/10-20 mg of PCHTs. \n\n \n\n4.2.7. h-AdMSCs isolation and pre-cultivation \n\nHuman subcutaneous adipose tissue initially acquired from liposuction surgery \n\nwas washed with sterile PBS, separated into 10 g samples, digested with 20 mg of \n\ncollagenase type 1A and maintained in 20 mL of DMEM-LG containing 10% bovine \n\nserum albumin (BSA) and 10 \u00b5L of gentamicin for 30 min in a 37\u00b0C bath. After complete \n\ndigestion, the reaction was quenched with 10 mL fetal bovine serum (FBS) and \n\nimmediately centrifuged for 15 min at 1500 rpm. The supernatant was discarded, and \n\nthe pellet was suspended in 10 mL DMEM-LG with 10% FBS. After pre-cultivation for 24 \n\nh, the culture medium was changed every 3 days and after the fourth passage, the cells \n\nwere characterized by immunophenotyping using flow cytometry and adipogenic, \n\nosteogenic and chondrogenic differentiation (data not shown), then were used in the \n\nsubsequent experiments. \n\n \n\n4.2.8. h-AdMSCs-seeding in the composite scaffolds \n\nThe pre-cultured h-AdMSCs were trypsinized and re-suspended in P-PRP to a \n\nfinal cell concentration of 1 x 104 cells/ mL. P-PRP containing h-AdMSCs was activated \n\nand immediately embedded in the SPCHTs in a 24-well tissue culture plate using 200 \u00b5L \n\nof h-AdMSCs+aP-PRP/10-20 mg of SPCHTs. The composite scaffolds seeded were \n\nwith h-AdMSCs and incubated at room temperature for 45 minutes for the consolidation \n\nof the fibrin network. aP-PRP was used as the control.  \n\n \n\n4.2.9. Characterization of the composite scaffold  \n\n4.2.9.1. Release of GFs \n\nThe release of platelet-derived growth factor AB (PDGF-AB) and transforming \n\ngrowth factor ?1 (TGF-?1) was assessed after 1 hour gelation of aP-PRP associated to \n\nSPCHTs in the presence of the culture medium (Dulbecco's Modified Eagle's Medium \n\n(DMEM-LG) (Gibco, Grand Island, NY, USA) with low glucose concentration). The \n\nculture medium (1.5 mL) was added to aP-PRP/SPCHTs in 48 well microplates, which \n\n\n\n78 \n\n \n\nwere maintained in an incubator with 5% CO2 for the duration of the assays. The total \n\nvolume of culture medium was removed at 3, 6, 12, 24 and 72 hours, and the same \n\nvolume of fresh medium was replaced without removing the hydrogels from the wells. \n\nThe samples were stored at -80\u00baC for further characterization. The concentration of the \n\nreleased GFs PDGF-AB and TGF-?1 were measured using enzyme-linked \n\nimmunosorbent assay (ELISA) kits (R&amp;D Systems, Minneapolis, MN, USA) according to \n\nthe manufacturer\u2019s instructions and specifications.  \n\n \n\n4.2.9.2. Images of the cell-seeded composite scaffolds \n\nThe images of cell-seeded composite scaffolds were obtained by scanning \n\nelectron microscopy after 5 days of h-AdMSCs proliferation. The cell-seeded composite \n\nscaffolds were fixed in a solution of 4% paraformaldehyde and 2.5% glutaraldehyde in \n\nphosphate buffer, pH 7.4, for 2 hours. The samples were then dehydrated in ethanol for \n\n15 min intervals in aqueous 50%, 70%, 95% and 100% ethanol solutions (2x) and dried \n\nat the critical point dryer BAL-TEC CPD 030 (Schalksm\u00fchle, Germany). After gold \n\ncoating (Sputter Coater POLARON, SC7620, VG Microtech), the cell-seeded composite \n\nscaffolds were visualized with a scanning electron microscope (Leo 440i LEO) with an \n\naccelerating voltage of 20 kV. \n\n \n\n4.2.9.3. h-AdMSCs proliferation \n\nThe cultivation of h-AdMSCs was performed in 24-well tissue culture plates by \n\nadding 1 mL of the DMEM culture medium to the seeded composite scaffolds (n=4) and \n\ncontrolling the temperature at 37\u00b0C for 10 days. Cell proliferation was quantified by MTT \n\nassay. After 3, 5, 7 and 10 days of cultivation, the composite scaffolds were removed \n\nand transferred to 24-well plates. Then, MTT (1 mL of 1 mg/mL) was added, and the \n\ncultivation proceeded at 37\u00b0C for 4 hours. The MTT solution was discarded, and 1 mL of \n\nDMSO was added to dissolve the purple formazan crystals. The samples were shaken \n\nat 120 rpm for 30 min to ensure homogeneous dissolution of the formazan dye, and then \n\n200 \u00b5L of each sample was transferred to a 96-well plate. The optical density was \n\nmeasured at 595 nm using a microplate reader (FilterMax F5 Molecular Devices).  \n\n \n\n\n\n79 \n\n \n\n4.2.9.4. Induction of osteogenic differentiation \n\nh-AdMSCs-seeded in the composite scaffolds were induced to differentiate into \n\nthe osteogenic lineage by providing osteogenic medium containing DMEM-LG \n\nsupplemented with 10% FBS, 1% ?-glycerol-phosphate (Sigma-Aldrich, St. Louis, MO, \n\nUSA), 1% L-ascorbic acid (Sigma-Aldrich, St. Louis, MO, USA), 1% dexamethasone \n\n(Sigma-Aldrich, St. Louis, MO, USA) and 1% Penicillin/Streptomycin solution (Gibco, \n\nGrand Island, NY, USA). The medium was changed every 7 days.  \n\n \n\n4.2.9.5. Alkaline phosphatase activity (ALP) \n\nThe level of alkaline phosphatase (ALP) activity in h-AdMSCs was determined on \n\nday 14. The supernatant (200 ?L) was collected and mixed with 200 ?L of the substrate \n\np-nitrophenyl phosphate (SIGMAFAST\u2122 p-nitrophenyl phosphate tablets, Sigma, Saint \n\nLouis, MI, USA) and incubated at room temperature for 30 minutes. Absorbance was \n\nread immediately on a spectrophotometer at 405 nm. \n\n \n\n4.2.10. Statistical analysis \n\nEach experiment was performed in triplicate unless otherwise specified. All of the \n\nresults are presented as the mean \u00b1 standard deviation (SD). The experimental data \n\nfrom all of the studies were analyzed using Analysis of Variance (ANOVA). Statistical \n\nsignificance was set to p-value ? 0.05. \n\n \n\n4.3. Results and discussion \n \n\n4.3.1. Modifications and surface chemistry  \n\nThe FTIR spectra of the SPCHTs from the various treatments is shown in Figure \n\n17. The FTIR spectra of non-treated scaffolds (NTPCHTs) were included as controls. \n\nFTIR spectra of SPCHTs/TNaOH and SPCHTs/TEtOH showed no significant \n\nmodification of the chemical structure of chitosan compared to the NTPCHTs, which \n\nshowed peaks at 1550 cm?1 and 1400 cm?1 corresponding to asymmetric and symmetric \n\ncarboxylate ion stretching, characteristic of the presence of acetate ions in the chitosan \n\n\n\n80 \n\n \n\nacetate salt and suggesting incomplete deacetylation of chitosan (Noriega &amp; \n\nSubramanian, 2011; Demarger-Andre &amp; Domard, 1994). Therefore, the chemical groups \n\nof SPCHTs/TNaOH and SPCHTs/TEtOH exposed to PRP and h-AdMSCs during in vitro \n\nassays are \u2013NH3+ and \u2013OH from the chitosan chain, which favor osteoblast \n\ndifferentiation (Chang &amp; Wang, 2011). \n\nThe formation of an intermolecular complex between the\u2013NH3+ group of chitosan \n\nand the P3O10-5 of TPP in the SPCHTs/CTPP was characterized by the presence of the \n\nP=O and P-O groups at the frequencies of 1100 cm-1 and 1232 cm-1, respectively (Mi et \n\nal., 1999). In this case, the crosslinking decreased the positive charge on the chitosan \n\nexposed to PRP and h-AdMSCs during the in vitro assays. However, there is increased \n\nscaffold hydrophilicity due to the presence of \u2013OH and P=O groups from TPP that favor \n\ncell spreading, proliferation and differentiation (Chang &amp; Wang, 2011). \n\nThus, the stabilized scaffolds prepared in this work show chemical surfaces \n\nfavorable for cell processes required for tissue regeneration as well as being suitable for \n\nthe adhesion and support of the fibrin network from PRP, which has a negative charge. \n\n2000 1600 1200 800\n70\n\n75\n\n80\n\n85\n\n90\n\n95\n\n100\n\n105\n\n \n\n \n\nT\nra\n\nn\ns\n\nm\nit\n\na\nn\n\nc\ne\n\n (\n%\n\n)\n\nWavenumber (cm\n-1\n)\n\nethanol series\n\nTPP\n\nNaOH\n\nno treatment\n\n \n\nFigure 17. ATR-FTIR spectra of SPCHTs/TNaOH, SPCHTs/TEtOH, SPCHTs/CTPP and \n\nNTPCHTs. \n\n \n\n4.3.2. Physicochemical and mechanical properties of SPCHTs \n\nIn addition to surface chemistry, physicochemical and mechanical properties such \n\nas porous structure, Young\u2019s modulus, swelling and degradation over time play \n\nimportant roles in the performance of scaffolds. It is known that the microstructural \n\n\n\n81 \n\n \n\ncharacteristics such as pore size and distribution, porosity and pore shape have \n\nprominent influences on cell intrusion, proliferation and function in tissue engineering \n\n(Ma et al., 2003). When PRP is associated, the microstructure might also induce \n\nactivation as well as support the fibrin network on the internal and external surfaces. \n\nThese properties in conjunction are shown in Figure 18, for an easier comparison of the \n\nSPCHTs. \n\nThe micrographs obtained by SEM [Figure 18(a)] showed three-dimensional \n\nstructures with visually interconnected pores in all cases. Scaffolds with open and \n\ninterconnected pores are essential for cell nutrition, proliferation and migration \n\npromoting the vascularization and formation of new tissues (Loh &amp; Choong, 2013). \n\nHowever, the surface chemistry provided by the treatments produced significant \n\ndifferences in the scaffolds.  \n\nThe Young\u2019s modulus values [Figure 18(b)] were similar for SPCHT/TNaOH and \n\nSPCHT/TEtOH, approximately 1.4 MPa, but significantly larger than NTPCHTs (1.1 \n\nMPa). SPCHT/CTPP exhibited the highest mechanical resistance (1.8 MPa) due to the \n\nphysical crosslinking, as expected. \n\nRegardless of the type of treatment, the mean pore diameter [Figure 18(b)] could \n\nbe controlled around 100-200 \u00b5m. Ti?li et al. (2007) also obtained a pore size in the \n\nrange of 100 \u00b5m. Although controversial, several researchers have suggested optimal \n\npore structures for the regeneration of specific tissues. Pore sizes of 100\u2013400 \u00b5m and \n\n200\u2013350 \u00b5m have been suggested for bone tissue regeneration and osteoconduction, \n\nrespectively (Oh et al., 2007). \n\nThe smallest pores from TPP treatment are from crosslinking and entanglement \n\nof the chains of chitosan.  \n\nAccording to Ma et al. (2003), an additional freeze-drying can induce the fusion of \n\nsome smaller pores to generate larger ones, or the slight collapse of the scaffold of the \n\nstructure might reduce pore size. Therefore, in our scaffolds, the collapse effect was \n\nmore prominent than fusion because the pores were smaller for all treatments. In \n\naddition, this effect seemed to be homogeneous in the structures.  \n\nAccording to Liu &amp; Ma (2004), high porosity of scaffolds (such as ? 90%) is \n\nimportant for any tissue engineering applications, including bone. \n\n\n\n82 \n\n \n\nPorosity was similar for SPCHT/TNaOH and NTPCHT. A significant reduction in \n\nporosity and pore size was observed after rehydration and new lyophilization for \n\nSPCHT/CTPP. Final porosities were in the range of 93-97% [Figure 18(c)]. These \n\nvalues agree with those reported by Amaral et al. (2006) for similar scaffolds.  \n\nThe water uptake property of the raw materials primarily influences the \n\nmaintenance of the chitosan scaffolds\u2019 shape. Deformations in the structure affect cell \n\nproliferation and migration. The SPCHTs/TNaOH and SPCHTs/TEtOH [Figure 18(d)] \n\nexhibited rapid swelling in PBS pH 7.4 within 5 minutes. After 24 h their SR values were \n\n11 \u00b1 1 and 14 \u00b1 3, respectively, indicating extremely hydrophilic structures with the \n\ncapacity to accommodate in their 3D structure large amounts of saline solution. \n\nSPCHTs/CTPP showed smaller SR in 24 hours (5.9 \u00b1 0.4) because the crosslinking that \n\nreduces the functional groups that hydrogen bond with water and decreased the pore \n\nsize and porosity. NTPCHT rehydrated in a neutral aqueous medium after 24 hours of \n\nrapid swelling and ultimately dissolved, indicating that the lyophilized structure was \n\ncomposed of soluble chitosan acetate. \n\nThe swelling was stabilized after 7.5 hours and increased in the following order: \n\nSPCHTs/TEtOH> SPCHTs/TNaOH> SPCHTs/CTPP. It was not possible to measure the \n\nswelling of NTCHTs after 7 days due to the fragility of its structure. \n\nDegradation profiles were similar over 30 days. These results indicated that the \n\ntreatments reduced the solubility of chitosan, providing stability to the scaffolds \n\ncompared to NTCHTs. The high weight loss (approximately 40%) of SPCHTs/TNaOH \n\nand SPCHTs/TEtOH likely occurs due to the presence of residual chitosan acetate that \n\ncan cause rapid swelling and subsequently dissolution in a neutral aqueous medium.  \n\nBoth processes, degradation and swelling, occur simultaneously and compete \n\nwith other. \n\n \n\n\n\n83 \n\n \n\n  \n\nNo treatment Ethanol series \n\n  \n\n  \n\nNaOH TPP \n\n (a) \n\n \n\n\n\n84 \n\n \n\n?\n\n?\n\n?\n\n?\n\nSP\nCH\n\nTs\n/T\n\nNa\nOH\n\nSP\nCH\n\nTs\n/C\n\nTP\nP\n\nSP\nCH\n\nTs\n/T\n\nEt\nOH\n\nNT\nPC\n\nHT\ns\n\n0.0\n\n0.5\n\n1.0\n\n1.5\n\n2.0\n\n2.5\n\n3.0\n\n \n\n(x\n) \n\nY\no\n\nu\nn\n\ng\n's\n\n m\no\n\nd\nu\n\nli\n (\n\nM\nP\n\na\n)\n\n0\n\n40\n\n80\n\n120\n\n160\n\n200\n\n240\n\n \n\n(=\n) \n\nP\no\n\nre\n S\n\niz\ne\n\n (\n?\nm\n\n)\n\n SPC\nHT\n\ns/T\nNa\n\nOH\n\nSP\nCH\n\nTs\n/TE\n\ntO\nH\n\nSP\nCH\n\nTs\n/C\n\nTP\nP\n\nNT\nPC\n\nHT\ns\n\n90\n\n92\n\n94\n\n96\n\n98\n\n100\n\n*\n\n NTPCHTs (1lyophilization)\n\n SPCHTs (2 lyophilizations)\n\n \n\n \n\nP\no\n\nro\ns\n\nit\ny\n\n (\n%\n\n)\n\n*\n\n \n\n(b) (c) \n\n0 5 10 15 20 25\n\n0\n\n5\n\n10\n\n15\n\n20\n\n25\n\n \n\n \n\nS\nR\n\n (\nw\n\ns\n/w\n\nd\n)\n\nTime (hours)\n \n\n0 4 8 12 16 20 24 28 32\n\n0\n\n10\n\n20\n\n30\n\n40\n\n50\n\n60\n\n \n\n \n\nW\ne\n\nig\nh\n\nt \nlo\n\ns\ns\n\n (\n%\n\n)\n\nTime (days)  \n\n \n\n(d) (e) \n\nFigure 18. Physicochemical and mechanical properties of the PCHTs. (a) Photographs \n\nand SEM micrographs of the cross-section of the scaffolds. Original magnification is \n\n\u00d7100 and the scale bar represents 200 \u00b5m. (b) Young\u2019s moduli and pore size; (c) \n\nPorosity (*The means difference are significant at level at p<0.05); (d) Swelling profile in \n\nPBS pH 7.4 at 37\u00b0C; (e) Degradation profile in PBS pH 7.4 at 37\u00b0C expressed as weight \n\nloss. Values are the mean \u00b1 standard deviation. (?) SPCHTs/TNaOH; (?) \n\nSPCHTs/TEtOH; (?) SPCHTs/CTPP and (?) NTPCHTs. \n\n \n\nThe freeze-drying technique limits the pores to medium sizes and the mechanical \n\nproperties of the porous structures even after cross-linking (Costa-Pinto et al., 2011). \n\nTherefore, the physicochemical characterization suggests that the SPCHTs might \n\n* \n\n* \n\n\n\n85 \n\n \n\nbe useful for bone regeneration. Stabilization provided pore sizes in the range of 100-\n\n150 \u00b5m and porosities higher than 90%. In addition, they prevented the collapse of the \n\nstructures after at least 10 days in PBS at pH 7.4 with swelling capacity. However, \n\nmechanical resistance was low, requiring further treatments for application in regions \n\nexposed to high shear. \n\n \n\n4.3.3. Biological properties of SPCHTs \n\nSEM characterization [Figure 19(a)] of the aP-PRP/PCHTs composite scaffolds \n\nafter 5th days of culture indicated cell attachment and a fibrin network inside the pores \n\nand on the surface of SPCHTs. aP-PRP was used as control. \n\nThe cell compatibility, as assayed by MTT, of h-AdMSCs cultured in the presence \n\nof SPCHTs is shown in [Figure 19(b)]. This assay is widely used to determine cellular \n\ntoxicity, viability and proliferation (G\u00fcm\u00fc?derelioglu &amp; Aday, 2011). The results revealed \n\nno potential cytotoxicity over 24 hours for the SPCHTs according to the standard values \n\n(PCT). However, we observe reduced viability compared to the negative control toxicity \n\n(NCT) for SPCHTs/TNaOH and SPCHTs/CTPP.  \n\n \n\n  \n\nNTPCHTs SPCHTs/TEtOH \n\nFIBRIN \n\n\n\n86 \n\n \n\n  \n\nSPCHTs/TNaOH SPCHTs/CTPP \n\n(a) \n\nC\nPT\n\n \nC\nN\nT\n\nN\nTP\n\nC\nH\nTs\n\nSP\nC\nH\nTs\n\n/C\nTP\n\nP\n\nSP\nC\nH\nTs\n\n/T\nN\naO\n\nH\n\nSP\nC\nH\nTs\n\n/T\nEt\n\nO\nH\n\n0\n\n1x10\n4\n\n2x10\n4\n\n3x10\n4\n\n4x10\n4\n\n \n\n \n\n \n\nC\ne\n\nll\n n\n\nu\nm\n\nb\ne\n\nr/\n w\n\ne\nll\n\n*\n\n*\n\n*\n\n \n\n2 3 4 5 6 7 8 9 10 11\n\n0.0\n\n5.0x10\n4\n\n1.0x10\n5\n\n1.5x10\n5\n\n2.0x10\n5\n\n2.5x10\n5\n\n3.0x10\n5\n\n3.5x10\n5\n\n4.0x10\n5\n\n4.5x10\n5\n\n \n\n \n\nC\ne\n\nll\n n\n\nu\nm\n\nb\ne\n\nr/\n w\n\ne\nll\n\nTime (days)\n \n\n(b)  (c) \n\n0 10 20 30 40 50 60 70 80\n\n0\n\n2000\n\n4000\n\n6000\n\n8000\n\n10000\n\n12000\n\n14000\n\n16000\n\n \n\n \n\nC\nu\n\nm\nu\n\nla\nti\n\nv\ne\n\n P\nD\n\nG\nF\n\n-A\nB\n\n p\ng\n\n/ \nm\n\nL\n P\n\nR\nP\n\nTime (hours)\n \n\n0 10 20 30 40 50 60 70 80\n\n0\n\n2000\n\n4000\n\n6000\n\n8000\n\n10000\n\n12000\n\n \n\n \n\nC\nu\n\nm\nu\n\nla\nti\n\nv\ne\n\n T\nG\n\nF\n-?\n\n1\n (\n\np\ng\n\n/ \nm\n\nL\n P\n\nR\nP\n\n)\n\nTime (hours)  \n\n(d) (e) \n\n\n\n87 \n\n \n\nSP\nC\nH\nTs\n\n/T\nEt\n\nO\nH\n\nSP\nC\nH\nTs\n\n/T\nN\naO\n\nH\n\nSP\nC\nH\nTs\n\n/C\nTP\n\nP\n\nN\nTP\n\nC\nH\nTs\n\nbl\nan\n\nk\n\n0.0\n\n0.2\n\n0.4\n\n0.6\n\n0.8\n\n1.0\n\n1.2\n\n1.4\n\n1.6\n\n1.8\n\n \n\n \n\nA\nb\n\ns\no\n\nrb\na\n\nn\nc\n\ne\n i\nn\n\n 4\n0\n\n5\n n\n\nm\n (\n\nU\n.A\n\n.)\n \n\nA\n\n*\n\n*\n\n*\n\n*\n\n \n\n \n\n(f) \n\nFigure 19. (a) SEM images of cells on aP-PRP/SPCHTs after 5 days of culture. Scale \n\nbars indicate 3 \u00b5m (magnification = 5,000x). (b) The compatibility of h-AdMSCs that \n\nwere exposed to SPCHTs. Negative control (NTC) = DMEM with 10% FBS; positive \n\ncontrol (PTC) = DMEM with phenol 0.5%. Mean \u00b1 standard deviation n = 3. The \n\npopulation means are significantly different from the positive control at *p<0.05. (c) \n\nProliferation profile of h-AdMSCs cultured in aP-PRP/SPCHTs as a function of time. aP-\n\nPRP and NTPCHTs were used as controls. Platelets were concentrated in aP-PRP at \n\napproximately 1.84 times the basal value. The average concentration was 393,000 \n\npq/mm3. (d) PDGF-AB release profile from aP-PRP/SPCHTs. Platelets were \n\nconcentrated in aP-PRP at approximately 2.09 times the basal value. The average \n\nconcentration was 472,250 pq/mm3. (e) TGF-?1 release profile from aP-PRP/PCHTs. \n\nPlatelets were concentrated in aP-PRP at approximately 2.09 times the basal value. The \n\naverage concentration was 472,250 pq/mm3. (f) ALP activity of cells cultured on \n\nSPCHTs (statistically significant differences from blank, n=3, *p<0.05). NTPCHTs is the \n\ncontrol group, blank = the reagents used in the assay only. Platelets were concentrated \n\nin aP-PRP at approximately 1.79 times the basal value. The average concentration was \n\n280,500 pq/mm3. (?) aP-PRP and (?) NTPCHT were both used as controls; (?) \n\nSPCHTs/TEtOH; (?) SPCHTs/TNaOH, and (?) SPCHTs/CTPP.  \n\nThe cell number per well as a function time for aP-PRP/ SPCHTs [Figure 19(c)] \n\n\n\n88 \n\n \n\nshowed that the number of viable cells determined after 3 days exceeded the number of \n\nseeded cells (1.4 x 104 cells/well) in all of the composite scaffolds, indicating that the \n\ncells grown in the matrices retained their viability, regardless of the treatment. The \n\nresults also indicated cell proliferation was significantly higher (p<0.05) for the aP-\n\nPRP/SPCHTs compared to the control aP-PRP. Cultivation in aP-PRP/SPCHTs/TNaOH \n\nshowed faster cell proliferation, and the stationary phase was reached in 5th days, \n\nwhereas for aP-PRP/SPCHTs/CTPP the proliferation shows a nearly linear increasing \n\nprofile. In aP-PRP/SPCHTs/TEtOH, the cells had a longer lag phase (5 days) followed \n\nby an exponential phase in the subsequent period.  \n\nTEtOH has the added advantage of allowing direct sterilization of samples in 70% \n\nethanol; however, after treatment, the scaffolds should be equilibrated with culture \n\nmedium or PBS for several hours prior to any cell seeding or in vivo implantation activity \n\n(Oh et al., 2007).  \n\nCultivation in aP-PRP/NTPCHT reached the exponential phase in 5th days and \n\ndecreased sharply afterward due to the collapse of the non-stabilized structure.  \n\nThe curves of Figure 19(d) and 19(e) show PDGF-AB and TGF-?1 release \n\nkinetics from aP-PRP/SPCHTs with aP-PRP and aP-PRP/NTPCHTs used as controls. \n\nThe curves show diffusive controlled profiles, indicating no collapse of the porous \n\nstructure of chitosan scaffolds over the duration of the assays. The differences in the \n\nprofiles are due to interactions of the GFs with the surface groups generated by the \n\nvarious stabilizing treatments.  \n\nThe ALP activity of h-AdMSCs assayed after 14 days of cultivation is shown in \n\nFigure 19(f). The ALP activity of the cells cultured on aP-PRP/SPCHTs and aP-\n\nPRP/NTPCHTs scaffolds showed significant differences from the control (p<0.05), \n\nsuggesting that the composite scaffolds favored osteogenic differentiation. Moreover, \n\nthe differentiation of the composite scaffold treated with TEtOH was significantly higher \n\nthan for non-stabilized PCHT. \n\n \n\n4.4. Conclusions \n \n\nComposite scaffolds of stabilized porous chitosan and activated P-PRP were \n\n\n\n89 \n\n \n\nprepared and characterized. The stabilization of the porous chitosan was accomplished \n\nby using various treatments. In general, the composite scaffolds controlled the release \n\nof growth factors and improved proliferation of h-AdMSCs that were seeded compared \n\nto activated P-PRP. Osteogenic differentiation evaluated by ALP marker was favored by \n\nthe stabilization provided mainly by the ethanol series treatment. These findings are \n\nimportant for optimizing composite scaffolds for applications in regenerative medicine.  \n\n \n\nAcknowledgements. The authors acknowledge the financial support from the National \n\nCouncil of Technological and Scientific Development (CNPq, Brazil). They also thank \n\nProf. Dr. William Dias Belangero and Dr. Ana Am\u00e9lia Rodrigues of the Faculty of \n\nMedical Sciences (University of Campinas) for assistance and Dr. \u00c2ngela Cristina \n\nMalheiros Luzo of the Haematology and Hemotherapy Center (University of Campinas) \n\nfor the donation of h-AdMSCs. \n\n \n\n4.5. References \n \n\nAMARAL, I.F., SAMPAIO, P., BARBOSA, M.A. Three-dimensional culture of human \nosteoblastic cells in chitosan sponges: The effect of the degree of acetylation. Journal \nof Biomedical Materials Research, vol.76A p.335-346, 2006. \n\nBHUMKAR, D.R.; POKHARKAR, V.B. Studies on Effect of pH on Cross-linking of \nChitosan with Sodium Tripolyphosphate: A Technical Note. AAPS Pharm Sci Tech, \nvol.7, n.2, p.E1-E6, 2006. \n\nBI, L.; CHENG, W.; FAN, H.; PEI, G. Reconstruction of goat tibial defects using an \ninjectable tricalcium phosphate/chitosan in combination with autologous platelet-rich \nplasma. Biomaterials, vol.31, p.3201\u20133211, 2010. \n\nCHANG, H-I.; WANG, Y. Cell Responses to Surface and Architecture of Tissue \nEngineering Scaffolds. In: Eberli, D. (Eds.). Regenerative Medicine and Tissue \nEngineering - Cells and Biomaterials, Cratia: InTech, chapter 27, p. 569-588, 2011. \n\nCHANG, S.J.; KUO, S.M.; LAN, C-W.; MANOUSAKAS, I.; TSAI P.H. Evaluation of \nchitosan/CaSO4/ platelet-rich plasma microsphere composites as alveolus osteogenesis \nmaterial. Biomedical Engineering: Applications, Basis and Communications, \nvol.21, n.2, p.115\u2013122, 2009. \n\n\n\n90 \n\n \n\nCORREIA, C.R.; TEIXEIRA, L.S.M.; MORONI, L.; REIS, R.L.; VAN BLITTERSWIJK, \nC.A.; KARPERIEN, M.; MANO J.F. Chitosan Scaffolds Containing Hyaluronic Acid for \nCartilage Tissue Engineering. Tissue Engineering Part C, vol.17, n.7, p.717-730, 2011. \n\nCOSTA-PINTO, A.R.; REIS, R.L.; NEVES, N.M. Scaffolds Based Bone Tissue \nEngineering: The Role of Chitosan. Tissue Engineering Part B, vol.17, p.331-347, \n2011. \n\nCRANE, D.; EVERTS, P.A.M. Platelet Rich Plasma (PRP) Matrix Grafts, PPM \nCommunications, vol.8, p.1-10, 2008. \n\nDEMARGER-ANDRE, S.; DOMARD, A. Chitosan carboxylic acid salts in solution and in \nthe solid state. Carbohydrate Polymers, vol.23, n.3, p.211-219, 1994. \n\nEHRENFEST, D.M.D.; RASMUSSON, L.; ALBREKTSSON, T. Classification of platelet \nconcentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich \nfibrin (L-PRF). Trends in Biotechnology, vol.27, p.158-167, 2009. \n\nG\u00dcM\u00dcS?DERELIO?LU, M.; ADAY, S. Heparin-functionalized chitosan scaffolds for \nbone tissue engineering. Carbohydrate Research, vol.346, p.606-613, 2011. \n\nHOM, D.B.; LINZIE, B.M.; TREVOR. C.; HUANG, T.C. The Healing Effects of \nAutologous Platelet Gel on Acute Human Skin Wounds. Archives of Facial Plastic \nSurgery, vol.9, n.3, p.174-183, 2007. \n\nJACOBSON, M.; FUFA, D.; ABREU, E.L.; KEVY, S.; MURRAY, M.M. Platelets, but not \nerythrocytes, significantly affect cytokine release and scaffold contraction in a \nprovisional scaffold model. Wound Repair Regeneration, vol.16, n.3, p.370-378, 2008. \n\nKANAJI, N.; SATO, T.; NELSON, A.; WANG, X.; LI, Y.; KIM, M.; NAKANISHI, M.; \nBASMA, H.; MICHALSKI, J.; FARID, M.; CHANDLER, M.; PEASE, W.; PATIL, A.; \nRENNARD, S.I.; LIU, X. Inflammatory cytokines regulate endothelial cell survival and \ntissue repair functions via NF-?B signaling. Journal of Inflammation Research, vol.4 \np.127\u2013138, 2011. \n\nKOJIMA, K.; OKAMOTO, Y.; MIYATAKE, K.; FUJISE, H.; SHIGEMASA, Y.; MINAMI, S. \nEffects of chitin and chitosan on collagen synthesis in wound Healing. Journal of \nVeterinary Medical Science, vol.66, p.1595-1598, 2004. \n\nKUTLU, B.; AYDIN, R.S.T.; AKMAN, A.C.; G\u00dcM\u00dc?DERELIO?LU, M.; NOHUTCU, R.M. \nPlatelet-rich plasma-loaded chitosan scaffolds: Preparation and growth factor release \nkinetics. Journal of Biomedical Materials Research, vol.101B, p.28-35, 2012. \n\nLANA, J.F.S.D.; SANTANA, M.H.A.; BELANGERO, W.D.; LUZO, A.C.M. Platelet-Rich \nPlasma: Regenerative Medicine: Sports Medicine, Orthopedic, and Recovery of \nMusculoskeletal Injuries (Lecture Notes in Bioengineering), 1st ed., Springer, 2014. \n\n\n\n91 \n\n \n\nLEE, Y.M.; PARK, Y.J.; LEE, S.J.; KU, Y.; HAN, S.B.; CHOI, S.M.; KLOKKEVOLD, P.R.; \nCHUNG, C.P. Tissue engineered bone formation using chitosan/tricalcium phosphate \nsponges. Journal of Periodontology, vol.71, p.410-417, 2000. \n\nLIU, X.; MA, P.X. Polymeric Scaffolds for Bone Tissue Engineering. Annals of \nBiomedical Engineering, vol.32, n.3, p.477-486, 2004. \n\nLIU, Y.B.A.; KAL\u00c9N, A.; RISTO, O.; WAHLSTR?M, O. Fibroblast Proliferation due to \nExposureto a Platelet Concentrate in Vitro is pH Dependent. Wound Regeneration, \nvol.10 p.336-340, 2002. \n\nLOH, Q.L.; CHOONG, C. Three-Dimensional Scaffolds for Tissue Engineering \nApplications: Role of Porosity and Pore Size. Tissue Engineering - Part B, vol.19, n.6, \np.485-503, 2013. \n\nMA, L.; GAO, C.; MAO, Z.; ZHOU, J., SHEN, J.; HU, X.; HAN, C. Collagen/chitosan \nporous scaffolds with improved biostability for skin tissue engineering. Biomaterials, \nvol.242, p.4833-4841, 2003. \n\nMADIHALLY, S.V.; MATTHEW, H.W.T. Porous chitosan scaffolds for tissue \nengineering. Biomaterials, vol.20, p.1133-1142, 1999. \n\nMANJUBALA, I.; SCHELER, S.; B?SSERT, J.; JANDT, K.D. Mineralisation of chitosan \nscaffolds with nano-apatite formation by double diffusion technique. Acta Biomaterialia, \nvol.2, p.75-84, 2006. \n\nMARX, R.E. Platelet-rich plasma: Evidence to support its use. Journal of Oral and \nMaxillofacial Surgery, vol.62, p. 489\u2013496, 2004. \n\nMI, F-L.; SHYU, S-S.; LEE, S-T.; WONG, T-B. Kinetic Study of Chitosan-\nTripolyphosphate Complex Reaction and Acid-Resistive Properties of the Chitosan-\nTripolyphosphate Gel Beads Prepared by in-Liquid Curing Method. Journal of Polymer \nScience Part B: Polymer Physics, vol.37 p.1551-1564, 1999.   \n\nMOSSMAM, T.J. A rapid colorimetric assay of cellular growth and survival: application to \nproliferation and cytotoxicity assays. Journal of Immunological Methods, vol.65, p.55-\n63, 1983. \n\nNASTI, A.; ZAKI, M.N.; DE LEONARDIS, P.; UNGPHAIBOON, S.; SANSONGSAK, P.; \nRIMOLI, M.G.; TIRELLI, N. Chitosan/TPP and Chitosan/TPP-hyaluronic Acid \nNanoparticles: Systematic Optimisation of the Preparative Process and Preliminary \nBiological Evaluation. Pharmaceutical Research. vol.26, n.8, p.1918-1930, 2009. \n\nNORIEGA, S.E.; SUBRAMANIAN, A. Consequences of Neutralization on the \nProliferation and Cytoskeletal Organization of Chondrocytes on Chitosan-Based \nMatrices. International Journal of Carbohydrate Chemistry, p.1-13, 2011. \n\n\n\n92 \n\n \n\nNWE, N.; FURUIKE, T.; TAMURA, H. The Mechanical and Biological Properties of \nChitosan Scaffolds for Tissue Regeneration Templates Are Significantly Enhanced by \nChitosan from Gongronella butleri. Materials, vol.2, p.374-398, 2009. \n\nOH, S.H.; PARK, I.K.; KIM, J.M.; LEE, J.H. In vitro and in vivo characteristics of PCL \nscaffolds with pore size gradient fabricated by a centrifugation method. Biomaterials, \nvol.28, p.1664-1671, 2007. \n\nOKAMOTO, Y.; YANO, R.; MIYATAKE, K.; TOMOHIRO, I.; SHIGEMASA, Y.; MINAMI, \nS. Effects of chitin and chitosan on blood coagulation. Carbohydrate Polymers, vol.53, \np.337-342, 2003. \n\nOKTAY, E.O.; DEMIRALP, B.; DEMIRALP, B.; SENEL, S.; AKMAN, A.; ERATALAY, K.; \nAKINCIBAY, H. Effects of platelet-rich plasma and chitosan combination on bone \nregeneration in experimental rabbit cranial defects. Journal of Oral Implantology, \nvol.36, p.175\u2013184, 2010. \n\nOUYANG, W.; BUSCHMANN, M.; CHEVRIER, A. Soluble physiological chitosan \nformulations combined with platelet-rich plasma (PRP) for tissue repair. United States \nPatent: U.S. 0,004,474 A1, 2013.  \n\nPEREZ, A.G.M.; LANA, J.F.S.D.; RODRIGUES, A.A.; LUZO, A.C.M.; BELANGERO, \nW.D.; SANTANA, M.H.A. Relevant Aspects of Centrifugation Step in the Preparation of \nPlatelet-Rich Plasma. ISRN Hematolology, vol.2014, p.1-8, 2014. \n\nPEREZ, A.G.M.; LICHY, R.; LANA, J.F.S.D.; RODRIGUES, A.A.; LUZO, A.C.M.; \nBELANGERO, W.D.; SANTANA, M.H.A. Prediction and Modulation of Platelet Recovery \nby Discontinuous Centrifugation of Whole Blood for the Preparation of Pure Platelet-\nRich Plasma. BioResearch Open Access, vol.2, p.307-314, 2013. \n\nREIS, R.L.; NEVES, N.M.; MANO, J.F.; GOMES, M.E.; MARQUES, A.P.; AZEVEDO, \nH.S. Natural-based polymers for biomedical applications. Cambridge: Woodhead \nPublishing, 2008. \n\nROSSI, S.; FACCENDINI, A.; BONFERONI, M.C.; FERRARI, F.; SANDRI, G.; DEL \nFANTE, C.; PEROTTI, C., CARAMELLA, C.M. Sponge-like dressings based on \nbiopolymers for the delivery of platelet lysate to skin chronic wounds. International \nJournal of Pharmaceutics, vol.440, p.207-215, 2013. \n\nSANO, M.; HOSOYA, O.; TAOKA, S.; SEKI, T.; KAWAGUCHI, T.; SUGIBAYASHI, K.; \nJUNI, K.; MORIMOTO, Y. Relationship between Solubility of Chitosan in Alcoholic \nSolution and Its Gelation. Chemical and pharmaceutical bulletin, vol.47, n.7, p.1044-\n1046, 1999. \n\nSEOL, Y.J.; LEE, J.Y.; PARK, Y.J.; LEE, Y.M.; YOUNG, K.; RHYU, I.C.; LEE, S.J.; HAN, \nS.B.; CHUNG, C.P. Chitosan sponges as tissue engineering scaffolds for bone \nformation. Biotechnology Letter, vol.26; p.1037-1041, 2004. \n\n\n\n93 \n\n \n\nSHEN, E.C.; CHOU, T.C.; GAU, C.H.; TU, H.P.; CHEN, Y.T.; FU, E. Releasing growth \nfactors from activated human platelets after chitosan stimulation: a possible bio-material \nfor platelet-rich plasma preparation. Clinical Oral Implants Research, vol.17, p.572-\n578, 2006. \n\nSHEN, F.; CUI, Y.L.; YANG, L.F.; YAO, K.D.; DONG, X.H.; JIA, W.Y.; SHI, H.D. A study \non the fabrication of porous chitosan/gelatin network scaffold for tissue engineering, \nPolymer International, vol.49, p.1596-1599, 2000. \n\nTAN, H.P.; CHU, C.R.; PAYNE, K.A.; MARRA K.G. Injectable in situ forming \nbiodegradable chitosan-hyaluronic acid based hydrogels for cartilage tissue engineering. \nBiomaterials, vol.30, p.2499\u20132506, 2009. \n\nTI?LI, R.S.; KARAKE\u00c7ILI, A.; G\u00dcM\u00dc?DERELIO?LU, M. In vitro characterization of \nchitosan scaffolds: influence of composition and deacetylation degree. Journal of \nMaterials Science: Materials in Medicine, vol.18, p.1665-1674, 2007. \n\nWANG, Y.; LIN, M.; WANG, D.; HSIEH H. Fabrication of a novel porous PGA\u2013chitosan \nhybrid matrix for tissue engineering. Biomaterials, vol.24, p.1047\u20131057, 2003. \n\n  \n\n\n\n94 \n\n \n\n \n\n  \n\n\n\n95 \n\n \n\nCAP\u00cdTULO 5 \u2013 IN VITRO BIOLOGICAL \nPERFORMANCE OF INJECTABLE CHITOSAN-\n\nTRIPOLYPHOSPHATE SCAFFOLDS COMBINED \n\nWITH PLATELET-RICH PLASMA \n\nArtigo submetido ao peri\u00f3dico Tissue Engineering and Regenerative Medicine. \n\n \n\nAndr\u00e9a Arruda Martins Shimojo1, Sofia Elisa Moraga Galdames1, Amanda Gomes \n\nMarcelino Perez1, Thiago Heiji Ito2, Maria Helena Andrade Santana1* \n\n \n\n1Department of Engineering of Materials and Bioprocesses, School of Chemical \n\nEngineering, University of Campinas (UNICAMP), Campinas, SP, Brazil. \n\n \n\n2Department of Physical Chemistry, Institute of Chemistry, University of Campinas, \n\n(UNICAMP), Campinas, SP, Brazil.  \n\n \n\n*Corresponding author: Maria Helena Andrade Santana; PHONE: +55 19 35213921; \n\nFAX: +55 19 35213890; e-mail: mariahelena.santana@gmail.com \n\n \n\nAbstract: This study aimed to evaluate the in vitro biological effectiveness of chitosan-\n\nsodium tripolyphosphate microparticles in combination with activated platelet-rich \n\nplasma as an injectable composite scaffold for growth factor release, cell proliferation \n\nand osteogenic differentiation. The microparticles were prepared by vortexing the \n\nchitosan and TPP solutions. The ionic crosslinking of chitosan with TPP was made at \n\nmass ratios of 2:1, 5:1, and 10:1 at pH 4.0. Pure platelet-rich plasma (P-PRP) was \n\nobtained via the controlled centrifugation of whole blood. The composite scaffolds were \n\nprepared by adding the microparticles to immediately activated P-PRP. The results \n\nshowed that the microparticles enhanced the physicochemical and mechanical \n\nproperties of aP-PRP. The proliferation of human adipose-derived mesenchymal stem \n\ncells was lower than in aP-PRP but significant at a 2:1 chitosan:TPP mass ratio. \n\nmailto:mariahelena.santana@gmail.com\n\n\n96 \n\n \n\nOsteogenic differentiation was stimulated at all studied mass ratios, as indicated by the \n\nALP activity. These results offer perspectives for optimizing the composite scaffold, and \n\nto prove its potential as an injectable scaffold in regenerative medicine. \n\n \n\nKeywords: Chitosan; tripolyphosphate; platelet-rich plasma; injectable scaffolds; \n\ncomposite. \n\n \n\n5.1. Introduction \n \n\nDue to their minimally invasive implantation procedures, injectable scaffolds have \n\nbeing widely investigated and are considered promising in tissue engineering (Kretlow et \n\nal., 2007). \n\nFrom the clinical perspective, the use of injectable scaffolds is advantageous \n\nbecause it minimizes patient discomfort, the risk of infection and scarring, and the cost \n\nof treatment (Hou et al., 2004). Furthermore, injectable scaffolds can homogeneously fill \n\nthe defect or repair point and can incorporate cells and various therapeutic agents such \n\nas growth factors prior to injection (Gutowska et al., 2001).  \n\nFrom the biomaterial perspective, adequate injectable scaffolds must be nontoxic, \n\nbiodegradable, and sterilizable. Moreover, they must solidify under mild conditions, \n\nshow mechanical strength and resistance to in situ forces and allow for the incorporation \n\nof bioactive molecules. \n\nVarious types of biodegradable materials have been proposed for the preparation \n\nof injectable scaffolds used in tissue engineering. Considerable attention has been given \n\nto chitosan-based materials, primarily due to their similarities with the extracellular \n\nmatrix, chemical versatility, good biological performance, and specific cellular \n\ninteractions (Costa-Pinto et al., 2011).  \n\nChitosan scaffolds has been prepared as hydrogels by physical association \n\n(Berger et al., 2004), coordination with metal ions (Brack et al., 1997) and chemical \n\ncrosslinking (Hennink &amp; Van Nodtrum, 2002). However, the use of chemical crosslinking \n\nagents are a major obstacle to scaffolds fluids due to their toxicity to the cells. Thus, \n\ntripolyphosphate (TPP) and genipin have become attractive alternatives to chitosan \n\n\n\n97 \n\n \n\ncrosslinking (Bhumkar &amp; Pokharkar, 2006; Ibezim et al., 2010; Harris et al., 2010; \n\nKarnchanajindanun et al., 2010).  \n\nThe electrostatic interaction between chitosan and TPP leads to the formation of \n\nbiocompatible crosslinked chitosan hydrogels, which could be used as injectable \n\nscaffolds in micro- and/or nanoparticles in non-surgical treatments.  \n\nPlatelet-rich plasma (PRP) is an autologous concentrate of platelets and other \n\ncomponents of plasma that is capable of releasing the growth factors and cytokines \n\nused in tissue regeneration (Anitua, 1999; Foster et al., 2009). PRP has been \n\nsuccessfully used in regenerative medicine (Crane &amp; Everts, 2008; Cole et al., 2010). \n\nWhen activated, aP-PRP produces a fibrin network with a gel-like structure that \n\nsupports cell proliferation and differentiation (Marx, 2004). Efforts have been made to \n\nimprove the stability and rheological properties of the fibrin network. \n\nIn our previous studies, we have shown that porous chitosan sponges stabilized \n\nby crosslinking with TPP had adequate physicochemical properties for tissue \n\nengineering uses. Moreover, in combination with aP-PRP, the sponges supported the \n\nfibrin network, increased its stability, delayed the release of PDGF-AB and TGF-?1 \n\ncompared to aP-PRP alone, and allowed the proliferation and differentiation of h-\n\nAdMSCs.  \n\n In the present work, we extended our previous findings by evaluating the \n\nperformance of the combination of chitosan microparticles and activated P-PRP as a \n\ncomposite scaffold. Our hypothesis is that the crosslinked microparticles will also \n\nimprove the properties of aP-PRP alone, with the benefits of an injectable formulation. \n\n \n\n5.2. Materials and Methods \n\n \n\n5.2.1. Materials \n\nChitosan (average molecular weight [Mw] = 4 x 105 Da, degree of deacetylation = \n\n83 \u00b1 4%) was purchased from Polymar\u00ae (Fortaleza, Brazil) and purified according to the \n\nprotocol described by Nasti et al. (2009). Other chemicals were reagent grade and were \n\nused without any further purification. All biological experiments were performed with \n\nhuman adipose-derived mesenchymal stem cells (h-AdMSCs) and approved by the \n\n\n\n98 \n\n \n\nEthics Committee of the Medical Sciences School of the University of Campinas \n\n(UNICAMP; CAAE: 0972.0.146.000-11). The donors were healthy individuals between \n\n30 and 40 years old and were previously assessed through their clinical examinations. \n\n \n\n5.2.2. Preparation of injectable scaffolds of chitosan-sodium \n\ntripolyphosphate (iCHT-TPPs) \n\nThe injectable scaffolds (iCHT-TPPs) prepared in this work are composed of \n\nhydrogels of chitosan microparticles that were ionically crosslinked with TPP. Initially, a \n\nchitosan solution 2.5% (w/v) was prepared by dissolution in acetic acid 5% (w/v). TPP \n\nsolution was prepared as a 5% (w/v) solution in Milli-Q water. The solutions were mixed \n\nat mass ratios CHT-TPP of 2:1, 5:1 and 10:1 and vortexed for 5 minutes to obtain the \n\nmicroparticles. The crosslinking was carried out at 25\u00b0C for 24 hours at pH 4. The \n\nhydrogels were washed three times with water and phosphate buffered saline (PBS) (LB \n\nLaborclin, Pinhais, PR, Brazil) at pH 7.4 and centrifuged at 10,000 rpm for 10 minutes. \n\n \n\n5.2.3. Physicochemical Characterization  \n\n5.2.3.1. Chemical modification.  \n\nThe ionic crosslinking was characterized by Fourier-transform infrared (FTIR) in a \n\nThermo Scientific Nicolet model 6700 (Thermo Scientific Nicolet\u2122, Waltham, MA, USA). \n\nMeasurements were made in the ATR mode with accessory SMART OMNI-SAMPLER, \n\nin the spectral range of 4000-675 cm-1 resolution of 4 cm-1 and 64 scans. Pure chitosan \n\nwas used as control. \n\nATR-IR (chitosan): 3500\u20133000 (? OH and NH2), 2875 (?CH), 1645 (amide I), \n\n1550 (amide II) 1380, 1067, 1020 cm?1 (Nasti et al., 2009). \n\n \n\n5.2.3.2. Crosslink density Flory-Rehner calculations.  \n\nCrosslink density was evaluated by measuring the volumetric swelling and using \n\na simplified version of the Flory-Rehner equation (Flory &amp; Rehner, 1943), according to \n\nCollins &amp; Birkinshaw (2008). The value used for chitosan\u2013water interaction parameter \n\n(?) was 0.5917 (Jin &amp; Song, 2006). \n\n\n\n99 \n\n \n\n \n\n5.2.3.3. Particle diameter measurements \n\nThe mean diameter of the particles was evaluated by laser light scattering in a \n\nMastersizer S particle size analyzer, model Long Bench-MAM 5005 (Malvern \n\nInstruments, Worcestershire, UK). The particle size analysis was performed with the \n\nhydrogels dispersed in water. The standard deviation was calculated from five \n\nmeasurements of the mean diameter. \n\n \n\n5.2.3.4. Rheology measurements.  \n\nRheological measurements were performed in steady and oscillatory regimes at \n\n25\u00b0C, using a parallel plate geometry of 20 mm. Steady shear measurements were \n\nobtained at shear rates of 0.1-50 s-1. Oscillatory measurements were conducted in the \n\nlinear region, at a stress of 1.188 Pa and in the frequency range of 0.01 to 10 Hz. All \n\nrheological measurements were performed on a rheometer Haake RheoStress 1 \n\n(Haake, Karlsruhe, Germany).  \n\n \n\n5.2.3.5. Extrusion force.  \n\nInitially the iCHT-TPPs were loaded in 1-mL plastic syringes with 30-gauge \n\nneedles. Subsequently, the force required to extrude was measured using a MTS 810 \n\nServo-hydraulic Universal Testing Machine (MTS Systems Corporation, Eden Prairie, \n\nMN, USA) (Load Cell 1.5 kN) at 25\u00b0C at a 5.0 mm/ min extrusion rate. \n\n \n\n5.2.3.6. Swelling ratio (SR).  \n\nThe microparticles were weighed after swelling in phosphate buffered saline \n\n(PBS) at pH 7.4, and their dry weight was determined by drying under vacuum (1 \n\nmmHg) at 25\u00b0C after 3 days. SR was calculated using the Equation (1): \n\n \n\nSR =  \nws\n\nwd\n                                                                                                            Equation (1) \n\n \n\nwhere ws and wd are the weights of the scaffolds at the swelling state and the dry state, \n\n\n\n100 \n\n \n\nrespectively. \n\n5.2.3.7. Degradation in phosphate buffered saline.  \n\nThe degradation of iCHT-TPPs was examined with respect to weight loss. The \n\nweight loss of the initially weighed iCHT-TPPs (wo) was monitored as a function of \n\nincubation time in PBS at 37\u00b0C. At specified time intervals, iCHT-TPPs were removed \n\nfrom the PBS and weighed (wt). The weight loss ratio was defined as in Equation (2) \n\n(Tan et al., 2009). \n\n \n\nweight loss (%) =\n(w0?wt)\n\nw0\n? 100                                                                        Equation (2) \n\n \n\n5.2.4. Biological characterization \n\n5.2.4.1. Cell compatibility.  \n\nThe compatibility of the iCHT-TPPs was carried out by exposure to h-AdMSCs \n\nand cultivation at 37\u00b0C for 24 hours. The cell compatibility was evaluated using a \n\nmodified MTT (3-[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay \n\n(MTT, Molecular Probes\u00ae, S\u00e3o Paulo, SP, Brazil) (Mossmam, 1983). The MTT assay is \n\na colorimetric test that is based on the reduction of yellow tetrazolium salt into a purple \n\nformazan product in presence of cells (G\u00fcm\u00fc?derelio?lu &amp; Aday, 2011).  \n\n \n\n5.2.5. Preparation of pure platelet-rich plasma (P-PRP) \n\nP-PRP, a PRP type that is rich in platelets and poor in leukocytes, was prepared \n\naccording to Perez et al. (2013). Briefly, whole blood (WB) was collected into 3.5 mL \n\nvacuum tubes (Vacuette\u00ae, Campinas, SP, Brazil) containing sodium citrate 3.2% (w/v) \n\nas an anticoagulant. WB was initially centrifuged in a Rotina 380R centrifuge (Hettich\u00ae \n\nZentrifugen, Tuttlingen, Germany) at 100 xg for 10 minutes at 25\u00b0C. After the formation \n\nof three layers (a bottom layer composed primarily of red blood cells (RBCs); an upper \n\nlayer composed of plasma, platelets and some WBCs; and an intermediate layer, or \n\nbuffy coat, composed primarily of WBCs), only the upper layer was collected to obtain P-\n\nPRP. The concentrations of platelets, WBCs and RBCs in WB and in P-PRP were \n\ndetermined using the ABX Micros ES 60 hematology analyzer (HORIBA ABX \n\n\n\n101 \n\n \n\nDiagnostics, Montpellier, France). \n\n5.2.5.1. Activation of P-PRP (aP-PRP) \n\naP-PRP was prepared via the activation of P-PRP with autologous serum (Ser) \n\nand 10% (w/v) CaCl2 solution as agonists using the following proportions: agonist/P-\n\nPRP=20%; Ser/CaCl2 volumetric ratio=9. Autologous serum was prepared by collecting \n\n5 mL of WB in tubes without anticoagulant. After 30 minutes of clot formation, WB was \n\ncentrifuged at 2000 xg for 10 minutes.  \n\n \n\n5.2.6. Preparation of composite scaffold (aP-PRP/iCHT-TPPs) \n\naP-PRP/iCHT-TPPs was prepared by embedding by dripping aP-PRP, \n\nimmediately after activation, into iCHT-TPPs. The preparation was carried out in 48-well \n\nmicroplates using 200 \u00b5L of aP-PRP/ 100-200 mg of iCHT-TPPs. \n\n \n\n5.2.7. Characterization of aP-PRP/iCHT-TPPs \n \n\n5.2.7.1. Release of GFs \n\nThe release of platelet-derived growth factor AB (PDGF-AB) and transforming \n\ngrowth factor ?1 (TGF-?1) was performed after a 1 hour gelation of aP-PRP associated \n\nto iCHT-TPPs in the presence of the culture medium Dulbecco's Modified Eagle's \n\nMedium with low glucose concentration (DMEM-LG, Gibco, Grand Island, NY, USA). \n\nThe culture medium (1.5 mL) was added to aP-PRP/iCHT-TPPs in 48-well microplates, \n\nwhich were maintained in an incubator with 5% CO2 throughout the assays. The total \n\nvolume of culture medium was withdrawn at 3, 6, 12, 24 and 72 hours, and the same \n\nvolume of fresh medium was replaced without removing the hydrogels from the wells. \n\nThe samples were stored at -80\u00b0C for further characterization. The concentrations of the \n\nreleased GFs PDGF-AB and TGF-?1 were measured using enzyme-linked \n\nimmunosorbent assay (ELISA) kits (R&amp;D Systems, Minneapolis, MN, USA) according to \n\nthe manufacturer\u2019s instructions and specifications.  \n\n \n\n\n\n102 \n\n \n\n5.2.8. h-AdMSCs isolation and pre-cultivation \n\nHuman subcutaneous adipose tissue, initially acquired from liposuction surgery, \n\nwas washed with sterile PBS, separated into fractions of 10 g, digested with 20 mg of \n\ncollagenase type 1A and maintained in 20 mL of DMEM-LG containing 10% BSA \n\n(bovine serum albumin) and 10 \u00b5L of gentamicin for 30 min in a bath at 37\u00b0C. After \n\ncomplete digestion, the reaction was quenched with 10 mL fetal bovine serum (FBS) \n\nand immediately centrifuged for 15 min at 1500 rpm. The supernatant was discarded, \n\nand the pellet was suspended in 10 mL DMEM-LG with 10% FBS. After pre-cultivation \n\nfor 24 h, the culture medium was changed every 3 days; after the fourth passage, the \n\ncells were characterized by immunophenotyping using flow cytometry and by \n\nadipogenic, osteogenic and chondrogenic differentiation (data not shown) and were then \n\nused in the subsequent experiments. \n\n \n\n5.2.9. Culture of h-AdMSCs-seeding in the composite scaffolds \n\nThe pre-cultured h-AdMSCs were trypsinized and resuspended in P-PRP to a \n\nfinal cell concentration of 1 x 104 cells/mL. P-PRP containing h-AdMSCs was activated \n\nand immediately embedded into the iCHT-TPPs in a 24-well tissue culture plate, using \n\n200 \u00b5L of h-AdMSCs+aP-PRP/100-200 mg of iCHT-TPPs. The composite scaffolds with \n\nh-AdMSCs were kept at room temperature for 45 minutes for the consolidation of the \n\nfibrin network. Activated PRP was used as a control.  \n\n \n\n5.2.9.1. h-AdMSCs proliferation  \n\nThe cultivation of h-AdMSCs was carried out in 24-well tissue culture plates by \n\nadding 1 mL of the culture medium DMEM to the seeded composite scaffolds (n=4). The \n\nseeded composite scaffolds was maintained at 37\u00b0C along 10 days. Cell proliferation \n\nwas quantified using the thiazolyl blue tetrazolium bromide (MTT) assay. At cultivation \n\ndays 3, 5, 7 and 10, the composite scaffolds were removed and transferred to 24-well \n\nplates. MTT (1 mL of 1 mg/mL) was then added, and the cultivation proceeded at 37\u00b0C \n\nfor 4 hours. The MTT solution was then discarded, and 1 mL of dimethylsulfoxide \n\n(DMSO) was added to dissolve the purple formazan crystals. The samples were shaken \n\n\n\n103 \n\n \n\nat 120 rpm for 30 min to ensure the homogeneous dissolution of the formazan dye, and \n\n200 \u00b5L of each sample was then transferred to a 96-well plate. Optical density was \n\nmeasured at 595 nm using a microplate reader (FilterMax F5 Molecular Devices). \n\n5.2.9.2. Images of the cell-seeded composite scaffolds \n\nThe images of cell-seeded composite scaffolds were obtained by scanning \n\nelectron microscopy after 5 days of h-AdMSCs proliferation. The cell-seeded composite \n\nscaffolds were fixed in a solution of 4% paraformaldehyde and 2.5% glutaraldehyde in \n\nphosphate buffer, pH 7.4, for 2 hours. The samples were than dehydrated in ethanol for \n\n15-min intervals in aqueous 50%, 70%, 95% and 100% ethanol solutions (2x) and dried \n\nusing the critical point dryer BAL-TEC CPD 030 (BAL-TEC\u00ae, Schalksm\u00fchle, Germany). \n\nAfter gold coating in Sputter Coater POLARON SC7620 (VG Microtech, Ringmer, UK), \n\nthe cell-seeded composite scaffolds were visualized using a scanning electron \n\nmicroscope Leo440i (LEO Electron Microscopy/Oxford, Cambridge, UK) with an \n\naccelerating voltage of 20 kV. \n\n \n\n5.2.9.3. Induction of osteogenic differentiation \n\nh-AdMSCs-seeding composite scaffolds were induced to differentiate into the \n\nosteogenic lineage by providing the osteogenic medium containing DMEM-LG \n\nsupplemented with 10% FBS, 1% ?-glycerol-phosphate (Sigma-Aldrich, St. Louis, MO, \n\nUSA), 1% L-ascorbic acid (Sigma-Aldrich, St. Louis, MO, USA), 1% dexamethasone \n\n(Sigma-Aldrich, St. Louis, MO, USA) and 1% Penicillin/Streptomycin solution (Gibco, \n\nGrand Island, NY, USA). The medium was changed every 7 days.  \n\n \n\n5.2.9.4. Alkaline phosphatase activity (ALP) \n\nThe alkaline phosphatase (ALP) activity produced by h-AdMSCs was determined \n\non day 14. Here, 200 ?L of the supernatant was collected and mixed with 200 ?L of p-\n\nNitrophenyl phosphate (SIGMAFAST\u2122 p-Nitrophenyl phosphate Tablets, Sigma, Saint \n\nLouis, MI, USA) as substrate and subsequently incubated at room temperature for 30 \n\nminutes. Absorbance was read immediately on a spectrophotometer at 405 nm.  \n\n \n\n\n\n104 \n\n \n\n5.2.10. Statistical analysis \n\nEach experiment was carried out in triplicate unless otherwise specified. All \n\nresults are presented as the mean \u00b1 standard deviation (SD). The experimental data \n\nfrom all of the studies were analyzed using Analysis of Variance (ANOVA). Statistical \n\nsignificance was set at a p-value ? 0.05. \n\n \n\n5.3. Results and discussion \n \n\n5.3.1. Crosslinking in the injectable scaffolds of chitosan-sodium \n\ntripolyphosphate (iCHT-TPPs). \n\nAccording to Bhumkar and Pokharkar (2006), chitosan (pKa 6.3) may be \n\ncrosslinked with TPP (pKa 9.7) by two different pH-dependent mechanisms (Figure 20). \n\nThe ionic crosslinking occurs at low pH values by a reaction between NH3+ \n\ngroups of chitosan and P3O10-5 of TPP [Figure 20(a)]. The deprotonation mechanism \n\noccurs at high pH values using the OH- groups of TPP that are present in solution \n\n[Figure 20(b)]. In this work, the pH of the reaction mixture was maintained at pH 4, which \n\nfavored the ionic crosslinking mechanism.  \n\n \n\n \n\n \n\n \n\n(A) (B) \n\nFigure 20. Interaction of chitosan with TPP by (a) ionic crosslinking or (b) deprotonation. \n\n \n\nThe FTIR spectra of pure chitosan and iCHT-TPPs 2:1 are shown in Figure 21. \n\n\n\n105 \n\n \n\nPure chitosan was characterized by bands at 3449 cm\u20131 attributed to the \u2013NH2 \n\nand \u2013OH groups\u2019 stretching vibration and the band of amide I at 1639 cm\u20131 (Bhumkar &amp; \n\nPokharkar, 2006).  \n\nThe ionic crosslinking between the \u2013NH3+ group of chitosan and P3O10-5 of TPP in \n\niCHT-TPPs (2:1) was characterized by the presence of the P=O and P-O groups at the \n\nfrequencies of 1100 cm-1 and 1232 cm-1, respectively (Mi et al., 1999).  \n\n \n\n4000 3600 3200 2800 2400 2000 1600 1200 800\n\n80\n\n85\n\n90\n\n95\n\n100\n\n105\n\n \n\n \n\nT\nra\n\nn\ns\n\nm\nit\n\na\nn\n\nc\ne\n\n (\n%\n\n)\n\nWavenumbers (cm\n-1\n)\n\nPure chitosan\n\niCHT-TPP 2:1\n\n \n\nFigure 21. FTIR spectrum of pure chitosan and iCHT-TPPs 2:1. \n\n \n\n5.3.2. Physicochemical and mechanical properties of iCHT-TPPs.  \n\nThe water absorption capacity (swelling properties) of scaffolds must be carefully \n\ncontrolled to allow handling during cell implantation and promote cell growth. When \n\nhydrated, the scaffolds became fragile being deformed and/ or broken with the \n\napplication of small forces. Thus, a balance between the viscoelastic and swelling \n\nproperties is essential to maintain the integrity of scaffolds and support the cell \n\nproliferation and differentiation.  \n\nTable 2 shows the physicochemical and rheological properties of iCHT-TPPs \n\nprepared by varying the CHT-TPP mass ratio. The iCHT-TPPs showed a high swelling \n\ncapacity (SR), allowing for fast hydration when culture medium was added. Moreover, \n\nSR decreased with the degree of crosslinking because of the decreased availability of \n\nfunctional groups to hydrogen bonds with water.  \n\nFlory-Rehner calculations were used to determine the effective crosslink density (Ve) \n\n\n\n106 \n\n \n\nand the molecular weight between crosslinks (Mc). The decrease of the CHT-TPP mass \n\nratio increased Ve, as expected (Flory &amp; Rehner, 1943). Moreover, we observed lower \n\nMc values, indicating higher entanglement of chains.  \n\nWe also estimated the charge ratio (R+/-) of iCHT-TPPs according to R\u00e4dler et al. \n\n(1998). The values of R+/- were negative for iCHT-TPPs 2:1 and positive for iCHT-TPPs \n\n5:1 and 10:1. Therefore, the increase in the crosslinking degree decreased the positive \n\ncharge of chitosan in the complex. These modifications to the charge ratio may change \n\nthe interactions with the fibrin network and alter the electrostatic interaction with growth \n\nfactors.  \n\nThe microparticles in iCHT-TPPs had a mean diameter in the range of 150 to 220 \n\n\u00b5m, which was proportional to the CHT-TPP mass ratio. These diameters are within the \n\nadequate range for an injectable application (<700 \u00b5m) (Kablik et al., 2009). \n\n \n\nTable 2. Physicochemical and mechanical properties of iCHT-TPPs. \n\nPhysicochemical properties \n\nMass ratio CHT:TPP SR Ve (mol.cm-3) Mc  (g.mol-1) R+/- Particle diameter (\u00b5m) \n\n2:1 \n\n5:1 \n\n10:1 \n\n22 \u00b1 1 \n\n31 \u00b1 1 \n\n44 \u00b1 1 \n\n2.4 x 10-4 \n\n1.3 x 10-4 \n\n7.5 x 10-5 \n\n5110 \n\n9450 \n\n16669 \n\n0.7 \n\n1.8 \n\n3.6 \n\n152 \u00b1 4 \n\n205 \u00b1 3 \n\n215 \u00b1 4 \n\nRheological properties \n\nMass ratio CHT:TPP G\u2019 in 1 Hz (Pa) n tan ? Extrusion force (N) \n\n2:1 \n\n5:1 \n\n10:1 \n\n522 \n\n333 \n\n72 \n\n0.04 \n\n0.15 \n\n0.32 \n\n0.134 \n\n0.174 \n\n0.276 \n\n12.6 \u00b1 0.9 \n\n10.8 \u00b1 0.4 \n\n11.1 \u00b1 0.8 \n\nSR=swelling ratio; \nVe=Effective crosslink density; \nMc=Molecular weight between crosslinks; \nR+/-=charge ratio; \nG\u2019=elastic moduli; \nG\u201d=viscous moduli; \ntan ?=G\u201d/G\u2019; \nn= flow behavior index. \n\n \nThe rheological data (Table 2) show that the iCHT-TPPs exhibited behavior that \n\nis typical of so-called weak gels, irrespective of their mass ratios, as analyzed by the \n\nstorage (G\u2019) and loss moduli (G\u201d). The moduli had low frequency dependence, and tan ? \n\n>0.1 (Ikeda &amp; Nishimari, 2001; Clark &amp; Ross-Murphy, 1987). \n\n\n\n107 \n\n \n\nWe also observed an increase in the G\u2019 values with the number of crosslinks or \n\nentanglements (high Ve and low Mc), which indicated stiffer gels.  \n\nIn addition, the values of tan ? indicated an increment in gel strength with an \n\nincrease in Ve. Regardless of the CHT-TPP mass ratio, iCHT-TPPs showed G\u2019 values \n\nthat are adequate (<700 Pa) for injectable application (Kablik et al., 2009).  \n\nConsidering the Ostwald de Waele power law (?=K.?n-1), the flow indices (n) of \n\niCHT-TPPs showed a viscoelastic behavior that was dependent on mass ratio. The \n\npseudoplastic behavior is an important parameter in injectable applications, where the \n\nflow viscosity should be lower than the rest viscosity. \n\nIn addition to the beneficial rheological properties and microparticle size, the \n\ninjectable scaffolds must have an extrusion force to allow for their easy injection through \n\nan appropriately sized needle and thereby prevent side effects such as pain (Kablik et \n\nal., 2009). \n\n In iCHT-TPPs, we measured extrusion forces between 10 and 12 N, which were \n\nadequate (<20 N) for injectable applications (De Melo &amp; Marijnissen-Hofste, 2012; \n\n\u00d6hrlund, 2010). No modifications were observed in the extrusion force with the degree \n\nof crosslinking, particle size and distribution, as reported by Bentkover (2009). \n\nFigure 22 shows the loss weight of iCHT-TPPs after incubation in PBS, pH 7.4, at \n\n37\u00b0C. The microparticles can be considered stable for 30 days, irrespective of the CHT-\n\nTPP mass ratio. The maximum loss weight was approximately 4%, for CHT-TPP 2:1.  \n\n0 4 8 12 16 20 24 28 32\n\n0\n\n1\n\n2\n\n3\n\n4\n\n5\n\n \n\n \n\nL\no\n\ns\ns\n\n w\ne\n\nig\nh\n\nt \n(%\n\n)\n\nTime (days)\n \n\nFigure 22. Degradation profile of iCHT-TPPs in PBS pH 7.4 at 37\u00b0C. (?) iCHT-TPPs \n\n2:1; (?) iCHT-TPPs 5:1 and (?) iCHT-TPPs 10:1. \n\n\n\n108 \n\n \n\n \n\n5.3.3. Biological characterization \n\nFigure 23 shows the PDGF-AB and TGF-?1 release kinetics from aP-PRP/iCHT-\n\nTPPs.  \n\nThe curves shows predominantly diffusive profiles, indicating no collapse of the \n\nscaffold structure at the time of the assays. Controlled GF release was achieved from \n\naP-PRP/iCHT-TPPs compared with aP-PRP alone. The maximum PDGF-AB release \n\nwas obtained at 24 hours [Figure 23(a)], whereas a concentration plateau was not \n\nobserved for TGF-?1 at 72 hours [Figure 23(b)].  \n\nIn addition to the barrier of the structures, the interactions of GF and scaffolds \n\nplay an important role in the release. According to Hokugo et al. (2005) and De Cock et \n\nal. (2012), because GFs are generally basic proteins, in physiological conditions, they \n\ninteract ionically with negatively charged surfaces.  \n\nIn this work, we observed a slower release in the PDGF-AB for the scaffold aP-\n\nPRP/iCHT-TPPs mass ratio 2:1 compared with aP-PRP, suggesting electrostatic \n\ninteractions with negative charges of the scaffold. At physiological pH, PDGF-AB bore a \n\nnet positive charge (isoelectric point 9.8-10.5) (De Cock et al., 2012). \n\nFor TGF-?1, a slower release was observed for the scaffolds aP-PRP/iCHT-TPPs \n\nat mass ratios of 5:1 and 10:1 compared with aP-PRP. Because TGF-?1 has the \n\nisoelectric point of 8.2, which is near the physiological pH (7.4), the positive charges of \n\nthe scaffolds had a smaller influence on controlled release (Wang et al., 2011).  \n\nIn this case, we hypothesized that the slower release was primarily due to the \n\ninteraction of the negative fibrin network and the positive scaffold, which entrapped the \n\nGF molecules.  \n\n\n\n109 \n\n \n\n0 10 20 30 40 50 60 70 80\n\n0\n\n2000\n\n4000\n\n6000\n\n8000\n\n10000\n\n12000\n\n \n\n \n\nC\nu\n\nm\nu\n\nla\nti\n\nv\ne\n\n p\ng\n\n o\nf \n\nP\nD\n\nG\nF\n\n-A\nB\n\n/ \nm\n\nL\n P\n\nR\nP\n\nTime (hours)\n \n\n0 10 20 30 40 50 60 70 80\n\n0\n\n2000\n\n4000\n\n6000\n\n8000\n\n10000\n\n12000\n\n \n\n \n\nC\nu\n\nm\nu\n\nla\nti\n\nv\ne\n\n p\ng\n\n o\nf \n\nT\nG\n\nF\n-?\n\n1\n/ \nm\n\nL\n P\n\nR\nP\n\nTime (hours)\n \n\n \n\n(a) (b) \n\nFigure 23. Growth factor release profiles from aP-PRP combined with CHT-TPP \n\nscaffolds. (a) PDGF-AB and (b) TGF-?1. (?) PRP activated with Ca+2/serum used as \n\ncontrol; (?) aP-PRP/iCHT-TPPs 2:1; (?) aP-PRP/iCHT-TPPs 5:1 and (?) aP-PRP-iCHT-\n\nTPPs 10:1. The concentration of platelets in whole blood donors (average of 2 donors) \n\nwas 234,250 pq/mm3. After preparation of the P-PRP, the platelets were concentrated \n\napproximately 2.09 times, with an average final concentration of 472,250 pq/mm3. \n\n \n\nScanning electronic microscopy (Figure 24) of aP-PRP showed a tangled network \n\nthat was similar to the extracellular matrix. The microparticles were entrapped by the \n\nfibrin network, which provided an additional matrix for h-AdMSCs adherence and \n\nproliferation. \n\n  \n\naP-PRP aP-PRP/iCHT-TPPs 2:1 \n\n\n\n110 \n\n \n\n  \n\naP-PRP/iCHT-TPPs 5:1 aP-PRP /iCHT- TPPs 10:1 \n\nFigure 24. Scanning electron microscopic images of aP-PRP and aP-PRP/iCHT-TPPs \n\nafter 5 days of cultivation of h-AdMSCs.  \n\n \n\nThe proliferation of h-AdMSCs cultured in the presence of iCHT-TPPs, as \n\nassayed by MTT is shown in Figure 25(a). In all of the prepared mass ratios, the iCHT-\n\nTPPs had a higher proliferation compared with the positive control, which indicated \n\ncompatibility.  \n\nThe proliferation kinetic profiles in presence of PRP [Figure 25(b)] showed a long \n\nlag phase (~7 days) for aPRP and aP-PRP/iCHT-TPPs at 2:1 and 5:1.  \n\nThe proliferation of h-AdMSCs was lower than aP-PRP in the composite scaffolds \n\nat 2:1 and 5:1 mass ratios, whereas no proliferation was observed at 10:1 aP-\n\nPRP/iCHT-TPPs.  \n\n \n\n\n\n111 \n\n \n\nN\nTC\n\niC\nH\nT-\n\nTP\nP\ns \n2:\n\n1\n\niC\nH\nT-\n\nTP\nP\ns \n5:\n\n1\n\niC\nH\nT-\n\nTP\nP\ns \n10\n\n:1\n\nB\nla\nnk\n\nP\nTC\n\n0\n\n20\n\n40\n\n60\n\n80\n\n100\n\n120\n\n \n\n \n\nC\ne\n\nll\n c\n\no\nm\n\np\na\n\nb\na\n\nli\nty\n\n (\n%\n\n o\nf \n\nN\nT\n\nC\n)\n\nA\n \n\n2 3 4 5 6 7 8 9 10 11\n\n0\n\n1x10\n4\n\n2x10\n4\n\n3x10\n4\n\n4x10\n4\n\n5x10\n4\n\n6x10\n4\n\n \n\n \n\nC\ne\n\nll\n n\n\nu\nm\n\nb\ne\n\nr/\n w\n\ne\nll\n\nTime (days)\n \n\n \n\n(a) (b) \n\nFigure 25. (a) % of NTC as a measurement of the compatibility of h-AdMSCs that were \n\nexposed to the iCHT-TPPs. Negative control (NTC) = DMEM with 10% FBS; positive \n\ncontrol (PTC) = DMEM with phenol 0.5%. The population means are significantly \n\ndifferent from positive control at *p<0.05. (b) Proliferation profile of h-AdMSCs cultured \n\nin aP-PRP/iCHT-TPPs scaffolds as a function of time. Activated PRP was used as \n\ncontrol. (?) aP-PRP; (?) aP-PRP/iCHT-TPPs 2:1; (?) aP-PRP/iCHT-TPPs 5:1 and (?) \n\naP-PRP/iCHT-TPPs 10:1. The concentration of platelets in whole blood donors (average \n\nof 2 donors) was 215,375 pq/mm3. After preparation of the P-PRP, the platelets were \n\nconcentrated approximately 1.79 times, with an average final concentration of 383,500 \n\npq/mm3. Mean \u00b1 standard deviation n = 3. \n\n \n\nFigure 26 shows significant ALP activity in the aP-PRP/iCHT-TPPs, indicating \n\nstimulation of osteoblast differentiation. It is known that ALP enzymatic activity is \n\nessential for mineralization. Differences among the structures could not be inferred \n\nbecause ALP activity was determined in the culture medium and thus did not include the \n\nconcentrations inside the gels. This may have also contributed to the lower values of \n\nALP activities of the composite scaffolds compared with aP-PRP, due to the higher \n\nviscosity, which delayed the release of ALP. \n\n* \n\n\n\n112 \n\n \n\niC\nH\nT-\n\nTP\nP\ns \n\n2:\n1\n\niC\nH\nT-\n\nTP\nP\ns \n\n5:\n1\n\niC\nH\nT-\n\nTP\nP\ns \n\n10\n:1\n\nB\nla\n\nnk\n\n0.0\n\n0.5\n\n1.0\n\n1.5\n\n2.0\n\n2.5\n\n \n\n \n\nA\nL\n\nP\n a\n\nc\nti\n\nv\nit\n\ny\n a\n\ns\n a\n\nb\ns\n\no\nrb\n\na\nn\n\nc\ne\n\n i\nn\n\n 4\n0\n\n5\n n\n\nm\n\nA\n \n\nFigure 26. ALP activities of h-AdMSCs cultured on composite scaffolds (*statistically \n\nsignificant differences from blank, n=3, p<0.05). Blank = the reagents used in the assay \n\nonly). The concentration of platelets in whole blood donors (average of 2 donors) was \n\n214,000 pq/mm3. After preparation of the P-PRP, the platelets were concentrated \n\napproximately 2.31 times, with an average final concentration of 473,500 pq/mm3.  \n\n \n\n5.4. Conclusions \n \n\nWe have demonstrated that the injectable composite scaffolds (aP-PRP/iCHT-\n\nTPP) promoted the controlled release of PDGF-AB and TGF-?1 from platelets primarily \n\nduring the first 10 h. Although the physicochemical and rheological properties of iCHT-\n\nTPP increased the stability of the fibrin network, a significant proliferation of AdMSCs \n\nwas observed only for the composite scaffold containing 2:1 chitosan:TPP. However, the \n\nosteogenic differentiation was promoted in all mass ratios. Thus, the injectable \n\ncomposite scaffolds could be optimized to demonstrate their potential for regenerative \n\nmedicine applications.  \n\n \n\nAcknowledgments. The authors acknowledge the financial support from the National \n\nCouncil of Technological and Scientific Development (CNPq, Brazil). They also thank \n\nProf. Dr. Edvaldo Sabadini of the Chemical Institute (University of Campinas) for the use \n\nof the rheometer; Prof. Dr. William Dias Belangero and Dr. Ana Am\u00e9lia Rodrigues of the \n\n* \n\n\n\n113 \n\n \n\nFaculty of Medical Sciences (University of Campinas) for assistance, and Dr. \u00c2ngela \n\nCristina Malheiros Luzo of the Haematology and Hemotherapy Center (University of \n\nCampinas) for the donation of h-AdMSCs.  \n\n \n\nConflict of Interest. Andr\u00e9a Arruda Martins Shimojo, Sofia Elisa Moraga Galdames, \n\nAmanda Gomes Marcelino Perez, Thiago Heiji Ito and Maria Helena Andrade Santana \n\ndeclare that they have no conflict of interest in the presented work. \n\n \n\n5.5. References  \n \n\nANITUA, E. Plasma Rich in Growth Factors: Preliminary Results of Use in the \nPreparation of Future Sites for Implants. International Journal of Oral &amp; Maxillofacial \nImplants, vol.14, p.529-535, 1999. \n\nBENTKOVER, S.H. The Biology of Facial Fillers. Facial Plastic Surgery, vol.25, n.2, \np.73-85, 2009. \n\nBERGER, J.; REIST, M.; MAYER, J.; FELT, O.; PEPPAS, N.; GURNY, R. Structure and \ninteractions in covalently and ionically crosslinked chitosan hydrogels for biomedical \napplications. European Journal of Pharmaceutics and Biopharmaceutics, vol.57, \np.19\u201334, 2004. \n\nBHUMKAR, D.R.; POKHARKAR, V.B. Studies on Effect of pH on Cross-linking of \nChitosan With Sodium Tripolyphosphate: A Technical Note. AAPS Pharm Sci Tech, \nvol.7, n.2, p.E138-143, 2006. \n\nBRACK, H.P.; TIRMIZI, S.A.; RISEN JR, W.M. A spectroscopic and viscometric study of \nthe metal ion-induced gelation of the biopolymer chitosan. Polymer, vol.38, p.2351-\n2362, 1997. \n\nCLARK, A.H.; ROSS-MURPHY, S.B. Structural and mechanical properties of \nbiopolymer gels. Advances in Polymer Science, vol.83, p.57-192, 1987. \n\nCOLE, B.J.; SEROYER, S.T.; FILARDO, G.; BAJAJ, S.; FORTIER, L.A. Platelet-Rich \nPlasma: Where Are We Now and Where Are We Going? Sports Health, vol.2, n.3, \np.203-210, 2010. \n\nCOLLINS, M.N.; BIRKINSHAW, C. Investigation of the Swelling Behavior of Crosslinked \nHyaluronic Acid Films and Hydrogels Produced Using Homogeneous Reactions. \nJournal of Applied Polymer Science, vol.109, p.923-931, 2008. \n\n\n\n114 \n\n \n\nCOSTA-PINTO, A.R., REIS, R.L., NEVES, N.M. Scaffolds Based Bone Tissue \nEngineering: The Role of Chitosan. Tissue Engineering Part B, vol.17, n.5, p.331-347, \n2011. \n\nCRANE, D.; EVERTS, P.A.M. Platelet Rich Plasma (PRP) Matrix Grafts. PPM \nCommunications, vol.8, p.1-10, 2008. \n\nDE COCK, L.J.; DE WEVER, O.; HAMMAD, H.; LAMBRECHT, B.N.; VANDERLEYDEN, \nE.; DUBRUEL, P.; DE VOS, F.; VERVAET, C.;  REMON, J.P.; DE GEEST, B.G. \nEngineered 3D microporous gelatin scaffolds to study cell migration. Chemical \nCommunications, vol.48, p.3512-3514, 2012. \n\nDE MELO, F.; MARIJNISSEN-HOFSTE, J. Investigation of Physical Properties of a \nPolycaprolactone Dermal Filler when Mixed with Lidocaine and Lidocaine/Epinephrine. \nDermatology and Therapy, vol.2, n.13, p.1-10, 2012. \n\nFLORY, P.J.; REHNER, J. Statistical Mechanics of Cross?Linked Polymer Networks I. \nRubberlike Elasticity. Journal of Chemical Physics, vol.11, p.512-520, 1943. \n\nFOSTER, T.E.; PUSKAS, B.L.; MANDELBAUM, B.R.; GERHARDT, M.B.; RODEO, S.A. \nPlatelet-Rich Plasma: From Basic Science to Clinical Applications. American Journal \nof Sports Medicine, vol.37, p.2259-2272, 2009. \n\nG\u00dcM\u00dc?DERELIO?LU, M.; ADAY, S. Heparin-functionalized chitosan scaffolds for bone \ntissue engineering. Carbohydrate Research, vol.346, p.606\u2013613, 2011. \n\nGUTOWSKA, A.; JEONG, B.; JASIONOWSKI, M. Injectable Gels for Tissue \nEngineering. Anatomical Record, vol.263, p.342-349, 2001. \n\nHARRIS, R.; LECUMBERRI, E.; HERAS, A. Chitosan-Genipin Microspheres for the \nControlled Release of Drugs: Clarithromycin, Tramadol and Heparin. Marine Drugs, \nvol.8, p.1750-1762, 2010. \n\nHENNINK, W.E.; VAN NODTRUM, C.F. Novel crosslinking methods to design \nhydrogels. Advanced Drug Delivery Reviews, vol.54, p.13-36, 2002. \n\nHOKUGO, F.; OZEKI, M.; KAWAKAMI, O.; SUGIMOTO, K.; MUSHIMOTO, K.; MORITA, \nS.; TABATA, Y. Augmented Bone Regeneration Activity of Platelet-Rich Plasma by \nBiodegradable Gelatin Hydrogel. Tissue Engineering, vol.11, n.7/8, p.1224\u20131233, \n2005.  \n\nHOU, Q.; BANK, P.A.; SHAKESHEFF, K.M. Injectable scaffolds for tissue regeneration. \nJournal of Materials Chemistry, vol.14, p.1915-1923, 2004. \n\nIBEZIM, E.C.; ANDRADE, C.T.; MARCIA, C.; BARRETTO, B.; ODIMEGWU, D.C.; DE \nLIMA, F.F. Ionically Cross-linked Chitosan/Tripolyphosphate Microparticles for the \nControlled Delivery of Pyrimethamine. Ibnosina Journal of Medicine and Biomedical \nSciences, vol.3, n.3, p.77-88, 2010. \n\n\n\n115 \n\n \n\nIKEDA, S.; NISHINARI, K. Weak Gel-Type Rheological Properties of Aqueous \nDispersions of Nonaggregated K-Carrageenan Helices. Journal of Agricultural and \nFood Chemistry, vol.49, p.4436-4441, 2001. \n\nJIN, J.; SONG, M. Chitosan and Chitosan\u2013PEO Blend Membranes Crosslinked by \nGenipin for Drug Release. Journal of Applied Polymer Science, vol.102, p.436-444 \n(2006).  \n\nKABLIK, J.; MONHEIT, G.D.; YU, L.; CHANG, G.; GERSHKOVICH, J. Comparative \nPhysical Properties of Hyaluronic Acid Dermal Fillers. Journal of dermatologic \nsurgery, vol.35, p.302-312, 2009. \n\nKARNCHANAJINDANUN, J.; SRISA-ARD, M.; SRIHANAM, P.; BAIMARK, Y. \nPreparation and characterization of genipin-cross-linked chitosan microparticles by \nwater-in-oil emulsion solvent diffusion method. Natural Science, vol.2, n.10, p.1061-\n1065, 2010. \n\nKRETLOW, J.D.; KLOUDA, L.; MIKOS, A.G. Injectable matrices and scaffolds for drug \ndelivery in tissue engineering. Advanced Drug Delivery Reviews, vol.59, p.263-273, \n2007.  \n\nMARX, R.E. Platelet-rich plasma: Evidence to support its use. Journal of Oral and \nMaxillofacial Surgery, vol.62, p.489\u2013496, 2004. \n\nMI, F-L.; SHYU, S-S.; LEE, S-T.; WONG T-B. Kinetic Study of Chitosan-\nTripolyphosphate Complex Reaction and Acid-Resistive Properties of the Chitosan-\nTripolyphosphate Gel Beads Prepared by in-Liquid Curing Method. Journal of Polymer \nScience Part B: Polymer Physics, vol.37, p.1551-1564, 1999. \n\nMOSSMAM, T.J. A rapid colorimetric assay of cellular growth and survival: application to \nproliferation and cytotoxicity assays. Journal of Immunological Methods, vol.65, p.55-\n63, 1983. \n\nNASTI, A.; ZAKI, M.N.; DE LEONARDIS, P.; UNGPHAIBOON, S.; SANSONGSAK, P.; \nRIMOLI, M.G.; TIRELLI, N. Chitosan/TPP and Chitosan/TPP-hyaluronic Acid \nNanoparticles: Systematic Optimization of the Preparative Process and Preliminary \nBiological Evaluation. Pharmaceutical Research, vol.26, n.8, p.1918-1930, 2009. \n\n\u00d6HRLUND \u00c5. Lifting capacity of hyaluronic acid (HA) dermalaluronic acid (HA) dermal \nfillers. Poster presentation at 8 th Anti-aging Medicine World Congress (AMWC), \nMonte-Carlo, Monaco, 2010.  \n\nPEREZ, A.G.M.; LICHY, R.; LANA, J.F.S.D.; RODRIGUES, A.A.; LUZO, A.C.M.; \nBELANGERO, W.D.; SANTANA, M.H.A. Prediction and Modulation of Platelet Recovery \nby Discontinuous Centrifugation of Whole Blood for the Preparation of Pure Platelet-\nRich Plasma. BioResearch Open Access, vol.2, p. 307-314, 2013. \n\n\n\n116 \n\n \n\nR\u00c4DLER, J.O.; KOLTOVER, I.; JAMIESON, A.; SALDITT, T.; SAFINYA, C.R. Structure \nand Interfacial Aspects of Self-Assembled Cationic Lipid?DNA Gene Carrier Complexes. \nLangmuir, vol.14, n.15, p.4272-4283,1998. \n\nTAN, H.P.; CHU, C.R.; PAYNE, K.A. Injectable In Situ Forming Biodegradable Chitosan-\nHyaluronic acid Based Hydrogels for Cartilage Tissue Engineering. Biomaterials, \nvol.30, p.2499-2506, 2009. \n\nWANG, C.; LI, J.; YAO, F. Application of Chitosan-Based Biomaterials in Tissue \nEngineering. In: YUJI, Y. (Eds.). Chitosan-Based Hydrogels: Functions and \nApplications. New York: CRC Press, p.424, 2011.  \n\n  \n\n\n\n117 \n\n \n\nCAP\u00cdTULO 6 \u2013 IMPROVEMENTS IN PLATELET-\nRICH PLASMA PERFORMANCE BY ASSOCIATION \n\nWITH MICROPARTICLES OR SPONGES OF AUTO-\n\nCROSSLINKED HYALURONIC ACID \n\nArtigo submetido ao peri\u00f3dico Journal of Applied Polymer Science. \n\n \n\nAndr\u00e9a Arruda Martins Shimojoa, Isabela Cambraia de Souza Brissaca, Sofia Elisa \n\nMoraga Galdamesa, Amanda Gomes Marcelino Pereza, Jos\u00e9 F\u00e1bio Santos Duarte \n\nLanab and Maria Helena Andrade Santanaa,* \n\n \n\naDepartment of Engineering of Materials and Bioprocesses- School of Chemical \n\nEngineering, University of Campinas, Campinas-SP, Brazil. \n\n \n\nbInstitute of Bone and Cartilage (IOC), Indaiatuba-SP, Brazil \n\n \n\n*Correspondence to: Maria Helena Andrade Santana, phone: +55-19-35213921, FAX: \n\n+55-19-35213890, e-mail: mariahelena.santana@gmail.com \n\n \n\nAbstract. The association of platelet-rich plasma (PRP) to fluid hyaluronic acid (HA) has \n\nyielded beneficial outcomes in vivo in orthopedic applications. However, aside from \n\nneeding to repeat the applications, the literature is not conclusive about the \n\nimprovements to efficiency or long-lasting effects related to PRP alone. Auto-crosslinked \n\nhyaluronic acid (ACP) may introduce benefits to the stability of fibrin network from \n\nactivated PRP (aP-PRP) and to the mechanical properties of fluid HA. The main \n\nadvantage of ACP is not introducing foreign molecules to the formulation. This study \n\nwas undertaken to investigate in vitro association of aP-PRP and ACPs as composite \n\nscaffolds for growth factors release, the proliferation of human adipose-derived \n\nmesenchymal stem cells (h-AdMSCs) and differentiation by osteogenic marker alkaline \n\nphosphatase (ALP). ACP was prepared by organocatalyzed auto-esterification and \n\nmailto:mariahelena.santana@gmail.com\n\n\n118 \n\n \n\nstructured into microparticles or sponges to create injectable or solid scaffolds, \n\nrespectively. The structured ACP were not cytotoxic and had better mechanical \n\nproperties than does fluid HA. PRP was obtained by centrifuging whole blood without \n\nthe buffy-coat layer (P-PRP). Autologous serum and calcium were used for P-PRP \n\nactivation. Most of PDGF-AB (platelet-derived growth factor AB) and TGF-?1 \n\n(transforming growth factor ?-1) was released from aP-PRP alone or from the composite \n\nscaffolds in the first 10 hours. The release occurred in concert with the degradation time \n\nof the structured ACPs. The composite scaffolds improved h-AdMSCs proliferation and \n\npromoted ALP activity suggesting potential osteogenic differentiation. Therefore, aP-\n\nPRP combined with ACP is a promising biomaterial for further biological studies and \n\napplications in regenerative medicine.  \n\n \n\nKeywords: auto-crosslinked hyaluronic acid; controlled release; microparticles; PDGF-\n\nAB; platelet-rich plasma; sponges; TGF-?1.  \n\n \n\n6.1. Introduction \n\nPlatelet-rich plasma (PRP) is a platelets concentrate prepared from whole blood, \n\nwhich is able to release growth factors following induced activation (Anitua 1999; Foster \n\net al., 2009). PRP have been widely applied in various regenerative therapies and its \n\nbeneficial effects has been proven mainly in cartilage regeneration, wound healing and \n\nsports medicine (Crane &amp; Everts, 2008; Civinini et al., 2011; Kon et al., 2011; Amable et \n\nal., 2013). \n\nSince the 1990s, when clinical application of PRP began, three generations of \n\nformulations can be identified: the first generation applied PRP only; the second-\n\ngeneration included bone marrow cells in PRP; and the third and current generation \n\nuses PRP and human adipose derived mesenchymal stem cells (h-AdMSCs). It has \n\nbeen reported that AdMSCs are comparable to bone marrow-derived MSCs (BM-MSCs) \n\nwith respect to multi-lineage potential, growth kinetics, and cells senescence (de Ugarte \n\net al., 2003). \n\nRecently, PRP has been used in combination to high molecular weight HA aimed \n\nto ensure better stability of the fibrin network, control release of GF and decrease pain \n\n\n\n119 \n\n \n\nrelated to inflammation caused by injury in the application of PRP (Pak, 2012; de \n\nAngelis et al., 2012; Chen et al., 2014; Fathi, 2012; de Boulle et al., 2013). \n\nPak (2012) has described different methods and pharmaceutical compositions \n\ncomprising PRP, h-AdMSCs, HA and CaCl2 for the treatment, preventions or alleviation \n\nof bone and cartilage diseases.  \n\nDe Angelis et al. (2012) have treated patients with wound dehiscence and tendon \n\nexposure, showing that PRP combined with fluid hyaluronic acid (fHA) enables a more \n\nrapid regeneration of damaged tissues. \n\nRecently, Chen et al. (2014) demonstrated synergic effects of the anabolic \n\nactions of PRP-fHA on cartilage regeneration and the inhibition of osteoarthritis \n\ninflammation. Cytokine-induced degeneration was reduced through the recovery of \n\nchondrogenic signaling. \n\nThe benefits of using platelet-rich plasma and hyaluronic acid when used alone or \n\nin combination on wound healing were evaluated by Fathi (2012). This author observed \n\nthat the use of PRP alone or in combination with HA accelerate wound healing, while the \n\nuse of low concentration of HA alone presents no improvement of wound healing in \n\ncomparison with normal one. \n\nHowever, the need for repeated applications of free HA in vivo has directed the \n\nstudies for the use of biocompatible crosslinked derivatives (de Boulle et al., 2013; \n\nCollins &amp; Birkinshaw, 2013; Stern et al., 2000).  \n\nPreliminary studies from our group have shown that the addition of divinyl sulfone \n\n(DVS) crosslinked HA microparticles to activated P-PRP (aP-PRP) improves the \n\nmechanical properties of the natural fibrin networks by increasing its viscoelasticity and \n\neliminating strain hardening (unpublished data). Furthermore, the HA microparticles \n\nstimulate h-AdMSCs proliferation on the thin fibers (~65 nm) of the fibrin network. \n\nHowever, the long-term effects of DVS-crosslinked HA microparticles remain unclear, \n\nand the release of the chemical crosslinkers causes inflammatory outcomes (Prasadam \n\net al., 2013). \n\nThus, auto-crosslinked polysaccharide (ACP) represents an interesting strategy \n\nfor improving the stability of HA. ACP polymers are inter- and intra-molecular esters of \n\nHA for which some of the carboxyl groups have been esterified with hydroxyl groups of \n\n\n\n120 \n\n \n\nthe same and/ or different molecules, thus forming a mixture of lactones and inter-\n\nmolecular ester bonds (Mensitieri et al., 1996). \n\nThe main advantage for ACP is the formation of ester bonds without the addition \n\nof toxic crosslinking agents. As no foreign molecules are used to create the crosslink, \n\nthe gel is de-esterified upon degradation and hyaluronic acid is liberated. HA is a \n\nnaturally occurring molecule that has a biological role and is eliminated through a known \n\nmetabolic pathway (Mensitieri et al., 1996). \n\nFurthermore, ACP can be prepared with various degrees of crosslinking by \n\nmodulating the reaction conditions, which allow the adaption of its mechanical and/or \n\nrheological properties for many applications (de Laco et al., 1998)  \n\nACP has been widely used on the prevention of postsurgical adhesions (de Laco \n\net al., 1998; Belluco et al., 2001; Ko\u00e7ak et al., 1999; Yerushalmi et al., 1994). However, \n\nas far as we know, the application of ACP as scaffolds is still scarce.  \n\nSolchaga et al. (2005) demonstrated that porous sponges of ACP\u00ae seeded with \n\nchondrocytes or osteoblasts improve the cartilage and bone regeneration in \n\nosteochondral defects of rabbits compared to HYAFF\u00ae-11 (a benzyl ester of HA that is \n\ncompletely esterified). The degradation time of ACP\u00ae led to rapid bone formation while \n\nthe slow degradation of HYAFF\u00ae-11 prolonged the presence of cartilage and delayed \n\nendochondral bone formation. \n\nThe present work extends the previous findings by investigating the association \n\nof activated aP-PRP and ACP structured in microparticles or sponges as a composite \n\nscaffold for growth factors (GFs) release, the proliferation of h-AdMSCs and osteogenic \n\ndifferentiation in vitro. Our hypothesis is that the composite scaffolds will improve \n\nproliferation and differentiation of h-AdMSCs by providing better structural and \n\nmechanical properties compared to fHA or aP-PRP alone.  \n\nThis study might offer promising approaches for further biological applications \n\nand should provide alternatives in orthopedic treatments. \n\n \n\n6.2. Experimental  \n\n \n\n\n\n121 \n\n \n\n6.2.1. Materials \n\nHA in sodium form (MW = 2 x 106 Da) was obtained from Spec-Chem Ind. \n\n(Nanjing, China). All other reagents were purchased from Synth\u00ae (Diadema, SP, Brazil) \n\nunless specified otherwise. PRP was prepared from whole blood (WB) of donors, who \n\nwere healthy individuals aged between 30 and 40 years old and previously assessed \n\nthrough their clinical examinations. The human adipose tissue-derived mesenchymal \n\nstem cells, h-AdMSCs, were provided by Umbilical Cord Blood Bank of Haematology \n\nand Hemotherapy Center of University of Campinas. All biological experiments were \n\napproved by the Ethics Committee of the Medical Sciences School of the University of \n\nCampinas (UNICAMP; CAAE: 0972.0.146.000-11). \n\n \n\n6.2.2. Methods \n\n6.2.2.1. Preparation of HA-TBA \n\nAn aqueous solution of 0.5% (w/v) sodium hyaluronate (Na-HA) was stirred in \n\nstrongly acidic ion exchange resin Dowex\u00ae 50-8WX-400 mesh (Sigma-Aldrich, St. Louis, \n\nMO, USA) for 8 hours. The suspension was centrifuged in a Rotina 380R centrifuge \n\n(Hettich\u00ae Zentrifugen, Tuttlingen, Germany) at 10,000 rpm for 10 minutes to remove the \n\nresin and neutralized with tetrabutylammonium hydroxide (TBA-OH) 0.2 mol.L-1 (Vetec\u00ae, \n\nDuque de Caxias, Rio de Janeiro, Brazil) to form the quaternary ammonium salt of HA \n\n(HA-TBA). The solution was then frozen and lyophilized in lyophilizer Liobras L101 \n\n(Liobras, S\u00e3o Carlos, SP, Brazil) for 48 hours (Khetan &amp; Burdick, 2010). \n\n \n\n6.2.2.2. Preparation of ACP \n\nThe auto-crosslinked HA (ACP) was prepared by an autoesterification reaction \n\naccording to the protocol described by Bellini et al. (2001) (Figure 27). HA-TBA with a \n\nmolecular weight of approximately 2 x 106 Da and corresponding to 10 mEq of \n\nmonomeric units was solubilized in 50 mL of dimethylsulfoxide (DMSO) at 25\u00b0C. \n\nTriethylamine (0.5 mEq) was added and the resulting solution was agitated for 30 \n\nminutes. A solution of 2-chloro-1-methyl pyridinium iodide (CMPI) (0.5 mEq) (Sigma-\n\nAldrich, St. Louis, MO, USA) in 15 mL of DMSO was slowly added drop by drop over 1 \n\n\n\n122 \n\n \n\nhour and the mixture was kept at 30\u00b0C for 15 hours. A solution of sodium chloride 2.5% \n\n(w/v) was then added and the resulting mixture was poured slowly into 150 mL of \n\nacetone, maintaining continual agitation. The formed precipitate was centrifuged at \n\n10,000 rpm for 10 minutes, washed three times in 100 mL of 5:1 acetone: water and \n\nthree times with 100 mL of acetone and vacuum-dried for 24 hours at 30\u00b0C.  \n\n \n\nFigure 27. Auto-crosslinking reaction using CMPI-activated HA intermediate (Schant\u00e9 et \n\nal., 2011). \n\n \n\n6.2.2.3. Characterization of ACP \n\nACP was characterized by Fourier-transform infrared (FTIR) in a Thermo \n\nScientific Nicolet model 6700 (Thermo Scientific Nicolet\u2122, Waltham, MA, USA). \n\nMeasurements were made in the ATR mode with accessory SMART OMNI-SAMPLER, \n\nin the spectral range of 4000-675 cm-1 with a resolution of 4 cm-1 over 64 scans.  \n\n \n\n6.2.2.4. Preparation of structured ACP \n\nThe ACP structured in microparticles (mACP) or sponges (sACP) were prepared \n\nfrom plain ACP swollen in Milli-Q water. The microparticles were obtained by shearing in \n\nan Ultra-Turrax T25 homogenizer (IKA Labortechnik, Staufen, Germany) at 18,000 rpm \n\nby 20 minutes, according to Shimojo et al. (2013). The sponges were initially placed in \n\npolystyrene 24-well microplates (TPP\u00ae, Trasadingen, Switzerland), frozen at -20\u00b0C and \n\nlyophilized at temperature of approximately -30\u00b0C for 48 hours. \n\n \n\n6.2.2.5 Characterization of structured ACP \n\nHA structured in sponges (sHA) and fluid HA (fHA) were characterized like the \n\nstructured ACP and used as control as necessary. \n\n\n\n123 \n\n \n\n \n\nMorphology and pore size. The morphology of ACP sponges was evaluated by \n\nscanning electron microscopy (SEM) using an LEO 440i Electron Microscopy/Oxford \n\n(Cambridge, England) operated at 5 kV accelerating voltage. The scaffolds were gold \n\ncoated using a sputter coater POLARON SC7620, VG Microtech (Uckfield, England) for \n\n180 s at a current of 3 mA. Pore size (n=20) was measured using Image J 1.47t. \n\n \n\nMechanical Properties. Mechanical compression tests of ACP sponges (? = 3) \n\nwere performed using a Universal Testing Machine, MTS model 810-Flex Test 40 (MTS \n\nSystems Corporation, Eden Prairie, MN, USA) up to 60% strain, according to Correia et \n\nal. (2011). The testing machine was equipped with a 1.5 kN load cell, and the loading \n\nrate was 5 mm/min. Young\u2019s modulus was calculated in the initial linear section of the \n\nstress-strain curve, when the strain was lower than 10%.  \n\n \n\nDegradation time. The gravimetric method described by Tang et al. (2007) was \n\nused to estimate the degradation time of the structured ACP through measurements of \n\nremaining weight. The assay was carried out with the ACP microparticles and ACP \n\nsponges in phosphate buffer saline solution (PBS, pH 7.2) (LB Laborclin, Pinhais, PR, \n\nBrazil) at 37\u00b0C. \n\n \n\nAverage diameter. The average diameter was measured for the ACP \n\nmicroparticles suspended in water. The measurements were performed in a Malvern \n\nMastersizer S laser diffraction (Malvern Instruments Ltd, Malvern, UK). The standard \n\ndeviation was calculated from ten consecutive measurements. \n\n \n\nRheology. Rheological measurements were performed in steady and oscillatory \n\nregimes at 25\u00b0C using a parallel plate geometry of 20 mm. Steady shear measurements \n\nwere obtained at shear rates of 0.1-50 s-1. Oscillatory measurements were conducted in \n\nthe linear region with a stress of 1.188 Pa and in the frequency range of 0.01 to 10 Hz. \n\nAll rheological measurements were performed using the swollen ACP microparticles \n\nequilibrated in Milli-Q on a rheometer Haake RheoStress 1 (Haake, Karlsruhe, \n\n\n\n124 \n\n \n\nGermany). \n\n \n\nExtrusion force. Initially the ACP microparticles were loaded in 1-mL plastic \n\nsyringes with 30-gauge needles. Afterward, the force required to extrude was measured \n\nin a MTS 810 Servo-hydraulic Universal Testing Machine (MTS Systems Corporation, \n\nEden Prairie, MN, USA) (Load Cell 1.5 kN) at 25\u00b0C at a 5.0 mm/min extrusion rate. \n\n \n\nSwelling ratio. Swelling measurements of the ACP microparticles were performed \n\nin PBS at 25\u00b0C after 72 h of incubation, according to Shu et al. (2004). The swelling ratio \n\n(SR) was calculated using the following Equation (1). \n\n \n\n?? =\n??\n\n??\n                                                                                                            Equation (1) \n\n \n\nwhere ?s and ?d are the weights of the scaffolds in the swelled state and the dry state, \n\nrespectively. \n\nThe swelling measurements of the ACP sponges was determined by swelling the \n\nfreeze-dried ACP sponges (with known weights) in PBS at 37\u00b0C for 24 hours. The \n\nswollen ACP sponges were weighed after the removal of excess of water by keeping the \n\nsurfaces on a filter paper. The swelling ratio (SR) was also calculated using Equation \n\n(1). \n\n \n\nPorosity. The porosity (?) of the ACP sponges was determined according to the \n\nprotocol used by Wang et al. (2011), and calculated by Equation (2). \n\n \n\n? (%) =  \n???(\n\n??\n\n?\n)\n\n??\n . 100                                                                                      Equation (2) \n\n \n\nwhere Vm is the total volume of ACP sponges (cm3), ? is the density of non-porous HA \n\n(1.0016 g/cm3) and ?m is the weight of sponges (g). Values are expressed as the mean \n\n\u00b1 standard deviation (n=3). \n\n \n\n\n\n125 \n\n \n\nCell compatibility. The compatibility of the structured ACP with h-AdMSCs cells \n\nwas carried out by exposing them to cell culture at 37\u00b0C for 24 hours. Then, cell viability \n\nwas evaluated by using an MTT assay (3-[4,5-dimethyl-thiazol-2-yl]-2,5-\n\ndiphenyltetrazolium bromide) (MTT, Molecular Probes), according to modified Mosmann \n\nmethod (1983). The MTT assay is a colorimetric test based on the reduction of yellow \n\ntetrazolium salt into a purple formazan product in presence of cells (G\u00fcm\u00fcs?derelio?lu &amp; \n\nAday, 2011). \n\n \n\n6.2.2.6. Preparation of PRP  \n\nPRP rich in platelets and poor in leukocytes (P-PRP) was prepared according to \n\nPerez et al. (2014). Briefly, whole blood (WB) was collected into 3.5 mL vacuum tubes \n\n(Vacuette\u00ae, Campinas, SP, Brazil) containing sodium citrate 3.2% (w/v) as \n\nanticoagulant. WB was initially centrifuged in a Rotina 380R centrifuge (Hettich\u00ae \n\nZentrifugen, Tuttlingen, Germany) at 100 ? g for 10 minutes, at 25\u00b0C, After the formation \n\nof three layers (a bottom layer composed mainly of red blood cells (RBCs); an upper \n\nlayer composed of plasma, platelets and some WBCs; and an intermediate layer, or \n\nbuffy coat, composed mostly of WBCs), only the upper layer was collected to obtain P-\n\nPRP. The concentration of platelets, WBCs and RBCs in WB and P-PRP was \n\ndetermined using the ABX Micros ES 60 hematology analyzer (HORIBA ABX \n\nDiagnostics, Montpellier, France). \n\n \n\n6.2.2.7. Preparation of activated P-PRP (aP-PRP) \n\naP-PRP was prepared via the activation of P-PRP with autologous serum (Ser) \n\nand 10% (w/v) CaCl2 solution as agonists using the following proportions: agonist/P-\n\nPRP=20% (v/v); Ser/CaCl2 volumetric ratio=9. Ser was prepared by collecting 5 mL of \n\nWB in tubes without anticoagulant. After 30 minutes for clot formation, WB was \n\ncentrifuged at 2000 ? g for 10 minutes (Perez et al., 2013).  \n\n \n\n6.2.2.8 Preparation of composite scaffolds \n\nFor preparation of the composite scaffolds, immediately after activation, aP-PRP \n\nwas mixed with the ACP microparticles or embedded by dripping into the ACP sponges, \n\n\n\n126 \n\n \n\nboth in 48-well microplates. In all biological assays performed in this work, the following \n\nproportions of aP-PRP to structured ACP were used: aP-PRP: microparticles = 200 \n\n\u00b5L:100-200 mg and aP-PRP: sponges = 200 \u00b5L:10-20 mg in order to guarantee the \n\nsame proportion PRP to HA. \n\n \n\n6.2.2.9. Characterization of composite scaffolds \n\nRelease of growth factors. The release of platelet-derived growth factor AB \n\n(PDGF-AB) and transforming growth factor ?1 (TGF-?1) was performed after a 1 hour \n\ngelation of composite scaffolds in the presence of the culture medium Dulbecco's \n\nModified Eagle's Medium with low glucose concentration (DMEM-LG, Gibco, Grand \n\nIsland, NY, USA) in 48-well microplates. The microplates were maintained in an \n\nincubator with 5% CO2 over the assays. After sampling, the volume was replaced with \n\nfresh medium at 3, 6, 12, 48 and 72 hours without removing the hydrogels from the \n\nwells. The samples were stored at -80\u00b0C until all samples were collected. The \n\nconcentrations of the released GFs were measured using enzyme-linked \n\nimmunosorbent assay (ELISA) kits (R&amp;D Systems, Minneapolis, MN, USA) according to \n\nthe manufacturer\u2019s instructions and specifications. \n\n \n\nh-AdMSCs-seeding in the composite scaffolds. The pre-cultured h-AdMSCs were \n\ntrypsinized and resuspended in P-PRP to a final cell concentration of 1 x 104 cells/ mL. \n\nP-PRP containing h-AdMSCs was activated and immediately pipetted onto the surface \n\nof the microparticles or embedded into the sponges, both in 24-well tissue culture plates. \n\nThe composite scaffolds were kept at room temperature for 45 minutes for consolidation \n\nof the fibrin network. The cells seeded in fHA or in sHA were used as controls.  \n\n \n\nh-AdMSCs cultivation in the composite scaffolds. Cultivation of the h-AdMSCs \n\nwas carried out in 24-well tissue culture plates, by adding 1 mL of the culture medium \n\n(DMEM) to the seeded composite scaffolds (n=4). The culture was maintained at 37\u00b0C \n\nover 10 days. Cell proliferation was quantified using the thiazolyl blue tetrazolium \n\nbromide (MTT) assay. At 3, 5, 7 and 10 cultivation days, the substrates were removed \n\nand transferred to 24-well plates. MTT (1 mL of 1 mg/mL) was then added, and the \n\n\n\n127 \n\n \n\ncultivation proceeded at 37\u00b0C for 4 hours. The MTT solution was then discarded, and 1 \n\nmL of DMSO was added to dissolve the purple formazan crystals. The samples were \n\nshaken at 120 rpm for 30 min to ensure homogeneous dissolution of the formazan dye, \n\nand then 200 \u00b5L of each sample was transferred to a 96-well plate. Optical density was \n\nmeasured at 595 nm using a microplate reader (FilterMax F5 Molecular Devices, \n\nSunnyvale, CA, USA). The cell concentration was obtained from the previously built \n\ncalibration curve. \n\n \n\nImages of the cell-seeded composite scaffolds. Images of cell-seeded composite \n\nscaffolds were obtained by scanning electron microscopy (SEM) after 5 days of h-\n\nAdMSCs proliferation. The substrates were fixed in a solution of 4% paraformaldehyde \n\nand 2.5% glutaraldehyde in PBS, for 2 hours. The samples were than dehydrated in \n\nethanol for 15-min intervals in aqueous 50%, 70%, 95% and 100% ethanol solutions \n\n(2x) and dried at the critical point dryer BAL-TEC CPD 030 (BAL-TEC\u00ae, Schalksm\u00fchle, \n\nGermany). After gold coating in a Sputter Coater POLARON, SC7620 (VG Microtech, \n\nRingmer, UK), the samples were visualized with a scanning electron microscope \n\nLeo440i (LEO Electron Microscopy/Oxford, Cambridge, UK) with an accelerating voltage \n\nof 20 kV. \n\n \n\nInduction of osteogenic differentiation. h-AdMSCs-seeding composite scaffolds \n\nwere induced to differentiate into the osteogenic lineage by providing the osteogenic \n\nmedium containing DMEM-LG supplemented with 10% fetal bovine serum (FBS), 1% ?-\n\nglycerol-phosphate (Sigma-Aldrich, St. Louis, MO, USA), 1% L-ascorbic acid (Sigma-\n\nAldrich, St. Louis, MO, USA), 1% dexamethasone (Sigma-Aldrich, St. Louis, MO, USA) \n\nand 1% Penicillin/Streptomycin solution (Gibco, Grand Island, NY, USA). The medium \n\nwas changed every 7 days.  \n\n \n\nAlkaline phosphatase activity (ALP). The level of alkaline phosphatase (ALP) \n\nactivity of h-AdMSCs was determined on day 14. Two hundred microliters of the \n\nsupernatant was collected and mixed with 200 ?L of p-nitrophenyl phosphate \n\n(SIGMAFAST\u2122 p-Nitrophenyl phosphate Tablets, Sigma, Saint Louis, MI, USA) as \n\n\n\n128 \n\n \n\nsubstrate and incubated at room temperature for 30 minutes. Absorbance was read \n\nimmediately on a spectrophotometer at 405 nm. \n\n \n\n6.2.2.10. Statistical analysis \n\nEach experiment was carried out in triplicate unless otherwise specified. All \n\nresults are presented as the mean \u00b1 standard deviation (SD). The experimental data \n\nfrom all the studies were analyzed using Analysis of Variance (ANOVA). Statistical \n\nsignificance was set to p-value ? 0.05.  \n\n \n\n6.3. Results \n \n\n6.3.1. Characterization of ACP  \n\nThe IR spectra from ACP (Figure 28) shows peaks between 1000 and 850 cm-1, \n\ncorresponding to deformation out of the plane of the OH group, which is related to the H-\n\nbonds; between 1250-1080 cm-1, corresponding to the asymmetrical stretching CC(=O)-\n\nO and CHO; at approximately 1400 cm-1, corresponding to the deformation of COH \n\nbond; and in the region of 1800-1700 cm-1, which is attributed to the stretching vibration \n\nof C=O of carboxylic acyl groups (~1725 cm -1) and ester groups (1780-1760 cm-1) \n\n(Schant\u00e9 et al., 2011; Silverstein et al., 1974). \n\nThese results ensured the auto-crosslinking and its unique feature that no foreign \n\nbridge molecules are present between the crosslinked HA chains. \n\n2000 1600 1200 800\n\n50\n\n55\n\n60\n\n65\n\n70\n\n75\n\n80\n\n \n\n \n\n%\n T\n\nra\nn\n\ns\nm\n\nit\na\n\nn\nc\n\ne\n\nWavenumber (cm\n-1\n)\n\n1780\n\n1725\n\n1410\n\n1080\n\n1035\n\n1150\n\n1324\n\n1625\n\n1560\n1372\n\n947\n1205\n\n \n\nFigure 28. ATR-FTIR spectra of ACP with 5% of carboxylic groups esterified.  \n\n\n\n129 \n\n \n\n \n\n6.3.2. Characterization of ACPs structured scaffolds \n\nThe rheological behavior determined by oscillatory and steady measurements of \n\nthe ACP structured in microparticles in relation to 1% fHA is shown in Figure 29(a) and \n\n29(b), respectively. The microparticles exhibited the gel-like behavior, as analyzed by \n\nthe storage (G\u2019) and loss moduli (G\u201d), where G\u2019 is higher than G\u201d in all studied frequency \n\nranges and the curves are parallel to the frequency axis, indicating crosslinking. The 1% \n\nfHA showed crossover (G\u2019=G\u201d) around 1 Hz indicating concentrated solution behavior, \n\nas expected. Moreover, mACP exhibited behavior typical of so-called weak gels with tan \n\n? (G\u201d/G\u2019)=0.19 in 1 Hz (Ikeda &amp; Nishimari, 2001; Clark &amp; Ross-Murph, 1987).  \n\n0.1 1 10\n\n1\n\n10\n\n100\n\n1000\n\n \n \n\nG\n' \na\n\nn\nd\n\n G\n\"\n (\n\nP\na\n\n) \n\nFrequency (Hz)\n \n\n0.1 1 10 100\n\n1\n\n10\n\n100\n\n1000\n\n \n\n \n\nV\nis\n\nc\no\n\ns\nit\n\ny\n (\n\nP\na\n.s\n\n)\n\nShear rate (s\n-1\n)\n\n \n\n(a) (b) \n\nFigure 29. (a) Oscillation spectrum and (b) flow curve of (?) ACP Microparticles and (?) \n\nfluid HA (1% wt.). G\u2019 (closed symbol) and G\u201d (open symbol).  \n\n \n\nThe flow curve (Figure 29b) showed a shear thinning behavior characteristic of \n\npseudoplastic fluids for mACP and the microparticles were more resistant to shearing \n\n(up to1 s-1) than 1% fHA.  \n\nMoreover, the microparticles showed G\u2019 (~300 Pa) values between 100-700 Pa, \n\nwhich are adequate for injectable application (Kablik et al., 2009). \n\nIn addition to the beneficial rheological properties and microparticle size, the \n\ninjectable scaffolds must have an extrusion force to allow for their easy injection through \n\nan appropriately sized needle and thereby prevent side effects such as pain, bruising, \n\ncrossover \n\n\n\n130 \n\n \n\nbleeding, and edema (Kablik et al., 2009). \n\nFor injectable applications, extrusion force values must \n\n be smaller than 20 N and the mean diameter of particles smaller than 700 \u00b5m \n\n(Shimojo et al., 2013; Kablik et al., 2009). \n\nIn ACP microparticles, we standardized the mean diameter to values smaller than \n\n200 \u00b5m by adequate conditions of shearing. Thus, the ACP microparticles showed \n\nextrusion forces around 20N, which is adequate for injectable applications (Table 3). \n\nMoreover, the extrusion force of the microparticles was five times higher than the \n\n1% fHA, indicating crosslinking and improvement of mechanical properties.  \n\n \n\nTable 3. Properties of fHA, sHA, and structured ACP (microparticles and sponges). \n\nScaffold Extrusion Force \n\n(N) \n\nYoung\u2019 s moduli \n\n(kPa) \n\nSwelling ratio \n\n(SR=ws/wd) \n\nPorosity \n\n(%) \n\nACP microparticles 20 \u00b1 1 - 61 \u00b1 8 - \n\nfHA (1% w/v) 4.3 \u00b1 0.1 - - - \n\nACP sponges - 30 \u00b1 0.1 91 \u00b1 5 97.6 \u00b1 0.2 \n\nsHA - &lt;10 - 97.8 \u00b1 0.3 \n\n \n\nThe Young\u2019s modulus of ACP sponges (Table 3) was approximately 3 times \n\nhigher than for the sHA with similar porosity (~97%). This result is evidence of the \n\nimprovements to mechanical resistance imparted by ACP, which is one of the most \n\nimportant requirements for scaffolds in tissue engineering.  \n\nThe capacity to hydration is also an essential factor for cell migration inside the \n\nscaffolds. The 5% auto-crosslinking did not greatly affect the capacity for hydration of \n\nthe structured ACP. Although the hydration capacity is directly linked to the functional \n\ngroups capable of forming H-bonds with water, in this case, the higher hydration \n\ncapacity of the ACP sponges (~90%) can be attributed to the porous structure of the \n\nscaffold, which retains greater amount of unbound water. For the ACP microparticles, \n\nthe swelling was ~60%, due to a smaller porous size structure. \n\nThe porosities of the ACP sponges and sHA were similar, which evidence the \n\nsuperiority of the ACP sponges as a scaffold, when associated to its mechanical \n\n\n\n131 \n\n \n\nresistance. The porosity values of ACP sponges and sHA ranged around 97%, which \n\nare adequate for tissue engineering. \n\nDifferent aggregations of the HA chains in ACP sponges or sHA are shown in \n\nFigure 30. In both cases, highly porous structures were formed, confirming the \n\ndetermined values for porosity in Table 2. However, the structure of ACP sponges has \n\nmore round pores [Figure 30(a)], whereas the sHA has a leaf structure [Figure 30(b)].  \n\n \n\n  \n(a) (b) \n\nFigure 30. Figure 4. SEM micrographs of cross-sectional of (a) ACP sponges and (b) \n\nHA sponge. \n\n \n\nThe proliferation of h-AdMSCs results, as assayed by MTT, shown in Figure \n\n31(a) indicated that the structured ACP, sHA and fHA could be considered compatible to \n\nthe cells, by comparison with the positive toxicity control (PTC).  \n\nWe also observed that the proliferation of h-AdMSCs on ACP sponges was \n\nsignificantly higher than the negative control (p<0.05).  \n\nMoreover, ACP microparticles showed lower cell proliferation compared to fHA, \n\nwhile there were no significant differences between the cell proliferation of ACP sponges \n\nand sHA. \n\n\n\n132 \n\n \n\nP\nTC\n\nN\nTC fH\n\nA\n\nA\nC\nP\n m\n\nic\nro\n\npa\nrt\nic\nle\ns\n\nS\nH\nA\n\nA\nC\nP\n s\npo\n\nng\ne\n\n0.0\n\n2.0x10\n4\n\n4.0x10\n4\n\n6.0x10\n4\n\n8.0x10\n4\n\n1.0x10\n5\n\n*\n\n*\n\n**\n\n \n\n \n\nC\ne\n\nll\n n\n\nu\nm\n\nb\ne\n\nr/\n w\n\ne\nll\n\n*\n\n \n\n0 2 4 6 8 10 12 14 16\n\n40\n\n50\n\n60\n\n70\n\n80\n\n90\n\n100\n\n110\n\n \n\n \n\nR\ne\n\nm\na\n\nin\nin\n\ng\n w\n\ne\nig\n\nh\nt \n\n(%\n)\n\nTime (days)\n\n \n\n(a) (b) \n\nFigure 31. (a) Viability of h-AdMSCs exposed to the structured ACP or HA (fluid and \n\nsponge). Negative control (NTC) = DMEM with 10% FBS; positive control (PTC) = \n\nDMEM with phenol 0.5%. Mean \u00b1 standard deviation n = 3. The population means are \n\nsignificantly different from the positive control at *p<0.05. (b) The weight remaining of \n\nthe structured ACP under the time course of degradation (at 37\u00b0C, in PBS). (?) ACP \n\nmicroparticles and (?) ACP sponges.  \n\n \n\nFigure 31(b) shows the degradation kinetics of the structured ACP in PBS in \n\nterms of remaining weight. Most of the weight reduction, around 40% was observed in \n\nthe first day for both structures. Scaffolds for regenerative medicine applications should \n\ndegrade over the course of tissue regeneration to allow complete repair by host tissue. \n\nTherefore, degradation must be adjusted to release GFs and allow for cell proliferation.  \n\n \n\n6.3.3. Characterization of the composite scaffolds \n\nFigure 32 shows the release kinetic of PDGF-AB and TGF-?1 from the composite \n\nscaffolds. The GFs were from aP-PRP containing average platelet concentration \n\n407,000 pq/mm3. The fibrin network from activated aP-PRP alone was used as control.  \n\n\n\n133 \n\n \n\n0 10 20 30 40 50 60 70 80\n\n0\n\n1000\n\n2000\n\n3000\n\n4000\n\n5000\n\n6000\n\n7000\n\n8000\n\n9000\n\n \n\n \n\np\ng\n\n o\nf \n\nP\nD\n\nG\nF\n\n-A\nB\n\n/ \nm\n\nL\n o\n\nf \nP\n\nR\nP\n\nTime (hours)  \n\n0 10 20 30 40 50 60 70 80\n\n0\n\n2000\n\n4000\n\n6000\n\n8000\n\n10000\n\n12000\n\n14000\n\n \n\n \n\np\ng\n\n o\nf \n\nT\nG\n\nF\n-?\n\n1\n/ \nm\n\nL\n o\n\nf \nP\n\nR\nP\n\nTime (hours)\n \n\n(a) (b) \n\nFigure 32. Growth factor release profiles from P-PRP combined with HA and ACP \n\nstructured scaffolds. (a) PDGF-AB and (b) TGF-?1. (?) ACP microparticles; (?) fHA; (?) \n\nP-PRP alone; (?) ACP sponges and (?) sHA. The concentration of platelets in P-PRP \n\nwas 407,000 pq/mm3. \n\n \n\nControlled release of GFs was achieved from the composite scaffolds. The \n\ncurves show parallel diffusive profiles. The bulk of the GFs were released in the first 12 \n\nhours. For both GFs, the initial release rate was higher in aP-PRP alone and aP-PRP-\n\nACP sponges, followed by aP-PRP-ACP microparticles, aP-PRP-fHA and aP-PRP-sHA. \n\nSubsequently, the release rates reduced and different amounts of the GFs were \n\nreleased from the scaffolds over the 72 hours assay.  \n\nThe release of the most of the GFs occurred in concert with the degradation time \n\n(12 hours) of the structured ACP [Figure 31(b)]. \n\nThe structured ACP promoted proliferation of h-AdMSCs (Figure 33), which was \n\nevidence of the benefits of the porous structure, swelling and mechanical properties on \n\ncell adhesion and migration. \n\nThe importance of the stability of the porous structures for cultivation is clear from \n\ncomparing the performances of aP-PRP-ACP microparticles and aP-PRP-ACP sponges.  \n\nThe aP-PRP-ACP sponges showed better cell proliferation compared to aP-PRP \n\nalone. The effect was similar to aP-PRP-sHA [Figure 33(b)]. However, aP-PRP-ACP \n\nmicroparticles [(Figure 33(a)] showed reduced cell proliferation related to aP-PRP alone \n\nand fHA showed no cell proliferation attributed to the very small pore size and to high \n\n\n\n134 \n\n \n\nviscosity.  \n\naP-PRP fHA ACP microparticles\n\n0\n\n1x10\n4\n\n2x10\n4\n\n3x10\n4\n\n4x10\n4\n\n5x10\n4\n\n6x10\n4\n\n7x10\n4\n\n \n\n \n\nC\ne\n\nll\n n\n\nu\nm\n\nb\ne\n\nr/\n w\n\ne\nll\n\n 0 day\n\n 3 days\n\n 5 days\n\n 7 days\n\n 10 days\n\n \naP-PRP sHA ACP sponges\n\n0.0\n\n2.0x10\n4\n\n4.0x10\n4\n\n6.0x10\n4\n\n8.0x10\n4\n\n1.0x10\n5\n\n1.2x10\n5\n\n1.4x10\n5\n\n1.6x10\n5\n\n \n\n \n\nC\ne\n\nll\n n\n\nu\nm\n\nb\ne\n\nr/\n w\n\ne\nll\n\n 0 day\n\n 3 days\n\n 5 days\n\n 7 days\n\n 10 days\n\n \n\n(a) (b) \n\nFigure 33. The proliferation profiles of h-AdMSCs cultured in structured HA and ACP \n\ncomposite scaffolds as a function of time. (a) Microparticles (concentration of platelets in \n\nP-PRP = 393,000 pq/mm3) and (b) sponges (concentration of platelets in P-PRP = \n\n472,250 pq/mm3). Activated P-PRP alone was used as control.  \n\nThe micrographs of the composite scaffolds after 5 days of cultivation with h-\n\nAdMSCs are shown in Figure 34. The fibrin network formed on the surfaces of the \n\nmicroparticles [Figure 34(a)] and in the pores of the sponge [Figure 34(c)], providing a \n\nlarge area covered by fibrin fibers for cell adhesion and proliferation. The porous \n\nstructure of the microparticles could not be observed because they collapsed under the \n\ndehydration necessary to obtain the images.  \n\n \n\n  \n(a) (b) \n\n\n\n135 \n\n \n\n  \n\n(c) (d) \n\nFigure 34. Scanning electron microscopy images of HA and ACP composite scaffolds \n\nafter 5 days of cultivation of h-AdMSCs. (a) ACP microparticles; (b) fluid HA; (c) ACP \n\nsponges and (d) HA sponge. Original magnification is \u00d75,000 and the scale bar \n\nrepresents 3 \u00b5m. \n\n \n\n \n\nOsteogenic differentiation of h-AdMSCs was investigated after HA and ACP \n\ncomposite scaffolds induction at days 14. ALP activity, an early marker of osteogenic \n\ndifferentiation, was measured and shown in Figure 35. ALP activity was significantly \n\nhigher in the sponges and in ACP microparticles compared with the fHA (control) \n\nsuggesting stimulation of osteogenic differentiation. \n\nAC\nP \n\nsp\non\n\nge sH\nA\n\nAC\nP \n\nmi\ncr\n\nop\nar\n\ntic\nles fH\n\nA\nBl\n\nan\nk\n\n0.0\n\n0.2\n\n0.4\n\n0.6\n\n0.8\n\n1.0\n\n1.2\n\n*\n\n*\n\n \n\n \n\n \n\nA\nL\n\nP\n a\n\nc\nti\n\nv\nit\n\ny\n (\n\nA\nb\n\ns\no\n\nrb\na\n\nn\nc\n\ne\n i\nn\n\n 4\n0\n\n5\n n\n\nm\n) *\n\n \n\nFigure 35. Alkaline phosphatase (ALP) activity of h-AdMSCs-seeded cultured in the HA \n\nand ACP composite scaffolds on day 14. Blank = the reagents used in the assay only. \n\n\n\n136 \n\n \n\nStatistically significant differences from blank, n=3, *p<0.05. The concentration of \n\nplatelets in P-PRP was 473,500 pq/mm3. \n\n \n\n6.4. Discussion \n\nIn this study, we prepared novel composite scaffolds by associating aP-PRP to \n\n3D-ACP structured in microparticles or sponges.  \n\nACP is a crosslinked derivative of hyaluronic acid biocompatible, obtained by \n\norganocatalyzed auto-esterification (Bellini et al., 2001). ACP was used to increase the \n\nresidence time at the site of application and improve the physicochemical and \n\nmechanical properties of free HA, reducing the need for repeated applications. \n\nThe auto-esterification reaction of HA was performed with the quaternary \n\nammonium salt of HA (HA-TBA) as the intermediate. CMPI was used as activating agent \n\nof the carboxyl groups of HA according to Magnani et al. (2000). The anhydrous organic \n\nsolvent DMSO was used to minimize CMPI hydrolysis. CMPI reacts with a carboxyl \n\ngroup of HA, forms a pyridinium intermediate and releases a chloride ion, which is \n\nneutralized by tetrabutylammonium. Triethylamine neutralizes the released iodide ion. \n\nWhen no amine is added to the reaction medium, esterification occurs as the CMPI-\n\nactivated HA reacts with its own hydroxyl groups, forming an ester crosslink between the \n\nHA chains. The product is the auto-crosslinked HA, usually called ACP. \n\nThe ACP ensures that only the HA, a naturally occurring molecule that has a \n\nbiologic role, is released and eliminated through a known metabolic pathway during its \n\ndegradation in the organism (Mensitieri et al., 1996). According Ko\u00e7ak et al. (1999), ACP \n\nis slowly resorbed within 2 weeks and is excreted within 40 days by the kidneys. \n\nIn this work, ACP was structured in microparticles and sponges to create \n\ninjectable or solid scaffolds, respectively. Furthermore, aiming ensure better stability of \n\nthe fibrin network from PRP and control the release of GFs, we associate PRP with \n\nstructured ACP. \n\nP-PRP was obtained by centrifugation to about twice the concentration relative to \n\nWB. Haynesworth et al. (2002) showed that the proliferation and differentiation of adult \n\nmesenchymal stem cells are directly related to the platelet concentration. Platelet \n\n\n\n137 \n\n \n\nconcentrations ranged from 0.8 to 1.2 x 106 platelets/\u00b5L have been proposed to be \n\neffective for in vivo applications by Weibrich et al. (2004) and Fennis et al. (2005). In our \n\nbiological assays, we used around 0.5 x 106 platelets/\u00b5L due to the platelet \n\nconcentration factor (2x) inherent to the process used to obtain PRP. \n\nP-PRP was activated with autologous serum and Ca+2 in specific conditions to \n\nobtain fibrin network architectures with thin fibers with an average radius of \n\napproximately 65 nm. This type of fiber favors proliferation of h-AdMSCs due to its \n\nparacrine nature for the cells (Ye et al., 2013)  \n\nThe composite scaffolds were obtained by mixing the microparticles or \n\nembedding the sponges with immediately activated P-PRP to ensure that the fibrin \n\nnetwork was gelled in the scaffold.  \n\nThe structured ACP were characterized by physicochemical and mechanical \n\nproperties.  \n\nThe effect of ACP structured on biological performance of aP-PRP/ACP was \n\nevaluated by the kinetics of growth factor release (PDGF-AB and TGF-?1), h-AdMSCs \n\nproliferation and osteogenic differentiation by marker ALP. \n\nBeyond that, the scaffolds structured in sponges were characterized in terms of \n\nporosity, pore shape and interconnectivity, because these aspects are determinant for \n\ncellular colonization in vitro since they affect the diffusion of physiological nutrients and \n\ncells through the scaffold (Leong et al., 2003; Liu &amp; Ma, 2004). In addition, the high \n\nporosity (>90%) and the interconnectivity of pores compromised the mechanical and \n\nstructural stability of the scaffolds. According to Loh &amp; Choong (2013), these aspects \n\nmust be evaluated in accordance with the application and degradation rate of materials \n\nused. For order to guide tissue regeneration, the mechanical properties of scaffolds \n\nmust maintain the spaces required for cell in-growth and matrix elaboration during in \n\nvitro cultivation (Leong et al., 2003). The ACP sponges presented morphological \n\nproperties adequate to tissue engineering, whereas the mechanical properties indicated \n\napplication for soft tissues (Hollister, 2005).  \n\nThe scaffolds structured in microparticles were characterized by rheological and \n\nmechanical properties, which allowed injectable applications (Kablik et al., 2009). The \n\naverage diameter of the microparticles of 190 \u00b1 5 \u00b5m was supported by our previous \n\n\n\n138 \n\n \n\nwork on viscoelasticity and injection force (Shimojo et al., 2013). \n\nMoreover, we observed that h-AdMSCs cultured in ACP structured scaffolds \n\nproliferated ensuring the non-cytotoxicity. \n\nIt is well known that growth factors greatly contribute to wound healing and tissue \n\nregeneration at various stages of cell proliferation and differentiation (Stocum, 1997). \n\nMoreover, the fibrin converted from fibrinogen works in concert with these GF in \n\npromoting of tissue regeneration. \n\nHowever, the release of most of these growth factors from PRP occurs within the \n\nfirst hours after platelet activation and the gradual release of GF is essential for cascade \n\nof events involved on regeneration process (McCarrel &amp; Fortier, 2009).  \n\nTsay et al. (2005) showed in their in vitro study that PRP gels had a burst release \n\nof 80% of PDGF-AB and 82% of TGF-?1 in the medium after 24 h and a sustained \n\nrelease for another 14 days. Thus, to protect the GFs against proteolysis and to extend \n\nits activity, Tabata (2003) suggested combining the functions of scaffolds with controlled \n\nrelease technology.  \n\nScaffolds can be an interesting alternative to gradual release of GFs increasing \n\nthe effectiveness of PRP, and therefore, the regeneration of tissues.  \n\nAside from the barrier of the ACP structures, the interactions among GFs and the \n\nscaffolds also play an important role in the controlled release.  \n\nIn order to control the release of growth factors into scaffolds, chemical bonding \n\n(covalent and non-covalent) or physical interaction have been used (Tabata, 2003; King \n\n&amp; Krebsbach, 2012). However, the physical interactions using hydrophilic polymers has \n\nbeen the most commonly used approach to incorporate growth factors into scaffolds \n\n(King &amp; Krebsbach, 2012). Increasing the magnitude of these electrostatic interactions \n\ndecreases the initial burst release.  \n\nThe increase of the concentration of charge on scaffold is the common technique \n\nto increase the electrostatic attraction between growth factors and scaffolds. Although, \n\nsome studies reported that specific intermolecular interactions may be more effective at \n\nminimizing the initial burst release of growth factors when compared to non-specific \n\nelectrostatic interactions because these interactions are stronger and localized (Gao et \n\nal., 2001; Jha et al., 2009; Lee et al., 2011). \n\n\n\n139 \n\n \n\nBecause growth factors are generally basic proteins (isoelectric point > 7), in \n\nphysiological pH, they will have positive charge interacting ionically with the acidic \n\nspecies. (Hokugo et al.,2005; Okuda et al., 2003) \n\nThus, when a scaffold is prepared from a biodegradable polymer with negative \n\ncharges, such as hyaluronic acid and ACP, the growth factors with a positively charged \n\nsite interact electrostatically with the polymer and can be physically immobilized. If \n\nenvironmental changes, such as increasing in ionic strength, occurs, the immobilized \n\ngrowth factor will be released. However, if such an environmental change does not take \n\nplace, degradation of the scaffolds will be responsible for growth factors release.  \n\nHokugo et al. (2005) and Tabata &amp; Ikada (1998) reported the controlled release \n\nof TGF-?1 and PDGF from the hydrogel of acidic gelatin and demonstrated successful \n\nbone regeneration in rabbit and monkey skull defects, in marked contrast to defects \n\ntreated with free TGF-?1. According theses authors, TGF-?1 and PDGF are sorbed into \n\nthe acidic gelatin hydrogel mainly due to electrostatic interaction between the gelatin \n\nand GFs molecules. The immobilized growth factors were released from the hydrogel \n\nsince hydrogel degradation occurs. \n\nScaffold degradation plays an important role in controlled release in scaffolds that \n\nstrongly interact with growth factors. Generally, growth factor released from these \n\nscaffolds has been correlated to the rate of degradation of material after the initial burst \n\nrelease period (King &amp; Krebsbach, 2012).  \n\nIn vivo, it is known that the growth factors are normally stored in the body ionically \n\nbound to the acidic polysaccharides of the ECM. These bounds protects growth factors \n\nagainst denaturation and enzymatic degradation in vivo. In this case, the growth factors \n\nare released from the ECM complex due to polysaccharide degradation according to the \n\nneed (Tabata, 2003). \n\nGrowth factor released from degradable scaffolds can be tuned by controlling \n\neither factor diffusion or degradation. Fast degradation will lead to rapid release of \n\ngrowth factors, while slowing degradation will retard release of factors (Fournier et al., \n\n2003).  \n\nDespite the controlled release compared to aP-PRP alone, we observed that the \n\ninitial burst of release within 12 hours occurred in concordance with higher degradation \n\n\n\n140 \n\n \n\nof scaffolds. After this first step, both release and degradation rate are reduced, \n\nindicating that the GFs release is governed mainly by degradation of scaffolds. \n\nVan der Dolder et al. (2006) and Lucarelli et al. (2003) showed that PRP had a \n\nstimulating effect on the initial cell growth and differentiation of osteoblast-like cells and \n\nstromal cells. \n\nMoreover, according to Okuda et al. (2003), PRP modulates the cell proliferation \n\nby PDGF- and/or TGF-?1 mediated-mechanisms.  \n\nAlthough controversial, it is known that these effects are dependent of PRP \n\nconcentration. Choi et al. (2005) and Arpornmaeklong et al. (2004) showed in their \n\nstudies that the cell viability, proliferation and differentiation were affected by PRP \n\nconcentrations. The results obtained by Choi et al. showed that the viability and \n\nproliferation of alveolar bone cells were suppressed by high PRP concentrations, but \n\nwere stimulated by low PRP concentrations (1\u20135%). In contrast, Arpornmaeklong et al. \n\n(2004) showed that a high concentration of PRP inhibited osteoblastic differentiation and \n\nincreased the proliferation of pre-osteoblast-like cells or osteoblast precursor cells. PRP \n\nin low concentration did not show a marked effect on cell proliferation or differentiation. \n\nWe found that despite the high concentration of PRP (20% v/v) used in the \n\nassays, the presence of aP-PRP in the scaffolds was benefic on cell proliferation and \n\ndifferentiation.  \n\nWe also verified that the differences on structuration of scaffolds in microparticles \n\nor sponges produced a more prominent effect on cell proliferation of the composite \n\nscaffolds compared to stimulating of osteogenic differentiation.  \n\n \n\n6.5. Conclusions \n\n \n\nWe have demonstrated that the composite scaffolds released PDGF-AB and \n\nTGF-?1 from platelets mainly during the first 12 h. The released amounts depended on \n\nthe architecture of the structures and on the interactions of the GFs and HA. We also \n\nshowed the composite scaffolds in microparticles or sponges promoted h-AdMSCs \n\nproliferation and stimulated osteogenic differentiation as evaluated by ALP activity. \n\nThus, our results provide evidence that composite scaffolds with superior mechanical \n\n\n\n141 \n\n \n\nproperties are promising biomaterials for future clinical use in osteoarthritis therapies. \n\nThe flexibility to obtain injectable formulations (microparticles) or solid sponges opens \n\nperspectives to use the ACP-derived biomaterials in non-surgical applications, for \n\nsurgical implants or even for wound healing. \n\n \n\nAcknowledgments. The authors acknowledge the financial support from the National \n\nCouncil of Technological and Scientific Development (CNPq, Brazil). They also thank \n\nProf. Dr. Edvaldo Sabadini of the Chemical Institute (University of Campinas) for the use \n\nof the rheometer; Prof. Dr. William Dias Belangero and Dr. Ana Am\u00e9lia Rodrigues of the \n\nFaculty of Medical Sciences (University of Campinas) for assistance; and Dr. \u00c2ngela \n\nCristina Malheiros Luzo of the Haematology and Hemotherapy Center (University of \n\nCampinas) for the donation of h-AdMSCs. \n\n \n\n6.6. References \n \n\nAMABLE, P.R.; CARIAS, R.B.; TEIXEIRA, M.V.; PACHECO, I.C.; AMARAL, R.J.C.; \nGRANJEIRO, J.M.; BOROJEVIC, R. Platelet-rich plasma preparation for regenerative \nmedicine: optimization and quantification of cytokines and growth factors. Stem Cell \nResearch &amp; Therapy, vol.4, p.67-79, 2013.  \n\nANITUA, E. Plasma Rich in Growth Factors: Preliminary Results of Use in the \nPreparation of Future Sites for Implants. International Journal of Oral &amp; Maxillofacial \nImplants, vol.14, p.529-535, 1999. \n\nARPORNMAEKLONG, P.; KOCHEL, M.; DEPPRICH, R.; K\u00dcBLER, N.R.; W\u00dcRZLER, \nK.K. International Journal of Oral and Maxillofacial Surgery, vol.33, p.60-70, 2004. \n\nBELLINI, D.; PAPARELLA, A.; O\u2019REGAN, M.; CALLEGARO, L. Autocross-linked \nhyaluronic acid and related pharmaceutical compositions for the treatment of \narthrophaties. United States Patent: U.S. 6,251,876 B1, 2001. \n\nBELLUCO, C.; MEGGIOLARO, F.; PRESSATO, D.; PAVESIO, A.; BIGON, E.; DONA, \nM.; FORLIN, M.; NITTI, D.; LISE, M. Prevention of Postsurgical Adhesions with an \nAutocrosslinked Hyaluronan Derivative Gel. Journal of Surgical Research, vol.100, \np.217\u2013221, 2001. \n\nCHEN, W-H.; LO, W-C.; HSU W-C.; WEI, H-J.; LIU, H-Y.; LEE, C-H.; CHEN, S-YT.; \nSHIEH, Y-H.; WILLIAMS, D.F.; DENG, W-P. Synergistic anabolic actions of hyaluronic \nacid and platelet-rich plasma on cartilage regeneration in osteoarthritis therapy. \nBiomaterials, vol.xxx, p.1-9, 2014. \n\n\n\n142 \n\n \n\nCHOI, B-H.; ZHU, S-H.; KIM, B-Y.; HUH, J-Y.; LEE, S-H.; JUNG, J-H. Effect of platelet-\nrich plasma (PRP) concentration on the viability and proliferation of alveolar bone cells: \nan in vitro study. International Journal of Oral and Maxillofacial Surgery, vol.34, \np.420\u2013424, 2005. \n\nCIVININI, R.; MACERA, A.; NISTRI, L.; REDL, B.; INNOCENTTI, M. The use of \nautologous blood-derived growth factors in bone regeneration. Clinical Cases in \nmineral and bone metabolism, vol.8, n.1, p.25\u201331, 2011. \n\nCLARK, A.H.; ROSS-MURPHY, S.B. Structural and mechanical properties of \nbiopolymer gels. Advances in Polymer Science, vol.83, p.57-192, 1987. \n\nCOLLINS, M.N.; BIRKINSHAW, C. Hyaluronic Acid Solutions\u2014A Processing Method for \nEfficient Chemical Modification. Journal of Applied Polymer Science, vol.130, p.145-\n152, 2013.  \n\nCRANE, D.; EVERTS, P.A.M. Platelet Rich Plasma (PRP) Matrix Grafts, PPM \nCommunications, vol.8, p.1-10, 2008. \n\nDE ANGELIS, B.; LUCARINI, L.; ORLANDI, F.; AGOVINO, A.; MIGNER, A.; CERVELLI, \nV.; IZZO, V.; CURCIO, C. Regenerative surgery of the complications with Morton's \nneuroma surgery: Use of platelet rich plasma and hyaluronic acid. International Wound \nJournal, vol.10, n.4, p.372-376, 2012. \n\nDE BOULLE, K.; GLOGAU, R.; KONO, T.; NATHAN, M.; TEZEL, A.; ROCA-MARTINEZ, \nJ-X.; PALIWAL, S.; STROUMPOULIS, D. A Review of the Metabolism of 1,4-Butanediol \nDiglycidyl Ether-Crosslinked Hyaluronic Acid Dermal Fillers. Dermatologic Surgery, \nvol.39, p.1758-1766, 2013.  \n\nDE LACO, P.A.; STEFANETTI, M.; PRESSATO, D.; PIANA, S.; DONA, M.; PAVESIO, \nA.; BOVICELLI, L. A novel hyaluronan-based gel in laparoscopic adhesion prevention: \npreclinical evaluation in an animal model. Fertility and Sterility, vol.69, p.318\u2013323, \n1998. \n\nDE UGARTE, D.A.; MORIZONO, K.; ELBARBARY, A.; ALFONSO, Z.C.; ZUK, P.A.; \nZHU, M.; DRAGOO, J.L.; ASHJIAN, P.; THOMAS, B.; BENHAIM, P.; CHEN, I.; \nFRASER, J.; HEDRICK, M.H. Comparison of Multi-Lineage Cells from Human Adipose \nTissue and Bone Marrow. Cells Tissues Organs, vol.174, p.101\u2013109, 2003. \n\nFATHI, W.K. The Effect of Hyaluronic Acid and Platelet - Rich Plasma on Soft Tissue \nWound Healing: An Experimental Study on Rabbits. Al\u2013Rafidain Dental Journal, \nvol.12, n.1, p.115-125, 2012. \n\nFENNIS, J.P.M.; STOELINGA, P.J.W.; JANSEN, J.A. Reconstruction of the mandible \nwith an autogenous irradiated cortical scaffold, autogenous corticocancellous bone-graft \nand autogenous platelet-rich plasma: an animal experiment. International Journal of \nOral &amp; Maxillofacial Surgery, vol.34, p.158-166, 2005. \n\n\n\n143 \n\n \n\nFOSTER, T.E.; PUSKAS, B.L.; MANDELBAUM, B.R.; GERHARDT, M.B.; RODEO, S.A. \nPlatelet-Rich Plasma: From Basic Science to Clinical Applications. American Journal \nof Sports Medicine, vol.37, p.2259-2272, 2009. \n\nFOURNIER, E.; PASSIRANI, C.; MONTERO-MENEI, C.N.; BENOIT, J.P. \nBiocompatibility of implantable synthetic polymeric drug carriers: focus on brain \nbiocompatibility. Biomaterials, vol.24, p.3311-3331, 2003.  \n\nGAO, T.; KOUSINIORIS, N.; WINN, S.R.; WOZNEY, J.M.; ULUDAG, H. Enhanced \nretention of rhBMP-2 in vivo by thermoreversible polymers. Materwiss Werksttech, \nvol.32, n.12, p.953\u2013961, 2001. \n\nG\u00dcM\u00dcS?DERELIO?LU, M.; ADAY, S. Heparin-functionalized chitosan scaffolds for \nbone tissue engineering. Carbohydrate Research, vol.346, p.606-613, 2011. \n\nHAYNESWORTH, S.E.; KADIYALA, S.; LIANG, L.N.; BRUDER, S.P. Mitogenic \nstimulation of human mesenchymal stem cells by platelet release suggest a mechanism \nfor enhancement of bone repair by platelet concentrates. Presented at the 48th \nMeeting of the Orthopedic Research Society, Boston 2002. \n\nHOKUGO, F.; OZEKI, M.; KAWAKAMI, O.; SUGIMOTO, K.; MUSHIMOTO, K.; MORITA, \nS.; TABATA, Y. Augmented Bone Regeneration Activity of Platelet-Rich Plasma by \nBiodegradable Gelatin Hydrogel. Tissue Engineering, vol.11, n.7/8, p.1224\u20131233, \n2005.  \n\nHOLLISTER, S. J. Porous scaffold design for tissue engineering. Nature Materials, \nvol.4, p.518-590, 2005. \n\nIKEDA, S.; NISHINARI, K. Weak Gel-Type Rheological Properties of Aqueous \nDispersions of Nonaggregated K-Carrageenan Helices. Journal of Agricultural and \nFood Chemistry, vol.49, p.4436-4441, 2001. \n\nJHA, A.K.; HULE, R.A.; JIAO, T.; TELLER, S.S.; CLIFTON, R.J.; DUNCAN, R.L.; \nPOCHAN, D.J.; JIA, X. Structural Analysis and Mechanical Characterization of \nHyaluronic Acid-Based Doubly Cross-Linked Networks. Macromolecules, vol.42, p.537-\n546, 2009. \n\nKABLIK, J.; MONHEIT, G.D.; YU, L.; CHANG, G.; GERSHKOVICH, J. Comparative \nPhysical Properties of Hyaluronic Acid Dermal Fillers. Journal of dermatologic \nsurgery, vol.35, p.302-312, 2009. \n\nKHETAN, S.; BURDICK, J.A. Patterning network structure to spatially control cellular \nremodeling and stem cell fate within 3-dimensional hydrogels. Biomaterials, vol.31, \np.8228-8234, 2010. \n\nKING, W.J.; KREBSBACH, P.H. Growth factor delivery: How surface interactions \nmodulate release in vitro and in vivo. Advanced Drug Delivery Reviews, vol.64, n.12, \np.1239\u20131256, 2012. \n\n\n\n144 \n\n \n\nKO\u00c7AK, I.; \u00dcNL\u00dc, C.; AK\u00c7AN, Y.; YAKIN, K. Reduction of adhesion formation with \ncross-linked hyaluronic acid after peritoneal surgery in rats. Fertility and Sterility, \nvol.72, n.5, p.873-878, 1999. \n\nKON, E.; MANDELBAUM, B.; BUDA, R.; FILARDO, G.; DELCOGLIANO, M.; \nTIMONCINI, A.; FORNASARI, P.M.; GIANNINI, S.; MARCACCI, M. Platelet-Rich \nPlasma Intra-Articular Injection Versus Hyaluronic Acid Viscosupplementation as \nTreatments for Cartilage Pathology: From Early Degeneration to Osteoarthritis. \nArthroscopy: The Journal of Arthroscopic and Related Surgery, vol.27, n.11, \np.1490-1501, 2011.  \n\nLEE, K.; SILVA, E.A.; MOONEY, D.J. Growth factor delivery-based tissue engineering: \ngeneral approaches and a review of recent developments. Journal of the Royal \nSociety Interface, vol.8, p.153-170, 2011. \n\nLEONG, F.; CHEAH, C.M.; CHUA, C.K. Solid freeform fabrication of three-dimensional \nscaffolds for engineering replacement tissues and organs. Biomaterials, vol.24, \np.2363\u20132378, 2003. \n\nLIU, X.; MA, P.X. Polymeric Scaffolds for Bone Tissue Engineering. Annals of \nBiomedical Engineering, vol.32, n.3, p.477\u2013486, 2004. \n\nLOH, Q.L.; CHOONG, C.; Three-Dimensional Scaffolds for Tissue Engineering \nApplications: Role of Porosity and Pore Size. Tissue Engineering: Part B, vol.19, n.6, \np.485-503, 2013. \n\nLUCARELLI, E.; BECCHERONI, A.; DONATI, D.; SANGIORGIO, L.; CENACCHI, A.; \nDEL VENTO, A.M.; MEOTTI, C.; BERTOJA, A.Z.; GIARDINO, R.; FORNASARI, P.M.; \nMERCURI, M.; PICCI, P. Platelet-derived growth factors enhance proliferation of human \nstromal stem cells. Biomaterials, vol.24, p.3095-3100, 2003. \n\nMAGNANI, A.; RAPPUOLI, R.; LAMPONI, S.; BARBUCCI, R. Novel Polysaccharide \nHydrogels: Characterization and Properties. Polymers for Advanced Technologies, \nvol.11, p.488-495, 2000. \n\nMCCARREL, T.; FORTIER, L. Temporal Growth Factor Release from Platelet-Rich \nPlasma, Trehalose Lyophilized Platelets, and Bone Marrow Aspirate and Their Effect on \nTendon and Ligament Gene Expression. Journal of Orthopaedic Research, vol.27, \np.1033\u20131042, 2009. \n\nMENSITIERI, M.; AMBROSIO, L.; NICOLAIS, L.; BELLINI, D.; O' REGAN, M. \nViscoelastic properties modulation of a novel autocrosslinked hyaluronic acid polymer. \nJournal of Materials Science: Materials in Medicine, vol.7, n.11, p.695-698, 1996. \n\nMOSSMAM, T.J. A rapid colorimetric assay of cellular growth and survival: application to \nproliferation and cytotoxicity assays. Journal of Immunological Methods, vol.65, p.55-\n63, 1983 \n\n\n\n145 \n\n \n\nOKUDA K, KAWASE T, MOMOSE M, MURATA M, SAITO Y, SUZUKI H, WOLFF LF, \nYOSHIE H. Platelet-rich plasma contains high levels of platelet-derived growth factor \nand transforming growth factor-? and modulates the proliferation of periodontally related \ncells in vitro. Journal of Periodontology, vol.74, p.849-857, 2003. \n\nPAK, J. Compositions and methods for treating, preventing and alleviating bone or \ncartilage diseases. United States Patent: 2012/0,171,169 A1, 2012.  \n\nPEREZ, A.G.M.; LANA, J.F.S.D.; RODRIGUES, A.A.; LUZO, A.C.M.; BELANGERO, \nW.D.; SANTANA, M.H.A. Relevant Aspects of Centrifugation Step in the Preparation of \nPlatelet-Rich Plasma. ISRN Hematolology, vol.2014, p.1-8, 2014. \n\nPEREZ, A.G.M.; LICHY, R.; LANA, J.F.S.D.; RODRIGUES, A.A.; LUZO, A.C.M.; \nBELANGERO, W.D.; SANTANA, M.H.A. Prediction and Modulation of Platelet Recovery \nby Discontinuous Centrifugation of Whole Blood for the Preparation of Pure Platelet-\nRich Plasma. BioResearch Open Access, vol.2, p.307-314, 2013. \n\nPRASADAM. I.; MAO, X.; SHI, W.; CRAWFORD, R.; XIAO, Y. Combination of MEK-\nERK inhibitor and hyaluronic acid has a synergistic effect on anti-hypertrophic and pro-\nchondrogenic activities in osteoarthritis treatment. Journal of Molecular Medicine, \nvol.91, p.369-380, 2013. \n\nSCHANT\u00c9, C.E.; ZUBER, G.; HERLIN, C.; VANDAMME, T.F. Chemical modifications of \nhyaluronic acid for the synthesis of derivatives for a broad range of biomedical \napplications. Carbohydrate Polymer, vol.85, p.469-489, 2011. \n\nSHIMOJO, A.A.M.; PEREZ, A.G.M.; GALDAMES, S.E.M.; BRISSAC, I.C.S.; SANTANA, \nM.H.A. Performance of PRP Associated with Porous Chitosan as a Composite Scaffold \nfor Regenerative Medicine. The Scientific World Journal, vol.2015, p.1-12, 2015. \n\nSHIMOJO, A.A.M.; PIRES, A.M.B.; TORRE, L.G.; SANTANA, M.H.A. Influence of \nParticle Size and Fluid Fraction on Rheological and Extrusion Properties of Crosslinked \nHyaluronic Acid Hydrogel Dispersions. Journal of Applied Polymer Science, vol.128, \nn.3, p.2180-2185, 2013. \n\nSHU, X.Z.; LIU, Y.; PALUMBO, F.S.; LUO, Y.; PRESTWICH, G.D. In situ crosslinkable \nhyaluronan hydrogels for tissue engineering. Biomaterials, vol.25, p.1339-1348, 2004. \n\nSILVERSTEIN, R.M.; BASSLER, G.C.; MORRILL, T.C. Spectrometric identification of \norganic compounds. 3rd ed. New York: John Wiley, 1974. \n\nSOLCHAGA, L.A.; TEMENOFF, J.S.; GAO, J.; MIKOS, A.G.; CAPLAN, A.I.; \nGOLDBERG, V.M. Hyaluronic Acid-B based Polymers as Cell Carriers for Tissue-\nEngineered Repair of Bone and Cartilage. Osteoarthritis and Cartilage, vol.13, n.4, \np.297-309, 2005. \n\nSTERN, S.; LINDENHAYN, K.; SCHULTZ, O.; PERKA, C. Cultivation of porcine cells \nfrom the nucleus pulposus in a fibrin/hyaluronic acid matrix. Acta Orthopaedica \n\n\n\n146 \n\n \n\nScandinavica, vol.71, n.5, p.496-502, 2000. \n\nSTOCUM, D.L. Frontiers in medicine: regeneration. Science, vol.276, p.59-87, 1997. \n\nTABATA, Y. Tissue regeneration based on growth factor release. Tissue engineering, \nvol.9, n.1, p.S5-15, 2003. \n\nTABATA, Y.; IKADA, Y. Protein release from gelatin matrices. Advanced Drug Delivery \nReviews, vol.31, p.287-301, 1998. \n\nTANG. S.; VICKERS, S.M.; HSU, H-P.; SPECTOR, M. Fabrication and characterization \nof porous hyaluronic acid\u2013collagen composite scaffolds. Journal of Biomedical \nMaterials Research, vol.82A, p.323\u2013335, 2007. \n\nTSAY, R.C.; VO, J.; BURKE, A.; EISIG, S.B.; LU, H.H.; LANDESBERG, R. Differential \nGrowth Factor Retention by Platelet-Rich Plasma Composites. Journal of Oral and \nMaxillofacial Surgery, vol.63, p.521-528, 2005. \n\nVAN DER DOLDER, J.; MOOREN, R.; VLOON, A.P.G.; STOELINGA, P.J.W.; JANSEN, \nJ.A. Platelet-Rich Plasma: Quantification of Growth Factor Levels and the Effect on \nGrowth and Differentiation of Rat Bone Marrow Cells. Tissue Engineering, vol.12, n.11, \np.3067-3073, 2006. \n\nWANG, C.; LI, J.; YAO, F. Application of Chitosan-Based Biomaterials in Tissue \nEngineering. In: YUJI, Y. (Eds.). Chitosan-Based Hydrogels: Functions and \nApplications. New York: CRC Press, p.424, 2011.  \n\nWEIBRICH, G.; HANSEN, T.; KLEIS, W.; BUCH, R.; HITZLER, W.E. Effect of platelet \nconcentration in platelet-rich plasma on peri-implant bone regeneration. Bone, vol.34, \np.665-671, 2004. \n\nYE, L.; ZIMMERMANN, W-H.; GARRY, D.J.; ZHANG, J. Patching the Heart: Cardiac \nRepair from Within and Outside. Circulation Research, vol.113, n.7, p.1-28, 2013. \n\nYERUSHALMI, N.; ARAD, A.; MARGALIT, R. Molecular and cellular studies of \nhyaluronic acid-modified liposomes as bioadhesive carriers for topical drug delivery in \nwound healing. Archives of Biochemistry and Biophysics, vol.313, n.2, p.267-273, \n1994. \n\n  \n\n\n\n147 \n\n \n\nCAP\u00cdTULO 7 \u2013 STRUCTURATION OF HIGH \nMOLECULAR WEIGHT HYALURONIC ACID IN \n\nMICROPARTICLES OR SPONGES IMPROVES ITS \n\nPERFORMANCE WHEN ASSOCIATED TO \n\nPLATELET-RICH PLASMA \n\nArtigo submetido ao peri\u00f3dico Trends in Biomaterials &amp; Artificial Organs. \n\n \n\nAndr\u00e9a Arruda Martins Shimojoa, Sofia Elisa Moraga Galdamesa, Adriana da Silva \n\nSantos Duarteb, Lucas Martins Pinaa, Ana Am\u00e9lia Rodriguescb, \u00c2ngela Cristina \n\nMalheiros Luzob, William Dias Belangeroc and Maria Helena Andrade Santanaa,* \n\n \n\naDepartment of Engineering of Materials and Bioprocesses, School of Chemical \n\nEngineering, University of Campinas, Campinas, SP, Brazil. \n\nbHaematology and Hemotherapy Center, Umbilical Cord Blood Bank, University of \n\nCampinas, Campinas, SP, Brazil \n\ncDepartment of Orthopedics and Traumatology, Faculty of Medical Sciences, University \n\nof Campinas, Campinas, SP, Brazil. \n\n \n\n*Correspondence to: Maria Helena Andrade Santana, telephone: +55-19-35213921, \n\nFAX: +55-19-35213890, e-mail: mariahelena.santana@gmail.com \n\n \n\nAbstract. Nowadays, high molecular weight hyaluronic acid (HA) has been widely used \n\nassociated with platelet-rich plasma (PRP) in regenerative medicine. This study aimed \n\nto investigate in vitro the association of HA crosslinked with 1,4-butanediol diglycidyl \n\nether (BDDE), structured in microparticles (mHA-BDDE) and sponges (sHA-BDDE), with \n\nPRP as composite scaffolds for growth factors release, proliferation of human adipose-\n\nderived mesenchymal stem cells (h-AdMSCs) and differentiation by osteogenic marker \n\nalkaline phosphatase (ALP). The reason for using BDDE is to increase the residence \n\nmailto:mariahelena.santana@gmail.com\n\n\n148 \n\n \n\ntime in vivo, improve the mechanical stability of free HA (fHA) and provide a larger \n\nsurface area for cell proliferation and differentiation in a new tissue. PRP was obtained \n\nvia controlled centrifugation of whole blood and activated with autologous serum and \n\ncalcium. The results showed that structuration benefited the physicochemical and \n\nmechanical properties compared to fHA. Both structures were non-cytotoxic. The \n\nrelease of GFs from PRP was lower than fHA but higher than the fibrin network. The \n\neffects on the proliferation of seeded mesenchymal cells were not intense. However, a \n\nremarkable activity of the osteogenic marker alkaline phosphatase was observed. We \n\nconcluded the structuration of HA provides injectable (mHA-BDDE) or solid (sHA-BDDE) \n\nformulations with better properties compared to fHA, which associated to PRP may be \n\npromising for regeneration of bone tissue. \n\n \n\nKeywords: Platelet-rich plasma; hyaluronic acid; 1,4-butanediol diglycidyl ether; \n\nmicroparticles; sponges. \n\n \n\n7.1. Introduction \n\n \n\nPlatelet Rich Plasma (PRP) is an autologous product prepared from whole blood, \n\nconsisting of a concentrate of platelets, leukocytes, protein and other components \n\ndispersed in a small fraction of plasma (Marx et al., 1998; Marx, 2004). Platelets and \n\nleukocytes are sources of growth factors (GFs) which promote wound healing and tissue \n\nregeneration, through proliferation and differentiation of specific cells.  \n\nIn the last decade, PRP has been widely used in medical practice in various \n\ntherapies, especially in orthopedics and sports medicine. This is mainly due to its ability \n\nto regenerate bone lesions, tendons and cartilage, often avoiding surgical interventions \n\n(Lana et al., 2014). \n\nPure PRP, named as P-PRP, is rich in platelets and poor in leukocytes, according \n\nto the classification of Ehrenfest et al. (2009). \n\nPreparation of PRP is composed of two main steps: concentration and activation. \n\nThe fibrin network is formed by the activation of platelets and the breakdown of \n\nfibrinogen from plasma. The fibrin network is also a weak gel, which acts as a barrier for \n\n\n\n149 \n\n \n\nrelease of growth factors and also as a natural scaffold for proliferation and \n\ndifferentiation of mesenchymal cells.  \n\nHowever, the fibrin network is fragile, has low viscosity and viscoelasticity, and \n\nalso undergoes rapid degradation in a biological environment. In addition to this, the \n\nreleased GFs have a half-life of only few hours.  \n\nIn order to overcome these limitations, in the last decade the PRP has been used \n\nin orthopedics, associated with free hyaluronic acid (HA) of high molecular weight (Pak, \n\n2012; De Angelis et al., 2012; Chen et al., 2014). Clinical studies in literature have \n\nshown that tissue regeneration with free HA associated with PRP is greater than HA or \n\nPRP alone (Pak, 2012; De Angelis et al., 2012). Furthermore, the presence of the HA in \n\nthe formulation is responsible for the reduction of pain resulting from inflammation \n\ncaused by injury in the application of PRP (Fathi, 2012; Chen et al., 2014). \n\nIn our previous studies, we observed that free HA, when combined with PRP, \n\ninteracted with fibrin network improving their mechanical and viscoelastic properties and \n\npromoting the gradual release of GFs. However, the low mechanical stability of the free \n\nHA and the need for repeated injections in vivo have limited their application in \n\nregenerative medicine. \n\nThus, aiming to overcome these limitations, we structured HA in microparticles or \n\nsponges, which were chemically crosslinked by 1,4-butanediol diglycidyl ether (BDDE) \n\nfor stabilization. The microparticles must meet the requirements of injectable \n\nformulations while the sponges works as solid scaffolds.  \n\nOur hypothesis is that by improving the structural and mechanical properties of \n\nthe fibrin network we benefit the proliferation and differentiation of h-AdMSCs, thereby \n\nincreasing the efficiency of the PRP in tissue regeneration.  \n\nHA crosslinked by BDDE has been widely used in medical and cosmetic area, \n\nmainly as dermal fillers on tissue augmentation and regeneration (Allemann &amp; \n\nBaumann, 2008; Andre, 2004; Beasley et al., 2009; Falcone &amp; Berg, 2008) and also as \n\na viscosupplement for joint diseases (Schant\u00e9 et al., 2011; Malson &amp; Lindqvist, 1987).  \n\nHA can be crosslinked by BDDE under alkaline conditions, in which it reacts with \n\nthe deprotonated hydroxyl group of HA to form a stable covalent ether linkage between \n\nHA and the epoxide groups of the crosslinker (Kenne et al., 2013; Malson &amp; Lindqvist, \n\n\n\n150 \n\n \n\n1986; Garg &amp; Hales, 2004; Schant\u00e9 et al., 2011). Its ability to crosslink is attributed to \n\nthe reactivity of the epoxide groups present at the two ends of the molecule (De Boulle \n\net al., 2013).  \n\nBesides the biodegradability and stability of the ether bond relative to the ester or \n\namide bond, BDDE shows lower toxicity (rat oral LD50=1134 mg/kg) compared to others \n\ncrosslinkers (Yeom et al., 2010). \n\nLa Gatta et al. (2013) obtained HA sponges for soft tissues regeneration by \n\nlyophilization and then reacted with BDDE in heterogeneous conditions. The scaffolds \n\nshowed promising physicochemical and mechanical properties, good cellular viability, \n\nhigh stability in cell culture and for enzymatic degradation.  \n\nZawko et al. (2009) engineered novel dual-crosslinked hyaluronic acid hydrogel \n\nscaffolds with photopatterned anisotropic swelling using BDDE and glycidyl \n\nmethacrylate, but only the physicochemical and mechanical properties were evaluated. \n\nBesides the limited number of studies with HA-BDDE, as far as we know, there is \n\nnone report in the literature on the use of HA-BDDE associated to PRP for applications \n\nin tissue regeneration.  \n\n  \n\n \n\n7.2. Experimental Section  \n \n\n7.2.1. Materials \n\nHA in sodium form (MW = 2 x 106 Da) was obtained from Spec-Chem Ind. \n\n(Nanjing, China). 1,4-Butanediol diglycidyl ether (BDDE) was obtained from Aldrich \n\nChemical Co. (Milwaukee, WI, USA). All other reagents were purchased from Synth\u00ae \n\n(Diadema, SP, Brazil) unless specified otherwise. PRP was prepared from whole blood \n\n(WB) of donors, who were healthy individuals aged between 30 and 40 years old and \n\npreviously assessed through clinical examinations. The human adipose tissue-derived \n\nmesenchymal stem cells, h-AdMSCs, were provided by Haematology and Hemotherapy \n\nCenter, Umbilical Cord Blood Bank, University of Campinas. All biological experiments \n\nwere approved by the Ethics Committee of the Medical Sciences School of the \n\n\n\n151 \n\n \n\nUniversity of Campinas (UNICAMP; CAAE: 0972.0.146.000-11). \n\n \n\n7.2.2. Methods \n\n7.2.2.1. Preparation and characterization of HA crosslinked with BDDE \n\nThe plain hydrogel of HA/BDDE was prepared in a 1:1 ratio by weight, according \n\nto the methodology described by Wang (2005). Sodium hyaluronate was dissolved in \n\n0.25 mol.L-1 NaOH aqueous solution in a stirrer vessel at room temperature for 4 hours. \n\nBDDE was added to the solution under stirring, and then the solution was kept at 50\u00b0C \n\nfor four hours. Then, phosphate buffer saline solution (PBS, pH 7.4) (LB Laborclin, \n\nPinhais, PR, Brazil) was added to the stirrer vessel to wash and hydrate the obtained \n\ngel. After 2.5 days, washing with six changes of fresh PBS, the gel was centrifuged to \n\nremove free PBS. The HA-BDDE crosslinking was characterized by Fourier-transform \n\ninfrared (FTIR) in a Thermo Scientific Nicolet model 6700 (Thermo Scientific Nicolet\u2122, \n\nWaltham, MA, USA). Measurements were made in the ATR mode with accessory \n\nSMART OMNI-SAMPLER, in the spectral range of 4000-675 cm-1 with a resolution of 4 \n\ncm-1 over 64 scans.  \n\n \n\n7.2.2.2. Preparation of structured HA-BDDE \n\nThe HA-BDDE structured in microparticles (mHA-BDDE) or sponges (sHA-BDDE) \n\nwere prepared from HA-BDDE plain hydrogel swollen in Milli-Q water. The \n\nmicroparticles were obtained by shearing in an Ultra-Turrax T25 homogenizer (IKA \n\nLabortechnik, Staufen, Germany) at 18,000 rpm by 20 minutes (Shimojo et al., 2013). \n\nThe sponges were initially placed in polystyrene 48-well microplates (TPP\u00ae, \n\nTrasadingen, Switzerland), frozen at -20\u00b0C and lyophilized at controlled temperature of \n\napproximately -30\u00b0C for 48 hours (Shimojo et al., 2015). Non-crosslinked sponges (sHA) \n\nwas also prepared as control, as well as fluid HA (fHA).  \n\n \n\n7.2.3. Characterization of the structures \n\nDegradation time. The gravimetric method described by Tang et al. (2007) was \n\nused to estimate the degradation time in PBS at 37\u00b0C of the structured HA-BDDE \n\n\n\n152 \n\n \n\nthrough measurements of remaining weight. \n\n \n\nCell compatibility. The compatibility of the structured HA-BDDE with h-AdMSCs \n\ncells was carried out by exposing them to cell culture at 37\u00b0C for 24 hours. Then, cell \n\nviability was evaluated by using an MTT assay (3-[4,5-dimethyl-thiazol-2-yl]-2,5-\n\ndiphenyltetrazolium bromide) (MTT, Molecular Probes), according to modified Mosmann \n\n(1983) method. The MTT assay is a colorimetric test based on the reduction of yellow \n\ntetrazolium salt into a purple formazan product in presence of cells (G\u00fcm\u00fcs?derelio?lu &amp; \n\nAday, 2011). \n\n \n\n7.2.3.1. mHA-BDDE \n\nAverage diameter. The average diameter was measured for the mHA-BDDE \n\nsuspended in water. The measurements were performed in a Malvern Mastersizer S \n\nlaser diffraction (Malvern Instruments Ltd, Malvern, UK). The standard deviation was \n\ncalculated from five consecutive measurements. \n\n \n\nRheology. Rheological measurements of mHA-BDDE were performed in steady \n\nand oscillatory regimes at 25\u00b0C using a parallel plate geometry of 20 mm. Steady shear \n\nmeasurements were obtained at shear rates of 0.1-50 s-1. Oscillatory measurements \n\nwere conducted in the linear region with a stress of 1.188 Pa and in the frequency range \n\nof 0.01 to 10 Hz. All rheological measurements were performed using the swollen mHA-\n\nBDDE equilibrated in Milli-Q on a rheometer Haake RheoStress 1 (Haake, Karlsruhe, \n\nGermany). \n\n \n\nExtrusion force. Initially the mHA-BDDE were loaded in 1 mL plastic syringes with \n\n30 gauge needles. Afterward, the force required to extrude was measured in a MTS 810 \n\nServo-hydraulic Universal Testing Machine (MTS Systems Corporation, Eden Prairie, \n\nMN, USA) (load cell 1.5 kN) at 25\u00b0C at a 5.0 mm/min extrusion rate. \n\n \n\nSwelling ratio (SR). Swelling measurements of the HA-BDDE microparticles were \n\nperformed in PBS at 37\u00b0C after 72 h of incubation, according to Shu et al. (2004). SR \n\n\n\n153 \n\n \n\nwas calculated using the following Equation (1). \n\n \n\nSR =\nWs\n\nWd\n                                                                                                            Equation (1) \n\n \n\nwhere ws and wd are the weights of the scaffolds in the swelled state and the dry state, \n\nrespectively. \n\n \n\n7.2.3.2. sHA-BDDE \n\nMorphology and pore size. The morphology of sHA-BDDE was evaluated by \n\nscanning electron microscopy (SEM) using an LEO 440i Electron Microscopy/Oxford \n\n(Cambridge, England) operated at 5 kV accelerating voltage. The sponges were gold-\n\ncoated using a sputter coater POLARON SC7620, VG Microtech (Uckfield, England) for \n\n180 s at a current of 3 mA. Pore size (n=20) was measured using Image J 1.47t. \n\n \n\nSwelling ratio (SR). The swelling measurements of the HA-BDDE sponges was \n\ndetermined by swelling the freeze-dried HA-BDDE sponges (with known weights) in \n\nPBS at 37\u00b0C for 24 hours. The swollen HA-BDDE sponges were weighed after the \n\nremoval of excess of water by keeping the surfaces on a filter paper. The swelling ratio \n\nwas also calculated using Equation (1). \n\n \n\nPorosity. The porosity (?) of the sHA-BDDE was determined according to the \n\nprotocol used by Wang et al. (2003), and calculated by Equation (2). \n\n \n\n? (%) =  \nVm?(\n\nWm\n\n?\n)\n\nVm\n . 100                                                                                      Equation (2) \n\n \n\nwhere ?m is the total volume of sHA-BDDE (cm3), ? is the density of HA (1.0016 g/cm3) \n\nand wm is the weight of sHA-BDDE (g). Values are expressed as the mean \u00b1 standard \n\ndeviation (n=3). \n\n \n\nMechanical Properties. Mechanical compression tests of sHA-BDDE (? = 3) were \n\n\n\n154 \n\n \n\nperformed using a Universal Testing Machine, MTS model 810-Flex Test 40 (MTS \n\nSystems Corporation, Eden Prairie, MN, USA) up to 60% strain, according to Correia et \n\nal. (2011). The testing machine was equipped with a 1.5 kN load cell, and the loading \n\nrate was 5 mm/min. Young\u2019s modulus was calculated in the initial linear section of the \n\nstress-strain curve, when the strain was lower than 10%.  \n\n \n\n7.2.4. PRP preparation and activation \n\nThe P-PRP (rich in platelets and poor in leukocytes) was prepared according to \n\nPerez et al. (2013). Briefly, whole blood (WB) was collected into 3.5 mL vacuum tubes \n\n(Vacuette\u00ae, Campinas, SP, Brazil) containing sodium citrate 3.2% (w/v) as an \n\nanticoagulant. WB was initially centrifuged in a Rotina 380R centrifuge (Hettich\u00ae \n\nZentrifugen, Tuttlingen, Germany) at 100 ? g for 10 minutes, at 25\u00b0C, After the formation \n\nof three layers (a bottom layer composed mainly of red blood cells (RBCs); an upper \n\nlayer composed of plasma, platelets and some WBCs; and an intermediate layer, or \n\nbuffy coat, composed mostly of WBCs), only the upper layer was collected to obtain P-\n\nPRP. The concentration of platelets, WBCs and RBCs in WB and P-PRP was \n\ndetermined using the ABX Micros ES 60 hematology analyser (HORIBA ABX \n\nDiagnostics, Montpellier, France). \n\nAutologous serum (Ser) and 10% (w/v) CaCl2 solution were used as agonists to \n\nactivate the PRP preparations (aP-PRP). The Ser was prepared by collecting 5 mL of \n\nWB in tubes without anticoagulant. After 30 minutes for clot formation, WB was \n\ncentrifuged at 2000 ? g for 10 minutes The conditions of agonist/PRP=20%; Ser/CaCl2 \n\nvolumetric ratio=9 were used for getting an architecture of the fibrin network composed \n\nof thin fibers (average radius 65 nm), according to Perez et al., 2014).  \n\n \n\n7.2.5. Release of growth factors  \n\nImmediately after activation, aP-PRP was mixed with the mHA-BDDE or \n\nembedded by dripping into the sHA-BDDE, both in 48-well microplates. In all biological \n\nassays performed in this work, the following proportions of aP-PRP to structured HA-\n\nBDDE were used: aP-PRP: microparticles = 200 \u00b5L:100 mg and aP-PRP: sponges = \n\n\n\n155 \n\n \n\n200 \u00b5L:10 mg in order to guarantee the same proportion PRP to HA. After 1 hour of \n\ngelation, 1.5 mL of Dulbecco's Modified Eagle's Medium (DMEM) (Gibco, Grand Island, \n\nNY, USA) with low glucose concentration was added to the composed hydrogels. The \n\nmicroplates were maintained in an incubator with 5% CO2 over the assays. After \n\nsampling, the volume was replaced with fresh medium at 3, 6, 12, 48 and 72 hours \n\nwithout removing the hydrogels from the wells. The samples were stored at -80\u00b0C until \n\nall samples were collected. The concentrations of the released GFs, platelet-derived \n\ngrowth factor AB (PDGF-AB) and transforming growth factor beta 1 (TGF-?1), were \n\nmeasured using enzyme-linked immunosorbent assay (ELISA) kits (R&amp;D Systems, \n\nMinneapolis, MN, USA) according to the manufacturer\u2019s instructions and specifications. \n\n \n\n7.2.6. Association of mHA-BDDE or sHA-BDDE with P-PRP and h-\n\nAdMSCs-seeding \n\nThe pre-cultured h-AdMSCs were trypsinized and resuspended in P-PRP to a \n\nfinal cell concentration of 1 x 104 cells/mL. P-PRP containing h-AdMSCs was activated \n\nand immediately pipetted onto the surface of the microparticles or embedded into the \n\nsponges, both in 24-well tissue culture plates. The plates were kept at room temperature \n\nfor 45 minutes for consolidation of the fibrin network. The cells seeded in fHA or in sHA \n\nwere used as controls.  \n\n \n\n7.2.7. h-AdMSCs cultivation \n\nCultivation of the h-AdMSCs was carried out in 24-well tissue culture plates, by \n\nadding 1 mL of the culture medium (DMEM) to the seeded structures (n=4). The culture \n\nwas maintained at 37\u00b0C for 10 days. Cell proliferation was quantified using the thiazolyl \n\nblue tetrazolium bromide (MTT) assay. At 2, 4, 7 and 10 cultivation days, the substrates \n\nwere removed and transferred to 24-well plates. MTT (1 mL of 1 mg/mL) was then \n\nadded, and the cultivation proceeded at 37\u00b0C for 4 hours. The MTT solution was then \n\ndiscarded, and 1 mL of DMSO was added to dissolve the purple formazan crystals. The \n\nsamples were shaken at 120 rpm for 30 min to ensure homogeneous dissolution of the \n\nformazan dye, and then 200 \u00b5L of each sample was transferred to a 96-well plate. \n\n\n\n156 \n\n \n\nOptical density was measured at 595 nm using a microplate reader (FilterMax F5 \n\nMolecular Devices, Sunnyvale, CA, USA). The cell concentration was obtained from the \n\npreviously built calibration curve.  \n\n \n\n7.2.8. Images of the cell-seeded composite scaffolds \n\nImages of cell-seeded composite scaffolds were obtained by scanning electron \n\nmicroscopy after 5 days of h-AdMSCs proliferation. The substrates were fixed in a \n\nsolution of 4% paraformaldehyde and 2.5% glutaraldehyde in PBS for 2 hours. The \n\nsamples were than dehydrated in ethanol for 15 min intervals in aqueous 50%, 70%, \n\n95% and 100% ethanol solutions (2x) and dried at the critical point dryer BAL-TEC CPD \n\n030 (BAL-TEC\u00ae, Schalksm\u00fchle, Germany). After gold coating in a Sputter Coater \n\nPOLARON, SC7620 (VG Microtech, Ringmer, UK), the samples were visualized with a \n\nscanning electron microscope Leo440i (LEO Electron Microscopy/Oxford, Cambridge, \n\nUK) with an accelerating voltage of 20 kV. \n\n \n\n7.2.9. Induction of osteogenic differentiation \n\nThe seeded h-AdMSCs were induced to differentiate into the osteogenic lineage \n\nby providing the osteogenic medium containing DMEM-LG supplemented with 10% \n\nFBS, 1% ?-glycerol-phosphate (Sigma-Aldrich, St. Louis, MO, USA), 1% L-ascorbic acid \n\n(Sigma-Aldrich, St. Louis, MO, USA), 1% dexamethasone (Sigma-Aldrich, St. Louis, \n\nMO, USA) and 1% Penicillin/Streptomycin solution (Gibco, Grand Island, NY, USA). The \n\nmedium was changed every 7 days.  \n\n \n\n7.2.10. Alkaline phosphatase activity (ALP) \n\nThe level of alkaline phosphatase (ALP) activity produced by h-AdMSCs was \n\ndetermined as an osteogenic marker on day 14 under differentiation conditions. Two \n\nhundred microliters of the supernatant was collected and mixed with 200 ?L of p-\n\nnitrophenyl phosphate (SIGMAFAST\u2122 p-Nitrophenyl phosphate Tablets, Sigma, Saint \n\nLouis, MI, USA) as substrate and incubated at room temperature for 30 minutes. \n\nAbsorbance was read immediately on a spectrophotometer at 405 nm. \n\n\n\n157 \n\n \n\n \n\n7.2.11. Statistical analysis \n\nEach experiment was carried out in triplicate unless otherwise specified. All \n\nresults are presented as the mean \u00b1 standard deviation (SD). The experimental data \n\nfrom all the studies were analyzed using Analysis of Variance (ANOVA). Statistical \n\nsignificance was set to p-value ? 0.05.  \n\n \n\n7.3. Results and Discussion \n\n \n\n7.3.1. Experimental design \n\nIn this study, we associated P-PRP to HA-BDDE structured into microparticles or \n\nsponges. First, the synthesized HA-BDDE was characterized by FT-IR to guarantee the \n\nabsence of toxics non-bound chemicals before building the microparticles or sponges. \n\nSecondly, the structural and mechanical properties of the structured HA-BDDE were \n\ncharacterized and evaluated for cell compatibility. The association was obtained by \n\nmixing the microparticles or embedding the sponges with immediately activated P-PRP \n\nin a 24 well microplates. P-PRP was obtained by centrifugation to about twice the \n\nconcentration relative to WB. Activation of P-PRP was performed by Ca+2 and \n\nautologous serum to obtain fibrin network architectures with thin fibers and an average \n\nradius of approximately 65 nm. This type of fiber favors proliferation of h-AdMSCs due to \n\nits paracrine nature for the cells. The release of the GFs (PDGF-AB and TGF-?1) was \n\nevaluated in DMEM culture medium. Cell seeded in the fibrin network alone or \n\nassociated with HA-BDDE structured into microparticles or sponges was obtained by \n\nadding pre-cultured h-AdMSCs to P-PRP before activation. An in vitro examination of \n\nkinetics of h-AdMSCs proliferation was determined after 10 days of cultivation, whereas \n\nALP activity as an osteogenic marker was evaluated under differentiation conditions \n\nafter 14 days of cultivation. \n\n \n\n7.3.2. Chemical modifications  \n\nThe chemical modifications of HA crosslinked with BDDE were identified in FTIR \n\n\n\n158 \n\n \n\nspectra of the HA-BDDE by the characteristic peak for BDDE appearing in 1310 cm-1, \n\nwhich was attributed to the stretch ether (?C-O, 1320-1100 cm-1) and in 1460 cm-1 \n\nattributed to CH2 deformation (Silverstein et al., 1974; Kim et al., 2014). These results \n\nensure the absence of free BDDE before structuring in microparticles or sponges. \n\n \n\n7.3.3. Physicochemical and mechanical properties of HA forms  \n\nAt physiological pH, the HA and its derivatives are hydrated extensively by water \n\nbecause the water forms hydrogen bonds with the N-acetyl and carboxyl groups. The \n\ndipole attraction of the hydrogen bond to the carboxyl group results in HA\u2019s affinity for \n\nretaining water. The swelling capacity is dependent upon concentration, crosslinking \n\ndensity, and the processes used for hydration.  \n\nThe crosslinking reduced the water swelling in the HA-BDDE structures providing \n\nstability to HA (highly soluble), although they still exhibit high levels of water uptake, as \n\nshown in Table 4 by the SR values: 43.2 \u00b1 0.7 (sHA-BDDE) and 28 \u00b1 2 (mHA-BDDE). \n\nThe larger hydration capacity of the sponges was attributed to its porous structure, \n\nwhich can retain unbound water (Collins &amp; Birkinshaw, 2008; Shimojo et al., 2014).  \n\n \n\nTable 4. Physicochemical and mechanical properties of HA in the forms: free (fHA), \n\nstructured in sponge (sHA), crosslinked with BDDE and structured in sponges (sHA-\n\nBDDE) or microparticles (mHA-BDDE). \n\nHA form* SR Young\u2019s moduli \n\n(kPa) \n\nG\u2019 (Pa) \n\nat 1 Hz \n\nExtrusion force \n\n(N) \n\nPore Size \n\n(\u00b5m) \n\nPorosity (%) Particle size \n\n(\u00b5m) \n\nfHA - - * 4.3 \u00b1 0.1 - - - \n\nsHA -&lt;10 - - - 97.8 \u00b1 0.3 - \n\nsHA-BDDE 43.2 \u00b1 0.7 14 \u00b1 5 - - 218 \u00b1 24 97.4 \u00b1 0.1 - \n\nmHA-BDDE 28 \u00b1 2 - 3181 78 \u00b1 7 - - 160 \u00b1 18 \n\n*Forms prepared from 1% fHA. \n**Newtonian behavior. \n\n \n\nThe stability in PBS of the structures was studied by means of gravimetric \n\nanalyses in terms of remaining weight up to 14 days incubation [Figure 36(a)]. Most of \n\nthe weight reduction (~40%) of HA-BDDE sponges was observed until the seventh day, \n\nwhereas most of the weight reduction (~40%) of HA-BDDE microparticles was observed \n\n\n\n159 \n\n \n\nin the third day. The sHA did not retain their shape during incubation becoming a \n\nviscous gel.  \n\nWe also evaluated the cytotoxicity of HA-BDDE structures by MTT method \n\n[Figure 36(b)]. The results showed that the HA-BDDE structures exhibit a good \n\ncompatibility to the cells, not only because the proliferation was greater than the positive \n\ntoxicity control (PTC), but it was also significantly higher than positive control NTC \n\n(p<0.05). \n\n0 2 4 6 8 10 12 14 16\n\n40\n\n60\n\n80\n\n100\n\n \n\n \n\nR\ne\n\nm\na\n\nin\nin\n\ng\n w\n\ne\nig\n\nh\nt \n\n(%\n)\n\nTime (days)\n \n\nmBDDE sBDDE sHA fHA PTC NTC\n\n0\n\n1x10\n4\n\n2x10\n4\n\n3x10\n4\n\n4x10\n4\n\n5x10\n4\n\n6x10\n4\n\n7x10\n4\n\n \n\n \n\nC\ne\n\nll\n n\n\nu\nm\n\nb\ne\n\nr/\n w\n\ne\nll\n\n \n\n \n\n(a) (b) \n\nFigure 36. (a) The weight remaining of the HA-BDDE structures under the time course \n\nof degradation (At 37\u00b0C, in PBS). (?) sHA-BDDE and (?) mHA-BDDE. (b) Viability of h-\n\nAdMSC exposed to the HA-BDDE structures, sHA and fHA for 24 hours. Negative \n\ncontrol (NTC) = DMEM with 10% FBS; positive control (PTC) = DMEM with phenol \n\n0.5%. Mean \u00b1 standard deviation n = 3. The population means are significantly different \n\nfrom positive control at p<0.05.  \n\nDue to the nature of the assay, the higher cell number for mHA-BDDE could be \n\njustified due to their greater surface area available for cell adhesion compared to fHA. \n\nMoreover, the fewer number of cells for sHA-BDDE may indicate limitations in cell \n\nmigration due to the porous structure created by the crosslinking. \n\n \n\n7.3.3.1. mHA-BDDE  \n\nThe mHA-BDDE [Figure 37(a)] exhibited typical gel-type mechanical spectra, with \n\n\n\n160 \n\n \n\nG\u2019 higher than G\u201d in all studied ranges and both moduli lying parallel to the frequency \n\naxis (Ikeda &amp; Nishimari, 2001).  \n\nThe shear viscosity spectra of HA-BDDE showed a pseudoplastic behavior \n\n[Figure 37(b)], while fHA 1% is a Newtonian fluid. The pseudoplastic behavior is an \n\nimportant parameter in injectable applications, where the flow viscosity should be lower \n\nthan the rest viscosity.  \n\n0.1 1 10\n\n1\n\n10\n\n100\n\n1000\n\n10000\n\n \n\n \n\nG\n' \na\n\nn\nd\n\n G\n\"\n (\n\nP\na\n\n)\n\nFrequency (Hz)\n\n \n\n0.1 1 10\n\n0.1\n\n1\n\n10\n\n100\n\n1000\n\n10000\n\n \n\n \n\nV\nis\n\nc\no\n\ns\nit\n\ny\n (\n\nP\na\n.s\n\n)\n\nShear rate (s\n-1\n)\n\n \n\n \n\n(a) (b) \n\nFigure 37. (a) Oscillation spectrum of mHA-BDDE and mHA-BDDE/aP-PRP. (?) aP-\n\nPRP; (?) mHA-BDDE; ( ) mHA-BDDE/aP-PRP 2:1; (?) mHA-BDDE/aP-PRP 1:1; (?) \n\nmHA-BDDE/aP-PRP 1:2. G\u2019 (closed symbol) and G\u201d (open symbol). (b) Shear viscosity \n\nspectra of (?) fluid HA (1% wt.) and (?) mHA-BDDE. \n\n \n\nThe microparticles showed a mean diameter (Table 4) around 160 ?m, which is \n\nadequate for an injectable application (<700 ?m) (Shimojo et al., 2013; Kablik et al., \n\n2009).  \n\nG\u2019 values were around 3000 Pa in 1 Hz that are out of the adequate range (100-\n\n700 Pa) for injectable application. Therefore, they should be dispersed in a fluid phase \n\nor to have the crosslinking degree decreased to fit in the required range (Shimojo et al., \n\n2013; Kablik et al., 2009). \n\nIn addition to viscoelasticity, the injectable scaffolds must have an extrusion force \n\nto allow their easy injection through an appropriately sized needle (27-30 g needle) and \n\n\n\n161 \n\n \n\nthereby prevent side effects such as pain (Shimojo et al., 2013; Kablik et al., 2009). The \n\ncrosslinking increased the extrusion force of HA-BDDE (78 \u00b1 7 N) compared to fHA 1% \n\n(4.3 \u00b1 0.1 N) as expected (Table 4), however, it was not adequate for injectable \n\napplications (<20 N) (de Melo et al., 2012; \u00d6hrlund et al., 2010).  \n\nThus, the G\u2019 and extrusion force values obtained indicated the need to adjust the \n\nformulation for injectable application by adding a fluid phase and/or decreasing the \n\ndegree of crosslinking (Shimojo et al., 2013). \n\nIn this work, we utilized aP-PRP in different volumetric ratio as fluid phase. We \n\nobserved that the addition of the activated P-PRP maintained the pseudoplastic gel-type \n\nbehavior of composite and adequate the rheological properties with reduction of G\u2019, as \n\nrequired. The volumetric ratio mHA-BDDE/aP-PRP 1:2 was more suitable for fit the \n\nrequirements for injectable application. (G\u2019 in 1Hz = 503 Pa). This volumetric ratio was \n\nmaintained in the biological assays. \n\n \n\n7.3.3.2. sHA-BDDE  \n\nThe results of compression test (Table 4) showed that the crosslinking improved \n\nto mechanical resistance of the sHA-BDDE compared to non-crosslinked sHA. The \n\nYoung\u2019s modulus value (~14 kPa) was higher for the sHA-BDDE than for the sHA with \n\nthe same porosity (~97%).  \n\nThe porosity is also an important aspect of cell migration and proliferation, \n\nguiding and promoting the formation of new tissue. A porosity higher than 90% and pore \n\ninterconnectivity are basic requirements for scaffolds in tissue engineering because they \n\naffect the diffusion of physiological nutrients and gases to and the removal of metabolic \n\nwaste and by-products from cells that have penetrated the scaffold (Leong et al., 2003; \n\nLiu &amp; Ma, 2004). The porosity values of sHA-BDDE and sHA obtained in this study, both \n\naround 97%, are adequate for tissue, engineering, particularly for bone tissue. \n\nThe cross-section morphologies of sHA-BDDE and sHA obtained by SEM are \n\nshown in Figure 38. In both cases, highly porous structures were formed, confirming the \n\ndetermined values for porosity in Table 4. However, the structure of HA-BDDE sponges \n\nhas more open round pores [Figure 38(a)], whereas the sHA has a leaf structure [Figure \n\n38(b)].  \n\n\n\n162 \n\n \n\n \n\n \n\n(a) \n\n \n\n (b) \n\nFigure 38. Scanning electron micrographs. Cross-section morphologies of (a) HA-BDDE \n\nscaffold and (b) sHA.  \n\n \n\nAlthough there is a large distribution of sizes, sHA-BDDE showed pores around \n\n200 ?m, which is adequate for regeneration of hard tissues (Salgado et al., 2004). \n\nMoreover, because human adipose tissue-derived mesenchymal stem cells (h-AdMSCs) \n\nexhibit a spindle-like shape and are 80\u2013100 ?m in diameter and ~200 ?m in length, the \n\nrange of pore sizes in sHA-BDDE allows cells to migrate freely into the scaffolds, \n\nfavoring the formation of a new tissue (Chavez-Munoz et al., 2013). \n\nThese values were slightly larger than the ones reported by La Gatta et al. (2013) \n\n(70-130 \u00b5m) for the matrices crosslinked with comparable equivalents of BDDE. This \n\ndifference may be due to the differences in processing conditions that used \n\nheterogeneous conditions for preparation. \n\n \n\n7.3.4. Effects of the association with P-PRP  \n\n7.3.4.1. SEM images \n\nSEM images (Figure 39) shows the activated P-PRP associated to HA-BDDE \n\nform a composite scaffold with the fibrin network formed inside the microparticles or \n\nsponges.  \n\n100 \u00b5m\nFEQ/UNICAMP\n\nEHT=20 kV\nI Probe=100 pA\n\nDetector=SE1\nWD=22 mm\n\n200 \u00b5m\nFEQ/UNICAMP\n\nEHT=5 kV\nI Probe=50 pA\n\nDetector=SE1\nWD=22 mm\n\n\n\n163 \n\n \n\nFigure 39(b) also shows a cluster of cells on the fibrin fibers.  \n\n  \n\n(a) (b) \n\n  \n\n(c) (d) \n\nFigure 39. Scanning electron microscopic images of aP-PRP/HA-BDDE scaffolds after \n\n5 days of cultivation of h-AdMSCs. Microparticles: (a) magnification of 2,500X and (b) \n\nmagnification of 10,000X. Sponges: (c) magnification of 1,000X and (d) magnification of \n\n10,000X.  \n\n \n\n \n\n7.3.4.2. Release of growth factors \n\nThe release kinetics of PDGF-AB and TGF-?1 from the structured HA associated \n\nwith activated P-PRP in DMEM are shown in Figure 40.  \n\nThe curves show parallel diffusive profiles, indicating no collapse of the structure \n\nduring the assays. The maximum TGF-?1 and PDGF-AB release was not observed up \n\nto 72 hours of assay.  \n\n\n\n164 \n\n \n\nFor PDGF-AB, we observed a slower release from P-PRP/HA-BDDE than from P-\n\nPRP alone for the first 48 hours. For TGF-?1, we did not observe significant differences \n\nin the release profiles during the assay time. \n\nThe release of the most of GFs occurred in agreement with the degradation time \n\nof the scaffolds as could be observed in Figure 40 and Figure 36(a).  \n\n0 10 20 30 40 50 60 70 80\n\n0\n\n2000\n\n4000\n\n6000\n\n8000\n\n10000\n\n12000\n\n14000\n\n16000\n\n18000\n\n20000\n\n22000\n\n \n\n \n\np\ng\n\n o\nf \n\nP\nD\n\nG\nF\n\n-A\nB\n\n/ \nm\n\nL\n o\n\nf \nP\n\nR\nP\n\nTime (hours)\n \n\n0 10 20 30 40 50 60 70 80\n\n0\n\n2000\n\n4000\n\n6000\n\n8000\n\n10000\n\n12000\n\n14000\n\n16000\n\n \n\n \n\np\ng\n\n o\nf \n\nT\nG\n\nF\n-?\n\n1\n/ \nm\n\nL\n o\n\nf \nP\n\nR\nP\n\nTime (hours)\n \n\n(a) (b) \n\nFigure 40. Growth factor release profile from PRP combined with HA-BDDE scaffolds. \n\nPDGF-AB (a) and TGF-?1 (b). (?) PRP activated with serum/Ca+2 was used as control; \n\n(?) sHA-BDDE; (?) mHA-BDDE. The GFs were measurements from activated P-PRP \n\ncontaining average platelet concentration 495,000 pq/mm3.  \n\n \n\n7.3.4.3. Proliferation of h-AdMSCs and ALP activity \n\nThe kinetic profiles of proliferation were determined for h-AdMSCs cultured in the \n\npresence of composite scaffolds in 10 days, in comparison with fHA and the activated \n\nPRP alone [Figure 41(a)].  \n\nAt a macroscopic observation, the scaffolds appeared homogeneously colored \n\nafter the MTT treatment at each tested time thus supporting the presence of living and \n\nmetabolically active cells. The cell number per well determined after 2 days exceeded \n\nthe number of seeded cells (1.4 x 104 cells/ well) in the structures associated to PRP, \n\nmeaning that the cells kept in the matrices retained their viability.  \n\nAlthough the cell proliferation was not intense in the composite scaffolds, it was \n\nhigher than in fHA. The association of PRP with the structures reduced cell proliferation, \n\n\n\n165 \n\n \n\ncompared with the fibrin network (activated PRP alone), mainly for the crosslinked mHA-\n\nBDDE and sHA-BDDE. \n\nIn counterpart, the structured HA promoted the ALP activity [Figure 41(b)], an \n\nearly osteoblastic marker, which reflected both the population of viable cells and the cell \n\ndifferentiation. The ALP activity was remarkable in mHA-BDDE. Although the necessity \n\nof determining other factors, the ALP activity points out to the structured HA associated \n\nto PRP is promising for osteogenic regeneration. \n\nThese results point to the opposite directions of the proliferation and ALP activity, \n\nwhich require more detailed studies regarding its mechanisms in the presence of growth \n\nfactors and the composite scaffolds. \n\nsHA sHA-BDDE mHA-BDDE fHA aP-PRP\n\n0.0\n\n5.0x10\n4\n\n1.0x10\n5\n\n1.5x10\n5\n\n2.0x10\n5\n\n2.5x10\n5\n\n3.0x10\n5\n\n* *\n\n*\n\n*\n\n \n\n \n\nC\ne\n\nll\n n\n\nu\nm\n\nb\ne\n\nr/\n w\n\ne\nll\n\n 0 day\n\n 2 days\n\n 4 days\n\n 7 days\n\n 10 days\n\n*\n\n*\n\n \n\nsHA-BDDE sHA mHA-BDDE fHA Blank\n\n0.0\n\n0.5\n\n1.0\n\n1.5\n\n2.0\n\n2.5\n\n3.0\n\n \n\n \n\nA\nL\n\nP\n a\n\nc\nti\n\nv\nit\n\ny\n (\n\nA\nb\n\ns\no\n\nrb\na\n\nn\nc\n\ne\n i\nn\n\n 4\n0\n\n4\n n\n\nm\n) \n\n \n\n(a) (b) \n\nFigure 41. (a) Kinetic proliferation profiles of h-AdMSCs seeded in aP-PRP/HA-BDDE \n\nscaffolds structured in sponges and microparticles. aP-PRP was used as control. The \n\nconcentration of platelets in P-PRP was 273,000 pq/mm3. (b) ALP activities of cells \n\ncultured on aP-PRP/HA-BDDE scaffolds structured in sponges and microparticles \n\n(statistically significant differences from blank, n=3, *p<0.05). Blank = the colorimetric \n\nreagent used in the assay only. The concentration of platelets in whole blood donors \n\n(average of 2 donors) was 468,500 pq/mm3. \n\n \n\n7.4. Conclusions \n\n \n\nNovel composite scaffolds were prepared from hyaluronic acid crosslinked with \n\n\n\n166 \n\n \n\n1,4-butanediol diglycidyl ether and structured in sponges and microparticles, in \n\nassociation with activated platelet-rich plasma. The crosslinked structures improved the \n\nphysicochemical, mechanical and biological properties as compared to free hyaluronic \n\nacid. Thus, our results provide evidences that the composite scaffolds are promising \n\nbiomaterials for future clinical use in tissue engineering, with perspectives for osteogenic \n\nregeneration. The flexibility to obtain injectable formulations (microparticles) or solid \n\nsponges expands their applications.  \n\n \n\nAcknowledgments. The authors acknowledge the financial support from the National \n\nCouncil of Technological and Scientific Development (CNPq, Brazil). They also thank \n\nProf. Dr. Edvaldo Sabadini and Dr. Thiago Heiji Ito of the Chemical Institute (University \n\nof Campinas) for the use of the rheometer. \n\n \n\n7.5. References \n \n\nALLEMANN, I.B.; BAUMANN, L. Hyaluronic acid gel (JuvedermTM) preparations in the \ntreatment of facial wrinkles and folds. Clinical Interventions in Aging, vol.3, n.4, p.629-\n634, 2008. \n\nANDRE, P. Hyaluronic acid and its use as a \u201crejuvenation\u201d agent in cosmetic \ndermatology. Seminars in Cutaneous Medicine and Surgery, vol.23, p.218-222, \n2004. \n\nBEASLEY, K.L.; WEISS, M.A.; WEISS, R.A. Hyaluronic acid fillers: A comprehensive \nreview. Facial Plastic Surgery, vol.25, p.86-94, 2009. \n\nCHAVEZ-MUNOZ, C.; NGUYEN, K.T.; XU, W.; HONG, S.J.; MUSTOE, T.A.; GALIANO, \nR.D. Transdifferentiation of adipose-derived stem cells into keratinocyte-like cells: \nengineering a stratified epidermis. PLOS One, vol.8, n.12, p.1-13, 2013. \n\nCHEN, W-H.; LO, W-C.; HSU, W-C.; WEI, H-J.; LIU, H-Y.; LEE, C-H.; CHEN, S-Y.T.; \nSHIEH, Y-H.; WILLIAMS, D.F.; DENG, W-P. Synergistic anabolic actions of hyaluronic \nacid and platelet-rich plasma on cartilage regeneration in osteoarthritis therapy. \nBiomaterials, vol.35, n.36, p.9599-9607, 2014. \n\nCOLLINS, M.N.; BIRKINSHAW, C. Investigation of the Swelling Behavior of Crosslinked \nHyaluronic Acid Films and Hydrogels Produced Using Homogeneous Reactions. \nJournal of Applied Polymer Science, vol.109, p.923-931, 2008. \n\nCORREIA, C.R.; TEIXEIRA, L.S.M.; MORONI, L.; REIS, R.L.; VAN BLITTERSWIJK, \nC.A.; KARPERIEN, M.; MANO, J.F. Chitosan Scaffolds Containing Hyaluronic Acid for \n\n\n\n167 \n\n \n\nCartilage Tissue Engineering. Tissue Engineering \u2013 Part C, vol.17, n.7, p. 717-730, \n2011. \n\nDE ANGELIS, B.; LUCARINI, L.; ORLANDI, F.; AGOVINO, A.; MIGNER, A.; CERVELLI, \nV.; IZZO, V.; CURCIO, C. Regenerative surgery of the complications with Morton's \nneuroma surgery: Use of platelet rich plasma and hyaluronic acid. International Wound \nJournal, vol.10, n.4, p.372-376, 2012. \n\nDE BOULLE, K.; GLOGAU, R.; KONO, T.; NATHAN, M.; TEZEL, A.; ROCA-MARTINEZ, \nJ-X.; PALIWAL, S.; STROUMPOULIS, D. A Review of the Metabolism of 1,4-Butanediol \nDiglycidyl Ether\u2013Crosslinked Hyaluronic Acid Dermal Fillers. Dermatologic Surgery, \nvol.39, p.1758-1766, 2013. \n\nDE MELO, F.; MARIJNISSEN-HOFSTE, J. Investigation of Physical Properties of a \nPolycaprolactone Dermal Filler when Mixed with Lidocaine and Lidocaine/Epinephrine. \nDermatology and Therapy, vol.2, n.13, p.1-10, 2012. \n\nEHRENFEST, D.M.D.; RASMUSSON, L.; ALBREKTSSON, T. Classification of platelet \nconcentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich \nfibrin (L-PRF). Trends Biotechnology, vol.27, p.158-167, 2009. \n\nFALCONE, S.J.; BERG, R.A. Crosslinked hyaluronic acid dermal fillers: A comparison of \nrheological properties. Journal of Biomedical Materials Research, vol.87A, p.264-\n271, 2008. \n\nFATHI, W.K. The Effect of Hyaluronic Acid and Platelet - Rich Plasma on Soft Tissue \nWound Healing: An Experimental Study on Rabbits. Al\u2013Rafidain Dental Journal, \nvol.12, n.1, p.115-125, 2012. \n\nGARG, H.G.; HALES, C.A. Chemistry and Biology of Hyaluronan, Boston: Elsevier, \n2004. \n\nG\u00dcM\u00dcS?DERELIO?LU, M.; ADAY, S. Heparin-functionalized chitosan scaffolds for \nbone tissue engineering. Carbohydrate Research, vol.346, p.606-613, 2011. \n\nIKEDA, S.; NISHINARI, K. Weak Gel-Type Rheological Properties of Aqueous \nDispersions of Nonaggregated K-Carrageenan Helices. Journal of Agricultural and \nFood Chemistry, vol.49, p.4436-4441, 2001. \n\nKABLIK, J.; MONHEIT, G.D.; YU, L.; CHANG, G.; GERSHKOVICH, J. Comparative \nphysical properties of hyaluronic acid dermal fillers. Dermatologic Surgery, vol.35, n.1, \np.302-312,  2009. \n\nKENNE, L.; GOHIL, S.; NILSSON, E.M.; KARLSSON, A.; ERICSSON, D.; KENNE, A.H.; \nNORD, L.I. Modification and cross-linking parameters in hyaluronic acid hydrogels\u2014\nDefinitions and analytical methods. Carbohydrate Polymer, vol.91, p.410-418, 2013. \n\nKIM, Z.H.; LEE, Y.; KIM, S.M.; KIM, H.; YUN, C.K.; CHOI, Y.S. A Composite Dermal \nFiller Comprising Cross-Linked Hyaluronic Acid and Human Collagen for Tissue \n\n\n\n168 \n\n \n\nReconstruction. Journal of Microbiology and Biotechnology, 2014. [Epub ahead of \nprint]  \n\nLA GATTA, A.; SCHIRALDI, C.; PAPA, A.; D\u2019AGOSTINO, A.; CAMMAROTA, M.; DE \nROSA, A.; DE ROSA, M. Hyaluronan scaffolds via diglycidyl ether crosslinking: Toward \nimprovements in composition and performance. Carbohydrate Polymer, vol.96, p.536-\n544, 2013. \n\nLANA, J.F.S.D.; SANTANA, M.H.A.; BELANGERO, W.D.; LUZO, A.C.M. Platelet-Rich \nPlasma: Regenerative Medicine: Sports Medicine, Orthopedic, and Recovery of \nMusculoskeletal Injuries (Lecture Notes in Bioengineering), 1st ed., Springer, 2014. \n\nLEONG, F.; CHEAH, C.M.; CHUA, C.K. Solid freeform fabrication of three-dimensional \nscaffolds for engineering replacement tissues and organs. Biomaterials, vol.24, p.2363-\n2378, 2003. \n\nLIU, X.; MA, P.X. Polymeric Scaffolds for Bone Tissue Engineering. Annals of \nBiomedical Engineering, vol.32, n.3, p.477-486, 2004. \n\nM\u00c4LSON, T.; LINDQVIST, B. Gels of crosslinked hyaluronic acid for use as a vitreous \nhumor substitute. United States Patent: U.S. 1987/4,716,154, 1987. \n\nMARX, R.E. Platelet-rich plasma: Evidence to support its use. Journal of Oral and \nMaxillofacial Surgery, vol.62, p.489-496, 2004. \n\nMARX, R.E.; CARLSON, E.R.; EICHSTAEDT, R.M.; SCHIMMELE, S.R.; STRAUSS, \nJ.E.; GEORGEFF, K.R. Platelet-rich plasma: Growth factor enhancement for bone \ngrafts. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, vol.85, p.638-\n646 1998. \n\nMOSSMAM, T.J. A rapid colorimetric assay of cellular growth and survival: application to \nproliferation and cytotoxicity assays. Journal of Immunological Methods, vol.65, p.55-\n63, 1983. \n\n\u00d6HRLUND \u00c5. Lifting capacity of hyaluronic acid (HA) dermalaluronic acid (HA) dermal \nfillers. Poster presentation at 8 th Anti-aging Medicine World Congress (AMWC), \nMonte-Carlo, Monaco, 2010.  \n\nPAK, J. Compositions and methods for treating, preventing and alleviating bone or \ncartilage diseases. United States Patent: U.S. 2012/0,171,169 A1, 2012. \n\nPEREZ, A.G.M.; LICHY, R.; LANA, J.F.S.D.; RODRIGUES, A.A.; LUZO, A.C.M.; \nBELANGERO, W.D.; SANTANA, M.H.A. Prediction and Modulation of Platelet Recovery \nby Discontinuous Centrifugation of Whole Blood for the Preparation of Pure Platelet-\nRich Plasma. BioResearch Open Access, vol.2, p. 307-314, 2013. \n\nPEREZ, A.G.M.; RODRIGUES, A.A.; LUZO, A.C.M.; LANA, J.F.S.D.; BELANGERO, \nW.D.; SANTANA M. H. A. Fibrin network architectures in pure platelet-rich plasma as \ncharacterized by fiber radius and correlated with clotting time. Journal of Materials \nScience: Materials in Medicine, vol.25(8), p.1967-1977, 2014.  \n\n\n\n169 \n\n \n\nSALGADO, J.; COUTINHO, O.P.; REIS, R.L. Bone Tissue Engineering: State of the Art \nand Future Trends. Macromolecular Bioscience, vol.4, p.743-765, 2004. \n\nSCHANT\u00c9, C.E.; ZUBER, G.; HERLIN, C.; VANDAMME, T.F. Chemical modifications of \nhyaluronic acid for the synthesis of derivatives for a broad range of biomedical \napplications. Carbohydrate Polymer, vol.85, n.3, p.469-489, 2011. \n\nSHIMOJO, A.A.M.; PEREZ, A.G.M.; GALDAMES, S.E.M.; BRISSAC, I.C.S.; SANTANA, \nM.H.A. Performance of PRP Associated with Porous Chitosan as a Composite Scaffold \nfor Regenerative Medicine. The Scientific World Journal, vol.2015, p.1-12, 2015. \n\nSHIMOJO, A.A.M.; PIRES, A.M.B.; LICHY, R.; RODRIGUES, A.A.; SANTANA, M.H.A. \nThe crosslinking degree controls the mechanical, rheological, and swelling properties of \nhyaluronic acid microparticles. Journal of Biomedical Materials Research, vol.103A, \nn.2, p.730-737, 2014. \n\nSHIMOJO, A.A.M.; PIRES, A.M.B.; TORRE, L.G.; SANTANA, M.H.A. Influence of \nParticle Size and Fluid Fraction on Rheological and Extrusion Properties of Crosslinked \nHyaluronic Acid Hydrogel Dispersions. Journal of Applied Polymer Science, vol.128, \np.2180-2185, 2013. \n\nSHU, X.Z.; LIU, Y.; PALUMBO, F.S.; LUO, Y.; PRESTWICH, G.D. In situ crosslinkable \nhyaluronan hydrogels for tissue engineering. Biomaterials, vol.25, p.1339-1348, 2004.  \n\nSILVERSTEIN, R.M.; BASSLER, G.C.; MORRILL, T.C. Spectrometric identification of \norganic compounds. 3rd Ed., New York: John Wiley, 1974. \n\nTANG, S.; VICKERS, S.M.; HSU, H-P.; SPECTOR, M. Fabrication and characterization \nof porous hyaluronic acid\u2013collagen composite scaffolds. Journal of Biomedical \nMaterials Research, vol.82A, p.323-335, 2007. \n\nWANG, W. Methods for making injectable polymer hydrogels. United States Patent: \nU.S. 2005/0,281,880 A1, 2005. \n\nWANG, Y.; LIN, M.; WANG, D.; HSIEH, H. Fabrication of a novel porous PGA\u2013chitosan \nhybrid matrix for tissue engineering. Biomaterials, vol.24, p.1047-1057, 2003. \n\nYEOM, J.; BHANG, S.H.; KIM, B-S.; SEO, M.S.; HWANG, E.J.; CHO, H.; PARK, J.K.; \nHAHN, S.K. Effect of Cross-Linking Reagents for Hyaluronic Acid Hydrogel Dermal \nFillers on Tissue Augmentation and Regeneration. Bioconjugate Chemistry, vol. 21, \np.240\u2013247, 2010. \n\nZAWKO, S.A.; SURI, S.; TRUONG, Q.; SCHMIDT, C.E. Photopatterned anisotropic \nswelling of dual-crosslinked hyaluronic acid hydrogels. Acta Biomaterialia, vol.5, p.14-\n22, 2009. \n\n  \n\n\n\n170 \n\n \n\n \n\n  \n\n\n\n171 \n\n \n\nCAP\u00cdTULO 8 \u2013 STERILIZATION OF AUTO-\nCROSSLINKED HYALURONIC ACID \n\nSTRUCTURED IN MICROPARTICLES OR \n\nSPONGES \n\nArtigo submetido ao peri\u00f3dico Biotechnology Letters. \n\n \n\nAndr\u00e9a Arruda Martins Shimojoa, Isabela Cambraia de Souza Brissaca, Lucas Martins \n\nPinaa, Carlos Salles Lambertb, Maria Helena Andrade Santanaa,* \n\n \n\naDepartment of Engineering of Materials and Bioprocesses, School of Chemical \n\nEngineering, University of Campinas, Campinas-SP, Brazil. \n\nbDepartment of Applied Physics, Institute of Physics \"Gleb Wataghin\", University of \n\nCampinas, Campinas-SP, Brazil. \n\n \n\nCorrespondence to: M. H. A. Santana (e-mail: mariahelena.santana@gmail.com) \n\n \n\nAbstract. This work aimed to evaluate the effects of UV irradiation, plasma radiation, \n\nsteam and 70% ethanol treatments on the sterilization and integrity of auto-crosslinked \n\nhyaluronic acid (HA-ACP) structured in microparticles or sponges. The integrity of the \n\nmicroparticles was characterized by rheological behavior, while for the sponges it was \n\ncharacterized by scanning electron microscopy, Fourier transform infrared spectroscopy \n\nand differential scanning calorimetry. The effectiveness of the sterilization treatment was \n\nverified by count of microorganism colonies in the samples after the treatments. In \n\nconclusion, plasma radiation was the best treatment for the sponges, while steam \n\nsterilization in autoclave at 126\u00b0C (1.5 kgf/cm2) for 5 minutes was the best one for the \n\nmicroparticles. \n\n \n\nKey Words: auto-crosslinked hyaluronic acid, sterilization, plasma radiation, steam, UV \n\nmailto:mariahelena.santana@gmail.com\n\n\n172 \n\n \n\nirradiation, ethanol treatment. \n\n \n\n8.1. Introduction \n\nHyaluronic acid (HA) and its crosslinked derivatives have been widely used as \n\nscaffolds for tissue engineering (Collins and Birkinshaw, 2013; Unterman et al. 2012). \n\nSterilization is of fundamental importance for storage as well as for in vitro and in vivo \n\napplications. \n\nSeveral sterilization methods have been used for the sterilization of natural \n\npolymers structured as scaffolds for cell culture. These methods use dry heat, high-\n\npressure vapor, ethylene oxide gas, supercritical carbon dioxide or radiation treatments \n\n(Danillof et al. 2009). An efficient treatment must provide sterility to the scaffold \n\npreserving its structure (Faraj et al. 2011). \n\nHA and its crosslinked derivatives are heat-sensitive and sensible to ?-rays, \n\npresenting chemical degradation and depolymerisation with a decrease of molecular \n\nweight average (Rehakova et al. 1994). Besides degrading effects, the porous structure \n\nof scaffolds can be destroyed because of plastic deformation from the heat treatment \n\n(Plikk et al. 2006). \n\nMoreover, since scaffolds usually have a porous structure, a sterilization method \n\nmust penetrate materials without leaving residues (Siritientong et al., 2011; Plikk et al. \n\n2002). \n\nIn this study, we evaluated the effects of different treatments (70% ethanol; UV \n\nirradiation; plasma radiation and steam) on sterilization and the integrity of auto-\n\ncrosslinked hyaluronic acid (HA-ACP) structured in microparticles or sponges. The \n\nintegrity of the microparticles was characterized by rheological behavior, while for the \n\nsponges it was characterized by scanning electron microscopy, Fourier transform \n\ninfrared spectroscopy and differential scanning calorimetry. The effectiveness of the \n\nsterilization method was verified by colonies counts of microorganisms after the \n\ntreatments. \n\n\n\n173 \n\n \n\n8.2. Materials and Methods \n\n8.2.1. Materials \n\nHA in sodium form (MW = 2 x 106 Da) was obtained from Spec-Chem. Ind. \n\n(Nanjing, China). All other reagents were purchased from Synth\u00ae (Diadema, SP, Brazil) \n\nunless specified otherwise.  \n\n \n\n8.2.2. Methods \n\n8.2.2.1. Preparation of the HA-ACP scaffolds  \n\nHA-ACP preparation. The auto-crosslinked HA was prepared by an \n\nautoesterification reaction according to protocol described by Bellini et al. 2001. HA-TBA \n\n(tetrabutylammonium hyaluronate) with a molecular weight of approximately 2 x 106 Da \n\nand corresponding to 10 mEq of monomeric units was solubilized in 50 mL of \n\ndimethylsulfoxide (DMSO) at 25\u00b0C. Triethylamine (0.5 mEq) was added and the \n\nresulting solution was agitated for 30 minutes. A solution of 2-chloro-1-methyl pyridinium \n\niodide (CMPI) (0.5 mEq) (Sigma-Aldrich, St. Louis, MO, USA) in 15 mL of DMSO was \n\nslowly added drop by drop over 1 hour and the mixture was kept at 30\u00b0C for 15 hours. A \n\nsolution of sodium chloride 2.5% (w/v) was then added and the resulting mixture was \n\npoured slowly into 150 mL of acetone, maintaining continual agitation. The formed \n\nprecipitate was centrifuged at 10,000 rpm for 10 minutes, washed three times in 100 mL \n\nof 5:1 acetone: water and three times with 100 mL of acetone and vacuum-dried for 24 \n\nhours at 30\u00b0C.  \n\n \n\nPreparation of structured HA-ACP scaffolds. The HA-ACP scaffolds structured in \n\nmicroparticles (mHA-ACP) or sponges (sHA-ACP) were prepared from plain HA-ACP \n\nswollen in Milli-Q water. The microparticles were obtained by shearing in an Ultra-Turrax \n\nT25 homogenizer (IKA Labortechnik, Staufen, Germany) at 18,000 rpm by 20 minutes, \n\naccording to Shimojo et al. 2013. For preparation of the sponges, the microparticles \n\nwere initially placed in polystyrene 48-well microplates (TPP\u00ae, Trasadingen, \n\nSwitzerland), frozen at -20\u00b0C and lyophilized at controlled temperature of approximately \n\n-30\u00b0C for 48 hours. \n\n\n\n174 \n\n \n\n \n\n8.2.2.2. Sterilization Treatments \n\nHA-ACP microparticles were submitted to UV-irradiation, plasma radiation, \n\nsteam, 70% ethanol treatments, aiming sterilization or disinfection. HA-ACP sponges \n\nwere submitted to the same treatments except to steam. Non-treated scaffolds were \n\nused as control. \n\n \n\nEthanol Treatment. The HA-ACP scaffolds were disinfected with 70% (v/v) \n\nethanol, according to Faraj et al. 2011. They were washed with 70% ethanol at ambient \n\ntemperature for 3\u00d71 h and 1\u00d716 h. Thereafter, three short washings with sterile \n\nphosphate buffered saline (PBS) (pH 7.4) were performed with changes of washing fluid \n\ndirectly after one another, and finally 5\u00d71 h and 1\u00d716 h washings with PBS were \n\nperformed. All washing changes were performed in a laminar flow cabinet. sHA-ACP \n\nwas re-frozen at -20\u00b0C and lyophilized again.  \n\n \n\nPlasma Irradiation. The scaffolds were evacuated and then, a pressure of 1 Torr \n\nwas established with the introduction of argon (Ar) gas that combined with an electrical \n\npotential difference (EPD) create Ar plasma inside the chamber. This treatment was \n\nperformed along 5 minutes. \n\n \n\nUV Irradiation. Irradiation was carried out with an ultraviolet lamp (Germetec, Rio \n\nde Janeiro, RJ, Brazil) at 254-nm wavelength at a distance of 5 cm (UV1) and at a \n\ndistance of 60 cm (UV2). HA-ACP microparticles and HA-ACP sponges were irradiated \n\nfor a total time of 30 min and were turned over halfway through the treatment to irradiate \n\nthe top and bottom surfaces.  \n\n \n\nSteam. Steam treatment was applied to the microparticles only. The treatment \n\nwas achieved by wet heating at 126\u00b0C, under a vapor pressure of 1.5 kgf/cm2 for 1, 2.5, \n\n5, 10 and 15 minutes in autoclave. \n\n \n\n\n\n175 \n\n \n\n8.2.2.3. HA-ACP sponges characterization \n\nFourier-transform Infrared (FTIR). FTIR was used to identify possible chemical \n\nmodifications on scaffolds resulting from sterilization processes. Infrared spectra were \n\nobtained using a Thermo Scientific Nicolet model 6700 (Thermo Scientific Nicolet\u2122, \n\nWaltham, MA, USA). Measurements were made in the ATR mode with accessory \n\nSMART OMNI-SAMPLER, in the spectral range of 4000 \u2013 675 cm-1 with a resolution of 4 \n\ncm-1 over 64 scans.  \n\n \n\nScanning electronic microscopy (SEM). The morphology of HA-ACP sponges \n\nsterilized was evaluated by scanning electron microscopy (SEM) using an LEO 440i \n\nElectron Microscopy/Oxford (Cambridge, England) operated at 5 kV accelerating \n\nvoltage. The scaffolds were gold-coated using a sputter coater POLARON SC7620, VG \n\nMicrotech (Uckfield, England) for 180 s at a current of 3 mA.  \n\n \n\nDifferential scanning calorimetry (DSC). The thermal characterization of the \n\nscaffolds was achieved by DSC using a Mettler-Toledo DSC1 (Mettler Toledo Co., \n\nZ\u00fcrich, Switzerland) module under a nitrogen atmosphere (nitrogen flow rate 50 mL/min) \n\nwith a sample mass around 10 mg and a heating rate of 10\u00b0C/min.  \n\n \n\n8.2.2.4. HA-ACP microparticles characterization \n\nRheological properties. HA-ACP microparticles sterilized were evaluated by \n\nrheological properties. The measurements were performed on a Rheometer Haake \n\nmodel RheoStress 1 (Haake, Karlsruhe, Germany). The properties of the scaffolds were \n\ncharacterized in the steady and oscillatory regimes at 25oC, using a parallel plate \n\ngeometry of 20 mm. Oscillatory measurements were conducted in the linear region, at a \n\nstress of 1.188 Pa and in the frequency range of 0.01 to 10 Hz. Steady shear \n\nmeasurements were obtained at shear rates of 0.1-50 s-1.  \n\n \n\n8.2.2.5. Sterility Tests  \n\nAll the scaffolds were tested for sterility for heterotrophic bacterial, molds and \n\nyeasts, immediately following the treatments using a standard assay (Method 61, USP \u2013 \n\n\n\n176 \n\n \n\n2012).  \n\n \n\n8.3. Results and Discussion \n\n \n\n8.3.1. Effects of the treatments on physicochemical properties of the HA-\n\nACP sponges \n\nThe effects of the treatments on HA-ACP sponges were evaluated by scanning \n\nelectron microscopy (SEM), Fourier transform infrared spectroscopy (FTIR) and \n\ndifferential scanning calorimetry (DSC).  \n\nThe micrographs of sponges obtained by SEM (Figure 42) showed that except to \n\nethanol disinfection [Figure 42(e)], the scaffolds remained their porous structure without \n\nmajor differences in morphology, regardless the treatments. Ethanol disinfection \n\nreduced substantially the porosity of HA-ACP sponge. Moreover, we observed loss in \n\nthe scaffold shape by swelling after washing with PBS. \n\n   \n\n(a) (b) (c) \n\n  \n\n(d) (e) \n\nFigure 42. SEM cross-section images of HA-ACP sponges. (a) Unsterile; (b) UV (5 cm); \n\n(c) UV (60 cm); (d) Plasma and (e) Ethanol disinfection. Bar = 100 \u00b5m. \n\n \n\nFigure 43(a) shows the FT-IR spectra of HA-ACP sponges. The spectra showed \n\nbands at 1617 and 1413 cm?1 attributed to the asymmetric (C=O) and symmetric (C-O) \n\n\n\n177 \n\n \n\nstretching modes of the planar carboxyl groups in the hyaluronate. The absorption \n\nbands at about 1650, 1561, and 1320 cm?1 are characteristic of the amide I, II, and III \n\nband, respectively. The weak absorption band around 1740 cm?1 was attributed to the \n\nstretching vibration of ester groups. The three signals centered at 1150, 1072, and 1040 \n\ncm?1 were assigned to C-O-C (O-bridge), C-O (exocyclic), and C-OH group, \n\nrespectively. The band at 945 cm-1 was assigned to asymmetrical out-of-phase ring \n\nvibration. \n\nThe spectra of HA-ACP disinfected with 70% ethanol showed a band at 990 cm-1 \n\nattributed to C-O of primary alcohols indicating ethanol residual in the structure. \n\nTherefore, except for the HA-ACP disinfected with 70% ethanol, the spectra were \n\nvery similar indicating that their chemical structure did not change significantly with the \n\ntreatments. \n\n2000 1800 1600 1400 1200 1000 800\n\n65\n\n70\n\n75\n\n80\n\n85\n\n90\n\n95\n\n100\n\n105\n\n(5)\n\n(4)\n\n(3)\n\n(2)\n\n \n\n \n\n%\n T\n\nra\nn\n\ns\nm\n\nit\na\n\nn\nc\n\ne\n\nWavenumber (cm\n-1\n)\n\n(1)\n\n \n\n50 100 150 200 250 300\n\n-6.0\n\n-4.5\n\n-3.0\n\n-1.5\n\n0.0\n\n1.5\n\n \n\n \nW\n\n.g\n-1\n\nTemperature (\no\nC)\n\n Unsterile\n\n UV irradiation (5 cm)\n\n UV irradiation (60 cm)\n\n Plasma radiation\n\n Ethanol disinfection\n\n \n\n(a) (b) \n\nFigure 43. (a) FT-IR spectra and (b) DSC of HA-ACP sponges after the different \n\ntreatments. (1) Unsterile; (2) UV irradiation (5 cm); (3) UV irradiation (60 cm); (4) plasma \n\nradiation and (5) ethanol disinfection. \n\n \n\nThe effects of treatments on the thermal behavior of the sponges are shown in \n\nFigure 43(b). All the scaffolds showed the presence of a broad endothermic peak \n\nbetween 150 and 160\u00b0C associated with the loss of moisture remaining after the drying \n\nprocedure. In addition, significant sharp exothermic peaks around 220 and 245\u00b0C were \n\nobserved, which probably represent decomposition (Collins &amp; Birkinshaw, 2008). We \n\n\n\n178 \n\n \n\nconsider, none significant changes in the thermal profiles after the treatments.  \n\n \n\n8.3.2. Effects of the treatments on physicochemical properties of HA-ACP \n\nmicroparticles \n\nInitially, we evaluated the influence of the steam treatment in autoclave, at 126\u00b0C, \n\nunder a vapor pressure of 1.5 kgf/cm2, on the rheological properties of HA-ACP \n\nmicroparticles. The rheological behavior determined by oscillatory and steady \n\nmeasurements are shown in Figure 44(a) and 44(b), respectively.  \n\nWe observe that until 5 minutes of steam treatment, the microparticles \n\nmaintained the gel-like behavior, as analyzed by the storage (G\u2019) and loss moduli (G\u201d). \n\n(Ikeda &amp; Nishimari, 2001). Moreover, considering the Ostwald de Waele power law \n\n(?=K.?n-1), the flow indices (n) indicate a viscoelastic behavior that is an important \n\nparameter in injectable applications where the flow viscosity should be lower than the \n\nrest viscosity. According to the curves, we should consider no significant differences on \n\nrheological behavior of the microparticles up to 5 minutes of autoclave.  \n\nAfter the first 5 minutes of treatment, the mechanical spectra showed a crossover \n\nand due to very low viscosity, it was not possible to determine the flow curve using the \n\nparallel plate geometry previously used. Thus, these results indicate rheological \n\nbehavior of solution and degradation of the structure.  \n\n0.1 1 10\n\n0.01\n\n0.1\n\n1\n\n10\n\n100\n\n1000\n\n10000\n\n \n\n \n\nG\n' \na\n\nn\nd\n\n G\n\"\n (\n\nP\na\n\n)\n\nFrequency (Hz)\n \n\n0.1 1 10 100\n\n1\n\n10\n\n100\n\n \n\n \n\nV\nis\n\nc\no\n\ns\nit\n\ny\n (\n\nP\na\n\n.s\n)\n\nShear rate (s\n-1\n)\n\n \n\n(a) (b) \n\nFigure 44. Rheological characterization of HA-ACP microparticles after treatment in \n\nautoclave at 126\u00b0C, under a vapor pressure of 1.5 kgf/cm2 for: (?) 0 minute; (?) 1 \n\n\n\n179 \n\n \n\nminute; (?) 2.5 minutes; (?) 5 minutes; ( ) 10 minutes and ( ) 15 minutes. (a) \n\nOscillation spectrum and (b) flow curves. G\u2019 (closed symbol) and G\u201d (open symbol) \n\nmoduli. \n\n \n\nFigures 45a and 45b show the rheological behavior of the microparticles under \n\nUV1, UV2, plasma and 70% ethanol treatments. The G\u2019 and G\u201d profiles show that only \n\nthe UV1 treatment, in which the ultraviolet lamp was at a distance of 5 cm from the \n\nsample, affected the rheological behavior of the microparticles [Figure 45(a)]. Moreover, \n\nthere was a drastic decreased of shear viscosity [Figure 45(b)]. This behavior was \n\nattributed to degradation of HA by the high UV intensity due to the very small distance \n\nbetween the lamp and the sample. \n\n0.1 1 10\n\n0.01\n\n0.1\n\n1\n\n10\n\n100\n\n1000\n\n10000\n\n \n\n \n\nG\n' \na\n\nn\nd\n\n G\n\"\n (\n\nP\na\n\n)\n\nFrequency (Hz)\n \n\n0.1 1 10 100\n\n1\n\n10\n\n100\n\n1000\n\n \n\n \n\nV\nis\n\nc\no\n\ns\nit\n\ny\n (\n\nP\na\n\n.s\n)\n\nShear rate (s\n-1\n)\n\n \n\n(a)  (b) \n\nFigure 45. Rheological characterization of HA-ACP microparticles after the treatments: \n\n(?) untreated; (?) UV1; (?) UV2; (?) plasma and ( ) ethanol disinfection. (a) Oscillation \n\nspectrum and (b) flow curves. G\u2019 (closed symbol) and G\u201d (open symbol) moduli. \n\n \n\n8.3.3. Sterility evaluation  \n\nTables 5 and 6 show the results of the sterility test for the sponges and the \n\nmicroparticles, respectively. The counts of colonies indicated that 70% ethanol \n\ndisinfection and UV2 treatment were the least effectives, while plasma radiation and \n\nUV1 were the most effective treatments for the sponges (Table 5). \n\n \n\ncrossover \n\n\n\n180 \n\n \n\nTable 5. Results of heterotrophic plate count (bacteria) and fungal count (molds and \n\nyeasts) obtained after treatment of HA-ACP sponges. \n\n Heterotrophic Plate Count Fungal Count  \n\nTreatment  Bacteria \n(CFU/mL) \n\nMolds \n(CFU/mL) \n\nYeasts \n(CFU/mL) \n\nUV (1) - - - \n\nUV (2) ++ - ++ \n\nPLASMA - - - \n\n70% ETHANOL  + - + \n\nUNSTERILISED ++ + ++ \n*CFU=colony-forming units \n\n? no growth (detection limit=10 CFU/mL), + amount of microorganism below 1\u00d7104 CFU/mL, ++ amount of microorganism \n\nbetween 1\u00d7104 and 1\u00d7106 CFU/mL, +++ amount of microorganism between 1\u00d7106 and 1\u00d7108 CFU/mL. \n\n \n\nThe results in Table 6 indicate that only steam sterilization in autoclave was \n\neffective for sterilization of the microspheres. \n\n \n\nTable 6. Results of heterotrophic plate count (bacteria) and fungal count (molds and \n\nyeasts) obtained after sterilization of HA-ACP microparticles.  \n\n Heterotrophic Plate Count \n \n\nFungal count \n\nTime (minute) Bacteria \n(CFU/mL) \n\nMolds \n(CFU/mL) \n\nYeasts \n(CFU/mL) \n\nS \nT \nE \nA \nM \n\n1 - - - \n\n2.5 - - - \n\n5 - - - \n\n10 - - - \n\n15 - - - \n\nUV (1) ++ + ++ \n\nUV (2) ++ ++ + \n\nPLASMA ++ ++ + \n\n70% ETHANOL  + - - \n\nUNSTERILISED ++ + ++ \n*CFU=colony-forming units. \n\n? no growth (detection limit=10 CFU/mL), + amount of microorganism below 1\u00d7104 CFU/mL, ++ amount of microorganism \n\nbetween 1\u00d7104 and 1\u00d7106 CFU/mL, +++ amount of microorganism between 1\u00d7106 and 1\u00d7108 CFU/mL. \n\n \n\nComparing the effects of the treatments on the sterilization and physicohemical \n\nproperties of the sponges and microparticles, our results showed that sterilization by \n\nplasma radiation was the most efficient treatment for sterilizing the auto-crosslinked \n\nhyaluronic acid sponges because it ensures the sterility and preserve their chemical \n\ncomposition and 3-D morphology. In contrast, the steam treatment in autoclave (at \n\n126\u00b0C, 1.5 kgf/cm2) up to 5 minutes was the method most adequate for sterilization of \n\n\n\n181 \n\n \n\nthe auto-crosslinked hyaluronic acid microspheres, because it did not change their \n\nrheological properties.  \n\n \n\n8.4. Conclusion \n\nThe sterilization by plasma radiation was the most efficient treatment for \n\nsterilizing the auto-crosslinked hyaluronic acid sponges, while the steam treatment in \n\nautoclave (at 126\u00b0C, 1.5 kgf/cm2) during 5 minutes was the most efficient treatment for \n\nthe microspheres. Thus, these methods can be used for sterilization of ACP structured \n\nscaffolds. \n\n \n\nAcknowledgments. The authors acknowledge the financial support from the National \n\nCouncil of Technological and Scientific Development (CNPq, Brazil). They also thank \n\nProf. Dr. Edvaldo Sabadini of the Chemical Institute (University of Campinas) for the use \n\nof the rheometer. \n\n \n\n8.5. References \n\nBELLINI, D.; PAPARELLA, A.; O\u2019REGAN, M.; CALLEGARO, L. Autocross-linked \nHyaluronic Acid and Related Pharmaceutical Compositions for the Treatment of \nArthrophaties. United States Patent: U.S. 2001/6,251,876 B1, 2001. \n\nCOLLINS, M.N.; BIRKINSHAW, C. Comparison of the Effectiveness of Four Different \nCrosslinking Agents with Hyaluronic Acid Hydrogel Films for Tissue-Culture \nApplications. Journal of Applied Polymer Science, vol.104, p.3183-3191, 2007. \n\nCOLLINS, M.N.; BIRKINSHAW, C. Hyaluronic acid based scaffolds for tissue \nengineering \u2013 A review. Carbohydrate Polymer, vol.92, p.1262\u20131279, 2013.  \n\nDANILOFF, G.Y.; SPIRO, R.C.; GRAVETT, D.M.; HILLAS, P.J.; HE, P. Sterile \nhyaluronic acid polymer compositions and related methods. United States Patent \nApplication: U.S. 2009/0,017,091, 2009. \n\nFARAJ, K.A.; BROUWER, K.M.; GEUTJES, P.J.; VERSTEEG, E.M.; WISMANS, R.G.; \nDEPREST, J.A.; CHAJRA, H.; TIEMESSEN, C.M.; FEITZ, W.F.J.; OOSTERWIJK, E.; \nDAAMEN, W.F.; VAN KUPPEVELT, T.H. The Effect of Ethylene Oxide Sterilisation, \nBeta Irradiation and Gamma Irradiation on Collagen Fibril-Based Scaffolds. Tissue \nEngineering &amp; Regenerative Medicine, vol.8, n.5, p.460-470, 2011. \n\n\n\n182 \n\n \n\nIKEDA, S.; NISHINARI, K. Weak Gel-Type Rheological Properties of Aqueous \nDispersions of Nonaggregated K-Carrageenan Helices. Journal of Agricultural and \nFood Chemistry, vol.49, p.4436-4441, 2001. \n\nPLIKK, P.; ODELIUS, K.; HAKKARAINEN, M.; ALBERTSSON, A.C. Finalizing the \nproperties of porous scaffolds of aliphatic polyesters through radiation sterilization. \nBiomaterials, vol.27, p.5335\u20135347, 2006. \n\nREHAKOVA. M.; BAKOS, D.; SOLDAN, M.; VIZAROVA, K. Depolymerization rections of \nhyaluronic acid in solution. International Journal of Biological Macromolecules, \nvol.16, n.3, p.121-124,1994. \n\nSHIMOJO, A.A.M.; PIRES, A.M.B.; TORRE, L.G.; SANTANA, M.H.A. Influence of \nParticle Size and Fluid Fraction on Rheological and Extrusion Properties of Crosslinked \nHyaluronic Acid Hydrogel Dispersions. Journal of Applied Polymer Science, vol.128, \nn.3, p.2180-2185, 2013. \n\nSIRITIENTONG, T.; SRICHANA, T.; ARAMWIT, P. The Effect of Sterilization Methods \non the Physical Properties of Silk Sericin Scaffolds. AAPS Pharm Sci Tech, vol.12, n.2, \np.771-781, 2011. \n\nUnited States Pharmacopeial Convention, Inc. USP/NF: The official compendia of \nstandards, 35th edition. Rockville: USP, 2012. \n\nUNTERMAN, S.A.; GIBSON, M.; LEE, JH.; CRIST, J.; CHANSAKUL, T.; YANG, E.C.; \nELISSEEFF, J.H. Hyaluronic Acid-Binding Scaffold for Articular Cartilage Repair. Tissue \nEngineering \u2013 Part A, vol.18, n.23-24, p.2497-2506, 2012. \n\n  \n\n\n\n183 \n\n \n\nCAP\u00cdTULO 9 \u2013 CONCLUS\u00d5ES \n \n\n9.1. Conclus\u00f5es \n\n \n\nNeste trabalho foram preparados e caracterizados os seguintes scaffolds \n\ncomp\u00f3sitos de quitosana (CHT) e/ ou \u00e1cido hialur\u00f4nico (AH) estruturados em esponjas \n\n(aP-PRP/PCHTs, aP-PRP/SPCHTs, aP-PRP/ACPs, aP-PRP/HA-BDDE e aP-\n\nPRP/PECs) e micropart\u00edculas (aP-PRP/iCHT-TPPs, aP-PRP/ACPs, aP-PRP/HA-BDDE \n\ne aP-PRP/PECs).  \n\nA efetividade in vitro dos scaffolds comp\u00f3sitos, foi avaliada atrav\u00e9s da cin\u00e9tica de \n\nlibera\u00e7\u00e3o de fatores de crescimento (PDGF-AB e TGF-?1) do P-PRP em meio DMEM, \n\nprolifera\u00e7\u00e3o e diferencia\u00e7\u00e3o de h-AdMSCs atrav\u00e9s do marcador osteog\u00eanico fosfatase \n\nalcalina (ALP). \n\nO desempenho individual dos scaffolds foi apresentado nos artigos e na patente \n\nque comp\u00f5em este trabalho. \n\nOs resultados obtidos permitem as seguintes conclus\u00f5es gerais:  \n\n? Os pol\u00edmeros naturais CHT e AH podem ser estruturados em esponjas ou \n\nmicropart\u00edculas que atuam como scaffolds para o PRP em formula\u00e7\u00f5es s\u00f3lidas \n\n(esponjas) ou fluidas injet\u00e1veis (micropart\u00edculas), com diferentes propriedades \n\nf\u00edsico-qu\u00edmicas e mec\u00e2nicas.  \n\n? As esponjas apresentaram elevada porosidade (>90%), alto grau de \n\nintumescimento adequados para a migra\u00e7\u00e3o e prolifera\u00e7\u00e3o celular e resist\u00eancia \n\nmec\u00e2nica adequada ao manuseio e cultivo celular. \n\n? As micropart\u00edculas apresentaram propriedades reol\u00f3gicas e mec\u00e2nicas \n\nadequadas para a inje\u00e7\u00e3o.  \n\n? Para os scaffolds de CHT estruturados em esponjas, a estabilidade em termos \n\nde perda de massa com o tempo em PBS foi atribu\u00edda \u00e0 presen\u00e7a de acetato \n\nresidual, enquanto que nas micropart\u00edculas foi atribu\u00edda ao grau de reticula\u00e7\u00e3o. \n\nNos scaffolds de AH, a estabilidade refletiu somente do grau de reticula\u00e7\u00e3o.  \n\n? Todos os scaffolds preparados neste trabalho n\u00e3o apresentaram citotoxicidade. \n\n? Nas esponjas a rede de fibrina formou-se preferencialmente no interior dos \n\nporos, enquanto que nas micropart\u00edculas a parti\u00e7\u00e3o da rede de fibrina entre o \n\ninterior e a superf\u00edcie das part\u00edculas foi dependente da sua rigidez, a qual \u00e9 \n\n\n\n184 \n\n \n\nfun\u00e7\u00e3o do grau de reticula\u00e7\u00e3o. \n\n? A libera\u00e7\u00e3o dos fatores de crescimento (PDGF-AB e TGF-?1) foi \n\npredominantemente difusiva em todos os scaffolds. A maior parte dos fatores \n\n(~80%) foi liberada nas primeiras 12 horas em concord\u00e2ncia com a estabilidade \n\ndos scaffolds. \n\n? A prolifera\u00e7\u00e3o de h-AdMSCs foi maior ou igual a do PRP para as esponjas de \n\nambos os pol\u00edmeros, exceto quando reticuladas com TPP (CHT) ou BDDE (AH). \n\nNas micropart\u00edculas, a prolifera\u00e7\u00e3o foi menor em rela\u00e7\u00e3o ao PRP e dependente \n\nda dureza e grau de reticula\u00e7\u00e3o. \n\n? A capacidade das h-AdMSCs para a produ\u00e7\u00e3o do marcador de diferencia\u00e7\u00e3o \n\nosteog\u00eanica ALP foi favorecida nas micropart\u00edculas em rela\u00e7\u00e3o \u00e0s esponjas.  \n\n? A capacidade de diferencia\u00e7\u00e3o osteog\u00eanica apresentou uma tend\u00eancia oposta \u00e0 \n\nprolifera\u00e7\u00e3o celular.  \n\n? A radia\u00e7\u00e3o por plasma foi o processo mais adequado para a esteriliza\u00e7\u00e3o por \n\ndas esponjas de ACP, enquanto que o tratamento com vapor em autoclave \n\n(126\u00b0C, 1,5 kgf/cm2), at\u00e9 5 minutos foi o processo mais eficaz para as \n\nmicroesferas de ACP. \n\nEmbora a reprodutibilidade de produ\u00e7\u00e3o dos scaffolds e o cultivo celular possam \n\nser bem controlados pelas condi\u00e7\u00f5es operacionais, a compara\u00e7\u00e3o precisa do \n\ndesempenho dos v\u00e1rios scaffolds \u00e9 complexa por contemplar os fatores inerentes ao \n\nPRP, tais como a variabilidade da concentra\u00e7\u00e3o de plaquetas e fatores de crescimento \n\nde diferentes doadores nos v\u00e1rios ensaios.  \n\nAssim, conclu\u00edmos que os scaffolds comp\u00f3sitos preparados neste trabalho s\u00e3o \n\npromissores para engenharia de tecidos, particularmente para a cicatriza\u00e7\u00e3o e \n\nregenera\u00e7\u00e3o \u00f3ssea, no \u00e2mbito da medicina regenerativa. \n\n \n\n9.2. Trabalhos Futuros \n\n \n\n? Minimiza\u00e7\u00e3o da variabilidade do PRP para uma precisa compara\u00e7\u00e3o do \n\ndesempenho dos scaffolds. \n\n? Produzir e caracterizar scaffolds com diferentes tamanhos e formatos para \n\nensaios pr\u00e9-cl\u00ednicos. \n\n? Estender os estudos realizados com P-PRP para o L-PRP (plasma rico em \n\nplaquetas e em leuc\u00f3citos). \n\n? Estudar a influ\u00eancia das esponjas e micropart\u00edculas na ativa\u00e7\u00e3o do PRP.  \n\n\n\n185 \n\n \n\n? Caracterizar as intera\u00e7\u00f5es moleculares entre a rede de fibrina e os scaffolds. \n\n\n\n186 \n\n \n\n  \n\n\n\n187 \n\n \n\nANEXO 1 \n \n\nCOMPOSI\u00c7\u00c3O E FORMULA\u00c7\u00c3O DE SCAFFOLDS DE \u00c1CIDO HIALUR\u00d4NICO E \n\nQUITOSANA PARA ASSOCIA\u00c7\u00c3O COM PLASMA RICO EM PLAQUETAS E SEUS \n\nUSOS EM TERAPIA REGENERATIVA  \n\n \n\nA presente inven\u00e7\u00e3o refere-se a scaffolds compostos de \u00e1cido hialur\u00f4nico (AH) e \n\nquitosana (CHT) em formula\u00e7\u00f5es s\u00f3lida ou fluida (injet\u00e1vel), para associa\u00e7\u00e3o com \n\nplasma rico em plaquetas (PRP), em aplica\u00e7\u00f5es no campo da medicina regenerativa, \n\nmais especificamente no campo da ortopedia. Nas formula\u00e7\u00f5es s\u00f3lidas os pol\u00edmeros \n\ns\u00e3o estruturados em esponjas e nas formula\u00e7\u00f5es fluidas em micropart\u00edculas. A \n\ninven\u00e7\u00e3o baseia-se no fato de que a associa\u00e7\u00e3o de PRP ao \u00e1cido hialur\u00f4nico livre tem \n\nsido amplamente usado na cl\u00ednica, em tratamento de les\u00f5es musculoesquel\u00e9ticas. \n\nEnsaios in vitro mostraram que a estrutura\u00e7\u00e3o do AH autorreticulado ou de quitosana \n\nestabilizada em esponjas ou micropart\u00edculas, promoveu a libera\u00e7\u00e3o gradual dos fatores \n\nde crescimento provenientes do PRP, estimulou a prolifera\u00e7\u00e3o de c\u00e9lulas tronco \n\nmesenquimais humanas de tecido adiposo, assim como a osteog\u00eanese. A associa\u00e7\u00e3o \n\ndo PRP com os scaffolds melhorou a estabilidade da rede de fibrina, e a estrutura\u00e7\u00e3o \n\nem esponjas ou micropart\u00edculas melhorou as propriedades mec\u00e2nicas em rela\u00e7\u00e3o aos \n\npol\u00edmeros livres. Entretanto, a elevada densidade de carga negativa do AH reduz a \n\nades\u00e3o celular que interfere na regenera\u00e7\u00e3o tecidual, enquanto que a elevada carga \n\npositiva da CHT pode resultar em danos celulares in vivo. Nesse contexto, a presente \n\ninven\u00e7\u00e3o que trata de scaffolds de AH autorreticulado e quitosana para associa\u00e7\u00e3o com \n\nPRP evidencia que esses scaffolds constituem biomateriais para uso cl\u00ednico que \n\nbeneficiam as aplica\u00e7\u00f5es do PRP em terapia regenerativa."}]}}}